0
""
dialysatefluxqd
equilibriumrateconstanttotheeffectcompartmentkco
peakconcentrationsatsteadystate
brain
distributionhalflifealphat12
reabsorptionrateconstantka
timetomeaningfulpainrelief
halflifeoflabel
auclastratio
fractionremoval
supplyrate
q2
halflifeoft12alpha
concentrationatsteadystatecss
t12m3
timetoreachthepeakplasmaconcentrationtmax
aucsratio
bloodbrainbarrierpermeabilitysurfaceareaproduct
apparentmeanvolumeofdistribution
fmugt
cthdlratio
concentrationsdosecds
systemicbioavailabilitiesf
auc0tiv
eliminationhalflifetl2
maximaldosage
fauc
detectiontime
transportclearancefrom
flowratefor
totalstudytime
plasmaactivemoietylevel
emulsificationtime
maximalmeasuredplasmaconcentration
troughcminday28concentration
apparentintrinsicmetabolicclearance
minimumconcentrationof
areaundertheeffectcurveaue
clsr
terminalhalflifeofmorphineelimination
clearancefromthesecondcompartmentcld2
latencie
peakactivatedpartialthromboplastintime
salinetoglucoseabsorptionratio
steadystadeconcentration
fmax1b
maximumdrugconcentrationscmaxd
initialplateauconcentration
ivybleedingtime
clearancecl0
terminalhalflifet50
ratioofmilktoplasmaconcentration
timerequiredtoreachcmaxtmax
peakplasmafirocoxibconcentrationscmax
areaundertheplasmaconcentrationtimecurvefrom0to270minute
ocularbioavailabilitie
metabolicclearancecl
sfac
ic100
50
ic90
releaserate
gastrointestinalbioavailability
ee
levelsatsteadystate
apparentrateconstantforabsorptionka
permeationclearancesclpi
t13
areaundertheplasmaconcentrationtimecurvetoinfinity
maximumconcentrationsofthensaidinplasmacmax
totalclearanceatsteadystate
clfss
peakrbtconcentration
semenplasmadrugconcentrationratio
areaundertheconcentrationtimecurvefromtimezerototimeinfinityaucinf
oralabsorptionrateconstant
peakserumdrugconcentration
totalrecoveredradioactivity
cmintxb2
noxideratio
clearanceduringfirstorderelimination
halfmaximalefficaciousauc
peakreachtime
initialdetectiontime
apparentdistributionvolumevc
clf
pulserate
maximumheparinactivity
micsusceptibilitybreakpoint
peaktumoruptake
ratioof
absolutenasalbioavailability
areaundertheplasmaconcentrationversustimecurveauc0last
hepaticextractionratio
maximallevel
timeto
ptl
areaundertheconcentrationtimecurveratioaucr
populationclearanceclf
areaundertheplasmatimeconcentrationcurveaucfrom0to12h
areaundertheconcentrationtimecurvetolastmeasurableconcentration
cndi
gastricph
passivemembranepermeabilitypapp
maturationhalftimetm50
activityhalflive
totalanalysistimepersample
keq
subcutaneousabsolutebioavailability
bloodtroughconcentrationc0
cminss
timetoreachthepeakdrugconcentrationtmax
timeofpeakserumconcentration
peakantifactorxa
percentagebound
peakplasmadipipanoneconcentration
apparentvolumeofdistributionofthecentralcompartmentvd1
peakblood14cformateconcentration
kcat
plasmaticauc024h
areasundertheconcentrationtimecurvesauc
areaunderthecurveofserumconcentrationversustime
renalclearancecr
apparentclearancefromthecentralclc
cumulativerenalexeretion
areaunderthecurveaucat0120min
areaundertheplasmaleveltimecurveauc
areaundertheconcentrationtimecurvefromtime0toinfinity
troughtak385concentration
stasisexposureindex
areasundertheconcentrationtimecurveconcentrationinplasmaversustime
effectcompartmentconcentrationat50maximum
auc012ss
areaunderthecurveauc0endofgir
totalareaunderthecurveuptothelastmeasurableconcentrationauclast
dmean
unboundbraintoplasmaaucratio
absorbeddosestonormalorgan
excretionindex
timetopeakimilevel
kg
gammaphaserateconstant
timetoachievemaximumplasmaconcentrationtmax
occurrenceprobabilitie
crossreactivity
extractionratio
cltf
apparentalphahalflife
peaklumbarcerebrospinalfluidlevel
relativelylo
totaltroughconcentrationsctrough
kipl
steadystateplasma5fuconcentration
painfreerate
pcta
timeittakestoreachpeakserumconcentrationtmax
totaladequivalent
timespan
50maximumeffectiveconcentration
antixa
braintoplasmabpratio
viabilityrate
maximumtestosteronelevel
areaunderthecurvefromzerotoinfinityauc0infinity
halfmaximumeliminationrate
auc060
nf54
minimumdetectionlevel
breakpoint
radiusofgyration
maximumplasmalevelscmax
areasundertheplasmadrugconcentrationtimecurve
timeofpeakconcentration
areaundertheconcentrationtimecurveextrapolatedtoinfinityauc
aqueoushumorconcentrationcmax
kbio
wholebloodconcentration
steadystatetroughconcentration
totalauc012
eliminationhalflifept12
zpotential
apparentconversion
concentrationfor50growthinhibition
serumconcentrationsafter24h
t12zeta
zerotimeplasmafentanylconcentration
totalperfusateclearance
highestobservedconcentrationinplasmacmax
rateofbiliaryelimination
matrixeffect
evening
plasmaauc24h
binding
maximumpossibleeffectae90
areaunderthecurvefromtime0toa
dropletsize
z
systemicclearancesofdrug
faecalrecoverie
systemicclearancecls
cl12
bactericidalindexe
percentageofdoseabsorbed
auc06hss
auc0ratio
biologicalhalflifebetaphase
compressibility
serumcmin
maximumadmlevelcmax
peakplasmaclonidineconcentration
apparentdrugavailability
fractionofalfentanilunboundinserumfu
areaunderthebractimecurve
td2
pulmonaryextractionratioep
cmaxthemaximumplasmaconcentration
ratiosofareaundertheplasmaconcentrationtimecurveduringanadministrationintervalof24hauc024hto
auec112
oralclearanceclo
prola
highestobservedconcentration
bindingcapacity
freebindingenergy
fractionavailablef
volumevcf
aucunboundprednisolone
plasmaauc014day
auc024areaundertheconcentrationtimecurvefromtime0hto24h
accumulationindex
dosenormalizedtotalc0
percentinhibition
vdssiv
bloodcirculationtimet12
k35
gastricresidualvolume
limitsofquantificationloq
penetrationintoperipheral
maximaltolerateddose
plasmadopamine
secondorderratesofreaction
peakplasmazonisamidecmax
nominaloraldose
fev1
aucim
tissueuptake
tl
maximallengthofeffectiveanalgesia
fractionalclearanceofglucosefrombraintobloodk2
minimumsteadystateconcentrationscmin
freeplasmaclearance
serumhalflifeforthebetaphaset12beta
vascularavailability
cssavg
vdss
areaundertheconcentrationtimecurvefrom0to120h
steadystatebrainextracellularfluidplasmaunboundconcentrationratio
systemapparentclearanceclf
systemicavailabilityf
uptakeclearance
peaknomacconcentrationcmax
distributionofthekineticvolume
betat12
aetaccumulatedexcretionamount
t12betaoftheeliminationphasebeta
areaundertheconcentrationtimecurvefrom0to180minute
drugaccumulation
maximumparacetamolconcentrationcmax
aucbrainaucplasmaratio
constantrate
minimumrelease
timetomaximumimprovement
auc300mininfinity
effectiveanalgesicconcentrationdurationseacds
halflifeofdecay
timetolossofresponsivenesslor
minimumconcentrationdruginserumcmin
noncompartmentalclearancecl1min
periodoftimetobeplacedonoral
lengthofsurvival
plasmadisappearancehalflife
sbp
areaundertheplasmacurvefromtimezerotoinfinity
fluidsplasmaauclastratio
fractionalexcretionofparaquatfepq
d1
totaleliminationratio
areaundertheplasmaconcentrationtimeprofile
nasalsecretoryconcentration
plasmsclearance
areaundertheplasmaconcentrationtimecurveforlamotrigineaucoinfinity
serumclearancehalflife
maximalbinding
h1ro
exitrateconstantfor
auc480
peakgentamicinplasmaconcentration
volumeratiosofantisolventtosolvent
halflifealpha
timetoreachcmax
tissueserumconcentrationratio
t12kappam
mtdrp2d
excretion
areaundertheconcentrationtimecurvefor0to12hoursaftertreatmentauc012
c0infinity
steadystatebioconcentrationfactor
aud024h
vcfvcumpagf
parentfraction
plasmapartitioncoefficient
freec5concentration
clmat50
halflifet12
cumula
peaktotalropivacaineconcentration
metabolicstability
ratioofaccumulation
peaktroughfluctuationdeltapt
totalibuprofenconcentrationinthecsfversu
cssmean
maximummeasuredyohimbineplasmaconcentration
formateclearancerate
integratedconcentrationofgrowthhormone
areasundertheconcentrationtimeprofilesauc
areaundertheplasmaconcentrationtimeprofileauc
auc1auctotratio
areasunderthecurveaucsfor
areaundertheconcentrationtimecurvefromtimezerotothelastsamplingtimepointauc0t
areasundertheplasmaconcentrationtimecurvesauc000
apparentdrugconcentration
areaundertheserumconcentrationversustimecurvetauc
areaunderthecurveauct
auc046h
dosenormalizedtroughconcentrationdntc
inflammationscore
cpss95
timeforinput
peakplasmacremophorconcentration
halflifeofdevelopment
drugloadingefficiencydle
ratioofbrainplasmaareaunderthecurve
plasmathresholdlevel
areaundertheplasmaegcgconcentrationtimecurveauc
areaunderthebloodconcentrationtimecurve
maximumofconcentration
eliminationclearancefromthecsf
troughplasmaaatlevel
cmaxc0
areaundertheconcentrationtimecurvefrom0to8h
timeofpomaximumbloodconcentration
deliveryefficiency
chloride
fractionalpotassiumreabsorption
concentrationatthesecondhourc2
netacidexcretion
teru50
peakplasmaghlevel
areaundertheplasmaconcentrationtimecurveoverthedosingintervalofdurationt
auc024hminimuminhibitoryconcentrationratio
plasmaproteinbindingratio
timeofpeak
fractionalconversion
areaundertheconcentrationtimecurveover24hour
qn
eliminationfractionef
maximumplasmaconcentration
hillslope
peaksystemiclevel
vlambda
auc06hr
plasmahalflife12
areaundertheplasmadisappearancecurveauc
bodyclearanceclf
plasmacmax
aucauc8
fractionofunchangeddrugexcretedinurine
areaunderthecurvefrom0to24hauc0
kelt12el
timeforreachinggirmaxtgirmax
ddqtcf
aqueoustoplasmaratio
areaundertheplasmaconcentrationfrom0to24h
overallspontaneousbleedingrate
activationenergyea
areaundertheplasmaconcentrationtimecurvefromtime0toinfinityauc0infinity
meanresidencetimesmrt024h
transmit
steadystateconcentrationathalfvmaxkm
accumulationindexr
maximumtriamcinoloneacetonidelevel
totalsufen
bleedingepisode
plasmahalflifeoftheterminalphase
peaklevelcmax
ratioofareaundercurve
maximumbuprenorphineconcentration
totalareaundertheplasmaparacetamolconcentrationtimecurvefrom0to180min
mesor
maximalconccmax
maximumacyclovirconcentration
fvp
totalfecalexcretion
weightadjustedmaximumplasmaconcentrationcmax
terminalclearancehalflife
halflivesofabsorptiont12dis
vodv
passivepermeability
volumeofdistributionvcvolumeofdistributionofcentralcompartment
maximumconcentrationattained
peakliverconcentration
totalc0
cox1cox2ratio
pc20metha
bioavailabilitylsmeansratio
timetoplatelet
peakbupivacaineconcentration
vm
milkeliminationhalflive
peakfleroxacinconcentration
v1sactivity
tmaxcmax
50effectiveconcentration
tau
apparenttotalbodyclearance
fractional
sceper
apparentrenalfluoride
maximumsolubility
cmaxriagcmsratio
peakradioactivity
softeningtemperature
totalrecoveryfromurine
bioavailabilityfm
timetoeyeopening
vo2
activationenergy
maximumfreeropivacaineconcentration
plasmaconcentration
relativebioavailabilitiesfrel
percentcminchange
cmax1224
totalmeanabsorptiontime
appearancehalflive
clbody
maximummesnaconcentration
absolutebioavailabilityafteroraladministrationf
totalareaundertheplasmaconcentrationtimecurveauc
cmaxmd
tlast
ser
intercompartmentalclearancebetweencentralandperipheralcompartmentsq12
halflifeoftheterminalphaseofelimination
areaunderthefreeplatinumplasmaconcentrationtimecurveaucfp
peritonealfluidplasmaaucratio
bioavailabilty
kpc
vo
bioavalability
timeassociatedwith
tmaxcmi
accumulationaccumulationrate
dissociationequilibriumconstant
plasmatissueplasminogenactivatortpa
cd19
timetoreachpeaktram
percentageentrapmentefficiency
daytime
effectivehalflifet12eff
timeafterdrugadministrationtoreachcmaxtmax
effectivedosefor50
populationabsorptionrateconstant
unboundvenouslevobupivacaine
kel3mx
maximallplactivity
halflifeoft12
maximumachievedconcentrationcmax
maximalspecificerythrocytebindingcapacitybmaxrbc
areasunderthedrugconcentrationcurvesauc
pmax
overallinhibitionconstantki
peakheartbinding
ld90
ce50wa
ae036
constantplasmaalcoholconcentration
plasmaresidue
t21
aucyen
time0toinfinityauc0infinity
cmaxthemaximumconcentration
steadystateimatinibplasmaconcentration
minimalcytotoxiclevel
lymphaticavailability
initialhalflifeofelimination
aucfromtimezeroto48hoursauc48
volumeofdistributionincentralvcf
timetominimumplasma
areaunderthebloodconcentrationtimecurveupto4hauc4hr
percentrecovery
areaundertheblooddrugconcentrationtimecurveauc
apparentmedianterminaleliminationrateconstantsassociatedhalflives
density
cav
tissuelevelscmax
gammahalflive
plasmalevelpeak
timetoreachthemaximumleveltmax
apparentsteadystatevolumeofdistributionv
absolutereactiontime
peakconcentrationb
competitiveinhibitionconstant
timetopatientcomfort
tumouruptake
peakformatelevel
timetoreachpeakleveltmax
maximummilkconcentration
massof
hillfactorg
t12a
areaundertheconcentrationtimecurvefromtimezerotoinfinityratio
volumeofdistributionvdss12
tubularsegmentalreabsorptionrate
permeationcharacteristic
ratioofhydro
areaundertheprocainamideplasmaconcentrationtimecurve
t95
areaundertheconcentrationtimecurveaucatsteadystate
auc0alpha
auc03
peakbileplasmaconcentrationratio
clmax
peaklevocetirizineconcentration
peakplasmalevelsofradioactivity
aucintrahepaticaucintraarterialratio
plasmaclearancehalflive
initialamount
halfoftheemaxec50
brainplasmaconcentrationintegralratio
maximum5fuconcentrationscpmax
halftimefordisappearance
maximalunboundplasmaconcentration
rateconstantk3
lagtimet10
firstordert12
apparentdistribution
deepdistributionvolumev2
plasmahalflifet12lambda2
salivaserumlevelratio
renalexcretionduring24hour
areaundertheci941plasmaconcentrationxtimecurveauc
ex4
apparentvolumeofdistributionvdssf
steadystateserum
areaundertheradioactivityconcentrationtimecurvesauc0infinity
peakplasmaqtconcentration
penetrationindexe
t12elim
areaundertheplasmaconcentrationcurveauc0infinity
timetoreachmaximumpeakplasmaconcentrationfollowingdrugadministrationtmax
diameterofbasement
csfplasmacssratio
inhibitordissociationconstantskivalues
maximumparasitekillingrate
residualcamphor
headacheresponserate
oralbloodclearance
accumulatedpermeation
halftimeofbloodbrain
dosenormalizedserumconcentration
totalsteadystatematernalplasmapropranololconcentration
urineflow
fetaltomaternal
totalbodyelimination
auc115
volumeofthefirstbraincompartment
maximumof4
radialcrushingstrength
equilibriumbloodcellplasmaratio
limitofdetectability
maximumobtainablereceptoroccupancyomax
concentrationsversustimeaucratio
peakplasmaimatinibconcentration
meantransittimemtt
areaundertheplasmaconcentrationtimecurvesforthe12hourdosingintervalauc012
peakplasmalsconcentration
totalbodyclearanceratec1b
intrinsicp
timeatmaximalconcentration
timetosustainedresponse
plasmasteadystateconcentrationratio
aucsbfaucspercentratio
haloperidolhaloperidolratio
cmaxauc0
maximumtolerableplasmasteadystateconcentration
unboundbrainextracellularfluidconcentrationratio
auclast
initialhalflifeforbiliaryelimination
timetoobservedmaximumplasmaconcentrationtmax
maximumsorafenibconcentrationstmax
aucsfromtimezerotoinfinity
eliminationhalflifet12elimination
areaunderthecurveofbloodconcentration
timetopeakdrugconcentrationtmax
milkserumultrafiltrateconcentrationsratio
steadystatecpnecessary
plasmaproteinbindingfp
proteinbindingfraction
halflifeoftheinitialalphaphaseofdistribution
clinicalduration
plasmalevelsatpeak
areaundertheexcretionratecurve
maximumzolpidemconcentration
nadircount
auc014day
maximumbloodclearance
halflivesassociated
efficiencyofabsorption
glucosedeltaauc
aucfinalaucinitialratio
totalareaundertheplasmamethylprednisoloneconcentrationtimecurve
absorptionrateconstantska
delayedreleasetimetlag
distributionhalflifealpha
areaundertheconcentrationtimecurvefromzerotoinfinity
bloodcelltoplasmapartitioningratio
tgd
zaveragediameter
initialt12alpha
steadystateauc024h
tumortomuscleratiotm
maximalpeakconcentration
areaundertheconcentrationtimecurvefrom0to4h
kineticvolumeofdistribution
steadystatetotalserumconcentration
overallamountexcreted
limitofquantificationloq
cumulativefractionoffauc024mic
t12alphaabsorption
troughhydroxy
peritonealplasmaareaundercurveaucratio
unboundbrainlevel
ratioofcldegtocl
inhaled
dispositionrateconstant
timetoresolution
aucgir010h
distributionphasehalflife
areaundertheigf1concentrationcurveauc
timetomaximumqtc
totalvolumeofdistributionvss
peakparacetamolconcentration
widthintimeathalfmaximalintensity
aic
95unbound
troughsynovialfluidminocyclineconcentration
timetomaximumconcentrationofdruginserumtmax
kddistributionrateconstant
plasmaticbioavailability
totalmaternalclearance
timeneededtoachieve
areaunderthedrugconcentrationintheahtimecurveauc
doseeliminatedinurine
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc
apparentvolumeofdistributioninthebetaphase
platelet
cluptake
areaundertheconcentrationtimecurveforthefreeunboundfractionofthedrugfauc
areaunderthetissueconcentrationversustimecurveauc
maximumserumcetirizineconcentration
percentageofdrugboundto
percentdrugentrapmentefficiency
liverwaterpartitionratio
il8
peakpleuralfluiddruglevel
salivatoplasmaconcentrationratio
relativebioavailabilityfpgs
systemicclearancecl1
adiposeconcentration
aucloinfinity
fractionallithiumexcretionfeli
placentalpartitioncoefficient
dem
plasmaauc012h
cmaxlevel
slowestrate
maximumtimetmax
hepaticclearancefraction
intrinsicbiliaryclearance
distributionhalflifet12lambda2
distributionratio
totaluptake
peakhaircodeineconcentration
apparentmaximumunboundconcentration
apparentcomposite1orderrateconstantsalpha
timetoreachmaximalconcentration
timetothemaximumplasmaconcentration
apparentltgclearanceclf
v3l
effectduration
tsublagsub
endogenouseliminationhalflife
ebapo
milktobloodratio
maximumaverageplasmaclonazepamconcentration
systemicavailability
initialarterialtovenousconcentrationratio
drop
firstordersrateconstant
peakresolution
betahalflifeofelimination
areaundertheconcentrationtimecurveauc024h
apparentvolumeofdistributionisvd
arterialcarbondioxidetensionpaco2
toxicityscore
areaundertheunbounddrugconcentrationtimecurvetominimuminhibitoryconcentrationratiofaucmic
halflivesofabsorption
finalphasehalflifet12beta
peripheralcompartmentvolume
drugretentionin
losscoefficient
rpf
t50clearance
timetocmaxatsteadystate
bloodtransfusion
maximumseruminsulinlevelcmax
timeabovetheminimuminhibitoryconcentration
penetrationratio
decayhalflife
milktoplasmaaucratio
peakfuraconcentration
absorptionlo
cauc
ic50
dosingrate
timetoachievemaximumconcentrationstmax
absorptionhalflifetabsfree
sequentialhalflive
fractionexcretedrenally
mmr
bindingenergy
areaunderthefirstmomentofcurvefrom0tot
peakofglucose
cittotalclearance
steadystateskinpermeationrate
drugabsorption
timeneededtoreachcmaxtmax
lambda
ratioofauc024h
nonrenalbloodclearance
estimated
overalldegradationrateconstant
clmp
limitsofquantitation
apparentcomparablehalflife
tissuetoplasmaratiosofradioactivity
mpcmicratio
relativetissuedistributionratio
peakincrement
timeaveragednonrenalclearance
afxa
areaunderthecurvefrom0to24hauc024
overallcurerate
totalareaunderthecurve
lengthsoftreatment
eliminationconstantratekel
peaktissuelevel
clearanceforthelinearfirstorderelimination
plasmaurateconcentration
troughgefitiniblevel
oralavailabilityf
plasmasteadystateconcentration
bloodplasma
t12lambda
minimalplasmaconcentrationcmin
generalplasmaconcentrationlevel
ab
troughsteadystateplasmaamantadineconcentrationcp
alphaphaset12
eliminationt12t12beta
observedmaximumplasmadrugconcentration
steadystatemcpflux
pexcretion
turnovertimes1kel
integratedacthresponse
maximumcotinineconcentration
aqueoussolubility
areaundercurvefromzerotoinfinity
vmaxdelta
removalof
dosenormalizedauc0t
maximumdrspconcentration
fractionoforaldoseabsorbed
maximumgir
r
detectionlimitlod
dominanthalflifet12a
hospitalsurvivalrate
peakplasmatolvaptanconcentration
maximalratiovsblood
airflowrate
time0tothelastquantifiablesampleauc0tlast
apparentvolumesofdistributionvd
plasmauptake
exposureauc048h
cmaxcfcmaxefratio
initialdispositionhalflifet12alpha
fastphase
durationofhospitalization
totaldistributionvolumevarea
timetoreacht025m
maxmic90ratio
clmet
plasmaeliminationhalflifet12
timeatwhichmaximumserumconcentrationswerereachedtmax
peakplasmacannabidiolconcentration
steadystatelevelscss
maximumclearancecapacity
peakofmeanconcentration
peakbreathalcoholconcentrationbrac
formationrateconstantkmf
stability
sa
poolofbindingsite
least
areaunderthebloodcsaconcentrationtimecurve
urinerecoveryrate
eliminationrateconstantbetaofbetaphase
tt
partitioncoefficientofipka
ratioofaucssaucsd
plasmaproteinbindingatsteadystate
weightadjustedapparenttotalbodyclearanceclf
meanresidencetimemrt
plasmacbconcentration
concentrationneededtoattainonehalfemax
areaunderthecurvefromtimezerotoinfinityauc0alpha
plasmak
apparentdistributionvolumesv
halflifeofthebetaphase
areaundertheplasmadrugconcentrationtimecurvefora012hintervalauc
90effectiveconcentrationec90
steadystatevolumesofdistributionvdss
areaundertheplasmaconcentrationbytimecurve
timetoreachmaximumplasmalevel
maximumqrsdurationemax
peakplasmaprednisoloneconcentration
excre
serumn
distributionvolumesatequilibrium
overallabsorption
timeofmaximum
effectiveconcentrationec50
meanresidencetimesmrts
apparentvolumeofdistributionavd
chemicalplasmahalflife
totalurinarycalciumexcretionrate
aucsaucr
apparentparacetamolclearance
rsd
totalrenalexcretiontue
urinaryexcretionofradio
troughtheop
eliminationpercentage
auc0tauc0
cmaxssratio
areaunderthecurvefromzerotoinfinitumauc0infinity
volumeofdistributionofcompartment3
dcratio
areaundertheconcentrationtimecurve048hauc
plasmapeakconcentrationcmax
vtihr
peaktrough
netfluidlo
tissuetoplasmatpconcentrationratio
eliminationhalflifet05b
troughlevelstl
partialpressureofcarbondioxidepaco2
halflivesofdisappearance
totaldistributionvolumevdarea
intrinsicclearanceclin
metabolicclearancecim
areaundercurveauc0tofconcentrationtime
accumulationt12
totalu
terminalslope
steadystateg3139concentration
clearanceclbioavailabilityf
maximumnaloxoneconcentrationcmax
areaunderthetotalplasmaplatinumconcentrationsversustimecurveaucpt0120
percentageentrapment
maximumseminalfluidbloodplasmaratio
eliminationhalflifeinthebetaphase
percentagebinding
areaundertheconcentrationtimecurveauclast
netrespiratoryuptake
quicklyreachedpeakconcentration
maximalspecificbindingcapacitytothetissuesbmaxtissue
cerebrospinalauc0t
areaundertheplasmadrugconcentrationovertimecurveauc
correctedbrainbloodratiobbrcorr
timeofpeakplasmaconcentration
serumterminalhalflife
firstorderdegradationhalflive
troughantifactorxaactivity
systemicplasmaclearanceclp
thvd
plasmaterminalhalflife
timetomaximumglucagonconcentration
peakigficoncentration
halflifeofacheinhibitionti12
auac024h
plasmahydromorphone
bloodtroughconcentration
urinaryrecoveryatsteadystate
clearancehalflifeoffibrinolyticactivity
apparentvolumeofdistributioninthecentralcompartmentbasedontheareaundertheplasmaconcentrationtimecurve
concentrationsrequiredtoachieve50ofmaximumneuromuscularblockec50
auctotal024hmictargetattainment
maximumconcentrationofthedrugcmaxmic
residueconcentration
areaundertheconcentrationstimecurveratio
eliminationlambdaz
netfluxe
ecp50ecp95
dosenormalizedareaunderthecurveaucdn
gasflow
capacityimax
fh
bodysurfaceareanormalizedareaunderthecurve
peakexposurecmax
alt
hepatickm
micsu
anti
ctrough6
cerebrospinalfluidtoserumratio
ratioofprogua
effectcompartmentconcentrationresultingin
maximaldeltadeltaqtcf
betaphaseconstant
arteriovenousextraction
dmotmoratio
auc01h
placebocorrectedchangefrombaselineddqtcf
totalareaundertheserumconcentrationtimecurve
injectedactivity
steadystateciprofloxacinconcentration
effectivepermeability
steadystateplasmamorphineconcentration
saconcentration
peaksecretion
areasundertheplasmaleveltimecurve
wholebloodresidencetime
t12oftheterminalsteadystateeliminationphase
unboundfractionatsteadystate
maximumbac
areaundertheconcentrationtimecurveat0to8hoursauc08
centralclearance
maintenancedose
oralbioavailabilityobav
tumoraccumulationefficiencyauctumoraucplasma
clearancem3g
mediumloadingresidualrate
t12g
bronchialtoplasmaexposureratio
effectivehalflife
peakphenytoinserumlevel
absorptionhalflifet05ab
maximumobservedeffectparameteremax
concentrationathalfmaximaleffect
totalareaunderthebloodconcentrationtimecurvefromtimezerototimeinfinity
clearancefromtheaqueoushumor
t50cmax
relativeextentsofabsorption
fcr
maximumunboundconcentration
concentrationtime
tinsmax
bonebioavailability
percutaneousabsorptionratio
maximumsurvivaltime
firstorderrateconstantk1
braintissuetoplasmaratio
maximumsulfamethoxazoleconcentration
areaunderthetacrolimusconcentrationtimecurveauc024h
maximumglucoseinfusionratermax
clrenal
terminaldisappearancet12
auc0to720
stomachdeposition
areaundertheplasmaconcentrationovertimecurveauc
betahalflifet12beta
fmcyp2d6
areaunderthecurvefromtime0toinfinityauc0
cit
tumortoblood
peaktotroughratio
timetofirstincreaseindose
effectivetroughconcentration
salivaryconcentration
absorbeddosetotumor
halfmaximuminhibitoryconcentration
s0
maximumflux
pravp
effluxintrinsicclearance
auc0to24hours
ptf
stimulusrequiredforhalfmaximalresponse
eliminationper
absolutep
timetoreachpeakserumconcentrationofdextmax
substitutionrate
redistribution
areaundertheconcentrationtimecurveover24hinthesteadystatedividedbythemicaucmic
clsecretionunbound
extractionrecoverie
flowrateofthemobilephase
aucooo
centraldistributionvolumevc
timetoreachthemaximumconcentrationtmax
proteinboundfraction
timetoinfluenzasymptomresolution
dissolutiontime
volumeofcudistribution
unboundplasmacefazolinconcentration
steadystateofc
aucdividedbydosinginterval
hepaticavailabilityfh
acuteeliminationhalflife
overallvolumesofdistribution
iontransition
serumeliminationt12
apparentcmax
peaknorfloxacinplasmalevel
areaundertheplasmaconcentrationtimecurvefrom0to72hour
effusiondrainagerate
cloral
timesofmaximumbloodconcentration
apparentdrugclearanceclffromthecentralcompartment
totaldermalabsorption
amountofdrugexcretedintheurineae01
holmanindex
objectiveresponse
ratesoflivermetabolism
peakurinarytconcentration
apparentterminalhalflifet12
peakplasmaconcentrationcmaxminimalinhibitoryconcentrationmicratio
clap
apparentabsorptionhalftimet12abs
troughfviiilevel
hepatocellularity
aucatsteadystate
cmaxminimuminhibitoryconcentrationmic
v2
eliminationrateconstantkel
relativebioavailabilityauc024h
0mz
temperaturecoefficient
tec50
eliminationofhalflifet12beta
observedaccumulationratio
cfree
maxim
cl3
latebiologicalhalflife
t12deg
antigen
urineconcentration
serumhalflifeoftheterminalslope
maximumconjugationyield
steadystateareaundertheconcentrationtimecurveover24hour
areaunderthecurveaucivlast
aucsfromzeroto15minute
plasmaconcentrationof
maximaldoseratevmax
totalrenalexcretionrate
transdermalfluxe
rateconstantforintermediatecompartment
areaundertheplasmaconcentrationtimecurvefrom0to24hoursauc24h
observedmaximumconcentrationscmax
penetrationelfplasmaratio
uptakeefficiency
wetweight
totalcontent
maximumnorbuprenorphineconcentration
iondiffusivity
totalcourseauc
clcrea
volumeofdistributionofcentralcompartment
timeformaximalserumconcentration
steadystatectrough
id30
peripheralvolumedistributionvperipheral
partitioncoefficientforunbounddrugkpuu
timevaluetopeakconcentration
2575
areaunderraconcentrationovertimecurve
peakplasmafreethc
peakbac
minimumalveolarconcentrationmac
areaundertheeffecttimecurvefromtimezeroto72h
overallpenetrationintotheinflammatoryfluid
encap
areaunderplasmaconcentrationcurveauco12hr
timeofdrugdisappearance
areaundertheplasmaconcentrationversustimecurvefromtime0hourto96hour
troughreduction
totalsteadystateclearanceclf
midazolamconcentration
troughlevelnaproxenconcentrationsatsteadystate
her
mic
ratioofaucglucuronidesulfateaucaglycone
extubation
residualdrug
aucfrom0to6h
betaeliminationhalflive
maximumconcentrationofvgbcmax
areaundertheplasmadrugconcentrationtimecurvefromtime0tothelastmeasurableconcentration
apparentturnoverrate
totalclearanceof14cactivity
areaundertheconcentrationtimecurveaucfromtimezerotoinfinityauc0
evl
steadystatetroughpeakconcentration
vascularabsorptiont12abs
maximumcrosssection
vzbeta
clearancefromventricularcsf
probabilityoftargetattainmentpta
bloodclf
rfbinh
topic
rateofcontinuousdripinfusion
ctotal
timetogallbladderemptying
milktoplasmaconcentrationratio
percentagediffusion
maximalobservedconcentration
bloodlo
percentfecalelimination
cmaxconcentration
deltahr
dlratio
renalclearanceae024hauc024h
rateofinfusion
areaunderthecurvein04h
concentrationxtimeproductscxts
ro
electroconvulsivethreshold
parasite
progressionfreesurvivalpfs
totalrenalclearance
halflivesofdistributiont12a
totalauccmax
bileserum
concentrationof
peakexposure
il2
areaunderthetacconcentrationtimecurve
pcra
clearanceofhaemofiltration
timesofmaximumplasmaconcentrationtmax
unboundcol
plasmafreefractionfreetotalconcentrationratio
apparentsteadystatevolumedistribution
mrtpo
areaundertheplasmaconcentrationtimecurvefrom0htoinfinityauc0
auc028d
areaunderthefirstmomentcurvefromzerotothetimeofinfinityaumc0
bioavailabilityauc024
kihigh
bindingaffinityconstantki
t12halflife
steadystatetroughplasmaconcentration
maximumquinidineconcentration
volumeofdistributionbytheareamethodvdarea
ec50
minimalmeanconcentration
eliminationhalflifet12ke
auc0672
timetomaximumaccumulation
minimumcminconcentration
areaundertheconcentrationtimecurvebetween0and12husingthetrapezoidalruleauc012
timeofobservedmaximumdrugconcentration
amountofdrugrecovered
redcellplasmawaterpartitioncoefficient
centralcompartmentvolume
ld
maximumconcentrationofdruginserummic
cmaxpf
areaundercurveconcentration
intrinsicclearanceofunbounddesipramine
bodyclearancec1b
auc0g
freemaximumplasmalevobupivacaine
extentofbioavailability
ece50
acidoutput
timetoplateletrecovery
concentrationsofschi
concentrationatfirstdose
activatedclottingtime
areaundertheplasmaparacetamolconcentrationtimecurvefrom0to180min
intrinsicactivityemax
firstpassfractioneliminated
areaunderthedrugconcentrationtimecurvesauc
cubccecf
areaundertheconcentrationtimecurvetoinfinity
extracellularfluidvolume
pd20
serumm1concentration
cumulativerelativefractionofdoseabsorbed
alpha
cumulativeurineexcretionratio
auctss
peakcimetidinelevel
fine
beta60max
50inhibitoryconcentrationic50
firstcomponenthalflife
rateofrelativebioavailability
kmforoverallelimination
dosenormalizedareaundertheplasmaconcentrationtimecurveduringthe24hourdosingintervalatsteadystateauc24ssd
equilibriumplasmatobloodcellspartitionratio
areaundertheconcentrationcurveauc0180
maximumtimeofpeakplasmaconcentrationtmax
apparentmichaelismentenconstantfortubularsecretion
areaunderthetimeconcentrationcurveauc08
aucd
stabilizedconcentration
durationofbolusactivity
highestserumconcentrationcmax
dissociationconstantski
maximumhydrocortisonelevel
peakplasmavp16concentration
minimumoptimalc1trough
maximumgemcitabineconcentration
maximummeasuredplasmabetamethasoneconcentration
areasunderthecurvefortotalplatinumconcentrationversustimeauc
minimallyeffectiveserumconcentration
percentageboneuptake
degree
wholeblood
apparentavailability
halflifeintheeliminationphase
analgeticconcentration
absorptionfraction
areaundertheconcentrationtimecurveextrapolatedtoinfinityauc0
totalverapamilclearance
areasofplasmahydroxyzineconcentrationversustimeareaunderthecurveaucs
completeruntime
peaksynovialconcentration
maximumcocconcentration
endotrachealaspirateserumconcentrationratio
skinpermeationrate
oxidationactivity
rac
peakplasmaoxytocinlevel
brainbloodration
drugretentionrate
areaundertheconcentrationtimecurveforthedosingintervalauc0t
drugtargetingindexdti
peakvalueofserumconcentration
protectivetime
initialfreep
minimuminhibitoryconcentrationsminimumbactericidalconcentrationsmicsmbcs
v
percentageofinjecteddose
areaundertheconcentrationtimecurveatsteadystatefrom0to24hafterdoseadministrationaucss024
maximumtt
peakserumtryptophanlevel
encapsulationpercentage
totalruntimeneeded
024hareaunderthecurveauc024h
availabilityf
fullruntime
cbefactor
distributionphaseplasmahalflife
peakplasmaresveratrolconcentrationcmax
areaundertheplasmaconcentrationtimecurveduringthedosingintervalauctau
betaphasehalflife
maximalinhibition
brainbloodexposureratio
maximumtnratio
renalexcretionratetime
weightcorrectedclearance
kmax
peakconcentrationattheendofmoxifloxacininfusioncmax
areaundertheconcentrationtimecurvefromtimezerotoinfinity
tt4concentration
totaleliminationrateconstantk
meanabsorptiontimemat0infinity
renalclearance072h
fullrate
fractionofeliminated
removalhalflife
lactateplasmaconcentration
timetoreachthepeak
1halflife
maximumrateofoxidativedesulfurization
alphahalflifet12
steadystateapparentclearanceclfssratio
terminalrateofeliminationt12
timeformaximumconcentration
totalbodyclearancecltotal
steadystateplasmatheophyllineconcentration
renaltobodyclearanceratio
systemicdrugclearance
absorptionrateconstantsalpha
ratioaucauc
pseudozeroordereliminationrateconstantbeta
plasmaapparenthalflife
auc024hthreshold
peakplasmarhghlevel
plasmaactivereninconcentration
relativetargetingefficiency
bioavailabilityeba
areaundertheplasmaconcentrationtimecurveauc024h
timestothehalfmaximalmioticeffect
99invitroinhibitoryconcentrationec99
halfeffectiveplasmaconcentration
exchangerate
areaundertheconcentrationtimecurveoveradosingintervalauc0tau
timetoreachthepeakacetaminophenconcentration
timetoreachsteadystate
mrt012h
grwr
aucinf
targettroughlevel
maximumconcentrationcpmax
peakserummiconazoleconcentration
apparenturinaryhalflife
totalplasmaauc0720min
areaundertheconcentrationtimecurveauc048h
m6gmorphine
totaltestosteroneconcentration
concentrationscss
timestoreachhalfpeakplasmagtnlevel
uic50
plasmaoxycodoneconcentrationsmec
pka
areaundertheinhibitorycurve
peakpharmacodynamiceffect
cumulativeamountpermeated
areaunderthedrugtimecurveauc
dosecorrectedsystemicavailability
otr
areaundertheconcentrationvstimecurveauc
plasmaultrafiltrate
vdinthecentralcompartmentv1
troughmethadoneconcentration
accumulationratiosrauc
r1
totaltimethatthe
amnioticfluidplasmaconcentrationratio
lambda2
clearanceci
areaunderconcentrationversustimecurveauc
meanresidencetime0
c1b
halflifeof
areaundertheconcentrationtimecurveauc018hoursratio
timetoreachaveragesteadystateconcentrationscss
plasmaconcentrationsec50
halflifeofdistributionphase
centralhipjointcapsulecompartmentclearanceq
centralvolume
from
peakplasmaantifxaactivitycmax
maximumplasmaantiiiaactivity
apparenthalflivest12app
tissuebloodconcentrationratio
peakplasmatime
aucimaucivratio
ratioofaqueoushumourserumconcentration
eliminationhalflifeduringthecpbphaset12cpb
steadystatepenetrationrate
durationofdrugabsorptiont
steadystatesaserumconcentration
timetofirstnadirglucose
amountof
stokesradiu
auc1
maximumbloodmorphineconcentration
areaundercurveauc
cmaxtotroughconcentrationratio
tissueabsorbeddose
timetoattainthepeak
timetomaximalmetaboliceffect
curerate
timetopeakdatoccupancy
unboundvolumeofdistributionofthecentralcompartmentvcu
sensitivitysc50
lagperiod
apparentclearancesc
areaundertheconcentrationversustimecurveaucinf
urinaryconcentrationscmax
activatedpartialthromboplastintimeratio
maximumactivatedpartialthromboplastintime
plasmafreefractionspercentunbound
1
steadystateaac
distributionvolumeatsteadystate
inhibitionfractionofkin
mbc50tomic50ratio
peakplasmalidocainelevel
maximumcarprofenconcentration
systemicvascularresistance
areaundertheadrconcentrationtimecurveauc
areaunderplasmaconcentrationtimecurveauc0infinity
areaunderconcentrationtimecurvemeasuredinsteadystateupto24hafterdosingauc024h
maximumrelativeactivatedpartialthromboplastintime
maximumfreebrainconcentration
totaldailydose
cf
areaundertheplasmanorethindroneversustimecurve
areaundertheconcentrationtimecurvefrom0to24hmic
hospitalstay
apparentdistributionvolumev
maximumqtc
areaundertheconcentrationtimecurvefromtimezerotothelasttimepointauclast
analgesicpotency
effectcompartmentconcentrationat50blockec50
ldratio
liverrecovery
signaltonoisesnratio
cumulativepermeation
halflifeofthesecondphase
clearanceclobs
pd2
auctaub
css
t12c
bileelimination
auc08hratio
maximalserumghconcentration
halfforelimination
irreversibleeliminationclearance
areaunderplasmaconcentrationversustimecurveauc012h
refractoryperiod
plasmasteadystateconcentrationcss
timetoonsetofanalgesia
timeofpeakexcretionrate
peakperitonealplasmaconcentrationratio
tramadolconcentration
radioact
auc024pge2
areaundertheinsulintimecurve
halflifeatbetaphaset12beta
eliminativehalftime
injectioninterval
drivingflowrate
peakplasmacamplevel
absorptiontimetmax
totallevelsoftststot
finalhalflive
timeto90ofsteadystate
halflifetimesoftheeliminationphase
totalactivity
maximumserum
pain
mrl
effluxfromtheshallowbraincompartmentkout
peaktemozolomideconcentration
drgp
peakconcentrationattmaxcmax
distributionspace
latehalflife
durationofanal
effectivehalflifeofplasmadecay
k12
extracteddose
areaunderthetimecurvefrom012h
cpred
maximalconcentrationcmax
degradationhalflive
boundpercentage
cpdr
maximumplasmaconcentrationofacitretincmax
oralfluidtoplasmamphratio
serumultrafiltrateconcentration
peakcd4saturation
serumtroughradio
c2c6ratio
per
serumclearancescs
endogenousinput
overallmeanrenalclearance
overallruntime
absorptionrateconstanth
maximalbrainconcentrationscmax
maximaldecrement
areaundertheplasmahydrocodoneconcentrationversustimecurvefromtime0toinfinityauc0
distributionvolumevd
totalareaunderthecurveauc0t
permeationrate
unboundareaundertheconcentrationcurve
michaelismenten
smallintestinaltransittime
ied
areaundertheserumconcentrationtimecurveauc
braintoplasmapartitioncoefficient
cumulativeexcretionofradioactivity
fractionsexcretedunchangedfe
polydispersityindex
areaundertheplasmaconcentrationcurveversustime
auc28d
peakmtxconcentration
aucfromzerotimeto7day
apparentdistributionvolumesofthecentralcompartment
serumproteinbindingrate
halflifet12time
clccll
retention
pla
auc02h
peakmeanconcentration
cpmaxmic
maximuminfusionrateduringsteadystatecondition
effluxrateconstant
metabolicratioof
totalbodyresidencetime
areaundertheplasmaconcentrationvstimecurveatsteadystate
absorptionhalflife
maximumdrugconcentrationinbloodserumcmax
totalbodyclearancecif
ftcavg
patchstrength
drugconcentration
apparentbioavailabilitie
amountexcretedae
tumourresponse
linearscope
otherroute
maximumethanolconcentration
concentrationatwhich50
kinactivationki
plasmaclearancecl
tmaxtimetoreachcmax
peakrateofabsorption
halfeliminationtime
timetopeakoftheplasmaconcentrationcurve
maximumpeakthrombingenerationptg
auc020min
plasmaareaunderthecurveaucratio
v1l
aucfrom0to48h
areaunderthedrugconcentrationtimecurveaucratio
areaunderplasmaconcentrationversustimecurveauc
concentrationintheeffectcompartmentassociatedwitha50drugeffectec50
areaunderthecurvefromtime0tothelastmeasurableconcentrationauc0t
timetopeakbloodlevel
serumt3concentration
maximumurinaryexcretionratermax
clptotal
surfacearea
cssminc1min
lcretentiontime
areaunderthefreecarboplatinplasmaconcentrationversustimecurve
plasmaeffectiveconcentrationec50
serumb
maturationhalftime
plasmarenalextractionratio
areaunderthecurve0120h
areasundertheserumlevelcurve
urinaryrecoveryofunchangedsubstance
ed95
totalretention
troughtconcentration
minimumfungicidalconcentration
systemicclearancecltsf
timetoreturntobaseline
anchoringefficiency
troughfviii
backgroundconcentration
maximalmetabolicratevmax
kappahalflife
capillarypermeabilityareaproduct
remedicationtime
flarearea
areaundertheplasmaconcentrationtimecurve0toinfinity
clff
24hplasmaconcentration
timetopeakwholebloodconcentration
regressionof
betapac
zpotentialzp
intestinalavailabilityfg
areaundertheplasmaconcentrationtimecurveauc0
plasmafentanyl
ratioofradioactivity
fabeliminationhalflife
peakcalcitriollevel
areaundertheglucosecurveauc
encapsulationcapacitie
totaldrugoutput
constantoftheprocessrate
sedationconcentration
vcmax
iri
plasmaunboundphenytoinconcentration
peakghresponse
serumauc
t12ofthebetaphase
timetopeakplasmalevodopaconcentration
ha
ubtsaubts
orientationrecoverytime
objectivetumourresponserate
percentageofthedosereleased
gastrointestinalabsorptionquotient
terminalt12beta
e2
apparentterminaleliminationrateconstant
boronratio
timewhenminimumplasmaglucoselevelappearedtmin
overallresponseratesorr
clearancefromthecsf
cmax024hratio
dosegivingmaximumpolarization
timestomaximalplasmaconcentrationtmax
totalareaundertheplasmaconcentrationtimecurvesauc
interactionenergy
delayedreleasetimet10
minimumantixalevel
maximuminactivationrateconstantkinact
durationofcontinuousin
bsa
auc024hbw
plasmaappearancerate
peakpaclitaxelplasmaconcentration
maximalsteadystateplasmaconcentration
timeuntilpeakplasmainsulinlevel
inductiontarget
areaundersalbutamolplasmaconcentrationsasafunctionoftimeauc07h
minimumtherapeuticserumconcentrationofdrug
initialt12
absorptionrateconstantksubasub
pqinterval
volumeofdistributionforthecentralcompartment
clearanceclb
pct99
unboundtumortoplasmapartitioncoefficientkptuu
areasundertheconcentrationversustimecurvechangesaucr
eliminationphasehalflife
fetomaternalratio
micdistributionfrequency
bacterialeradicationrate
timetopeaklevodopaconcentration
minimaleffectiveconcentration
braintoplasmaratioatsteadystate
terminalfetalmaternalratiosofbloodconcentration
leveldoseratio
eliminationrateconstantsk12
steadystatesaconcentration
clbulk
areaundertheconcentrationtimecurveauc
areaundertheconcentrationcurvefor08hauc08h
peakaqueoushumorlevel
eliminationkd
brainlevel
areaunderthecurve0to72h
peakplasmaorbifloxacinconcentration
proteinbindinglevel
totaldrugclearancefrom
totalurinaryrecoveryoflabel
relativebioavailabilityauc0infinityratio
overallpenetration
troughcmin
areaunderthecurvefor24hauc24
freeptconcentrationptfree
masstochargetransition
cerebrovascularpermeabilitysurfaceareapa
peakbloodconcentration
phofmaximumstability
areaundercurveaucofinsulinconcentration
apparentvd
plasmaconcentrationatsteadystatecssavg
effluxcloutpermeability
meanabsorptiontimemat
hairurineconcentrationratio
areaundertheconcentrationtimecurvesfrom0htoinfinity
areaunderthecurvefrom0to2hoursauc02
sputumtoplasmaratio
drugloadingcoefficient
fractionalexcretionof
apparentvolumeatsteadystate
apparentsystemicclearancecl
total6day
tissuedistributionvz
auct
halflifeteq
peak5fuconcentrationcmax
areaundertheconcentrationvstimecurve
initialclearancelevel
clearanceofunbounddiazepamintrinsicclearance
timetoreachmaximumplasmadrugconcentrationtmax
fluidplasmaconcentrationratio
ci
terminalgammaphase
onsettimeofmaximumeffect
ec20
areaundertheplasmaconcentrationtimecurvefrom0to1hour
apparenteliminationphasehalflife
accumulationindice
maximalplasmaconcentration
steadystatecmin
maximumrateofeliminationvm
meandispositionresidencetimemdrt
act
halflifeeliminationoft12el
peakplasmaacvconcentration
peaktaconcentration
doublingtime
peakexpiratoryflowpef
eliminationhalflifev0
auc012hours
halflifeinthebetaphase
correctedclearance
acylationrateconstant
micsusceptibility
apparentoralglibenclamideclearance
terminalbetahalflife
auc020
minimuminhibitoryconcentrationfor90oforganismsmic90
re
oralclearanceoftheophyllineatsteadystateclf
fluidvolume
disappearancetime
terminalhalflifet12betaor
auc0areaundercurve
terminaleliminationphasebeta
cnr
renalmeprobamateclearance
fluidtoultrafiltrate
expo
plasmaapparentsystemicclearance
t4absorption
peakaverageconcentration
freeplasmaconcentration
unboundpartitioningkpuu
failurerate
q6h
dosenormalisedcmax
renaltubularclearanceclt
halflivesforelimination
apparentformationt12
bindingstoichiometry
troughlevelcmin
peritonealfluidconcentration
apparentsteadystateplasmaconcentration
cumic
relativeoralbioavailability
sthiop
meandissolutiontime
plasmaeliminationhalflifet12el
eliminationratekel
terminalbloodhalflife
terminalexcretionhalflive
ic50concentration
tissueretentionhalflive
aucf
maximumplasmaconcentrationcmaxmic
shelflife
liverplasmaflow
auc0480min
crosslinktime
areasundertheconcentrationtimeprofile
responseduration
apparentoralsteadystatevolumeofdistribution
auc04
totalsystemicclearanceclt
maximuminactivationrateconstant
meta
encapsulationefficiencyee
apparentabsorptionhalflife
cea
paintolerancetime
wholebloodterminaldispositionhalflifet12
timeofpeakingtmax
serumpeaklevel
maximumrate
absorbeddosetothekidney
terminaleliminationhalflifetimet12
timetoserummethotrexatelevel
overallsurvival
minimummorphineconcentrationscmin
idml
totalmsruntime
maximalspecificbindingcapacitybmax
tmaxratio
peakacyclovirplasmalevel
vrc
minimumeffectivelevel
washin
decay
maximumeffectovertheentiresamplingphaseemax
plasmaconcentrationsatsteadystatecpss
ipf
apparentvolumeofdistributionatsteadystatevd
timetoinitialdisintegration
terminalexponentialhalflife
absolutebioavailabilitiesf
aucbrain
serumtmax
areaundertheblooddrugconcentrationtimecurve
timetomaximalconcentrationtmax
timetomaximalprolongation
initialuptakeclearance
unboundkm
maximumvenou
accumulativeurinaryexcretion
areaundertheplasmamelagatranconcentrationversustimecurve
k027
extractioneffect
basolateraltransport
apparentareavolumeofdistributionvdarea
percentageofmaximaldecline
initialeffectsiteconcentration
apparentvolumesofdistributionatsteadystate
perceiveddissolvetime
auc0tareaunderthecurve
timeelapsedtoachievemaximumplasmaconcentrationsin
peakmebendazoleconcentration
totalareaundertheplasmaconcentrationcurveauc
concentrationleadingto50occupancy
aucareaundertheconcentrationbloodcurve
cmaxpeak
urinaryrecoveryofunchangeddrug
areaunderthecurvelimitofquantificationauc0loqh
zetapotential
stableplasmatroughconcentration
peakurinarydrugconcentration
ratioofauc024
auc012750
standardizeduptake
areaundertheserumlevelversustimecurve
peakplasmacpibconcentration
hillcoefficientgamma
biliarytransittime50retentiontime
areaundertheserumconcentrationtimecurvexeliminationrateconstantaucxke
apparentbasalvalue
timefor
maximalantifactorxaantixaactivity
samplingtime
timetoattainthepeakconcentration
oralabsolutebioavailabilitie
595recoveryindexe
peakserumtheophyllineconcentration
clearanceat100bioavailability
urinaryglucoseexcretion
overallresponserateorr
peakplasmaphenylalaninelevel
timetopeakconcentrationtmax
cpsst
totalareaunderthecurveauct
unboundcl
steadystatefuraconcentration
apcl
troughconcentrationdoseratio
apparentvolumeofdistributionintheterminalphase
v3
activatedcoagulationtimedact
percentagefree
peritonealconcentrationat24hour
areaundertheplasmadrugconcentrationtimecurve
maximumwholebloodmefloquineconcentration
biologicalhalflifeofrapiddistributiont12alpha
timetoachievemaximalplasmaconcentration
dosenormalizedauc012
c0c2
ttr
auccmax
maximumnontoxicdosage
maximumee2
salivatoplasmaratio
areaundertheconcentration0to24hrcurveauc024
bloodethanol
apparentformationclearance
relativetumorgrowthratetc
similarityfactorsf2
freefractionfreetotalconcentrationratio
bloodplasmapartitioningbpratio
firstorderabsorptionka
apparentoralclearanceclf
peakwholebloodconcentrationcmax
precursorproducttransitionsmz
concentrationtoreach50ofkinactki
aucaucratio
oralbioavailability
peakplasmaketoprofenconcentration
metabolicclearancerate
totalplasmaclearancedividedbyavailability
vlambdazfatsteadystate
eliminationhalflifet12lz
apparenttotaloralclearance
controlhalflife
oraldoseclearance
constantplasmalevel
minimumeffectiveanalgesicconcentration
t75
plasmapeak
intermediaryt12
brainecfplasmaareaunderthecurveratio
timetoprogressionofbrainlesion
plasmaconcentrationcave
fractionofdoseexcretedinurine
bloodhalflifetime
serumsteadystateconcentrationscss
encapsulationefficiencypercentage
areaundertheenzymeactivitytimecurveaec
secondphaseeliminationhalflivest12beta
throughplasmalevel
hepaticextractionratioin
bioav
apparentdistributionvolumeoftheperipheralcompartmentv2
peakdose
steadystateim
serumfreec5concentration
auc036
intraoculartissueavailability
gastricresidenceperiod
kiub
timeabovethemic
apparentsteadystatevolumeofdistributionvdss
totalclearancef
hepaticinflowconcentrationscin
clearanceofunboundtemazepam
troughserumgrowthhormone
metabolicresponserate
excretedintourine
timetoreachthepeakconcentrationtmax
50inhibitionconcentration
placentaltissueplasmaconcentrationratio
cl3distributionclearance
absorptiont12
apparentcyclosporinbindingcapacitybmax
maximaltolerateddosemtd
netsecretion
fractionalcatabolicrateconstant
kalung
effectiveexposureindex
apparentfirstorderterminaleliminationhalflife
terminalphaseplasmahalflifet12b
effectivehalflifet12
ironutilizationrate
clearanceiv
tmaxtimetomaximumserumconcentration
td50
troughplasmasu0020concentration
nonrenalnonhemofiltrationclearance
tissueserumratio
areaundertheplasmaconcentrationtimecurvefromtimezerotothetimeofthelastmeasurableconcentrationauclast
bioavailabilitytrueabsorption
overallhealingrate
halfmaximumeffectec50
areasundertheinsulinconcentrationcurve
apparentvolumeofdistributionvzf1
migrationtime
clfunbound
ratiooftotaltocentraldistributionvolume
infractsize
electro
withdrawalvolume
aucsareasundertheconcentrationvstimecurve
maximumantifactorxaactivity
progressionfreesurvivalpfsrate
furconcentrationsic50s
therapeuticconcentration
extractionrecoveryrate
percentagedrugrelease
urinaryrecoveryrate
systemicleakage
maximumtransportcapacity
ischemictime
fab
tubularsecretion
dosecorrectedauc
apparentclearancerateclf
urineosmolality
timetoglucosenadir
fractionunbound
maximalconcentrationscmax
timestolossofresponse
wakingtime
massmedianaerodynamicdiametermmad
areasundertheconcentrationcurvesauc
durationofeffectiveplasmaconcentration
systemicbodyclearanceclb
effectivedose95
areaundertheconcentrationtimecurveauc06
ie
apparentvolumeofdistributionv2f
apparentdistributionvolumevz
ec80
k13
minimumdetectablequantity
relativesurvivalratesmaximalconcentrationscmaxs
braintumortissueconcentration
bbb
apparentreactionrateconstant
drugrecovery
clearanceatsteadystate
areaundertheconcentrationtimecurvefromtime0
volumeofthecentralv1f
peakatosibanconcentrationcmax
aucnoxide
areaundertheconcentrationtimecurvefrom0to24hforthefreeunboundfractionofadrugfauc024micratio
overallhalflife
bloodtoplasmaratio
peakmpconcentration
peakofloxacinlevel
areaundertheconcentrationtimecurvefrom0to2h
intercompartmentalclearanceq2f
tmaxatsteadystate
totalcumulativeurinaryexcretion
relativedoseintensityrdi
intrinsiccyclosporinclearance
maximumdegreeofinhibition
maximumurinarysodiumexcretionrate
maximalplasmalevelcmax
tct
aucmicratioauic
timetomaximalgir
standardizedmaximumconcentrationcmaxd
peaklevelinbilefluid
meltpa
peakcsfopioidconcentration
t12kle
areaundertheconcentrationversustimecurveauc0infinity
plasmaoxytocin
kpuu
maximumvenousconcentration
clearancerate
areaundertheplasmaconcentrationtimecurvefromtime0tothelastsamplingtime
t12pi
nefa
ca1
totalclearancect
firstorderrateconstantforabsorption
recoveryfromplasma
urinaryexcretionrate
apparentdistributionvolumesvdarea
biliaryexcretionclearance
conductance
maximumoralequivalentdose
freefractionff
plasmaconcentrationratio
enrichmentfactor
dissociationconstantpka
t12ofthedistributionphase
tc
apparentsystemicclearanceclf
firstphasehalflife
aucovertheentire12hdosageintervalauc012
c4
maximalgirgirmax
thalf
vdintheperipheralcompartmentv3
peaksitetoserumratio
tissuetobloodratio
apparentconcentration
maximumobservedconcentrationscmax
unboundfractionfubrain
overallextractionefficiencie
durationofthemotorresponse
timeto25recovery
maximumconcentrationsmeancmax
hepaticbioavailability1hepaticextractionratio
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityaucoinfinity
timesfor
totalcl
volumeofdistributionvt
peakvitreousconcentration
signalnoiseratio
formationrate
hydroxylationratio
unboundplasmalevel
iauc
transittimesthroughthesystemiccirculationts
mcra
vascularcardiacefficacyquotient
systemicplasmaclearance
tissueintracellularwaterpartitioncoefficient
maximumplasmatargetconcentration
aft
selectivityindicesefficacytoxicityratio
serumtequivalent
lethaldose
runtimeofanalysi
fractionofdrugabsorbed
alphahalflife
areaundertheconcentrationtimecurveextrapolatedtoinfinity
totalamountsaucpxcliv
transport
areaundertheplasmaconcentrationxtimecurveauc
dissociationhalflife
ne
t4
vrl
ivr
oralclearanceclf
excretionfractionintheurine
areasundertheplasmaconcentrationtimecurveoverthedosingintervalauc024
observedmaximumserumacvconcentrationcmax
timesuntilgirmax
areasundertheplasmaconcentrationtimecurvesauc0infinity
highestplasmaconcentration
tbw
aucinfareaunderthetimevsconcentrationcurvefrom0toinfinity
ae0t
areaunderthecurvefromzerotoinfinity
clrf
ratord
apparenthalflifeofelimination
lowestdetectionlimit
areaunderthecurvefrom0toinfinityoftheophyllineauc0infinity
clearanceperfractionabsorbed
inhibitoryquotient
rateofrelease
steadystatecerebralarterialconcentration
eliminationhalftime
acrophase
t12slow
maximumbuprenorphineplasmaconcentration
totalbodyplasmaclearance
recoveryofunchangeddrug
plateletcountnadir
0htoinfinityauc0inf
excitationemissionwavelength
peaktotalvenousdpconcentration
timetoreachthemaximum
areasundertheconcentrationvstimecurveaucmg
earlypeaklevel
fractionexcretedunchangedinurinefe
tissueratioofradioactivity
areaundertheconcentrationtimecurveauc024hour
clbcecf
plasmavolumeofdistribution
concentrationcausing50ofmaximumresponse
characteristictime
geometricmedian
mammaryuptake
normalizedsteadystateplasmaconcentration
aggregation
auczero24
cumulativeareaunderthecurve
tumorinhibitoryratetir
disappearance
eliminationhalflivest12alpha
troughplasmaconcentration
totalapparentvolumesofdistribution
leukocytenadir
timetomtxclearance
areaundertheplasmaconcentrationtimecurvefrom0htoinfinityauc0infinity
passivediffusion
timetoreachthe
naexcretion
fafg
areaunderthecurveaucfromtime0to24h
peakplasmadiclofenaclevel
maximalsafeplasmaconcentration
auc048h
halflifestabilizationtime
volumeofdistributionofcompartment2
peakclonidineconcentration
ec50nh
apparentsystemicavailability
base
0interceptbetacurveb
exponentn
areaunderconcentrationtimecurveauc024h
durationofcompleteremission
timetomaximumconcentrationtcpmax
percenturinaryexcretionofdoseue
cdw
clodoseoaucs
bileblooddistributionratio
tumoruptake
volumeofthecentralcompartmentvl
firstorderinternalizationrateconstant
peaktroughflu
inactivationconstantki
tci
maximaleliminationvelocityvmax
areaunderthescoretimecurvefrom0to8h
placentaltransferrate
survivorship
peakdetectionperiod
peakserumtriprolidineconcentration
steadystateeliminationhalflife
areaundertheinterstitialfluidconcentrationtimecurveauc
minimalviralinhibitoryconcentration
maximumvoluntaryventilation
apparentethanolvmax
plasmaip
areaunderthedxmplasmaconcentrationcurveauc
percentageentrapmentefficiencyee
sustainedplasmaconcentration
areaunderthedrugconcentrationtimecurvesauc024hr
trte
surfaceunderthethrombingenerationcurve
bodypool
extractionrecoverypercentage
ifngamma
024h
ec95
t05ab
bileplasmaconcentrationratio
auct0264
maximumdungconcentration
maximalserumlevel
auc72h
ocularclearanceqe
t1t0
proteinbound
plasmaeliminationhalflifeintheterminalphase
systemicextractionratio
areaunderthe24hoursconcentrationtimecurve
maximumplasmazonisamideconcentration
plasmaintrinsicclearanceforunbounddtzcli
maximal6mpplasmaconcentrationcmax
saturationcoefficient
ne2
surfaceundertheserumconcentrationcurve
auc096hareaunderthecurve
dauc
peakfecalconcentrationfcmax
releaserateconstant
firstorderrateconstantkeohalflife
areaunderthetimeconcentrationcurvesaucs
usal05
ke21
apparentvolumeofdistributionwasvdbeta
t12ofabsorption
maximumplasmamethadoneconcentration
minimumconcentrationcmin
plasmaic50
apparentvolumeofdistributionbodyweight
overallmeanrecovery
peakintra
timetothemaximumobservedconcentration
timefromdiagnosistohct
apparentintrinsicclearance
fractionunboundtoplasmaproteinsfu
particlediameter
distributionvolumevdf
peakplasmabudesonidelevel
maximumintracellulartumordrugconcentration
percentageofincorporationefficiency
interval
areaundertheplasmaconcentrationtimecurveaucfrom0to24hour
oralbioavailabilty
peakenrofloxacinconcentration
lc95
rateconstantofabsorptionka
totalcsfconcentration
maximumplasmalevelcmax
peakmeanserumtmpconcentration
areaundertheplasmaconcentrationtimecurvefromtime0tolastmeasuredtimeauct
tissuehalflive
tearconcentration
eliminationrateconstantlambda
eliminationconstantkel
radioactivehalflife
dosenormalizedoralbioavailability
volumeofdistributionve
dltrate
bloodtobile
kinv
logcount
activatedclottingtimeactratio
timetoreachtherapeuticconcentration
sensitivitie
terminalplasmaeliminationhalflifet12beta
smax
dosecorrectedauc06h
reabsorption
plasmaarterialalendronateconcentration
mrt0inf
t12betaeliminationhalflife
ft
areaunderthefutpconcentrationtimecurve
maximumincreaseincwaterdeltacwatermax
effective24hrenalplasmaflowerpf
ketoprofenconjugatesrratio
areasundertheconcentrationcurvesaucfrom0to12h
timetoreachmaximumobservedconcentrationcmax
clratio
auc05hr
enteralbioavailability
meanabsorptiontimesmat
clearanceofultrafiltration
sputumlevel
clbf
t0concentration
timetoobtain
timestostand
ic50pop
predosedrugconcentrationc0
steadystateauc012hplasmalevel
eliminationhalflivest12b
areaundertheplasmaconcentrationtimecurvesauc
steadystatemeanconcentration
clearanceclfpm
peakdaptomycinlevel
bioadhesiveforce
futp
trougha
ionizationconstantspkas
percentcumulativeurinaryexcretionin024hour
rc
striatalposteriorbrainratio
aucin
basallevel
terminalhalflivesofeliminationt12beta
floatingdurationtime
dosenormalizedauc04
surfaceratio
peripheralresistance
bloodtotalbodyclearance
basal
dropsize
timetopeaknifedipineconcentration
aucratioofradioactivity
abratio
maximummeanserumlevel
peripheralvolumeofdistributionv2f
areaunderthecurveauc0to48hours
i2ic50
plasmaactivitie
asbr
areaundertheanc
extracellularph
totalexcretedurinarymetabolite
peaksputumconcentration
oralfluidpeakconcentration
timeforhalfofthebioavailabledosetobeabsorbed
peakconcentrations
percentageofurinaryrecovery
areaundertheplasmaconcentrationtimecurvefrom0to25hoursauc025
vti
plasmaclearancet12
absolutelymphocytecount
la
minimumtroughserumconcentration
steadystateexposure
porevolume
conversionlevel
peakserumimiquimodconcentration
minimalczplevel
apparentinvitropartitioningratio
timetomaximumabsorptiontmax
relativebioavailabilityfr
timetomyeloid
auc15180min
plasmaconcentrationattimezero
kct
maximalplasmagsconcentrationsoccurred
overallsurvivalrate
steadystatefixtroughlevel
totalradioactivemetabolitesexcreted
areaunderthedocetaxelcurveauc0t
peakplasmamelatoninlevel
sal
minimumtroughplasmamodafinilconcentration
plasmareleasehalflife
bi
areaunderthecurveauc
areaunderthecuveauc612
ratior
clearanceclp
entrapmentyield
timeuntil50
tl201clearance
halflifefordrugrelease
biliaryrecovery
hvd
timetoreachtotal
srratioofauc
biopotency
troughimatinibconcentration
peakplasmatotaltconcentration
totalareasundertheconcentrationversustimecurvesaucs
effluxclearance
subliminaldose
eliminationphaseapparentdistributionvolumecoefficientdeltadarea
t12alphaalpha
peakrifampinconcentrationcmax
pseudofirstorderrateconstant
bonetoplasmaratio
timetopeakserumconcentration
abbc048
detectionlimit
concentrationpeak
c510h
auc0240
intestinalextractionratio
totalclearanceof1
apparent
floatingability
dispositionrateconstantalpha
tolbutamide
timetoreachthatconcentration
areaundertheplasmaconcentrationtimecurvefromzeroto12hoursauc012
recommendthroughconcentration
distributionalclearancebetweenthecentralandperipheralcompartment
concentrationrequired
relativeextractionratio
apparentphysiologicalvolumev
timetoaplateletcount
areaunderthecurvefrom0to60minafteradministration
peakperfusatemelphalanconcentration
halflifeofclearance
steadystatec
salivaplasmaquinine
drugentrapmentefficiency
centralvc
affinityka
timetostanding
plasmaunboundfraction
apparentvolumeofdistributionduringthebetaphase
esaindex
metabolitetoparentratio
overallrelativebioavailability
dosenormalizedareaundertheplasmacarboplatinconcentrationversustimecurveauc
maximumplasmabevantololconcentration
meanserumconcentration
intrinsickm
metaboliteclearance
relativebioavailabilityfa
areaunderthecurvetoinfinity
venousplasma
maximumplasmaprednisoloneconcentration
apparentabsoluteoralbioavailability
intrinsiceffluxclearance
areaundertheeffecttimecurvefrom0to24hoursaue024h
fecalexcretionrateconstant
steadystateeffectiveplasmaha
apparentterminalhalflive
peakeffectemax
analysistime
timetoachievethislevel
equilibriumplasmaconcentration
drugtargetingefficiencydte
arterialplasmanicotineconcentration
eauc50
codratio
tubularsecretionclearanceclt
kineticassociationrateconstantkon
cbf
steadystatemtxplasmaconcentration
areaunderthecurveauc06
maximalsf
timetoreachmaximumphenytoinserumconcentration
auc24hr
timefordisappearance
totalmidazolamdose
areaunderconcentration
bioavailabilityauc0360min
fur
elimination12
areaundertheconcentrationtimecurveauc24
rateconstantfromthecentraltotheperipheralcompartment
auic
minimumcsfmtx
timetopositivity
volumeofdistributionatsteadystatev
needfor
nadir
ic50ratio
distributionphaseconstantalpha
areaundertheplasmadrugconcentrationtimecurveauc
fcsf
break
peakvenousplasmalevel
timeofreturntobaseline
plasmatlevel
braintoplasmaratiokbrainplasma
areasundertheconcentrationtimecurve
vesi
marrowrequiringdose
tda
di
areaundertheconcentrationtimecurveupto24h
liverperfusateclearance
observedtimetoreachmaximumconcentration
extinctioncoefficient
log10
basedeficit
prostatetissueconcentration
systemicbodyclearancecls
areaundertheconcentrationtimecurveatsteadystate
apparentfirstorderdistributionlambda1
peakantixa
areaundertheeffecttimecurve
acuteld50
apparenthalflifeof
areaundertheplasmaconcentrationtimecurvefrom0tothelastmeasurableplasmaconcentration
timetomaximuminsulinconcentrationinserumtmax
halflifeoftheinitialphase
apparentclearanceclf1
timetopeakfev1response
alphadistributionhalflife
l1
dosebwratio
withdrawaltimewdt
timetomaximumplasmabuprenorphineconcentration
peakghbplasmaconcentration
csubmin
accumulation
apparentfirstordereliminationhalflife
areaunderthecurveaucfrom0to4h
peakpostinfusionlevel
peakbloodconcentrationcmax
areaunderserumconcentrationcurveauc08hour
urinaryoutput
percentageofunchanged
serumtheophyllineconcentrationstc
mobility
ked
m3gmorphineratio
fluidabsorption
metabolicratiompagaucmpaauc
steadystateserumtheophyllineconcentrationsstcs
areaunderthecurveauctometaboliteaucratio
plasmaclearance
ofclearance
steadystatetmax
serumtroughconcentrationctrough
csfplasmaconcentrationgradient
intrinsic
peripheralcompartmentdistributionvolume
clpou
apparentabsorptionfirstorderhalftimest12ka
plasmapeakconcentration
bonemarrow
auc054h
ratecharacteristic
unboundvpaclearance
centralnervoussystempenetration
maximumplasmamidazolamconcentration
tumorgrowthcontrolrate
inspiratoryflowrate
durationofclinicalrelaxationt125
kgst
plasmaammonialevel
formation
areaundertheplasmaconcentrationtimefrom0to48hoursauc048
areaunderthecurvefromtime0to480minutesauc0480
serumtest
halfmaximalinhibitoryconcentration
clearanceofunbounddrug
k1
v0f
plateauslilevel
acuteseriousbacterialinfectionrate
timeofthepeakplasmaconcentration
serumconcentrationscmax
infusionrate
cendofinfusion
clearanceofantixaactivity
wholebloodtoplasmadistributionratio
maximummeasuredconcentration
areaundertheplasmacurveauc096h
steadystateplasmaamrinoneconcentration
delta
peripheralcompartmentsv2
maximumtotalplasmaconcentration
cl
aucsrratio
dnox
adversereaction
vdintheperipheralcompartmentvdb
timetomaximumtotalplasmaropivacaineconcentration
peaksofplasmaconcentrationcmax
doseat
eliminationhalftimet12beta
peritonealfluidversusplasmaaucratio
troughcyclosporineconcentration
areaunderthemabplasmaconcentrationtimecurveauc07d
tgconcentration
timetmax
regressionoftolerance
bulkflowrate
timetoreachthesteadystateconcentration
fractionalextraction
cordbloodmaternalconcentrationratio
troughtopeakratiostp
noael
apparentvolumeofdistributioncorrectedforbioavailability
crystallitesize
peaklevofloxacinexposure
troughlevelatsteadystate
terminaleliminationrateconstantofunbounddrug
areaundertheplasmaconcentrationtimecurvefromtimezerotothetimeoflastquantifiableconcentrationauc0t
mzion
timetopeakserumdoxycyclineactivitytmax
percentageunbounddrugintheplasma
bloodflow
feverclearance
seruminhibitorytitre
multiple
timetomeanmaximumplasmaconcentration
overallefficacyfailurerate
timeinterval
totalapparentvolumeofdistribution
peakdialysatelevel
areaunderthetimeversusplasmaconcentrationcurve
halftimeforbzformation
totaltroughlevelttl
qf
betaaac
be
areaundertheconcentrationversustimecurveauc
maximumclearanceclmax
t4t1
clm
90fractionalabsorption
apparentoralabsorption
maternalresidencetime
maximumpainreliefscore
correctedqtqtc
metabolic
peakmaximumconcentrationcmax
bone
terminalharmonicmeanhalflife
c1h
membranepermeabilitypapp
apparentfetaleliminationhalflife
ratiooftumortoplasmaconcentration
areasundertheplasmaconcentrationtimecurveswithindosingintervalsauct
milkbloodratio
mrtins
cerebrallevel
percentrecoverie
halflivesofthecentral
90maximumeffectec90
bindingdistance
cumulativelevelofrenalexcretion
serumsteadystateconcentration
corticalboneplasmaconcentrationratio
peakexpiratoryflowrate
plasmareninactivity
peaknighttimeproductionrate
apparentvolumeofdistributionafteroraladministrationvdf
areaundertheplasmatriazolamconcentrationtimecurve
steadystatecmins
maximumseruminsulinconcentrationcmax
auctothelastmeasurableconcentrationattimet
hcg
ssowrate
conversiontime
areasundertheserumconcentrationtimecurveauc2425
cumulativedissolutionrate
articularcartilageconcentration
halflivesduringthedistributionphaset12alpha
braintoplasmaeffluxrateconstant
totalelimination
terminalt12gamma
wetdryratio
effectsiteconcentrationsces
steadystatemaximum
plasmactrough
urinary
meanreleasetime
steadystateflux
timetopatientextubation
peakbpreduction
lungretentiont12
diffusionrateconstantkie
clearancevia
unboundquinidinefraction
minimumsteadystatelevel
minimalinhibitoryconcentrationmic
dispersiontime
eg
areaunderthecurveauc144168h
igf1
halflivesforthefirstcompartment
auc060iri
tissueplasmaratioof
areaundertheconcentrationtimecurveauc0infinity
ck
areaunderthebloodconcentrationtimecurveauc024
ultrafiltrateflow
timerequiredtoreachthepeakconcentration
areaundertheconcentrationcurveauc03h
cl20
maximumabsorptionrateconstantka1max
t12z
btt12
intracellularpeakconcentration
plasmamcr6mp
maximuminactivationratekinact
drugplasmaconcentration
metabolicclearanceratemcr
areaundertheconcentrationtimecurve0168hours
thirdexponentialphasehalflife
appearanceratera
multipledoseaccumulationratio
terminaleliminationofhalflife
totalbodyclearancerate
hepaticbloodflow
hepatobiliaryclearance
faecalclearance
maximalplasmaconcentrationscmax
selectivitie
absorptionhalflivest12ka
cssplasmaconcentration
terminalhalflifeterminalt12
toplasmaratio
medianconcentration
brainuptakeclearance
maximumminimumconcentration
aaurnet
ratiosoftheareaundertheconcentrationtimecurveauctothemic
peakplasmaasalevel
maximumfoldofinductionemax
satietythreshold
molarratioof
concentration12hafterthestartofinfusioncmin
ratiosofabsorptionrateconstant
availabilitypa
tmaxpeaktime
halflifeofthesecondeliminationphase
knorketamine
clfilt
steadystateareaundertheplasmaconcentrationtimecurvefromtimezeroto24hoursauc024hss
cmaxd
alphat12alpha
parasitaemia
percentageunboundto
absorptionlagtimetlag
overallc0dose
residencemtt0last
systemictotalbodyclearancecl
uvwavelength
maximumsalivaconcentrationcsmax
areaundertheserumconcentrationtimecurvefrom024hoursauc024
hepaticextractioneh
maximuminjectiontime
thrombintime
totaldepositeddose
apparentrateofclearance
areaundertheconcentrationtimecurveauctomicratio
timetakentoreachthemaximumplasmaconcentration
areaundertheplasmarepaglinideconcentrationtimecurvefromtime0toinfinityauc0infinity
vdssf
auc120h
1ohmidazolammidazolamaucratio
precursortoproduction
timetopeakinsulinlevel
total7dayrecovery
apparentvolumeofmdistribution
areaundertheintravenouscurveauciv
proteinloading
halftimeatsteadystate
peritonealfluidtoplasmaratio
rootmeansquaredpredictionerror
volumeofdistributionvdss
halftimeofeliminationt12ke
maximumconcentrationofparacetamolcmax
volumedoublingtime
thl
releaset12
areaundertheunboundplasmaconcentrationtimeprofileofflurbiprofenaucu
maximalpbzconcentration
dtl
overallmetabolicratioatsteadystate
totalnumberof
relativetumorgrowthrate
transwellpermeabilityrate
unboundauctissuemic
timetomaximumplasmame
totaltlevel
vfratio
steadystaterecoverytime
reperfusiontime
durationsuntil25twitchrecovery
areaundertheplasmaconcentrationtimecurveauc072
dissociationconstantkss
targetconcentration
distributiont12
auc0tauauc0infinityratio
mcrrate
slowhalflife
fdet
intradialyticclearance
hepaticclearance
milkproteinbinding
absorbedselfdose
tac
ngttoigtratio
fauc024mic90ratio
overallefficacyrate
totalrecoveryofadministereddose
plasmamtx
tlu
areaundertheserumconcentrationtimecurvefromtimezerotoinfinityaucinf
fractionalcaabsorption
netultrafiltrationuf
peakbloodconcn
apparentoraldoseclearanceclf
noobservedeffectlevelnoel
muscleserum
netefflux
areaunderthecurveplasmaconcentration
concentrationcausinghalfofthemaximaleffect
transfercoefficient
timeresolution
zinccontent
alphat12
volumesofdistributionvi
maximumpossibleeffect
steadystatetransdermalabsorptionrate
areaunderthecurveauccret
50inhibitionconstant
austyn
insulinloadingcapacity
peritonealdrugconcentration
peakmeancsfconcentration
maximumobservedserumconcentration
bodyweightnormalizeddistributionvolume
firstorderabsorptionhalflive
areaunderthebaselinecorrectedserumconcentrationversustimecurvefromtime0to24hauc024
bioavailabilityauc0t
renalfractionallithiumclearance
faca
totalaucmic
areaundertheplasmadrugconcentrationversustimecurveauc024
areaundertheplasmaconcentrationversustimecurvefromtimeofdosingtotimeoflastdetectableconcentrationauc0t
auc0negativeinfinitydosebsa
peakplasmameanconcentrationcmax
relativesystemicbioavailabilitie
maximumdrugconcentrationinserumcmax
latencytimetlag
concentrationatthepeak
tminimuminhibitoryconcentrationmic
steadystatefentanylconcentration
peaksalivacocaineconcentration
clh
cpu
ratiooftumourtissuetonormalliveruptake
t12ratio
terminaleliminationhalflifet12
timeformaximumplasmaconcentrationtmax
steadystateplasmappcconcentration
urinaryexcretionratio
timetmaxtoreachthe
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityaucinf
apparentmeanbloodtotissuetransportk
peaklumbararaulevel
rs
peakdrugplasmaconcentrationcmax
systemicclearancerate
peaksteadystateplasmaphenobarbitoneconcentration
durationofinsulinactiontrlast
timeaveraged
withdrawal
effectivehalflive
plateauplasmalevel
totalplasmaticclearance
arterialhalflive
areaundertheconcentrationaucvstimeratio
timestoextubation
nethepaticglucoseuptake
normalizedcl
overalleliminationconstant
peakplasmasmvconcentration
areaundercurvefrom0to24hoursauc024hr
onsetofanalgesia
cumulativepermeationamount
druginteractionprobabilityscore
areasunderthealkaloidconcentrationtimecurvefrom0toinfinity
timepulse
concentrationat2hpostinfusionc2h
peaklevelsofdrug
dispositionhalflife
peakmtxplasmaconcentration
expiredfraction
timelagbeforeabsorption
meanoralabsorptiontime
initialin
residualradioactivity
aucs048h
cmedss
bioavailabilitiesf
timeforreachingcmaxtmax
peakserumifnlevel
auc012hh
maximuminhibitoryrate
auc03h
totalbodyclearancecltb
freefraction
weightcorrelatedapparenttotalbodyclearance
concentrationsatthetimeofbirtht0
apparentplasmaclearanceclf
maximalvelocityvmax
timeneededtoreachmaximalplasmalevel
urinerecovery24h
maximalpq
aucinfinity5hmt
progressionfreesurvivalmpfs
drugencapsulationefficiency
imcmin
aucmic24
volumesofdistributionvz
peakcodeineconcentration
areaundertheetoposideplasmaconcentrationtimecurveauc
uae
plasmaareaundercurve
areaunderthecurvefrom0hto24hauc024h
unboundcyaconcentration
cmaxsd
hepaticuptakeclearance
t12ke0
areaunderthebloodconcentrationtimecurvefromtimezeroto12hoursauc12
vssim
steadystatevolumeofdistributionvdssf
volumeofdistributionvss
urinaryrecovery
clearancesclp
percentdrugcontentdissolved
areaunderthecurveaucwithin72hauc072h
circ0
apparentvolumeofdistributionvdbeta
areaundertheplasmaconcentrationtimecurvefromzeroto24hoursauc24
pbf
maximumdrugsolubility
doseratecsstroughratio
firstdose
timetoreachthemaximalconcentrationstmax
plasmacmaxincrease
t12lambdaz
seconddistributionclearance
eliminationt12betahalflive
halflifet12l2
intrinsicclearancevmaxkm
apparentrelativevolumesofdrugdistribution
minimumplasmaconcentration
apparentdistributionvolumeofthecentralcompartmentv2f
apparentvolumeofdistributionduringterminalphase
peakplasmachlorzoxazoneconcentration
areaunderthecurvetothelastmeasurableobservationauc0t
conjugatedfreeratio
peakmilkconcentration
renalclearanceratec1r
timetoonsetofsymptomrelief
volumesofdistributionv
partialresponserate
timetocmaxtmax
deltan
faecalelimination
troughconcentrationsctrough
ratiooftheauclung
effectsiteconcentration
nitricoxideuptake
scitrcitratio
unboundoralclearancecloral
peakmic
peakimipraminebloodlevel
extrarenal
end
eliminationrateconstantbeta
tel
totalrestenosisrate
totalurinaryrecoveryofdrug
criticaltoxicsteadystatefuraplasmaconcentration
timeofpeakconcentrationtmax
maximumindividualconcentration
t12betaaftersteadystate
totalclearanceofunbound
absorptionconstantrate
fecalexcretionrate
volumesofdistributioninthecentralcompartmentv1
tumourdoxorubicin
totalsunitinibconcentration
amountofdrugabsorbed
12h
eliminationhalftimetbeta12
rateofethanoldisappearancefrombloodbetaslope
radioactivityexcreted
areaunderthemethylprednisoloneconcentrationtimecurve
absorptionhalflifet2a
kmkiratio
maximumpeakconcentration
areasundertheconcentrationtimecurvesfrom0to8hauc08
maintenancelevel
initialapparentvolumeofdistribution
reachingsystemiccirculation
timetopeakconcentrationofofloxacininserumcmax
timetofourthseizure
troughserumquinidineconcentrationsqc
ratepressureproduct
licmax
flowratesqdi
initialmaximumconcentration
overallrecoverie
fecalfatexcretion
timeaftertransplantation
timefromdiagnosistoinclusion
gtot
portalbloodflowrate
areaundertheconcentrationvstimecurvesauc
kfc
centralcompartmentvolumeofdistributionv1
peatstime
totalbodywater
terminalhalflifet12lambda2
plasmaareaundertheconcentrationtimecurve
maximaldiuresi
timetothereappearanceoftwitchresponse
timefromsugammadextorecoverytotrainoffourt4t1ratio
lagtimeofreabsorptiont
overallabsoluteoralbioavailability
basiclevel
finalelimination
overallun
maximumserumterbutalineconcentration
timetomaximumantixaactivity
minimal
rateofelimination
maximummetabolicrate
arterialoxygensaturation
timetopeakactiontpeak
eliminationrateconstantke0
dinitrateratio
steadystateghconcentration
totalbodyretention
limitofquantitationloq
distributionvolumesofthecentralcompartment
serumconcentrationratio
observedtroughconcentration
nh
asc
dv50
esct
totaldrugexposuretime
maximumserumurapidillevel
peaksitagliptinconcentration
halflifeincirculation
plasmawindow
peaktheophyllinebloodlevel
heightvelocity
peakexpiratoryflowratepefr
areaunderthecurveuntil
h1r
auc08h
lymphaticclearance
peakamplitude
timestoreachthepeakmaximum
distributionvd
steadystateserumghconcentration
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityauc0infinity
steadystatetheophyllineconcentration
unboundconcentration
24houraucratio
eiso
kapop
areaundertheplasmaconcentrationtimeprofilefromtime0to24h
clearanceofredituxtm
c6hr
peakghlevel
initialmaximum
disappearancehalflive
drugextractionratio
separationfactor
ratioauciaolaolauci
ic70
highsensitivitytroponinconcentration
serumeliminationhalflifetime
vdareaf
cerebralauc0infinityplasmaticauc0infinityratio
formationclearanceof
centrallunglevel
feo
maximumtheophyllineserumconcentration
fwh
areaundertheplasmaconcentrationtimecurvefromtimezerotothetimeofthelastmeasurableconcentrationauc0t
minimalinhibitoryconcentrationsmic90
peakplasmapczconcentration
km
tla
peakwholebloodlevel
peakplasmaglucagonlevel
current
oralec50
vesiclesizevs
halflifefortotalelimination
qtd
ctau
michaelsmenten
intrinsicclearancesclint
areaundertheserumdoxtimeconcentrationcurveauc024h
timeforsa
cldoc
terminalhalflifeofeliminationt12
apparentvolumeofdistributionbeta
maximumplasmaetoposideconcentration
eliminationclearanceclm
areaundertheconcentrationtimecurvesaucfrom0hto24h
vssratio
volumeofthereferencecompartment
distributingvolume
mz290
zeroorderdrugreleasekinetic
apparentliverbloodflow
absolutecatabolicrate
dol
dosetroughconcentrationratio
cumulativeradioactivityrecovery
tgi
peakserumcimetidineconcentration
treatmentrelatedcomplicationrate
minimuminhibitoryconcentrationmicaucmic
timetopeakbrac
timetoreachthismaximum
logd7
lexclemiss
steadystatematernalplasmalidocaineconcentration
cmaxratio
cssav
timetopeaklid
lowestdetectablelevel
timestoreachthreshold
metabolism
areasundertheinsulincurve
medianrecoverytime
minimumtransportarea
maximumsteadystatedrugconcentration
ratioofaucmilkplasma
t12el
peaksputumlevel
areaunderthecurveirinotecanareaunderthecurveratio
plasmaeliminationhalflifelambdazhalflife
maximalrelativeefficacyemax
kem
relativebioavailabilityfrel
relativebioavailiability
areaundertheconcentrationtimecurvefromtimezeroextrapolatedtoinfinityauc0
timepointofmaximumplasmaconcentrationtp
initialenhancementrateer
tconcentration
trough55
vg
peakplasmapggconcentrationscmax
durationofretention
secondphasehalflive
adjusted
fractionmetabolism
fractionofdrugexcretedunchangedfu
auc060pd
fractionalinhibitoryconcentrationindex
trainoffour
biotransformationratio
ratioofmeanresidencetime
spo2
effecthalftime
timetonearcompleterecovery
terminaldispositionhalflifet12lambdaz
areasundertheconcentrationtimecurvefromtimezerotoinfinity
timesofformation
peakarterialwholebloodconcentration
gastricemptyinghalftime
peakplasmabyl719
totalareaundertheserumconcentrationvstimecurve
steadystatetotalplasmaclearance
bindingconstant
areaundertheplasmaconcentrationtimecurveauc072h
steadystateplasmaconcentrationratio
peakbloodpbconcentration
areaunderthecurvefor024hour
doseinducinghalfmaximalresponse
p450
slowabsorptionhalflife
peakresponse
areaundertheplasmaconcentrationtimecurvefrom0to9hour
durationofsensory
w
timetakentoreachmaximumplasmaconcentration
relativeeliminationhalflifet12re
dispositionrateconstantbeta
totalcumulativeexcretion
peaknighttimeacylatedghrelinconcentration
aucfree09
clcr
halfdisappearancetime
systemicclearancecl
overalllevel
wobble
lungconcentration
betaexcretionrateconstant
areaundertheplasmaconcentrationtimecurvesto8hauc08
plasmahalflifeofeliminationt12beta
areaundertheconcentrationtimecurvefor0toinfinityauc0infinity
rateofhospitalizationsdue
totalamountofofloxacinexcretedinurine
insulin
apparentpermeabilitycoefficientspapp
tclr
oralld50
reversionmultiple
maximalplasmaphenobarbitalconcentration
vascularinterstitialpermeabilitysurfaceareaproduct
bioavailabilityf
peakplasmaeacaconcentration
biliaryelimination
peakabsorption
fecalelimination
entra
auc
terminalclearancerateconstantkt
pro
drugloadingcontent
c24
halflifeelimination
overallventilatoryresponse
alphahalftimet12alpha
volumeofcsfdistribution
circulationhalflife
areasunderthemiso
peakipplasmaratio
cmax3
apparentvolumesofdistributionduringthebetaphasevdbeta
prostatebloodratio
areaundercurveauc0clampend
brainhalflive
areaundertheconcentrationcurvefrom0to12hauc012
steadystateplasmaconcentrationcpss
maximumcefiximeconcentration
totalclearancecltot
ess
concentrationtimemaximum
t24
fastingplasmaconcentration
maintainplasmaconcentration
milkplasmaratio
relativevolumeofdistributiondelta
steadystatefuraplasmaconcentration
observed
maximumbiliaryconcentration
lo
terminalhalflifeeliminationt12
auc48
timetomaximumplasmaconcentrationafteroraladministrationtmax
liverclearance
unboundrenalclearance
mucoadhesivestrength
embryomaternalplasmaratio
maximalconcentrationsinplasmacmax
steadystatefetalarterialplasmaindometacinconcentration
peakconcentrationinbilefluid
overalleliminationrateconstantlambdaz
totalsteadystateconcentration
peakplasmaaracconcentration
clrate
volumeofdistributionduringthebetaphasevbeta
urinaryelimination
minimumabsoluterecoverypercentage
cerebraldistributionvolume
dosenormalisedauc04h
terminalvolumeofdistributionvz
bioconcentrationfactor
slopeofthelinearconcentrationresponserelationship
pdb
linearclearancecl
areaundertheconcentrationtimecurvefrom0to24hauc024
availabilityinserum
durationofseverepain
fllc12
distributionphasehalflifet12alpha
apparentsteadystatecondition
drugpayload
50inhibitoryconcentration
c10
apparentfirstorderintercompartmentaltransferrateconstantsk10
rateofdelivery
kob
recoveryscore
areaunderthecurvefrom0to72hauc072
minimaldetectablelevel
relativemobilitiesmr
firstphaset12
bioavailabilityforal
lowerlimitofdetectionlod
areaunderlocalconcentrationtimecurve
ratesofdecay
maximal
bioavailabilityaucoralauc
apparentvolumeofdistributionatasteadystatevdss
minimumplasmaticconcentration
auc071hratio
systemicbodyclearance
firstcmaxpeakcmax04
aucauc
catalyticefficienciesforp
mdt
overallclinicalsuccessrate
totalurinary
troughpasireotideconcentration
uppertherapeuticplasmaconcentration
pumpflow
terminaleliminationphasezido
c0atasteadystate
maximumintraocularpressureiop
brainrecoverie
auc021d
alphaphasedistributionhalflife
absoluteurinaryexcretionofsodium
halflivesofexcretion
michaelmentenconstantofthetubularsecretionmechanismkt
ovulationrate
areaunderthetimeconcentrationcurveovertheentire12hrdosageintervalauc012
minimalurinesodiumconcentration
steadystateconcentrationcs
areaundertheplasmaconcentrationtimecurve024h
renalexcretionrate
overallurinaryexcretion
relativephysiologicalavailabilitie
overallremissionrate
auto
infusionraterequirementstoachieve90musclerelaxation
areaundertheplasmaconcentrationtimecurveaucfromadministrationtothelastobservedconcentrationtimetauct
minimumtotalvolume
areaundertheconcentrationtimecurvewithinadosingintervaloftauct
firstpasselimination
seriousinfectionrate
totalplasmabupivacaineconcentration
eliminationhalflifevaluest12beta
apparentserumt12beta
clast
steadystateperfusateconcentrationproducinghalftheeffectc50
ofp
peripheralcompartmentvd
peaktroughconcentration
intercompartmentalclearanceafteroraladministrationqf
tissuebloodconcentrationsratio
fauc012
biliaryexcretionrateconstant
absorptionhalflifet12k
slowhalflive
mae
fractionalclearancerate
jmax
rbc
prothrombintime
freedrug
peakarteriallevel
drugdeliveryindex
radiationabsorbeddose
recoveryof3hradioactivity
peakplasmaotcconcentration
timecorrectedauc
maximumplasmaindometacinconcentration
potentialtp
halflethaldose
volumeofdistributionduringtheeliminationphasevdb
apparentabsorptionrateconstant
peakribavirinlevel
totalbodyclearanceofdigitoxincltot
apparenteliminationhalflive
timetoneutrophilreconstitution
maximumvolumevmax
cerebrospinalfluidtoplasmaratio
totalmeanclearance
tmsw
strl
timeto50ccr5receptoroccupancy
maximumexcretionrateddudtmax
immunoreactiveinsulinconcentration
initialphasehalflifet12alpha
sauc
betaphaseeliminationhalflife
aucrraucssratio
plasmaconcentrationat12hc12
timefromstartingtheinfusionpumptosteadystateflow
tumourarea
absolutesubcutaneousbioavailability
totalsystemicplasmaclearance
fractionaloralbioavailabilityf
peakfev1
troughconcentrationc0
cib
aucsub0tlast
fpc
minimumplasmaconcentrationcmin
time0tsh
netdialysisclearance
minimalinhibitoryconcentration
bodyclearancerate
totalbodyexposure
apparentdistributionvolumeofthecentralcompartmentv1
elap
phy
percentageconjugation
highestconcentration
adversereactionrate
enhancementratioer
tissueperfusionliquidratio
fraction
cmaxfor
totalareaundercurve
peakarterialplasmaconcentration
endofinfusionplasmaconcentration
noobservedadverseeffectlevel
ic80
equilibriumhalflife
auc0tmax
maximumrelativebioavailability
halflifeatbetaeliminationphase
maximumdeltat
t12ofrapiddistribution
distribution
terminaleliminationphasehalflifet12beta
aucminimuminhibitoryconcentrationmic
areaundertheconcentrationtimecurveauc0t
unboundpeakplasmaconcentration
bioavailabilityaucratio
terminaldistributionvolumevz
serumconcentrationj14
areaundertheplasmaconcentrationtimecurve0270min
absorptiontime
cl1f
troughlevelbeforethedosec0
auc012h
vcf
tenminuteplasmarecovery
volumeoftissuecompartment
volumeofdistributiondividedbyavailability
timeneededtoreachthi
fluxe
topicalabsorption
steadystatequinineplasmaconcentration
ratioauctonsilaucplasma
delayedreleasetime
peaksystemictnfalphalevel
tissuelevel
apparentoralclearanceclo
distributionvc
maximumnatriureticeffect
protection
salivaplasmaaucratio
serumstability
cl1systemicclearance
absoluteextractionefficiencie
emergencetimesfromsedation
peakleveltmax
maximalaptt
steadystateplasmapiroxicamconcentration
maximumclpinhibitionimax
nethb
totaligg
latencytoeffect
ratioofaucmorphineauccodeine
maximumeffectemax
maximumdurationofeffect
steadystatemaximumserumconcentration
insulintmax
kelco2eliminationrateconstantofco2
peakconcentrationininflammatoryfluid
steadystatetarget
peripheralvolumesofdistributionv2
volumeofdistributionduringsteadystate
ma68
maximumplasmafpconcentrationcmax
caverage
maximumplasmafentanylconcentration
areasundertheplasmaconcentrationvstimecurvesauc010days
areasundertheconcentrationtimecurvesfromtimezerotothetimeofthelast
halftimet12keo
kidney
areaunderthecurve090
timetoinduction
apparentauc
steadystateplasmatpaclearance
areasundertherespectiveconcentrationvstimecurvesauc
firsttramadolconcentration
c2doseratio
spontaneousrecoveryoft1t0
apparentunboundclearance
minimaltherapeuticconcentration
drugexposureauc024
areaundertheserumfamotidineconcentrationtimecurveupto10hour
totalrenalexcretion
dfi
totalbloodclearancecltotal
kaalpharelationship
braintoblood
overallratesofhealing
metabolichalflife
auc012ratio
throughconcentration
sba
thermalthresholdlatency
halflifet05
ktr
peakserumgentamicinlevel
fecal
recyclingeventtime
timetoreachmaximumplasmaconcentration
areaundertheplasmaconcentrationtimecurveforthedosingintervalauctau
percentagetransmittance
systemicdoseabsorbed
unbounddrugconcentration
hemoperfusionclearance
apparentifngammaclearance
disintegrationdissolutiontime
cxtratio
betahalflivesofelimination
rateconstantfromtheperipheralcompartmenttothecentralcompartmentkpc
maximumconcentrationofdrug
formula
peaktherapeuticserumconcentration
timetoconversion
midpoint
areaundertheconcentrationtimecurve024h
pappab
aucoptimized
areaundertheserumconcentrationtimecurveauc024h
minimumserumtheophyllineconcentrationsatsteadystate
apparenthalfliferemoval
peakiri
minimuminjectionvolume
peakprl
areasunderthecurvefromtime0to360h
peakamitriptylineplasmaconcentration
relativepotencyratio
distributionclearancebetweencentraland2ndcompartment
areasundermisoprostolconcentrationversustimecurvesupto5h
minimumvalproicacidconcentration
maximumcycloguanilconcentration
steadystatevdss
timeintervalofmaximalp
entrapment
knal
areaunderthecurvefromtimezerototimeoflastquantifiableconcentrationauc0t
volumesofdistributionvd
logd
auc112
mpf
peakbal
vmaxsu
durationofsedation
pd12
peakbactericidaltiter
logbb
fractionalzincabsorption
concentrationsat30minutesc05h
threshold
essmax
milktoplasmaratiosmp
troughocconcentration
transittime
aucs024
differentialtransportrate
ratioofsystemicunboundconcentration
timetosputumcultureconversion
regenerationrate
areaunderthetimeconcentrationcurveupto6hafterdoseauc06
minimumeffectivecsfclonidineconcentration
c2micratio
timeto90emptying
leadintime
phasetransitiontemperature
timetoreachumaxtmax
hourlyeliminationrate
timetopeakplasmamoricizineconcentration
aucmilktoaucserumratio
renalalclearance
peakserumdrugconcentrationcmax
feverclearancetime
maximalanti
peaktroughfluctuationinthesteadystate
vmaxxv
vmaxsec
dispositionratealpha
onsetofsensory
renalcortexplasmaconcentrationratio
renaldigoxinclearance
kpuucsf0360
cumulativeurineexcretionpercentage
auc0infinityareaundertheconcentrationtimecurve
totalnonspecificbindingratio
miosi
lossinurine
minimumconcentrationmic
evltroughlevel
plasmamagnesiumconcentration
peakseruminterferonconcentration
dg
timetopeaktmax
plasmaexposureaucinf
troughpeakdbpratio
criticalcytotoxicconcentration
absoluteoralbioavailibility
dosenormalizedc
maximumplasmaheparinactivitiescmax
maximumreductionemax
kep
influxconstant
c20tmic
clclearance
peakplasmahmbconcentration
alphaphase
apparentdistributionvolume
c12h
intracellulartoplasmaconcentrationratio
overalltimestodiseaseprogression
timetopeakgamelocytaemia
plasmahalflifebetaphase
totalbodyclearancesclb
bio
aucsfromtime0totheendofthedosingintervaltauauc0tau
timetoanabsoluteneutrophilcount
rapidphase
biliaryconcentration
maximaldiazepamconcentration
timeatwhichmaximalconcentration
renaloxypurinolclearance
absoluteoralbioavalabilityf
areaunderthecurveduringthefirst60minauc60
retentionvolume
maximumplasmaoxycodoneconcentration
maximumserumconcentrationtotroughconcentrationratio
fluctuationindice
annualisedspontaneousbleedingrate
eliminationrateconstant
clearancecirate
auc0144h
serumoralclearance
timerequiredtoreachmaximumplasmaconcentration
absoluteretentiontime
distributionhalftime
swellingindex
t3productionrate
halflivesoftheterminaleliminationphase
sspc
papp
auc42hours
firstordereliminationconstant
maximumdrugplasmaconcentration
apparentfirstorderterminaleliminationrateconstantbeta
recoveryfromurine
timetotreatmentresponse
firstpassuptake
troughpriortovblinjection
latet50
areasunderthecurvefromthetimeofdosingtothelastmeasurableconcentrationauc0t
timetoreachcssmaxtmax
areaundertheconcentrationtimecurvefromzerotolastmeasurableconcentration
relativeextentsofabsorptionfrel
areaunderthecurvefrom08hoursauc08
pao2
minimumserumconcentration
chighmic
volumeofdistributionareamethodvdarea
eliminationt05elphase
fractionofdepositeddose
areaundertheconcentrationtimecurvefrom0to48hour
minimalinhibitoryconcentrationmic90
clearanceclfss
beta
halflifeofthefirstdispositionphaset12alpha
intestinalavailability
peakconcentrationofdruginplasmacmax
concentrationinserumcmax
rateofplasmaclearance
aucsub
concentrationc0h
cd4cd8ratio
mz281
tumourfoci
areaunderthecurveinfaucinf
maximallytolerateddosemtd
centralvolumev2foral
aucareaunderthecurveratio
serummorphineconcentration
peakvenousplasmaconcentration
percentbiliaryexcretion
timeofendofaction
terminalhalflife
auc048ratio
auc0tausst
maximumbusulfanconcentration
isolationtime
steadystateplasmalevelscss
minimalinhibitoryconcentrationsmics
synthesisrate
peakplasmaconcentrationscmax
concentrationofradioactivity
plasmadistributionhalflife
halflivesofthebiexponentialeliminationt12alpha
maximalventricularcsfapomorphineconcentration
areaundertheconcentrationversustimecurveuptothelastmeasuredpointintimeauc0t
halfmaximumconcentrationec50
absoluteoralavailability
troughconcentrationcminss
timetomaximaltemperaturereduction
overall50
percentofheroinexcretedintourinea
transferof
plasmatobloodcellconcentrationratio
maximumtissuepressure
maximalplasmabiperidenconcentration
aucareaundertheplotofconcentrationagainsttime
peakplasmaganciclovirconcentration
fractionabsorbedf1
tubularmaximumtm
aucfromtime0toinfinityaucex
totalexcretionrecovery
aucratiosaucperitonealfluidaucplasma
fractionunbounddrug
totalmetabolicclearancecltbw
d
peakmilrinoneconcentration
sloweliminationphase
cumulativerenalelimination
auc240480
renalclearanceofdrug
halflifeinthecirculation
vd2
extentofbiologicalavailabilityeba
t01
csfplasmaratio
kmsec
rateofethanoleliminationfromblood
minimumplasmasaconcentration
maximalcsfplasmaconcentrationratio
areaunderthetimeconcentrationcurvefromdosinguntil24hpostdoseauc024
maximumpeakplasmaconcentrationppc
plasmaeliminationhalflive
halflifet12lz
steadystaterelease
maximummdmaconcentrationscmax
fractionofbounddrug
alphahalflifet12alpha
systemicexposure
t12ofdistribution
terminaleliminationphase
2ndperipheralcompartmentvolume
po2
peakserumhydroxyzineconcentration
areaundertheplasmaconcentrationtimecurveoveradosingintervalatthesteadystateaucss
lymphatictransport
netlosse
biologicalhalflifeofgammaphase
ce
apparentvolumeofdistributionrelatedtoweightv
cerebrospinalfluidtroughconcentration
fractionalrenalexcretion
enter
sstroughs
peaktriamtereneconcentration
ca
mpcsmicmpc
maximalttratio
intrinsicabilityclin
timeto50recoveryofeffectt12offset
troughplasmaconcentrationc0
timeofoccurrence
totalaucmicratio
apparentkidose
t12inversion
rp2d
tumortobloodtbboronratio
areaundertheplasmaconcentrationtimeprofilesauc0last
octanolwaterpartitioncoefficient
effecthalflife
renalquinidineclearance
mtdlevel
capacity
apoptosisindex
bbrcorr
totalactivecompound
apparentvolumedistributioninterminalphase
areasunderthecurvesaucs
diffusionexponent
maximalsverapamilconcentration
steadystateareaunderthecurveauc
firstorderabsorptionkir
betaplasmahalflive
apparentterminalhalflifet12z
inductiontime
steadystateplasmabaconcentration
diuresisatsteadystate
meanresidencetimemrt048
auc0120
halflifeduringtheeliminationphase
timetopeakinsulinconcentrationtmax
timerequiredtoachievegoodpaincontrol
entrappedefficiency
clearanceassociatedwithmaternalfetaltransferofthedrugcldf
048h
oralclearancebioavailabilityclf
totalclearanceofpclt
areaunderthebloodconcentrationvstimecurveauc
timetothesteadystate
areaunderconcentrationtimecurvemicratiosauc024hmic
osmolarity
arterialt12
apparentrateofelimination
peakcycloguanilconcentration
ec50concentrationrequiredfor50inhibition
milktoserumconcentrationratio
apparentvolumeofdistributionv
auc0168h
totalamountofmorphineexcretedinurine
totalintrinsicclearance
combinationkillslope
pancreastoliverratio
cgmaxss
criticalaggregationconcentrationcac
maximumseruminsulincmaxins
bactericidalindex
drugloadingcapacity
peakclearance
maximumconcentrationinserumcmax
concentrationelicitinghalfofemaxec50
hepaticflow
cpeekpeakplasmaconcentration
intracellularaccumulation
areaundertheplasmaconcentrationtimecurveauc24h
peakplasmaticconcentration
mrto50
maximalurinaryexcretion
cmaxcl
apparenteliminationhalflifetl2beta
halflifeateliminationphase
avb
halflifeofeffectdelay
auc0tz
plasmaareaunderthesubstrateconcentrationtimecurveauc0infinity
glasstransitiontemperature
weightnormalisedrenalclearance
ss
uge
tissueplasmapartitioncoefficientkp
initialmaximalrenalclearance
steadystateoralclearance
excretedwaterfraction
maximumserumconcentrationnormalizedfordosecmaxd
orderofassociationconstantk
upip012h
terminalhalflivest11
excretionconstant
steadystatepredoseserumconcentration
ve50
troughconcentrationctroughatsteadystate
peakmeanplasmacysteamineconcentration
volumeofdistributionv1clearancecl
volumevss
steadystatetrougherlotinibplasmaconcentration
halfinhibitoryconcentration
minimumsteadystateconcentration
apparentvolumeofdistributionof
areaundertheplasmaconcentrationversustimecurveauc0infinity
cl1353h
criticalmicellarconcentration
distributionvolumesatsteadystate
t12gammaelimination
maximalbioavailability
clearancebyultrafiltration
steadystateplasmadigoxinconcentration
clearanceg
firstpasslo
rateofproduction
nonprogressionrate
netextraction
timetoloc
elfplasmaratio
fbl
effectclearancesclmiosis
oralintravenousavailabilityratio
qtinterval
removalrateconstant
areaunderthecurveoftheconcentrationtimeprofilefromtimezerotoinfinityauc0
clearancerelativetobioavailability
clother
phasichalflive
absorptionmeantransittime
ctroughplasmaconcentration
steadystateinputrate
temporalresolution
maximalvelocityofelimination
distributionvolumel
teac
peakprobenecidlevel
bmax1
volumeofdistributionofcompartment
areaunderthekillcurveaukc
steadystatetargetconcentration
cohpxsscpxss
dnadecline
troughconcentrationc24
dosenormal
deformability
aucoaucpplasma
areaunderthedipyridamoleconcentrationtimecurvefrom04hour
extractionratioer
minimumtherapeuticserumconcentration
baroreflexsensitivity
systemicor
amountabsorbed
maximumparacetamolplasmaconcentrationscmax
maximumreduction
infusionrequirement
meanresidencetimet12
auctablet
maximumplasmaprazosinconcentration
finalamount
bloodeliminationhalflive
areaundertimeconcentrationcurveforibuprofenauc0360
minimumlopinavirconcentration
totalplasmaclearanceofthe
auc5fu
areaundertheserumdigoxinconcentrationcurve
totalbodyclearanceincrease
halflifet12lambdaz
pt
totalbodyclearancecorrectedforweightclw
overallabsolute
diseasefreesurvival
maximalbloodplasmaconcentration
effectt12
tmic
finalrate
localregionalcontrolrate
areaunderthecurvevaluesfor72hoursauc072
volumeofdistributionperkilo
dosecorrected
ctroughlevel
nonrenalclearancerate
percentageofpenetration
peakplasmaconcentrationoffentanylcmax
overallsystemicbioavailability
maximumconcentrationscmaxs
ket
serumdiazepamlevel
lambdaem
areaunderthetotalmtxconcentrationvstimecurve
fl
unboundvolumeofdistributionatsteadystatevssu
timefor90tobeabsorbedt90
reabsorptionfractionfb
percentmaximuminhibition
clearancesbioavailabilitycl1f
urinetofecesratio
clearancehalflive
systemicvolumeofdistribution
areasunderthecurveof
tumordrugconcentration
volumeofdistributionvdzf
volumeofdistributionatthesteadystatevss
areaunderthecurvefromday0to2auc02day
baselineclearance
areaundertheplasmaconcentrationtimecurveaucfromtime0toinfinityauc
volumeofdistributionss
apparenthepaticbloodclearance
totalgasflow
maximumfrequency
ce50bi
aucfrom0to24hoursauc24h
unboundplasmaclearance
timetoreachmaximalplasmaconcentration
peakplasmafreeinsulinlevel
volumeofdistributionvdatsteadystate
initialdistributionhalftime
timestmax
meanresidencetimeinthebodymrt
maximumdailydosage
stor
dc0dt
phpeakactivity
cytroughlevel
maximumcidofovirplasmaconcentration
lipemia
orallybioavailable
volumesofdistributionvbeta
amtoplasmaratio
totalapparentvolumeofdistributionvdbeta
ti
lengthofeffectiveanalgesia
dosenormalizedsteadystateconcentration
serumtroughconcentration
four
tbl
dcmax
formationhalflife
totalbodyclearancesclt
areaundertheplasmaconcentrationtimecurvefromtimezeroto480minauc0480
areaundertheconcentrationtimecurvewithextrapolationtoinfinityauc0inf
circulatinghalflive
areaunderthebloodconcentrationtimecurve0t
fractionsunbound
areaunderthecurveauc024h
timetorecoverto50ofmaximaltwitchdepression
unbound24h
transitrateconstant
maximalplasmaconcentrationcbmax
totalareaunderthecurveauc
peakmedianplasmabismuthconcentration
areaundertheconcentrationtimecurvefrom0to24hauc024h
mm6gratio
plasmaaucmic
vf
halfsaturationconstantkd
volumeofdistributioninthecentralcompartment
percentagef
tubulartransportmaximumtm
bloodconcentrationatsteadystate
apparentoralmpaclearanceclf
affinityconstantkm
peaknonfastinglevel
clearancefractionofquinineconverted
peaktime
amountexcreted
areaundertheeffectversustimecurve
totalmcd
constanttargetplasmaalfentanilconcentration
steadystatemtxconcentration
aucsub024h
k
t12terminalhalflifeinplasmaatsteadystate
maximalplasmaexposure
cumulativemexcretion
areaundertheplasmacotinineconcentrationtimecurvefrom0to8hour
distributionalpha
apparentfirstorderhalflive
rateconstantoftransport
durationsofeffect
minimumauic
timetoplasmapeaktmax
steadystatetroughplasmaitraconazoleconcentration
clmi
maximumplasmagabapentinconcentration
plasmapeakdrugconcentration
peaklumbarconcentration
bwt6096
tissuetoplasmapartitioncoefficientskpt
auc045h
steadystateserumconcentrationsoforaldigoxinauc024zeta
globulesize
visualantimode
printerval
peaktroughfluctuation
daparatio
maximumsystemicconcentration
auc0192
ratiosoffluorescence
mfdratio
renalclearancec1r
steadystateplasmaconcentrationcss
apparentsteadystateplasmalevel
areaunderthecurveofbrainconcentration
aucdn
dosenormalisedauc
onsetofneuromuscularblockade
apparentfirstorderhalflife
auc060min
numberofseizure
microbialkill
apparentvolumeofdistributionvs
aucratioaucperitonealfluidaucplasma
areaundertheplasmaconcentrationtimecurvefrom0to24hour
associationconstantk
wholebodyturnovertime
peripheralconcentration
peakquininelevel
spanfactor
serumtroughto
ka
chemicalhalflife
halfmaximaldiuresi
serumrobenacoxibconcentrationat240minc240
totalapparentvolumeofdistributionvdf
tumornormalbladderratio
sfserumconcentrationratio
intracellularhalflife
sct12
areasundertheconcentrationtimecurvefromtime0extrapolatedtoinfinityauczeroinfinity
distributionvolumeofcortisolatsteadystatevdss
of
plasmapeaktime
totalclerance
timetakentoachievemeanpeakplasmaconcentrationtmax
concentrationpeaktime
cmaxtmax
timetoreachmaximumplasmaconcentrationtmax
apparentt12lambdaz
maximumconcentrationcmax
timerequiredtoreachthemaximumplasmaetoposideconcentration
urinetoplasmapara
apparentvolumeofdistributionduringtheterminaleliminationphase
tmaxtimetomaximumconcentrationofdruginserum
set
cbccecf
areaunderplasmaconcentrationtimecurveaucratio
halflifet12ofelimination
auc0105
meanresidencetime
eliminationhalflifefromserum
observedclearance
minimum
inactivationrate
clintu
auc3d
timetotheonsetofmotorblock
peripheralcompartment
ccsf0nor
areaundertheconcentrationtimecurvefrom024hauc024
adhesiontime
50maximumplasmaconcentration
steadystatedcconcentration
overallobjectiveresponserate
fot
bphase
totalplasmaaucareaundertheplasmadecaycurve
timetoreperfusion
urinaryosmolality
exposureauc
plasmaredbloodcellconcentrationratio
availableenergy
oct
recoveryefficiency
eliminationconstantfromtheplasmakelim
fractionexcretion
biologicalhalflifet12beta
timeoftheconcentrationmaximumtmax
plasmanaconcentration
maximumrateofeliminationvmax
maximumserumbromideconcentration
portion
unboundtroughconcentration
ironbioavailability
maximumdexmedetomidineinfusiondose
kdiss
areaundertheconcentrationtimecurvefromtimezerotoinfinityauc
timetoreachthemaximumplasmaconcentrationstmax
areaunderthecurve03h
halftimeofthesecondexponentialt212
entrapmentefficiencyee
concentrationratioswwwv
peakduration
auc024micratio
totalbodyt12
volumeofthecentralcompartmentvplasmatissuefluids
flankratio
maximalinactivationrateconstantskinact
t12terminaleliminationhalflife
cfucount
secondperipheralcompartmentvolume
dosecorrectedconcentration
glucosaminelevel
peakno2level
steadystateplasmalevelsc
steadystatedistributionvolumevd
plasmaclearancecltar
ratioofconjugationdeconjugationrateconstant
braintoplasmaratiokp
urineoutput
oadh
topeakplasmalevelscmax
urinarymetabolicratiomr
steadystatevolumesofdistribution
standarduptakevaluessuvs
peakplasmappalevel
timetaken
peakplasmachloroquineconcentration
fractionofthedrugavailable
maximumdrugconcentration
areasundertheconcentrationtimecurveauc0
ultrafiltrateplasmaplatinumconcentration
auco4
alphahalflifeofdistribution
log
areaundertheconcentrationtimecurveauc48
plasmaconcentrationyielding50inhibitionc50
weightcorrecteddose
tmaxdcmi
apparentpkb
aortatoplasmaratio
peakserumitraconazoleconcentration
lowinhibitoryconcentrationic50
steadystateauc28
targetattainmentrate
annualbleedrate
clearancecl1
totalplasmaconcentration
fluctuationindexfi
inputrateconstant
aucachieving50ofthemaximumeffecteauc50
timetopeakplasmaconcentrationtmax
troughlevel
respiratoryrate
secondmaximum
ktvurea
maximumprednisoloneconcentration
mic50
maximumprednisoneconcentration
meantime
areaundertheconcentrationcurve
maximumdiltiazemconcentration
carrsindex
rateconstantfromthecentraltoperipheralcompartment
ffractionabsorbed
areasunderthetimeconcentrationcurvebetween0and12hoursauc012h
partition
peakmaximalconcentration
eliminationrateconstantkef
areaundertheace
maximumloadingcontent
motilityindex
areaundertheplasmaconcentrationtimecurvefromthetimeofdosingto12hourspostdoseauc12
withdrawtime
lastmeasurabletime
areaunderthetriazolamconcentrationtimecurve
fractionofacebutololunboundtoplasmaprotein
ni
troughvaluec0
c30
effectivebloodhalflife
auc0mrt
degradationt12
totalapparentvolumeofdistributionatsteadystate
basalendogenousreleaserateclearancex
cmaxc
digitalcompressiontime
serummidazolamconcentration
mma
braintoplasmaexposureratio
plasmamaximalconcentrationcpmax
timeatwhichpeakconcentrationsoccurred
critical
disappearancet12
drugreleaserateconstant
t12a2
mediummaintenanceresidualrate
maximuminfusionrate
halftimeofblockade
contentuniformity
flowratethroughthesystem
areaundercurveauc060
susceptibilityrate
impulseresponsefunction
renalclearancefromblood
timetoreachpeaktmax
vd3
cmaxss
steadystatealprenololconcentration
timetoreachthemaximalplasmaconcentration
aucelftoaucuplasmaratio
eliminationhalflifetv2lz
apparentvolumeofdistributionvarea
maximaplasmaconcentration
amountexcretedunchanged
steadystatemetoclopramideconcentrationmcpss
peakplasmacaffeineconcentration
kineticconstant
terminalhalflifeofelimination
areaundertheplasmaconcentrationtimecurveaucat
apparentclearanceclmfm
totalchroma
quantificationlimitloq
maximumbloodconccmax
volumeofthecentralcompartmentbioavailability
relativeclearancerate
normalizedrate
peripheralcompartmentv2
peakconcentrationtime
steadystateratio
aucuptoinfinity
el
turnoverrate
targetplasmaconcentrationcpt
timetopeakconcentrationtmaxss
eliminationrate
halfthekinactkiapp
firstdistributionhalflife
plasmapelvictosystemicexposureratio
cbr
auc0tcfauc0tefratio
glucoseinfusionrategir
reserve
terminaleliminationhalflivest12beta
apparenttotalclearancecltf
areaundertheplasmaconcentrationtimecurveauc036
peakurineelimination
rateoftransdermaldelivery
maximaltimetmax
brainbodyexposureratio
maximumcsfmorphineconcentration
auc016h
steadystateplasmaconcentrationcssavg
plasmadrugconcentrationcmax
lifespan
overalleliminationhalflifet12
serumhalftime
areaundertheconcentrationtimecurveaucdose
absorptiveclearance
timestocmax
areaunderthecurveauc024
limitsofdetectionslods
metabolicstabilityt12
initialplasmaclearance
areaundertheplasmaconcentrationtimecurvefromtimezerototimetauct
hydrolysishalflive
initialplasmaeliminationhalflife
penetrationcoefficient
sensitivityofdetection
pc20
urinarysodiumexcretion
aucliver
plasmabioavailabilitiesauc
peakdimesnaconcentration
ta
peakpregabalinconcentration
areaunderthecurveuptothetimecorrespondingtothelastmeasurableconcentrationauc0tlast
rpredob
absorptionhalflifet12ab
freepercentage
rect
peaknadololconcentration
peakplasmacocaineconcentration
sloweliminationhalflife
tumoridg
timewhenplasmaconcentration
observedclearanceclf
vdpf
healthassessmentquestionnairedisabilityindex
samplepreparationtime
peakconcentrationsinbile
benefitindex
halflivesofhepaticuptake
areasundertheconcentrationversustimecurvesaucs
percentageunbound
oralfluidtoserumratio
terminaleliminationhalfline
volumeofdistributionofthemetabolitecompartment
phvalue
clearanceratiorenalclearanceglomerularfiltrationrate
steadystatecnsfreeplasmaratio
doseadjustedtroughcyclosporinebloodconcentration
nonrenalclearanceclnr
concentrationsratio
peakserumantibodyconcentration
kapp
secondary
peaktumorconcentration
apparentequilibriumbindingconstantkivalue
resolution
beta1beta2selectivity
effectiveconcentrationfor50maximaleffect
timetoreachgirmax
areaunderthecurvefrom0to24h
intrinsicformationclearanceclf
serumdrugconcentration
biliaryexcretionconstant
steadypeakconcentration
plasmaclearancerateclp
intercompartmentclearancesq2
peakplasmaenrichmentlevel
apparentvolumeofdistributionvb
fractionabsorbedfa
minimalquantifiableconcentration
tpratio
urinet12beta
maximumadsorption
plasmaareaundertheconcentrationtimecurvefrom0to72hoursratio
0to24hour
timeofcmaxtmax
secondorderenzymeinactivationconstant
peakplasmadoxlevel
concentrationathalfofthevmaxkm
tissuetoplasmaauc0ratio
systemicplasmaclearancecltot
areaundercurvesauc0t
areaunderthecurveto24hauc024h
serumpeakconcentrationcmax
dntc
troughsteadystateserumconcentration
meandissolutiontimemdt
highestmeasuredconcentrationcmax
timetmaxtopeakconcentrationcmax
clgriii
ttdr
fatratio
apparentin
parasiteclearancetimepct
fetaltomaternalplasmaratio
c90
auc0dose
peakrise
areaundertheplasmatransretinoicacidconcentrationvstimecurve
maximumdosage
distributionvolumesv0
recoveryratefromurine
relativepharmacologicalavailabilitie
halfic50
cumulatedurinerecoverie
clearanceof
auc2425
rectalph
tsubmaxsub
apparentvolumeofdistributionassociatedwiththeterminalphase
plasmabioavailability
ecf
serumcorrectedcalciumcca
areaunderthecurveauc0
oilcarryingcapacity
peakfreetestosteroneconcentration
meanabsorptiontimeta
peakextrapol
peakgl331concentration
be50
maximumthoraciclevel
steadystateclearance
apparentdissociationconstant
auc0672h
maximumtolerancedose
intrinsicoralclearance
meanresidencetimeafteroraladministrationmrtpo
peakprilocaineconcentration
ratelossconstant
extractableradioactivity
sievingcoefficient
ca199
effectiveplasmahalflifeofaccumulationatsteadystate
baa
glomerularfiltrationrategfr
halflifeoftheterminalslope
peakplasmalevelscmax
c30min
maximalrateofeliminationvm10
arterialtovenousplasmaconcentrationratio
timeofpeaktestosteroneconcentration
peff
salivaoutput
apparenthalflifeofabsorption
maximumcysteamineplasmaconcentrationcmax
timetomaintainf
weightgain
unboundvolumeofdistribution
areaundertheplasmaconcentrationtimecurvefrom0toinfinityauc0
fragmentf12
areaundertheconcentrationtimecurveauc0inf
halftimeofeliminationforthefirstrapidphaset12alpha
halflifeforelimination
areaundertheplasmaconcentrationtimecurveduringthe12hdoseintervalauc012h
vmaxspg
csfavailability
plasmaticauc
effluxratio
etea
steadystatedistributionvolumevdss
c50
perme
maximumpossibletreatmentrelatedeffect
volumeofdistributionvalpha
maximummeanconcentration
maximalflecainide
bloodethanoldisappearancerate
timetakentoreachpeakplasmaconcentration
unitimpulseresponsefunction
areaundertheplasmaconcentrationtimecurveuptothelastquantifiabletime
timetomaximalserumglucoseconcentrationtmax
intracerebral
antixaantiiiaratio
halflifeofendogenousproteinturnover
productionrateconstant
timeofinfusion
areaundertheconcentrationvstimecurveauc0
serumalbumin
distributionalhalflifet12lambda1
ta12pip
maximumloadability
csftoserumconcentrationratio
areaunderthecurvevaluesonday13auc13day
trainoffourratio
venousplasmaconcentration
biologichalflifet12
absolutegranulocytecount
logpow
areaundercurve
plasmaconcentrationat12hc12h
equilibriumdissociationrateconstantkd
timestocmaxtmax
fatplasmaconcentrationratio
hepaticvenouspressuregradient
tetrahy
distributionplasmahalflife
percutaneouspermeabilitycoefficientkp
maximumexternalexposurerate
apparentvolumeofdistributionavdbeta
proteinbindingratio
peakstreptozotocinconcentration
tleg
disco
antixaactivitie
exposurefromtime0to240minauc0240
timetoreachmaximumconcentrationafterdrugadministrationtmax
ultrafiltrationefficiencyof
dmr
areaundertheconcentrationovertimecurve
freeplasmafraction
peakspqconcentration
steadystateplasmapanipenemconcentration
fineparticlefractionfpf
areaunderthecurve0t
t12mrt
eliminationhalflivest12
peakmidazolamconcentration
exposuretime
timetomaximalplasmaclopidogrelconcentrationtmax
minimumsteadystateplasmaconcentration
metabolict12
aqueoushumoreliminationhalflife
totalsystemicabsorption
volumeofdistributionv1
maximumcumulativepercentageofdrugrelease
viraldecline
grupo2
firstintercompartmentalclearance
uvealtractconcentration
clearanceindex
urinaryrecoverylevel
progressionfreesurvivalperiod
excretedintotheurinefromtime0to12hoursae012
timethat
maximumseruminsulinlevelscmax
areaundertheplasmamycophenolicacid
slowphase
absorptionhalflifet12a1
t05beta
halflivesfordistribution
peakplasmasdzconcentration
concentrationat50blockcpss50
maximumobservedserumconcentrationcmax
peripheralvolumeofdistributionv2
oralclearanceclsf
unboundaucaucu
24htroughlevel
bestoverallresponse
iscl
aeinfinity
centralcompartmentvc
tlr
peakplasmadantroleneconcentration
cumulativeamountof
measurablelowestconcentration
areaunderthecurveatsteadystate
timetopeakmetaboliceffecttgirmax
peakantigenlevel
centralvolumeofdistribution
effectivebloodlevel
aucif
bloodvolumeslost
apparentvolumeofdistributionofunbounddrugsteadystatevu
auc0192h
vdarea
apparentdistributionvolumeoftheperipheralcompartmentv3f
bindingdissociationconstantkd
fractionalmy
minimuminhibitoryconcentrationsfor90
m8ratio
peakplasmaconcentrationcpmax
apparenthalflifeofeliminationofphasebeta
objectiveresponserate
plasmat12z
timetoachievemaximuminhibition
peakplasmainorganicfluorideconcentration
cblood
water
limitofdetection
tpc
peakno3level
maximummeanserumconcentrationscmax
ppc
areaunderthe24hourinhibitoryconcentrationcurveauic24
peakconcentrationoflevofloxacinatsteadystatecmaxss
clcl
ctrough
limitofmsdetection
eliminationrateconstantkc1
druginputrate
inhibitionconstantki
areaundertheconcentrationxtimecurveauc
clpla
maximumconcentrationintheblood
areaundertheconcentrationcurvefromtime0
morcodratio
renalclearanceofunbounddrug
eliminationterminalhalflife
percentremaining
timerequiredfor50recoveryofbeta
timeto50maturation
tmaxtime
abusequotientcmaxtmax
timefromcomplementarydoseto25recovery
growthinhibitionrate
areaundertheplasmaconcentrationversustimecurvefromtime0hto96hauc096
terminaleliminationhalflifet12z
minimumsteadystateserumconcentration
pseudosteadystatec
sssc
plasmaammonian
invivoincrementalrecovery
recoveryfromblood
fractionofthiopentallossfromthecentralcompartment
plasmaantioxidantcapacity
cooh
maximumconcentrationachievedcmax
peritoneal
unboundtadalafil
plasmaplateauconcentration
areaundertheconcentrationtimecurvefromzerotoinfinityauc0
cumulativeauc
timetorenalresponse
maximumobservedard07concentrationrelativetodoseadministrationcmax
areaunderthetimeconcentrationcurvebetweentimezeroand32hauc032h
effectsitepeak
ccsfbasenorratio
firstserumconcentration
areaundertheplasmaconcentrationtimecurvefromtime0totimeoffinalquantifiablesampleaucs
interpulseinterval
completeabortionrate
plasmahalflifet12
mucosalconcentration
tcpmax
rateconstantsk12
molarsubstitutionratio
vt
apparentsteadystatebloodpropofolconcentration
partitioncoefficientinoctanolwaterlogp
maximumritodrinelevel
steadystatelevodopaconcentration
areaunderthecurvefrom0to24hour
maximaleffectinloweringtheiopemax
deliveryrate
accumulatedurinaryexcretion
volumeofdistribution
absoluteproximalreabsorptionoffluid
urinaryexcretionrateofdrug
eliminationhalflifeinserumduringsteadystate
maximumpercenteffect
peakbloodalcohol
areaundertheconcentrationcurveauc012
areaundertheserumconcentrationtimecurvefromzeroto4hoursforglucoseauc04glucose
fafa0
eliminationratio
samplerecovery
betat12eliminationorbetaphasehalflife
tumorinhibitionrate
tl2gamma
seizurerate
aucperfusateaucplasmaratio
meanplasmaconcentration
areaunderthecurvefrom0to24hauc240
peakdmdzlevel
volumeofdistributionatterminalphasevz
relativeeffectivene
toxicconcentration
biophaseconcentration
cho
betahalflive
relativeabsorption
peakinhibitionimax
steadyconcentration
volumeforthecentralcompartment
placentaltransfer
renalsecretion
consumption
areaundertheconcentrationversuscurveat24hauc024
partitioncoefficientkp
precipitationtime
peakinhibition
eliminationhalflivest12z
plasmaspconcentration
halflifeofabsorptiont12abs
areasundertheconcentrationtimecurvesaucsfrom0to8hauc08s
areaundertheetoposideserumconcentrationtimecurveauc
massbalancefactor
inductiondeliveryintervalidi
overall
areaundertheserumdrugconcentrationtimecurve
maximalloading
minimumhalflifeextensionratio
theresidencetime
penetrationdepth
areaunderthecurveratio
maternalinfant
biologict12betaphase
peakeffect
productionvelocity
peakplasmaptconcentration
areaunderthe
fsr
hepaticcystpenetration
cumulativerecoverie
maximumpeakplasmaconcentrationcmax
auc024mic
terminaldispositionphasehalflife
effectiveradiationdose
sideeffect
areaunderthecurvem1tramadolratio
cumulativeexcretion
c112
relativebasrbas
gellingpoint
selfdispersiontime
sustain
halflifeofeliminationt12beta
suv
volumeofapparentdistributionincenterv1f
timeforreachingmaximumconcentration
urineelimination
maximumtoleratedsystemicexposuremtse
timetoachievemaximumconcentrationtmax
releaseconstant
minimummeasurableconcentration
responserange
maximalitraconazoleconcentration
clbloodclearance
cminunboundlevel
omasalabsorption
timetomaximumplasmaconcentration
maximumunboundfreeplasmaconcentration
meantransittime
vd1
observedmaximumserumganciclovirconcentration
minimuminhibitoryconcentration
clearancebydial
totalsystemicclearanceclb
totalbodyclearancebioavailability
splitratio
secretionclearance
bloodclearance
halflivesterminalphases
ratioofthedrug
timeoftheconversion
auc312
totalexposurei
thc
areaundertheplasmaconcentrationtimecurveaucvalue
clcvvh
me
timedur4
bodyclearancerateclb
oralclearanceratio
peakserumbrompheniramineconcentration
firstorderrate
halfmaximalconcentrationic50
areaundertheconcentrationtimecurve
apparentdistributionvolumevbeta
firsthalflive
biologicalhalflifet12b
areaundertheplasmaconcentrationtimecurveauc024
14c
eliminationt12b
tumorgrowthinhibitiontgi
volumeofdistributionsteadystate
peripheralcompartmentvolumevp
ultrafiltrationflowrate
lungedemaclearance
terminalphaserateconstant
secondhalflive
totalcycletime
apparentsteadystatevolume
areaundertheplasmaconcentrationtimecurveauc08
loadingrate
totalareaundertheconcentrationtimecurveauc
maximumacceptablelevel
totalserumclearancecl
areasundertheconcentrationtimecurveauc096
totalbodyclearanceclb
volumeofdistributionvdc
plasmaareaunderthetimecurve0toinfinity
ratioofaucfrom0to24hour
auc06
initialdispositionphasehalflife
maximummeasuredlevel
maximumfineparticlefractionfpf
kcsf
initialpeak
limitsofdetectionsn
doseturnoverrate
timetopeakplasmaconcentration
vlzf
penetrationpercentage
v1f
maximumpeakplasmaconcentration
bonebloodratio
inhibitoryratioir
areaunderthecurvefromtime0to24h
respirablefraction
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityaucinfinity
peaksugammadexconcentration
totalreleaserate
cmaxdose
degradation
t80clearance
activityterminalt12
oralterminalhalflife
volumesofdistribution
serummorphineclearance
molarpercentage
areaundertheserumconcentrationtimecurvesauc0infinity
cmaxatsteadystate
tumortomuscleratio
peakplasma6tuconcentration
totalconcentration
metabolicratio
peakserumnicotineconcentration
peakcitrateconcentration
aumc0last
pulmonaryextractionratio
peakflecainideacetateconcentration
cumulativeexcretionof
auccsfaucpratio
areaunderplasmaconcentrationtimecurveatsteadystate
clearanceclt
urinaryeliminationrateconstantku
peakplasmacyclopentolateconcentration
maturationtime
perfusionratekp
residualvolume
areaundertheconcentrationtimecurve051hour
volumevf
auc07d
eliminationhalflifec
volumeofdistributionofthecentralcompartment
extentofplasmaproteinbinding
terminalphasehalflive
peakbrainlevel
icrcl
maximalrateofmetabolismvm
totaltumornecrosi
peritonealclearancerate
overallefficiency
mucoadhesion
glucuronidesulphateratio
timewhentheminimumplasmaglucoselevelwasobtained
heatproduction
ch
plasmahalflifet12beta
systemicclearanceof
teq
totalaucproduced
frna
braintounboundplasmaconcentrationratio
timetoreach50
halfmaximalconcentration
proth
cmaxsrratio
timesformaximalmetaboliceffect
concentrationratiofreefraction
peakplasmamifepristoneconcentration
tubulartransportmaximum
apparentvolumeofdistributionmax
halftimeofitsdisappearance
urinaryexcretionuefractionofunchanged
abundance
areasundertheconcentrationtimecurvesfrom0to24hoursauc024
kp
lognumber
rateconstantfordrugdistribution
charge
areaunderthecurveauc048h
vmaxmet1
constantoftransportrateofspeedk10
unboundfractionofms275fu
biologicwholebodyretentionhalflife
areaundertheplasmaconcentrationtimecurvesauc0t
peakurinaryconcentrations015h
timestomaximumplasmaconcentration
apparenttimelagbeforeabsorption
steadystatespeed
grade34toxicity
areaunderthecurvefor04h
maximumconcentrationofdruginthebraincmax
correctedeffluxratio
steadystateplasmadrugconcentration
terminalt12lambda
overallzetapotential
maximalmithramycinplasmaconcentration
areasundertheconcentrationcurvesauc12h
apparentoralvolumeofdistributionvf
salivatoplasmaratioofinhconcentration
areaunderthecocaineconcentrationversustimecurveauc
amplitudeofcontraction
bioavailabilityvssf
maximumentrapment
absoluteplasmabioavailabilitie
plasmaclearanceci
areaunderthecurvefromtime0toinfinity
apttratio
timestoreachpeakhaemodynamiceffect
maximumghbconcentration
urineconcentrationt2
milkserumratio
drugloadingdl
respiratory
incorporationefficiency
fasteliminationphaset12beta
plasmaapparentclearance
terminalhalflifet12lambdaz
b
terminaleliminationt12
cmaxic50
areaundertheteverelixplasmaconcentrationtimecoursefromzerototimeofthelastquantifiableplasmaconcentrationaucotlast
totalbodyclearance
auc24hmic
auc0th
observedpeaktime
auc31h
penetrationrate
initialdegradationrate
rapiddistributioncompartmentv2
successfuldose
tissueplasmatpratio
shelflive
cltp
aucfromzerotimetoinfinity
maximumipa
pleuralfluidplasmaratio
ruminalescape
relativesystemicbioavailability
peakvitreouslevel
clearance
weightadjustedmaximumconcentrationcmax
rateofdeclineoftheplasmaethanolconcentrationk0
intrinsicrenalclearanceclintkd
troughcsalevel
brainecf
timetopeakbudesonideplasmaconcentrationtmax
integrated4hplasmaethanolconcentration
maximumvelocityofmetabolismofethanolvm
steadystatevolumeofthedistribution
timetomaximumpimasertibconcentration
minimumsteadystateconcentrationcssmin
areaundertheplasmapropafenoneconcentrationtimecurve
timetopeakplasmaconcentrationsatsteadystate
dosenormalizedareaundertheplasmaconcentrationtimecurvefromtimezerotoinfinitetime
timeofpeaknifedipineconcentration
halflivest12s
aniongap
urinetoplasmaconcentrationratiosup
recoveryquality
ratiosaucecmic90
apparentcentralcompartmentvolumeofdistributionafteroraladministrationv1f
absorptionconstantrateka
aucsub0
excreteddose
troughcp
eliminationrateconstantsfromtheeffectsite
totalpercentageofadministeredradioactivedoserecovered
eliminationphasehalflifest12
plasmatoperitonealfluidaucratio
zeroordereliminationrate
timetosubtherapeuticlevel
areaundertheconcentrationtimecurveatthefirstdoseintervalauc16
productionratepr
renalclearancerate
halfofmaximumbindingcapacity
distributioncoefficientdelta
k51
filtratevolume
plasmafreedrugfraction
cltot
clearanceclo
peripheralvd
totalclearanceofracemicmirtazapineclf
eliminationhalftimet12gamma
steadystateddcplasmaconcentration
glucoseauc
pc50sgawamp
bioavailablelng
plasmaclearancew
peakestradiolconcentration
cl1753h
maximummorphineconcentrationscmax
period
distributionvolumevdext
maximumvenousplasmaconcentration
targetingfactor
systemicexposureauct
centralcompartmentvolumevc
receptorsaturation
apparentoverallvolumesofdistribution
urinaryrecoveryofadministereddose
aucauecratio
cerebralconcentration
totaldrugreleased
tfpi
distaltubularresorptionofsodium
midazolamclearance
detectionwavelength
areaundertheserumconcentrationcurve
timetofirstsupplementaryanalgesic
terminaldepositionhalflife
maximumconcentrationofthedruginplasmacmax
areaunderfev1
pwp
maximalacheinhibitionemax
meanresidencetimeinfmrtinf
timesto999killing
lesionsscore
maximumdialysateconcentration
totalfractioneliminated
rsratioofauc0
maximumrifampinconcentrationscmax
unbounddistribution
cmaxtocminratio
unboundserumrifampinconcentration
vdatsteadystatevss
criticalflickerfusion
halfmaximumeffectiveconcentrationec50
steadystateplasmaoxypurinolconcentration
maximumobservedplasmaconcentrationscmax
totalareaundertheserumconcentrationtimecurveauc0infinity
initialserumconcentrationco
levelofunboundvegfa
tissueplasmaretinamideratio
terminaldispositionhalflifeof
accumulationfactoraucssauc0t
timeofph5
plasmatroughconcentrationc0
plasmameanresidencetime
d90
volumeofdistributionvdssor
c3max
meanresidencetimemrtiv
timefromdoseadministrationtopeakwholebloodmefloquineconcentration
systemicvenousplasmaclearance
maximumeffectsatsteadystateplasmaconcentration
maximalconcentrationinserumcmax
correctedqtqtcinterval
recrudescencerate
meanclearancetime
maximalintraperitonealpaclitaxelconcentration
deltaaucmin
distributionvolumeatsteadystatewasv
peakplasmadiazepamconcentration
maximumplasmaotcconcentration
areaundertheethanolconcentrationtimecurveauc
steadystatedrugconcentration
areaundertheconcentrationtimecurveover24hauc024
cc
hillconstant
ratioaucbau
overalldiseasecontrolrate
overalldistributionvolume
maximummeaninhibition
areasunderthecurveauc012
terminalhalflifet12k10
biliaryexcretionhalflife
maximumenzymeinhibitionec50
areasundertheeffectversustimecurve
maximaleffectsemax
overallresponseproportion
onsetofappearance
specificradioactivitie
peakserumdigoxinlevelscmax
aucsr
totalamountofsleep
rapidphasehalflife
concentrationxtimeproductstoachieve50inhibitioniauc50
cumulativerecoveryofradioactivity
cssmaxcssmin
ultimateserumhalflife
percenturinaryelimination
aucpt0168h
apparentclearanceofclozapineclf
drugtargetingefficiencyindex
td
percentagesofdoserecovered
totalanalyticalruntime
auc0infininty
venousplasmaclearance
adma
fractionoforaldoseabsorbedfa
pta
steadystatecbzserumlevel
maximalserumsaconcentration
concentrationat12hc12h
ratioofmeta
totaldtg
brainplasmaratio
biologicalhalflive
halflifeoftheabsorptionphase
volumeofdistributionvf
steadystatepeak
morninglevel
intercompartmentalt12
eliminationhalflifetimet12
negativity
unboundplasmaprednisoloneclearance
methanolconcentration
areaundertheplasmaconcentrationtimecurvefromtime0to8hoursauc8
skinsurfaceresidue
mrpl
apparentmaximumvelocityvmax
firstorderrateconstantofeliminationke
areaundertheconcentrationtimecurveoverthefirst4hourspostdoseauc04h
peakplasmamethconcentration
metabolicclearanceclm
exudateplasmalevel
radioactivityconcentration
clearancesclf
totalatlglevel
ubratio
timetomaximalmetaboliceffectmaximumglucoseinfusionrategirmax
auc612
biocon
areaabovethe
halftimeofremovalt12beta
timetodeath
aucoral
constantvolume
imprintingfactor
effectiveplasmaconcentrationsat50recoveryofthetwitchheight
diffusionalclearance
inhibitoryconstant
k01
aucoomega
maximumdimesnaconcentration
semenblooddrugconcentrationratio
fractioneliminatedwithin
maximumbec
timeintervaltospontaneousrecovery
aucphase2aucphase1
logmetabolicratio
kout
filtrateflowrate
ci17524h
timetoachievecmaxtmax
emg
peakuptake
cumulativeexcretedradioactivity
ratiooftheauc
halflifeofdisposition
timetotreatmentdiscontinuation
auc0lastratio
clearanceofheroinfromthebloodatapparentsteadystate
areaundertheconcentrationtimecurvefromtime0extrapolatedtoinfinityauc0inf
intrinsicsteadystatepotency
exsorptionrate
effectivedosesed50
peakcsaconcentration
relativedrugrecovery
maximumtimestocmaxtmax
mic90
timeto50ofmaximumconcentrationtearly50cmax
timetoreachthemedianmaximumserumconcentration
timewhenthepeak
areaunderthecurvetothelastmeasurableconcentrationauc048
clearanceclffm
peakexogenousepinephrineconcentration
maximaleffect
completeresponsecrincompletecountrecoverycrirate
clearancethrough
sampleextractrecoverie
areaunderthezidovudineconcentrationtimecurveauc
fractionmetabolized
apparentrelativebioavailability
timeofpeaktheophyllineconcentration
clearanceq
volumeoftheperipheralcompartmentv2
ductalclosurerate
timetoreachthepeakplasmalevel
mravg
aqueoushumorconcentration
apparentfinalvolumeofdistribution
steadystateplasmafenoldopamconcentration
timetoreachthi
halflifeofdissociation
molecularweightmw
absorptiontimelag
initialplasmaconcentration
secondorderassociationrateconstantskome
areaunderthecurveminimuminhibitoryconcentration
gastricresidencetime
firstordergshconjugation
oraltotalclearance
fractionoftheabsorbeddosef3
betae
cd25saturation
halflifet12ke0
timeforreachingthem
absoluteoralbioavailability
apparentabsorption
kei
finallevel
slowerphaset12beta
peritonealeffluentconcentration
timeaveragedtrough
volumeofdistributionbioavailabilityvdf
mrtfaece
auc04glucose
steadystateplasmapaclitaxelconcentration
areaundertheplasmaleveltimecurveauc0infinity
peakplasmalidocaineconcentration
systemicauc
serumminimumconcentration
bia5961
concentrationsc0
aucfromtime0toinfinityauc0infinity
troughlevelc12
betaphaseplasmahalflive
unboundhydroxylationclearancerate
timeofhalflifeofeliminationphaset12
peakchloroquineconcentration
halfmaximaleffectconcentration
metabolicratiomr
permeationcoefficient
maximumfreefraction
peakplasmamelphalanconcentration
cmaxmaximumplasmaconcentrationratio
cumulativedrugreleaserate
betadistributionhalflive
areaundertheplasmaconcentrationtimecurveauc0t
icnb
terminalhalflifeincirculation
atpconcentration
areaundertheplasmaconcentrationtimecurveauc
ic50d
apparentdose
ratiooftheareaundertheconcentrationtimecurveauctothemicaucmicratio
betaphaset12
2ppex
volumeoftheinnercompartment
activity
tonsilserumratio
timetomaximalinsulinconcentrationtimemax
totalplasmaclearanceclf
cytotoxicityselectivityindice
glucuronidationrate
elutionatflowrate
tcl
transmembranephgradient
peakghconcentration
maximumarterialplasmaconcentration
rateofbiliaryexcretion
fractionalurinaryrecovery
diccic
timetoearlyhalfmaximalactivity
oralfluiddetectiontime
areaundertheplasmaconcentrationtimecurveinsteadystateaucss
placentalclearance
maximalabsorptionconcentrationcmax
plasmaconcentrationsat
osrate
recoverycoefficient
totalchromatographicanalysistime
steadystateplasmabupivacaineconcentration
totaltransittime
peaklidocaineserumconcentration
serumclearancerate
distributionvolumeatsteadystatevdss
probability
areaundertheplasmaconcentrationtimecurveoverthedosingintervalatsteadystate
maximumpeakconcentrationcmax
dose
minimumplasmaconcentrationduringsteadystate
cs50
peakplasmaepinephrineconcentration
areaunderthecurveauc240
selectivityindice
t05alpha
disappearanceraterapidphase
halfmaximaleffectiveconcentrationec50
timeto10
emaxec50
plasmaticclearance
extractionyield
rectalsystemicavailabilitie
peaksalivaaemeconcentration
maximaleliminationratesvmax
normalizedareaunderthecurvefor8hauc08
recoveriesofextraction
eliminationhalflifet12lambda
fractionallithiumexcretion
c0hd
areaundertheheartrateresponsetimecurve
maxvelocityofmetabolizing
peakserumaluminium
pct
totalrecoverie
fractionofthedoseabsorbed
areaunderthecurve24hours
taumax
volumeofdistributionvtyp
limitofquantification
apparentcyclosporinbindingaffinitykd
drug
totalareaunderthecurveauc0oo
t12halflifetime
k41
peakconcentrationscmaxobs
aucupto12hoursauc12h
areaunderthecurvefrom6to12hoursauc612
auczeroinfinity
sampleefficiency
volumeofdistributionatbetaphase
antixalevel
maximalrateoftransport
dryfaecalconcentration
halflifeoftheterminalphase
minimumeffectiveactiveglp1concentration
cl10
maximumaveragepeakconcentrationcmax
timetopeakserumganciclovirconcentration
peaksteroidconcentration
braintoplasmaconcentrationratiokpapp
steadystateterminalhalflife
apparentincorporationconstantka
apparentremacemideclearanceclf
apparentextent
troughplasmalevelctrough
kt
timestoinductionofan
aucmilkplasma
auc24mic90ratio
maximumplasmasalbutamolconcentration
volumeofdistributionduringtheterminalphase
areaunderthefreedrugplasmaconcentrationtimecurve
maximummeasuredplasmaisoflupredoneconcentration
rateofinsulinaction
maximumdoserate
percenttargetattainment
hourlyeliminationratess60
t30
masschlorideexcretion
activitylevel
auc0oo
aucchange
dwellingtime
048auc
maximumlatency
mucosatoplasmaratio
coefficientofpartition
aucforal
initialhalflive
timestoonsetofanalgesia
areaunderthetimeconcentration
relaxivity
timeofonsetofaction
halflifet12oftheeliminationphase
proximalabsolutereabsorptionoffluid
gammashape
a2aa1
areaundertheconcentrationtimecurvefromtimezeroto24hauc024h
intercompartmentalclearanceq
totalauc024
unboundcfzfractionatthepeakconcentration
massmedianaerodynamicdiameter
troughtopeakratiosatsteadystate
terminalexponentialconstant
areaundertheplasmaleveltimecurveaucinfinity
minimumplasmaaracconcentration
apparentcocaineeliminationhalflife
hfip
apparentterminalphasehalflife
distalsodiumreabsorption
overallorr
maximumabsorptioncmax
maximumtolerateddose
norclozapineconcentration
cvec
steadystateplasmadrugconcentrationduringmultipledoseadministrationcavss
closurerate
poststeadystateeliminationhalflifet12
peakdrugplasmaconcentrationscmax
bioavibility
maximumreticulocytecount
livertargetingindex
ebappo
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityratio
serumdigoxinconcentration
auc0max
totalserumlevel
steadystateplasmapropofolconcentration
areaunderthecurvein24hour
clwr
timesofthelastdetectablelevel
clottobloodratio
ratioofaucmic
keeliminationrateconstant
activated
k20
apparentvolumeofdistributionafteroraldosingvdf
constantplasmaconcentration
solubilizationefficiency
0toinfinity
maximummilkintake
cmaxauc0t
directtransportpercentindex
timetopeakabsorptionrate
constantofabsorptionrate
colonicarrivaltime
maximummeanserumatezolizumabconcentration
ic2xlt
permeabilitycoefficientpapp
deltaqtc
timetolatehalfmaximal
overallbioavailabilityf
mcrt
plasmaexposure
vdprocainamide
clearancehalftime
terminalhalftimet12
peakserumdiltiazemlevel
areasunderthetimeconcentrationcurve
clearancem6g
bloodcelltoplasmapartitioning
distributionalclearanceinplasmaq
decaytime
areaundertheplasmaleveltimecurveauctau
aucfrom0to72hoursauc72h
bioavailability
halflifeoftheslowerdistributiont12alpha
cd50
weightadjusted
50clearancetime
tissuecluptake
apparenteliminationrateconstant
volumeofdistributionvssf
accumulatedelimination
dosingratio
maximumtacrolimusbloodconcentrationcmax
zeroorderabsorptionrate
eliminationrateconstantsfromcompartments1
nh3output
latenttime
ccrit
aucverapamilauc
fractionalclearanceofc
rateconstantfromtheperipheraltothecentralcompartment
volumesofdistributionatcentral
totalclearence
peakplasmagrowthhormoneconcentrationscmax
rateofmildormoderateinfectionepisode
fromtime0toinfinityaucinfinity
areaundertheplasmaconcentrationtimeprofilesaucot
timelapsetopeakconcentration
biovailabilitynormalizedclearance
maximumplasmalevel
zerohalflifetimet12
haireliminationhalflive
actionperiod
dispositionhalflive
resolutionfactorrs
peakserumtriazolamconcentration
drugthroughlevel
areaunderthecurveareaunderthecurve0
areaunderthetimevsplasmaconcentrationcurve04h
rateofpenetration
cp50
robs
receptoroccupancylevel
ic50inhibitoryconcentration50
distributionvolumevz
systemicserumclearance
plasmaed50
areaundertheconcentrationtimecurvefromtimezeroto24hauc24
cnstoplasmaratio
drugtotroughratio
solubilizingcapacity
terminalhalflifet12m
plasmaauc0infinity
areaunderthelumiracoxibplasmaconcentrationtimecurvesauc0infinity
totalmpaareaunderthecurveforhours0to12auc012
aucfromzerotimeto5day
cdratio
aucfrom0to24hourspostdoseauc024
contacttime
peakmuscleconcentrationcmax
terminalphaseplasmahalflife
peakplasmatriazolamconcentrationcmax
systemicplasmaclearancecltp
eliminationt12
e0
maciso
aumcinfinity
peakplasmaexemestaneconcentration
timetoachievethefirsttherapeuticinr
plasmaflow
saturablebinding
plasmaconcentrationsof
apparentbiliaryclearance
orallybioavailability
metabolitetoparentdrugratio
infusionclearance
halftimeoftheshowphaseofelimination
dna
bileconcentration
auc0168
totalconcentrationratio
steadystatepaclitaxelconcentrationcss
areasundertheserumcurve
timeofdefecation
areaundertheconcentrationtimecurvefrom0to24h
cumulativeurinaryexcretionsigmaxusr
apparenteffluxclearance
siwv
mechanicalthreshold
suppressionhalflife
residuallevel
ttrough
plasmaconcentrationsc10
areaundertheplasmaconcentrationtimecurvefrom0to12hoursauc012
peakglyceryltrinitrateplasmalevel
ktv
totallungfudr
ecmax
halflifeofitselimination
maximalplasmaconcentrationsoftotalradioactivity
c2max
q5min
clic
loadingefficiency
circulatingplasmac
dosecorrectedauc024
totalbodycime
totallo
aucestradiol
urinaryexcretionconstant
objectiveresponsefrequency
firstorderabsorptionrateconstantka
rateofeliminationconstant
areaundertheplasmaconcentrationtimecurvefrom0to14hour
compartmentalhalflife
peakwidthfwhm
systemicrelativebioavailability
fauc024mic
peakaprepitantplasmaconcentration
maximumqtcprolongationemax
percentagepenetration
maximumdexamethasoneconcentration
peakmorphineconcentrationincsf
painscore
ic50concentrationofdrugrequiredtoachievehalfmaximalgrowthsuppression
michaelisconstantkm
peakstc
oralfluidserumratio
areaunderconcentrationtimecurvetominimalinhibitoryconcentrationratio
aucomegaalpha
clnrf
vdip
lungbioavailability
mp
apparentperipheralvolumeofdistribution
vuf
peakbec
maximumcorrectedqtqtcinterval
areaundercurveaucu
fractionsof
hepaticdrugextractionratio
volumeofdistributionbasedontheterminalphasev
percentagerelativebioavailabilityf
auc24
eliminationserumhalflifet12beta
leukocyterecovery
systembioavailability
sm1
stimulationconstant
areaundertheplasmaconcentrationversustimecurvefromtimezerotothelastquantifiableconcentration
clfs
oralplasmaclearanceclp
peakulcer
troughserumlevel
ic50value
totalrfviiaclearance
oralclearancevaluesclf
tbetas12
totalplatinumhalflife
maximalghproductionrate
steadystateminimumconcentration
cthrough
peakmitoxantronelevel
timetoadministration
forcesofdetachment
maximumconcentrationofdruginplasmacmax
peakplasmaalcoholconcentration
areaundertheethanolconcentrationversustimecurve
areaundertheplasmamorphineconcentrationtimecurvefrom024hauc024
braintoplasmaaucratio
areaunderthecurvefrom0toinfinity
apparentvolumeofdistributionofthecentralcompartment
aucintrahepaticaucintravenousratio
release
plasmaterminaleliminationt12
clearanceofglucose
minimumplasmaconcentrationcpinfinityminmic
totalplasmacarnitineconcentration
survivingfraction
timetoclearance
turnover
bg
serumbactericidalactivitytiter
percentagecumulativerelease
areaunderthecurvebetween0and30minute
brainplasmaconcentrationratio
intrathecalbioavailability
moleratio
bloodclearancet12
partialauc290
maximumserumzolpidemconcentration
plateauconcentration
timeto10of
areaundertheserumcbzconcentrationtimecurve
peakserumtetracyclineconcentration
cla
fractionalrenalclearance
steadystateclearanceclss
amount
maximumvpaconcentration
centralvolumevc
dor
cmaxb
clq
auctatsteadystate
plasmaterminaleliminationhalflife
braintoplasmaconcentrationratio
firstorderabsorptionrate
timetorelapse
plasmacentrationtimecurveauc0t
centraldistributionofvolume
steadystateplasmatroughconcentration
thresholdcerebrospinalfluidconcentration
transmittance
bioavailabilityareaundertheconcentrationtimecurveaucratio
volumeofdistributionatthesteadystatevdss
rateofsynthesi
timetoreachmaximumconcentrationtmax
peakheightratiotamis
absorptionhalflifet12ka
concentrationcmax
qtc
highestflux
receptorreactivity
ipauc
aucperitonealfluidplasmaratio
numberofsce
halflifeperiodofantipyrinet50
areasundertheplasmaconcentrationvstimecurve
troughvpaconcentration
totalburnsurfacearea
cockcroftgaultcrea
fexcretion
totalhplcruntime
plasmaclearancec1p
tumortoliveruptakeratio
ceratio
peaklumbarcsflevel
rateofreachingpeakplasmaconcentrationcmaxdividedbytheareaundertheconcentrationtimecurveauc
peakbloodtceconcentration
apparentsteadystateconcentration
plasmadialysisclearanceclp
zeroorderabsorption
perfusedtissuevolume
doseauc
peakserumtmplevel
timetoreachpeakplasmaconcentration
bloodbrain
totalapparentclearance
minimalbactericidalconcentrationmbc
volumeofdistributionatsteadystateperbodyweightvdssbw
initialdistributionphaset12pi
bloodplasmadistributionratio
overallauc
bioadhesionforce
totalserumclearancecltot
maximumfd4concentration
residualbloodlevel
bioavailabledose
durationofsurgery
initialconcentration
clrenalunbound
pea
intrinsicclearanceievmaxkm
firstorderabsorptionconstantka
42
vclbf
weightnormalizedoralclearanceclfclfweight70
totaltareaunderthecurve
kvo
peakplasmapconcentration
dosenormalizedc0
recoveryinurine
volumeinfused
timeafterdose
gastricemptyingt12
fractionofunboundepia
areaunderthecurvebetween012hoursauc012
totalsystemicplasmaclearancecl
penetrationratioelfplasma
minimumeffectiveconcentration
serumconcentrationtodosecdratio
aucsubtsssub
maximumtenoxicamconcentrationcmax
auc24pf
maximalmetabolicratevm
fractionofthedoseexcretedunchangedinurine
oraleliminationt12
icgr15
areaundertheconcentrationtimecurvefromtime0tothelasttimepointwithbloodsamplecollectionauc0t
cmaxmaximumserumconcentration
apparentic50
centralvolumeofdistributionafteroraladministrationv1f
totalplasmaclearance
kineticdistributionvolume
mothertofetustransferratio
highaffinityconstant
mape
liverextraction
maximalinhibitoryeffect
betaeliminationhalflifet12beta
serumproteinbinding
areaundertheconcentrationtimecurvefrom3to7day
bloodretention
peakabsoluteincrease
ratesofconcentrationdecline
absoluterecovery
plasmaconcentrationat24hoursafterdosingcmin
effectsiteconcentrationatrecoveryofconsciousne
occupancie
initialextractionratio
totalpathologiccompleteresponserate
limitofq
apparentmtxclearanceci
halflifetimet12
fa
peaki
areaunderthecurveover24hauc024
totalvpaclearancecltotal
volumetricproductivity
initialtargetconcentration
aucareaunderthecurvefromtime0toinfinity
numberofcontraction
percentexcretedunchanged
leukocytetransittime
wholebloodvolumeofdistribution
totaleliminationrateconstant
peakinsulin
aucex4
timestopeakvalue
maximalbrainconcentration
cpg
dosenormalizedauc
timestoreachthecmax
peaktopeakinterval
areaunderthedrugconcentrationtimecurveauc0
cmaxpeakdrugconcentration
firstorderabsorptionksr
maximuma771726concentrationecmax
extrarenalelimination
peakmaximumcmax
steadystatebiliaryclearance
ventilatoryresponse
recoverytimesfrommaximumblockto50recovery
areaundertheplasmaconcentrationtimecurvefromtimezeroto12h
maximumbloodconcentrationscmax
mmconstantkm
ed30
inputrateintotheextravascularcompartment2
ratesofsurvival
areaunderthebloodconcentrationvstimecurve
plasmaratio
apparentoraldiazepamclearance
serummaximalconcentration
plasmaterminalhalflifet50
biologicalhalflifeintheterminalphasebeta
spontaneousrecoverytime
completebioavailability
aucsubtsub
apparentinhibitionconstantki
timetofirstacuterejection
transplacentalpassage
increaseinserumiggdeltaigg
rateofgastricemptying
concentrationproducing50inhibitionofcontrolenzymeactivityic50
troughgentamicinconcentration
synovialfluidserumareaundercurveaucratio
transferrateconstraint
maximaleliminationratevmax
overallextractionrecoverie
maximumserumhydroxyzineconcentration
urinaryflowrate
maximalvenouslevobupivacaineconcentration
peakitraconazoleconcentration
k31
eliminationphasehalflivet12beta
fractionoftheadministereddoseabsorbedthrough
timerequiredtoreachthemaximumplasmadrugconcentrationtmax
apparentclearancef
90inhibitoryconcentrationic90
aucaucnorm
centralvolumeofdistributionvd
secondbetahalflife
plasmaratiors
areaunderthecurvefrom0to6h
aucfoldchange
mhratio
timeforthebeginningof
maximumcsfconcentrationcmax
peakcsflactoneconcentration
solubility
maximumconcentrationtmax
pka1
maximumrelease
activeeffluxrateconstant
clwh
toinfinityauc0oo
freet3level
90cl
maximumis5mnplasmaconcentration
fractionalabsorption
timetoonsetofrelief
stsp
intolerability
secondphaset12
t12offset
bloodclearancecl
salivaplasmaconcentrationsratio
auc1d
midazolam
unboundropivacaine
minimuminhibitionconcentration
timetothepeakbloodciclosporinconcentrationatsteadystatetmaxss
liverregenerationrate
si
totalplasmacl
tissueplasmaconcentrationratio
clearancevaluescl
timetopeakabsorption
incrementalrecoverie
perfusiontime
analytical
diffusionaltimeconstant
serummaximumconcentrationcmax
intrinsicnonrenalclearance
backwardsrate
urinaryexcretionamount
c120
lungbacterialconcentration
maximalantiplateleteffectemax
csftoplasmapartitioncoefficient
halflifeofthealphaphaseofdistribution
apparentoralvolumeofdistribution
maximumtumouruptake
kr
areaunderthecurveauc04h
halfmaximum
livertargetindex
maximumdrugloadingefficiency
areaundertheplasmaconcentrationtimecurveclr
t12ka2
apparentvolumeofdistributionarea
areasundertheplasmaconcentrationtimecurvesauc016
clearance2
qd
areaunderthempaconcentrationversustimecurveupto360min
toxic
encapsulationratio
apparenthexanewaterpartitioncoefficient
plasmaareasundertheconcentrationtimecurve
ionsuppression
totalclearanceafteroraladministrationclf
areaundertheserumconcentrationtimecurveauc0
centraldistributionvolumev1
halflifeoftheterminalpartofthe
concentrationinblood
tsub12sub
retentiontimefrom0totimemrt0t
maximumaceinhibition
k10hl
cfu
systemicplasmacl
timetoreachpeakconcentrationtmax
maximalbloodlevelscmax
minimumabsorption
rateconstantk
maximumurinesalbutamolconcentration
cldf
halfmaximalin
eliminationhalflifet05beta
peakfshconcentration
aucs0loq
eveningtomorningratio
concentrationstaysabovea
ktapp
terminaldrughalflife
ae048
amplitudeof
totaldrugexposureareaunderthecurve
maximaleosinopenic
areaundertheconcentrationxtimecurvefrom0toinfinityauc0infinity
onsetofaction
absolute
clinical
completeremission
peakradioactivityplasmalevel
areaunderthecurveauc012
maximumdmdcplasmaconcentration
plasmasteadystatetroughconcentration
plasmaconcentrationtodailydoseratiocd
kinactkiratio
accumulationratioforauc024hr
aucvaluefrom0to12hauc012h
volumeofdistributionatsteadystatevd
majorresponseratecrmr
areasundertheplasmaconcentrationtimecurvefrom0htoinfinityauc0s
dermistoplasmacmaxratio
maximumhydro
bioconversion
areaundertheplasma5fuconcentrationversusthetimecurve
bloodniklevel
notbound
cbt
deltacpave
stablemid
local
cumulativepercentofradioactivityexcreted
maximumplasmanicotineconcentration
clearancecls
timetolocaldiseaseprogression
fast
terminalhalflivest12lambdaz
cmaxmic90
totalsamplingtime
minimalsteadystateplasmadrugconcentrationcssmin
timetodiseaseprogression
releaseamount
plasmaultrafiltrateaucofccpufauc
peakcetirizineconcentration
volumeofdistributionofthecentralcompartmentafteroraladministrationv1f
clearancerateofelimination
substitutionflowrate
clearancecl7oh
constantofelimination
50ofmaximaleffectec50
ren
drugloadingcapacitydl
minimumdiameter
terminalslowphaset12gamma
timestomaximumcy
peakofplasmaconcentration
ttp
plasmaauc024hr
kcp
clearancerateclf
initialplasmat12
aucrtb
minimalclearance
excretionrateconstant
timetoreachthemaximalconcentrationtmax
human
maximumtumorconcentration
clearanceintheperitonealcavityclp
timeofmaximumconcentrationtmax
fc
unbounddrugfraction
peaktmplevel
peakconcentrationsratiocmaxrumencmaxplasma
permeabilityxcapillarysurfacearea
peakintoxication
plcl
concentrationatwhichtheeliminationwashalfmaximalkm
totalsedationrelatedadverseeventrate
areaundertheserumconcentrationtimecurveauc028
apparentsteadystatevolumesofdistribution
secondeliminationhalflifet12beta
areaunderconcentrationversustimecurve
aucsub0tsub
urinaryconcentration
ctc50
pulmonaryarteryocclusionpressure
meanabsorptiontransittime
an
maximumdurationofaction
rateconstantforthetransferbetweenplasmaandeffectcompartmentke0
detectionlimitofdrug
partitioningcoefficient
auctoinfinity
volumeofdistributionvm
amountremoved
peakcisternalcsfmorphineconcentration
clearancefromtheaqueoushumour
halftimeofcholinesteraserecovery
troughplasmaperhexilineconcentration
totalrecoveryinexcreta
concentrationin
peaksputumconcentrationatsteadystate
rectalabsorption
peritonealadvantageaucperitonealaucplasma
fractionalsodiumexcretionfena
firstperipheralcompartmentvolume
concentrationtimecurve
immunoreactivefraction
undertheplasmaconcentrationtimecurvefrom0to8hauc08h
mobilityspeed
steadystatethiopentalconcentration
eliminationhalflivest12el
maximalin
timetopeakpregabalinconcentration
terminalphasehalflivest12
steadystateplasmadfdclevel
timetoreachthemaximumplasmaconcentration
csfplasmaareaundertheplasmaconcentrationversustimecurveratio
totalfirstpasseffect
highestmeanurineconcentration
maximaluptakeratevmax
steadystateranitidineconcentration
absolutepulmonarybioavailibility
clearencecl
peakghplasmaconcentration
pumprate
totalsystemicexposure
halflifeoftotalradioactivity
absorptionrateconstant
peakplasmanifedipineconcentration
sgc
intracranialresponserate
auc01440min
areaundertheconcentrationtimecurvefromtimezerototimetauc0t
ec50b
vztf
bodyextractionratio
portalveinclearance
areaundertheconcentrationtimecurveduringthefirst4hoursauc04
aue04h
tmax2
effectiveconcentration
amountofradioactivity
peakplasmaethanolconcentration
timetoreachmaximumcsfconcentration
observedminimalplasmaconcentration
minimumeffectivetumorboronconcentration
urinevolume
timetoreturnto90
troughbloodlevel
steadystatemeanplasmaconcentration
tssmax
auc0288
percentageofresidualconcentration
halflifeofclearancet12beta
minimaltoxicconcentration
halftimeforlnclearancetc12
areaundertheconcentrationtimecurvefrom012hoursauc012
degreeofaccumulationra
volumeofdistributionvdarea
intrinsicactivity
milkplasmaaucratio
lodlimitofdetection
renalglucosethreshold
maximumdruglevel
serumconcentration
areasunderthecurvefromzerotoinfinityauc0infinity
totalareasunderthecurveauctot
totalbloodclearance
meansamplingtime
amountofdrugremoved
t12terminalhalflife
peritoneumplasmaconcentrationratio
terminalphaseplasmat12
freefractionin
remissionrate
oralsystemic
clint
areaundertheplasmaconcentrationtimecurvefromtime0to8h
centralvenouspressure
rateofchangeinvolumeofdistributionatzerotime
inversionratio
plasmaclearancecltot
fe
df
intervalfromoraladministrationuntilmaximalconcentration
knonur
ag
fractionofnonproteinbound
volumeofdistributionn
lossrate
timeproduct
auc0infareaundertheplasmaconcentrationtimecurvefromtimezerotoinfinity
areaunderthecurvefordrugconcentration
timetomaximumseruminsulinconcentrationtmax
systemclearancecl
apparentspecificvolumeofdistributionofthecentralcompartmentvc
releaseof
peakfmconcentration
progressfreesurvival
mostprobablesize
timetoachievetargetceruloplasmin
biologicalhalftime
awakening
absorptionrateconstantske
plasmafnrconcentration
aucot
k14
areaunderthedrugconcentrationtimecurve
earlyhalflifeincsf
apparentfirstorderrate
completeresponserate
plasmaconcentrationat10minutesafterdosingc10
timetothemaximumserumconcentration
quicktime
activityhalflife
maximumadministereddosemad
extractionof
painintensity
reversaltime
intestinalsecretion
totalt
areaundertheconcentrationtimecurveextrapolatedtoinfinityaucinf
peakplasmaeeconcentration
oralclearancerateclf
vssfm
peakplasmacocainelevel
kalpha
auc0300min
ultrafiltrateconcentration
ventilation
drugclearancec
overallmediansurvivaltime
ratiobetweenplateaulevel
dermalabsorption
areasunderthecurvetoinfinityauc
endtidalconcentration
encapsulationrate
biologicalhalflife
particlesizesd50
areaunderthekemserumconcentrationcurve
initialinfusionrate
meanresidencetimemrtab
plasmaeliminationhalflife
adultclearance
apparentfirstorderrateconstant
50inhibitionconcentrationsic50
structuralmeltingtemperaturetm
circulationhalflive
timeofmaximumplasmaconcentration
troughbloodconcentration
aucareaunderconcentrationtimecurveratio
totalcortisol
apparentclearanceoforalquinineclf
cmaxmaximumcomcentration
daily
absorptiontransittime
slopeparameter
peakplasmasunitinibconcentration
peaktotalreversingconcentration
mz
apparentterminalt12
halfofthemaximumdrugeffectisobservedec50
auc0infinityratio
coronarysinusbloodconcentration
1arauratio
cltb
longterminaleliminationhalflife
durationofaction
ctntratio
maximumplasmaconcentrationoffexofenadinetmax
urinaryexcretionofunchangeddrug
effectivehalflifeclearance
wholebodyhalflife
timetohalfmaximaleffect
inhibitionrate
halflivesofeliminationt12alpha
completeremissionrate
normalizedareasundertheplasmaconcentrationtimecurve
peritonealplasmapeakratio
unboundsystemicclearancecisu
breastmilklevel
timetotreatmentfailure
auc024hr
areaundertheresponsetimecurvefrom0to12h
tmaxtimetomaximalplasmaconcentration
troughsgc
occup
aciddissociationconstantpka
maximumglucoseinfusionrate
maximumtearfamciclovirconcentration
halflivest12alpha
auc024concentration
areaunderthecurveat010h
dialysisclearance
troughplasmaconcentrationsatsteadystate
minimuminhibitionconcentrationmic
timetomean
partitioncoefficient
peakact
peakplasmaaspartateconcentration
maximumserumtestosterone
tissueversusplasmaconcentrationratio
peakantixaactivity
apparentterminalplasmat12
areaunderthetimeconcentrationcurveauc0t
cornealabsorptionrateconstantka
peakmean
maximumprogesteroneconcentrationcmax
eliminationserumhalflife
c12hratio
eliminationtl2
aucoinfinity
absorptionconstantska
peaklomefloxacinconcentration
areaunderthecurvefrom0to12hoursauc012
troughigglevel
apparentnicotineclearance
vdbeta
relativeurinaryrecoverie
cfcmratio
apparentterminalvolumeofdistribution
fractionofmsmetabolized
timeatwhichthisconcentrationwasattainedtpeak
halflifeoflz
absolutebioavailabilitie
troughantixalevel
percentageofdoseexcretedin
timetogirmax
peakimiconcentration
receptorbindingactivitie
terminalphaset12beta
t12out
renalclearanceclren
timewhencmaxisobserved
baselineclearancecl
maximumsuppression
ventilatoryfrequency
aucoftheclosedringformaucclosed
mrttime
tissuemediumratio
auc12htomicratio
clearancesdoseauc
clappm2
initialclearancefrombloodtotissuek1
minimaldetectableconcentration
areaundertheserumconcentrationtimeprofile
areaunderthecurvetoinfinityauc
maximalradioactivity
cerebrospinalfluidconcentration
timetoarrivalinthecolon
timetomaximumplasmaconcentrationcmax
excretionhalflife
halflifest12ke0
areaunderthecurvefromtime0to36hour
unboundsr
eliminationhalflifetfrac12
onestagechromogenicratio
clearanceclcr
maximumtopotecanlactoneauc
absoluterecoverie
timetocmax
plasmaareaundertheplasmaconcentrationtimecurvefromtime0toinfinity
dailyexcretion
tcp02
maximumplasmaparacetamolconcentration
metabolicplasmaratioaucofalphaohmidazolamaucmidazolam
heartrateincrease
timetoachievethemaximumconcentrationtmax
antibody
totalbodyclearancescl
fcmaxmic
timetoreachmaximumconcentration
steadystateantixaconcentrationcss
plasmahalftimeofelimination
renalplasmaflowrpf
areaundercurve0
drugdetention
mtctrate
volumeofcentralcompartmentv3
peaktotal
clinicalbenefitratecbr
peakperitonealfluid
clarea
percententrapmentefficiency
relativecumulativeurinaryexcretion
concentrationscav
onsettimetomaximalneuromuscularblock
timeabovepaclitaxelplasmaconcentration
em
halflivest12
finaleliminationhalflifet12elim
clant
halflifeoftheabsorptionproce
ratioforauctominimuminhibitoryconcentration
halflifeofalphaphase
potencyparameter
distributionhalflifet12d
meanresidencetimeinthebodymrtiv
steadystateplasmainsulinconcentration
peakplasmaconcentrationscpmax
urinarysodiumexcretionunav
apparentperipheraldistributionvolume
maximumobservedconcentration
areaunderthecurveabovethemicfaucmic
cacrclearanceratio
maximumdailydose
plasmacirculationhalflife
apparentclearanceclf
first24hour
areaundertheplasmaalprazolamconcentrationversustimecurve
extentofaccumulationro
apparentoralclearance
unboundvpaconcentration
deltab
denitrationrate
maximumplasmamltconcentrationcmax
peakplasmalignocaineconcentration
mrp
apparenteliminationhalflifet12beta
50toxicitylevel
numberofpeak
halflifevaluest12
maximalpeakactivity
minimumeffectivedose
steadystatemcr
renalclrclearance
csfconcentration
areaundertheinhibitorycurvemicratioaucmic
regionalrecurrencerate
abscessfluidconcentration
cssratioofbraintoblood
apparenthalflifeoftheterminalphase
bloodbrainbarrierpermeabilitysurfacearea
criticalareaunderthecurvein24hoursatsteadystate
mbc90
peakarea
peakplasmascopolamineconcentration
drugconcentrationathalfmaximaleffectec50
timetomaximumicatibantconcentration
urinaryclearancerate
peakplasmarhtnflevel
areaundertheatovaquoneplasmaconcentrationtimecurvecalculatedfrom0to24hafterthelastdoseauc024h
systemiceliminationhalftime
maximumreleasetimetrm
overallkm
totaltumordose
apparentvolumeofdistributionbasedon
areaunderplasmaconcentrationtimecurveforthesteadystate
areaundertheconcentrationtimecurveaucinfinity
peakplasmadrugconcentration
maximumdailymaintenancedose
c24hour
maximummeasuredinsulinconcentration
steadystateplasmaaracconcentration
maximumplasma
excretionratio
totalamountexcreted
rateofeliminationk10
rateofcumulativelocalrecurrence
clmfm
tgamma
areaundertheserumconcentrationtimecurvesauc
tumortoplasmapartitioncoefficient
encapsulationyield
auc0336h
volumeofdistributionoftheperipheralcompartmentv2
timeofmaximalurinaryexcretionrate
ratioofperitonealfluidauctoserumauc
partitionratio
totalvolumeofdistributionvarea
serumpeakconcentrationsc
onsetofanal
nereleaseintotheextravascularcompartmentne2
plasmalevodopaconcentration
conjugationratio
continuousdrugconcentration
peakplasmadoxorubicinconcentration
rmin
auat
clformation
rateoffentanylabsorption
50protectivedose
totalclearancerate
receptoroccupancyhalflife
intrinsicclearancerate
dosenormalizedareaunderthecurveauc
totalintrinsiccl
plasmabetahalflife
areaundertheconcentrationtimecurvefromtimezerototimet
wholebloodtoplasmaconcentrationratio
steadystatecsfplasmaconcentrationratio
occupancyhalflife
oraluptake
oralapparentvolumeofdistribution
metabolicclearancecl1
fecrt
bac
areaunderthetimeconcentrationcurveaucfromtime0totimeofthelastconcentration
apparentrenalclearance
troughserumlevetiracetamconcentration
areaundertheconcentrationtimecurveover12hauc012h
cavitaryconcentration
areaundertheconcentrationtimecurvefrom0to24hfauc024
fractionofabsorptionofmethotrexatefafg
timetoreocclusion
igfi
timetmaxtoreachmaximalraltitrexedconcentration
auclimit
troughtiter
urinarytofecalexcretionratio
lagtimeofabsorptionalag
totaluop
aucinfinity
timetomaximumserumconcentrationtmax
thermalhalflife
totalbloodclearanceatsteadystate
plasmaauc096h
timetomaximumacetaminophenconcentration
boneagechronologicalageratio
areasundertheplasmaconcentrationcurvesauc024h
passiveuptakeclearance
oc50
unboundki
cssmax
gammahillcoefficient
maximumpercutaneousuptake
tbeta
aulot
plasmathyroxineconcentration
auc084h
compliancerate
areaunderthetimeversusradioactivitycurve
perfusateplasmaareaunderthecurveratio
myocardialtoplasmaconcentrationratio
peakd2occupancy
timetothecmax
bodysurfaceareanormalizedapparentclearance
firstpasseffect
hill
areasunderthe
t12km
peripheralvolumev3
terminalvolumeofdistribution
peripheraltocentralcompartment
excretionofradioactivity
areaundertheconcentrationtimeforetoposidecurve
onsetofmaximalclinicalimprovement
dpdtmax
fcmaxconcentration
durationof
peripheralvolume2
totaltrough
inhibitionconcentration50ic50
partialformationclearance
tumorstandardizeduptake
timedur3
auc0120min
peakfreedaconcentration
dlt
metabolicratios
ctot
clearancefromthecentralcompartmentclc
timetoreachmaximumserumconcentration
peakmelphalanconcentration
plasmapeaklevel
bloodbrainclearance
peakbloodalcohollevel
maximumconcentrationofepminplasmacmax
auc3
gfr
biologichalflifet12b
steadystatetroughplasmaconcentrationcpss
distributionphasealphahalflife
tclctrough
timetoreach50maximumglucoseinfusionrate
g
drugclearance
fatox
individualfreeplasmaconcentration
pru
im
milkmaternalserumconcentrationratio
maximumpercentageofinhibition
overallconversion
apparentperipheralcompartmentvolumeofdistributionafteroraladministrationv2f
areaundertheconcentrationtimecurvetothelastmeasurableconcentration
concentrationareaunderthecurveauc
polydispersionindex
targetrelease
peakenoxacinserumconcentration
peakbloodlevel
basaltoapicalflux
fvalue
tto
normalizedtotalnortriptylineconcentration
halfeliminationperiod
auc12
plasmaconcentrationat25recoveryofthetwitchheight
clssf
descent
ke1h
halflifeoftheeliminationphase
cmaxpo
initialclearancet12a
micro
equilibriumstateconcentrationratio
pk
plasmatarget
km1
cistransratio
crcl
timeabovethelethalconcentration50lc50
minimumsteadystateserumlevel
accumulatingeliminationrate
t12alpha1
c1f
ph
512beta
volumeofdistributionatthesteadystate
totalvpaconcentration
apparenthalflifeofitsformation
maximumresidue
sedationduration
sleeplatency
areaundertheserumconcentrationtimecurvefromzeroto35daysauc035days
secondpeak
maximumblood
epilevel
completiontime
overallresponderrate
halflivesofhydrolysi
aucfp
cmaxmaximumblooddruglevel
c0c2ratio
minimumconcentrationofdetection
rbclo
excretionfraction
aucdosebsa
terminalkinetichalflive
10v
acc
areasundertheplasmaconcentrationversustimecurveauc
volumeatsteadystatevdss
halflifeoftheelimination
beta60
maximumralevel
timetofirstpeakcortisol
cu50
areaunderthecurvefromtimezerotoinfinityauc0infinity
clearancecli
intrinsicclearanceof
terminaleliminationt12beta
plasmaterminalhalflifet112
ddqtci
plasmaclo
cumulativeamount
areaundertheconcentrationtimecurvefrom0to8hauc08
skintobloodratio
flexibility
renalexcretionofunchangeddrug
relativeuptakeratere
terminalphaseeliminationhalflive
clmen
peakobservedconcentration
apparenttotalvolumeofdistributionatsteadystate
treatmentcost
cumulativeurinaryexcretionamount
specificradioactivity
oralclf
timetothelastdetectable
tumorbloodboronconcentrationratio
auc1224
intrinsicsolubilitys0
t10
dissolutionreleasetimesmdt
ka1
total48hurinaryrecovery
amplitudeofsecretoryburst
meanresidencetimeratiosmrt
fe04ss
particlesizemps
vesiclessize
effectivedrugconcentration
milktoserumratio
lungserumratio
halflifet12lambda1
totalobjectiveresponserate
maximumobservedamifloxacinconcentration
perfusateplasmaareaunderthecurvefrom0to60minutesratio
ter
apparenthalftimeofabsorption
aucoaucpcsf
timeduration
auct96120hours
amnioticfluidfetalbloodratio
accura
peakplasmadesethylchloroquineconcentration
csfplasmapartitioncoefficient
thresholdconcentration
apparentcentral
boneconcentration
timeatwhichthemaximumconcentrationoccurred
timeabovethelc50
freefractionatthetimeofpeakplasmaconcentration
kd
gammaeliminationhalflifet12gamma
maximumaminoguanidineconcentrationcmax
partialmetabolicclearance
timestofeverclearance
clearancef
timetopeakcsfsufentanilconcentration
ultrafilt
totaleliminationclearance
totalapparentvolumeofdistributionvd
permeabilityconstantforthetransscleraldiffusionktrans
apparentspecificvolumeofcentralcompartment
peripheralbloodethanolconcentrationkm
steadystateapparentoralclearanceclfss
areaundercurveauc0infinity
timestothemaximumconcentration
areaundertheplasmaconcentrationtimecurveoverthedosingintervalauc06
dosenormalizedareaunderthecurveaucd
eliminationratehalflife
potencyratioic50
cmax2
hydroxylase
percentaucratio
arterialpropranololconcentration
totalareaundertheplasmazolpidemconcentrationtimecurve
partitioncoefficientdec
plasmahalflifeduringthebetaphase
vmkmratio
peakpulmonarythromboxaneb2txb2concentration
totalmedianclearance
timetoobservedmaximumconcentrationtmax
rapiddistributionclearancecl2
ribonucleotidetioguanineratio
t12gamma
totalclearancesclccl
troughpeak
runtime
growthvelocity
fpm
atsteadystatevss
limitsof
areaunderthecurveauc08
initialeffectsitetargetconcentration
breakability
ctthreshold
troughplasmaconcentrationatsteadystate
blank
degradationhalftime
maximuminsulinconcentrationcmax
minimumotcconcentration
peakplasmaconcentrationofomeprazolecmax
durationofdrugconcentration
transferrate
peakprogesteronelevel
ultrafilterability
effectivehalflifeforaccumulation
areaunderthetimeconcentrationcurvesauc
areasunderthecurve
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc0infinity
serumhalflifet12
areaunderplasmaconcentrationtimecurveauc
areaundertheconcentrationtimecurveof5fuauc5fu
plasmaamt
lagtimeintheabsorptionphasetlag
volumesofdistributionatsteadystatevdssofthecentralcompartment
timetoreachmaximumbloodconcentration
areaundertheconcentrationtimecurveauc012
timetakentoachievepeakplasmaconcentrationtmax
tumorhalflive
ic50tetraeth
auc15
eliminationhalflifebeta
d50
resolutionfactor
maximumbloodserumnadololconcentration
distributionvolumevf
unboundoralclearance
steadystateplasmaconcentrationscssp
salivaplasmaratio
t12ke
betaphasehalflifet12beta
unboundldpl
vlambdau
sssmin
maximumpaclitaxelplasmaconcentration
plasmameanhalflife
areaundertheplasmatriazolamconcentrationtimecurveauc0
areaunderthatcurve
centralvolumeofdistributionvdc
peakverapamilserumconcentration
apparentorallinearclearance
intrinsicclearanceper
steadystatedexplasmaconcentration
t12term
peaktheophyllinelevel
auc0infratio
maximalconcentrationofreceptor
aucall
troughsteadystateconcentration
eliminationrateconstantof
accumulationfactorr
ipc
oraleliminationhalflife
urinaryrecoverie
liverconcentration
lungbloodratio
auc0r
biologicaleliminationhalflife
rateofseriousbacterialinfection
cbz
plasmabound
vareaf
redistributionhalflifet12gamma
auc2
steadystatemeanpeakconcentration
progressionfreesurvival
eliminationcoefficient
apparentvolumeofdistributionvss
serumhalflivest12
dispositiont12
peakplasmabutorphanolconcentration
terminaleliminationrateconstantkel
a
rateofformation
areaundertheconcentrationtimecurveoverthedosageintervalauctau
ratioofthetotalclearancebioavailability
numberofsite
volumeofdistributionvfpm
recoveryofthe
totalareaunderthecurveaucoalpha
steadystateethanolconcentration
extractrecovery
steadystateplasmailoprostconcentration
totalfetalclearance
absorptivepapp
volumeofdistributionareamethod
maximalresidence
apparentfirstorderformationrateconstantki
auc024
cytochromep450content
milkplasmadistributionratio
collectiontime
steadystateconcentrationsoftopotecancss
boundconcentration
slow
auc17dratio
bloodbrainbarrierpermeability
aucperitonealaucplasma
maximumplasmamorphineconcentration
minimalplasmalevel
plasmaacetaminophenclearance
braintargetingindex
peripheralv2f
overallpatientresponserate
areaundertheplasmaconcentrationtimecurveauc1auc3
qbl
timestomaximumconcentration
urinaryhalflive
peakplasmaisosorbide5mononitrateconcentration
cpmin
peakserumofloxacinconcentration
initialtroughconcentration
proteinbindingfu
gradientflowrate
part
apparentinitialvolumeofdistribution
nadirneutrophilcount
rateconstant
peripheralvolumeofdistribution
bpratio
oraled50
durationofthisplateau
tensilestrength
timestopeakconcentration
steadystatetherapeuticconcentration
amax
sulfation
areaundertheconcentrationtimecurvefrom0to3hour
apparenthalftimeofdrugconcentrationdecay
totalareaundertheconcentrationtimecurveauc0infinity
apparentvolumeofdistributionatsteadystatev
bloodtoplasmatotalradioactivityconcentrationratio
hillcoefficientn
troughlevelconcentrationsc12h
maximalsorafenibconcentration
durationofadequateanalgesia
areaunderserumdrugconcentrationauc02h
cl0
timetomaximumserum
spontaneou
aucs028
eliminationhalflifest12l
overallhistologicresponserate
faucmictarget
infusionhalflife
arterialtension
peakcaconcentration
clobserved
totalareaunderthecurveaucinf
maximalextent
clsf
bloodconcentrationsafter8hour
timetorecoveryoft1t0
concentrationtoplasmaconcentrationratio
thirdcompartmentvolume
ratioofmaximumtominimumplasmalevel
meanresiduetimemrt
plasmaultrafiltratecmax
clearancefromserum
maximalfractionalsodiumexcretion
bioavailable
areaundertheplasmaconcentrationtimecurvesauclast
plasmadialysance
auc910
erythrocytetoplasmaratio
50recoverytime
plasmapeakconcentrationofradioactivity
limitofuvdetection
ec
50inhibitory
auccellauctotgmratio
diseasefreesurvivalrate
effectivethiopentalconcentration
vbf
aucfortissueauctissue
intercompartmentclearanceq
halflifefororalabsorption
aucs024h
prostaticserumantigen
meanresidencetimemrtd
kip
lloq
cumulativefractionexcretedunchanged
ultrafiltrate
clzf
ttf
constantkme
dmax
dbp
polydispersitie
timetoreachpeaklevel
totaltumorphysicaldose
drugavailability
logkcond
areaundertheplasmaconcentrationversustimecurveauc
areaunderthecpvstimecurve
troughprefilter
aeratio
totalsystemicclearancecl
minimumplasmatroughtenoxicamconcentrationcmin
tissueeliminationhalflife
timetakentoreachcmaxtmax
peakconcentrationinserum
wounddrainageconcentrationspeak
apparentpartitioncoefficient
windowoccupancy
targeteffectcompartmentconcentration
areaunderthecurveover24h
peakplasmacurcuminlevel
maximalplasmavalue
mrtliver
fauc24mic
clufunboundclearancedividedbybioavailability
timestomaximumconcentrationtmax
areaunderthecurveaucmicratio
srlwb
totalamikacinclearance
maximumracsalmeterolurineconcentration
halflifeatgammaphaset12gamma
minimaltherapeuticplasmaethacyzineconcentration
auc0ttotalauc0t
cscp
maximumlngconcentration
lequesnesindex
inhibitoryquotientswgiq
percentageofplasmaproteinbinding
areaunderthebrainconcentrationtimecurveaucbrain
constantinfusionratei
formationclearancecl2m1
cminunbound
activationratio
diseasecontrolratedcr
areaundertheplasmaconcentrationtimecurvefrom0to12hoursauc12
prostaticfluidplasmaratio
poresize
areaundertheconcentrationtimecurvefrom0to36hauc036
timetoreachdoxepinmaximumplasmaconcentrationtmax
steadystatebloodlevel
tissuetobloodconcentrationratio
ao
hepaticavailability
painintensityrating
suppressionratio
areaundertheplasmaconcentrationversustimecurvefromtimezerotoinfinityaucinfinity
minimumdetectablelimit
vsskg
areaundertheconcentrationtimecurvefromtimezerotoinfinityauc0infinity
areaunderthecurves08h
timetoattainpeakplasmaconcentration
auctoplasmaaucratio
maximumphenobarbitalserumconcentration
dispositionrateconstantsbeta
clearanceiscl
recirculationtimetc
peakserumpropranololconcentration
drugtargetingefficiencyte
pulmonaryfractionalextraction
totaldrugloadingrate
tounboundplasmaaucconcentrationratio
clearanceclf
indirect
clappm1
relativebioavailabilityaucsraucc
csfdrugpenetration
maximumindividualcmax
distributionpseudoequilbriumhalftimet12alpha
peakconcentrationcp
totaloxazepamclearance
rateofdrugabsorptiontmax
bmax2
arterialmagnesiumconcentration
objectivefunction
rba
peakserumradioactivity
maximumdeltaf
unboundaucfrom0to12hour
peakbupivacaineplasmalevel
latency
plasmadrugclearance
clintliver
fractionalinsulinlossrate
serumareaundertheconcentrationtimecurvemic
killrate
betahalftimet12beta
maximumplasmadamphetamineconcentration
cmaxaucfromtime0tothelastavailablemeasurementauclast
ratioofthefaecalauc
maximaleliminationrate
volumeofthecentralcompartmentofvc
totalbodyclearancecltot
capacitysmax
apparentvolumesofdistributionvf
plasmacbz
plasmaconcentrationinastablestate
timetoreachtheseconcentration
volumeoftheinitialdilutionspace
intracellulartoextracellularconcentrationratiocintracextra
areasundertheserumconcentrationtimecurve
peakplasmaneostxconcentration
centralcompartmentdistributionvolumevc
toplasmacmaxpeakconcentrationratio
newsteadystate
areaunderplasmaconcentrationtimecurveauc036
liverterminalhalflifet12
rapidvirologicresponserate
terminalplasmaeliminationhalflife
timetofullalertne
eliminationphasehalflifet12alpha
reactivityindex
cytotoxicity50inhibitoryconcentration
biochemicalhalflife
emitteddose
eliminationclearancecle
e50
volumeofdistributionincentralcompartment
q13
steadystatebloodconcentration
plasmaritanserinconcentration
unboundcsfunboundplasmaconcentrationratio
areaundertheplasmaconcentrationtimecurveatsteadystate
maximumplasmamycophenolicacidconcentration
chromatographictime
maximumserummtxconcentrationcmax
combinedeliminationconstantkel
timesoffirstnifedipineappearancetfa
suppressionduration
mrt0last
ratiosofareaundertheconcentrationtimecurveauctothemic
areaundertheplasmaleveltimecurve
totalvolumeof
troughlevelcminratiocyatacofcmin
plasmasalivaconcentrationratio
plasmaauc08
tissuereflectioncoefficientss
terminaldispositionhalflive
timetoreachthemaximumbloodconcentrationtmax
peakplasmaplatinumconcentration
totalexcretion
penetration
first
availabilityto
auc024hmic
ohitra
maximumconcentrationsinplasmacmax
peakplasmafenoldopamlevel
protein
maximummpaplasmaconcentration
peakcetirizinelevel
troughexogenousfixactivitylevel
timetopeakplasmadrugconcentration
steadystatematernaltotaldrugconcentration
aucsinfinity
particle
dosenormalizedareasundertheplasmaconcentrationtimecurvefromtime0toinfinityauc0infinity
bodyclearance
24hurine
tmaxinsaliva
steadystatetroughserumconcentrationscpsst
mcr2
auc12hr
rbcplasmaratio
areasunderthesalivaryprogesteronecurveauc024h
maximaltroughcaffeineconcentration
bulkdensity
payloaddrugtoantibodyratio
localization
peakbronchialconcentration
peakserumifc
troughsteadystateazimilideconcentration
maximumalmitrineconcentration
oralbiodisponibility
placentalclearancerate
rateconstantfordrugdistributionfromtheperipheral
steadystateconcentrationratiocssmcss
clearancefactorctrough0180
plasmadisappearancehalflifet12alpha
minimumplasmalevel
clinicalhalflife
ckseffluxratio
freeserumconcentration
ratioofhalflife
troughmetforminconcentration
therapeutichalflife
drugloading
median
relativebiologicaleffectivene
timeofpeaklevel
areaundertheserumconcentrationtimecurveofthe24hdosingintervalauc024
feedingrate
volumeofdistributiondividedbybioavailabilityvdf
testosteroneconcentrationcavg
timeatwhichthismaximumconcentrationofdrugtmax
ex130
camax
clearancefromcsf
apparentdistributionhalflifet12alpha
initialsteadystateconcentration
areaundertheconcentrationtimecurveaucfromtimezerotoinfinityhour
maximalmorphineconcentration
bindingcapacitybmax1
timetomaximum
timeofclearance
audrc
areaundertheeffectcurve
lifetime
baselineactivitiese0
albuminboundfraction
areaunderconcentrationtimecurveauc012h
excretiveratio
extrudability
areaunderthecurveofplasmaconcentration
sampleruntime
plasmaconcentrationtimecurveaucelimination
areaundertheaqueoushumorconcentrationversustimecurveauc08h
m8clearance
recommendedmaintenancedose
peakabsorptionrate
timetopeaklevelstmax
areaundertheplasmaconcentrationtimecurveforthe12hourdosingintervalauc012
apparentconstantplasmalevel
bioavailabilityfactor
maximumplasmamaravirocconcentration
apparenttotalclearanceofatorvastatinlactoneclmf
vascularresistance
areaundertheconcentrationtimecurvefrom0to24hoursauc024hauc024hss
hepaticuptakeclearancecluptake
flow
eliminationhalflifepostdistribution
overallresponse
totalbioaccessibility
concentrationscavg
civi
maximallungconcentrationscmax
reaching
injectionrate
steadystatecmaxcssmax
maximumvalue
durationofresponse
clearancescl
steadystateatovaquoneconcentration
timeofpeaktmax
bioavailabilityover6hoursauc06
bioaccumulation
aud
maximumconcentrationmic90ratio
distributionvolumevdarea
terminalphasehalflife
durationofzeroorderabsorption
terminaleliminationrateconstantbeta
plasmapeakconcentrationscmax
steadystateplasmalactoneconcentration
durationofeffectfrom
areaundertheplasmaconcentrationtimecurveaucfromtimezerototimeoflastmeasurableconcentration
eliminationhalflifet12lambda2
halflivesofequilibrium
syx
fractioneliminatedunchangedin
bodypoolsize
timeofconcentrationpeak
timerequiredtoreachthecmaxtmax
troughantibodytiter
curvefittedec50
steadystatedrugplasmaconcentration
auco72
directtransportpercentagedtp
dosenormalizedauc024
unboundcisplatinplasmaconcentration
apparentexcretoryhalflife
durationofclinicalbenefit
fauc024mictauc024mic
halflifeofeliminationt12el
minimumdetectableconcentration
apparentterminalplasmaeliminationratebeta
ecmaxminimuminhibitoryconcentrationmic
curssigma
observedplasmacmax
aucbasedaccumulationfactor
tg
terminalplasmahalflife
steadystateaverageconcentration
plasmahalflifetimeofclearancet12
peakserumcyclophosphamidelevel
apparentvolumeofdistributionvdlambdaz
troughinfliximabconcentration
fractionofunboundlidocainein
ratesofprogressionfreesurvival
proteinsynthesisrate
loadingcontent
unboundtrough
plasmamaximumconcentrationcmax
halflifeofradioactivity
timeofmaximalconcentration
vdbetaf
viralload
activitie
milkplasmadrugconcentrationratio
ke1
totalimprecision
mat
totaltreatmentresponse
gamma1
aucgz
renalbloodflow
sodiumpotassiumratio
auc060h
maximalantihbsconcentration
mcrdht
blooddialysateflowrate
fractionalremoval
doseadjustedtroughlevel
apparenterlotinibclearance
rsenantiomericratio
eliminationrateconstantfromtheeffectcompartment
imprecisioncv
peakfelbamateconcentration
steadystateritodrineconcentration
logp
volumeoftheperipheralcompartment
toreachpeakconcentration
areaunderthecurvefromtimezerotolastdatapoint
t12p
effect
clearancebioavailabilityclf
coc
minimumconcentrationatsteadystate
distributionhalflifet12lambda1
concentrationdeterminedatsteadystate
timetoreach90ofthesteadystateconcentration
maximumeffect
totalamount
areaunderthetimeplasmaconcentrationcurveauc
terminaleliminationconstant
vdpop
peakplasmaheparinactivity
dilutionrate
peritonealhalflife
peakserumdphconcentration
greatestplasmaconcentration
areasundertheplasmaconcentrationtimecurveaucfrom024hpostdoseauc024
halftimesofinitial
auc030h
valley
meanresidencetimeforabsorption
finh
meanresidencetimemrtinf
auc024hrmic
initialdistributionhalflife
totalendogenouspyridoxal
dissociationconstantskd
timetoreachthatpeaktmax
areaundertheplasmafpconcentrationtimecurveauctoinfinitetimeaucinfinity
steadystateserumphenobarbitalconcentration
peakserumtotalcortisolconcentration
affinity
minimumeffectiveplasmaconcentration
capacityfactork
peakplasmaibuprofenconcentration
maximumtoleratedtotaldose
peakserumghconcentration
auc0033h
minimumbactericidalconcentrationmbc
cl2
timetoreachmaximumlisinoprilconcentration
steadystateof
terminalhalflifet12z
vbetaf
plasmaicgclearance
circulationt12
areaunderthecurveauc0t
timetomaximumparacetamolconcentration
excretoryhalflife
drugantibodyratiodar
systemictoxic
absolutebioavailabiltiy
firststageeliminationhalflifet12beta
maximallidocaineconcentration
maternalmilkserumconcentrationratio
apparentuptakeclearanceclup
areasundertheenrichmenttimecurve
areaunderplasmaconcentrationcurvesauc
absorptiontmax
eliminationhalflifest12s
peakantixalevel
dwelltime
totalareaunderthecurveauc0infinity
maximumeffectauc50
auc012hratio
peakddqtcf
areaundertheplasmaconcentrationtimecurvefromtime0totimeofthelastmeasurableconcentrationauc0t
metabolicclearancec1m
maximumserumconcentrationofrobenacoxibcmax
auc0240min
activityindex
bleedingrate
apparentoralclearancedoseauc
bispectralindex
halflifetimet05
totalliverbloodflow
v2f
lagtimet0
centralvolumeofdistributionv1
resistanceindex
centralvdkg
timetopeakplasmadrugconcentrationtmax
serumantiviralactivityauc
timetoappearanceofantidrugantibodie
halflifeofinhibition
finaldecayconstant
reversibility
cmaxcmax
steadystateareaundertheplasmaconcentrationversustimecurveauc012
ratesofinfusion
apparenttotalclearanceclf
volumeofdistributionvbeta
vdkg
maximaloralabsorptionratevmax
dispositionalhalflive
maximumzpcaconcentration
transferconstantq
progressionfreeinterval
clearanceofdarbe
irreversiblebinding
areaundertheplasmapqconcentrationtimecurveauc0
apparentterminalhalflife
totalcompartmentclearance
productionrateofdhpgkin
clecfbc
eliminationfromthecentralcompartmentkel
cellviability
maximumplasmaconcentrationaftermultipleadministrationscmaxss
apparentkd
diffusion
seizurefrequency
weightnormalizedplasmaclearance
zerotimeconcentration
maximumbindingcapacity
stablediseaseresponserate
transfusionindependentplateletcountrecovery
hepaticclearanceclh
volumesofdistributionv1
ng
areaundertheplasmaconcentrationtimecurvefromtimezerotothelastquantifiabletimepointauclast
peaksalivaryconcentration
eliminationhalflifet123
areaundertheconcentrationcurvefor12hoursauc012
timeuntilmaximumconcentrationtmax
total14crecovery
unboundvpa
residencehalflife
lcratio
eliminationhalflifeafter
timetomaximalmetabolicactivity
troughplasmaconcentrationctrough
totalsystemicresistance
maximumpotentialamount
effectiveconcentrationat50ofmaximumec50
auccsfaucplasma
effectiverate
antifactorxaactivity
intracellularplasmaratio
volumeofdistributionatsteadystatevssreal
50effectivedosesed50s
areaunderserumconcentrationtimecurvefrom0to4hafterinhalationauc04
volumeatsteadystate
timetakentoreachthemaximumconcentration
totalchromatographicruntime
effectivet12
dlc
timetoachieveascendingplasmamphconcentration
peakheartrate
milkclearance
kbi
degradationrateconstant
maximumcsfnorpethidine
plasmacxtratio
pappblap
auc06ratio
intrinsicassociationconstant
totalareaundertheobservedplasmaconcentrationtimecurveauc012
totalvolumeofdistributionatsteadystate
steadystatebloodnicotineconcentration
steadystatefreephenytoinconcentration
tmigr
aucssblood
rateconstantk11
tumorviability
tcmax
aucamt
correctedauc05
areaunderthe24hconcentrationtimecurve
volumeofdistributionvz
netrenalclearancebytubularsecretion
executiontime
minimumplasmatheophyllineconcentration
therapeuticthresholdconcentration
peakdexamethasoneconcentration
inletconcentration
bioaccessible
aucareaunderblooddrugconcentrationcurve
apparentvolumesofdistributionavd
totalbodyclearanceofdrug
maximalppixconcentration
apparentvdkg
maximumenergy
maximalrateofdecline
urinaryexcretionofunchanged
peakserumtopiramatelevel
intrinsicclearance
areaunderthecurveforplasmaconcentrationofdrugxtimeauc
circulationtime
absoluteneutrophilcountanc
maximumserumlevetiracetamconcentration
minimumcmax
t12betadistribution
absorptionhalflifet12a
overallmediansurvival
totalplasmaclearanceofnifedipineclf
oralclearancecloral
mbc
effectcompartmentconcentrationat50block
totalvpa
ratiooftotalbodyclearance
onsetof
glucoseutilization
volumeofdistributionofunbounddrugatsteadystatevuss
releaselagtime
totaldoxorubicinclearance
dissociationt12
ve
peakbiletoplasmaotcconcentrationratio
steadystate90blockoft1
partitioninginto
troughconcentrationsc12h
maximumdrugdissolutionrate
eliminationhalflifeofthebetaphase
mrnalevel
maximumplasmaconcentrationscmaxatsteadystatecmaxss
secondaryhalflive
drugbioavailability
disappearancehalflife
separationefficiency
aucfrom0to4hour
plasmacortisolconcentration
vsskg1
buclcbw
relativeattenuationratio
peakplasmaheparinconcentration
minimumvalue
maximumdepletion
volumeofdistributionforthe
cave024
gitransittime
wholebodyclearancectot
rateofacutecellularrejection
volumeofdistributionbioavailabilityvf
eradicationrate
fastcompartmentvolume
equilibriumtime
timeofdistributiont12alpha
plasmaclearanceclpl
toplasmaaucratio
volumeofdistributionatequilibrium
areaundertheconcentrationtimecurveauc0tau
maximumpercentedemainhibition
netproteinbalance
icgpdr
timetopeakconcerntrationtmax
maximumbupivacaineconcentration
distributiont12t12
pharmacologicalavailability
percentagepermeatedamount
limitofquant
mcr0
areaunderconcentrationtimecurveauc028
transverserelaxationrateconstant
maximumdepressionofthefirsttwitch
q24
distributionrateconstant
firstordereliminationrateconstant
residualamount
centralclearanceclc
systemicclearanceofunbounddrugclu
centralcompartmentvolumeofdistributionvc
areasundertheconcentrationtimecurveauc0tn
eliminationbetahalflive
meantransittimeintheperipheraltissuesmttt
intrinsicgutwallclearance
prrate
totalbodyclearanceclt
brainecftoplasmaaucratio
qtmax
overallinfectionrate
maximalplasmaatenololconcentration
cp50bar
peakplasmadesmethyldiazepamconcentration
dosenormalizedauc024h
grt
se
plasmamconcentration
constantmobilephaseflowrate
kidneyplasmapartitioncoefficient
volumeofdistributionintheperipheralcompartmentv2
absorptionrateieka
fractionoffree
progressionfree
effectivedoseequivalent
apparentplasmaterminalhalflife
peakwholebloodarterialbupivacaine
eliminationtimeh
minimalsteadystateconcentration
maximumhr
concentrationtodoseratio
cppl
nonspecificbinding
bmr
areaundertheplasmaconcentrationcurveauc000
maximalresponseec50
areasunderthecurveto4hr
50recovery
anae
fvc
aucmicratio
cultureconversionrate
peakabt751concentration
absorptionhalflifeta12cin
timetomaximumplasmatelmisartanconcentration
serumeliminationrateconstant
timetoopioidrescue
peakmicrodialysatefenlevel
aucc03h
areaunderthecurveminimuminhibitoryconcentrationratio
poststeadystatehalflife
maximumleveloftestosteroneconcentration
cumulativeurinaryrecoveryof
terminalvolumeofdistributionatsteadystate
csfserumdrugratio
timetocompletecure
fetaltomaternalbloodratio
overallclinicalcurerate
recirculationrate
peakplasmatemazepamconcentration
nonsaturableclearance
absorptionrateconstantkaa
centralvolumeofdistributionatsteadystate
ethanol
areaundertheconcentrationtimecurveover24h
halflifeofnicotineelimination
serumhalflike
overallbodyclearance
maximumratesofuptakeinfluxes
serumt1druglevel
timetoinfieldprogression
volumeofdistributiononehalf
oralresidencehalftime
lunguptake
totalapparentoralclearance
plasmaeliminationofhalflife
eliminationrateconstantkbe
tt4
plasmahalflivesofdistribution
t12lambda1
t1time
halfmaximaleffectivedoseed50
atbf
apparenthalflifeoffirstorderinvasion
apparentbloodclearance
releasingduration
timetofirsttreatmentfailure
percentageurinaryrecoverie
equilibriumplasmabloodcellconcentrationratio
disappearancerateofethanol
dosenormalizedpeakconcentrationcmax
totalbodyserumclearancecltot
t12e
hepaticfirstpasseffect
systemicdiseasecl
areaunderthecsfconcentrationfrom0to24h
areaundertheconcentrationtimecurvefrom0hrto
cumulativeauc5wk
areaunderplasmaconcentrationversustimecurve
sm2
cerebrospinalfluidserumratio
apparentbloodhalflife
slopecoefficient
peakropivacaineconcentration
maximumheartrate
constantplasmabloodconcentrationratio
totalareaundertheplasmazolpidemconcentrationtimecurveauc0infinity
apparentvolumeofdistributionvdf
timeofthemaximummeasuredplasmaconcentration
areaunderthecurveauc048hrs
totalsalivaryconcentration
absorption
bte
relativenasalbioavailability
slowdispositionhalflifevaluest12beta
initialhalflife
apparentspecificvolumeofdistribution
volumesofdistributionatequilibriumvr
intestinal
selectivityindex
saturatedsolubility
totalareaundertheconcentrationtimecurveduringoraladministrationaucpo
apparentcentralvolumeofdistributionv2f
excretionrate
highestobservedplasmaketoprofenconcentration
halflifeoftheabsorbedmelatonint12elimination
milktoplasmampconcentrationratio
plasmatichalflifet12
selectivity
minimumdecreasemaximumdecreaseratio
apparenteliminationhalflifet12lz
areaundertheconcentrationauctimecurvetothelastmeasurableconcentrationauc012h
effectivepermeabilitypeff
totalserumbileacidconcentration
normalizedclearance
concentrating
concentrationattheendof24hdosingintervalcmin
maximuminhibitionofthezeroordersynthesisrate
extentoforalabsorption
aucuptotimeinfinityauc0
areaxtime
apparentvolumeofdistributionvf
bloodconcentrationpeakvalue
tissuetoplasma
totaldrugrelease
maximalcsaplasmalevel
areaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinity
peaka771726concentration
equilibriumaqueoussolubility
steadystatevp16concentration
capacityfactor
overallclosurerate
cevr
peaklocaltissuesirolimuslevel
peaktshresponse
bodyclearanceclb
troughsupinedbp
tumourresponserate
pulsedreleasetimetrm10
auc072hr
urineexcretionofunchangedform
csi
survivalduration
peakaqueousconcentration
apparentlagtime
relativebiopotency
timeaveragedbioavailability
timefrompeakplasmaconcentrationto50ofpeakconcentration
tmaxt12beta
map
apparentsystemicplasmaclearance
halftimeoftheterminalphase
maximummeaninhibinblevel
permeabilitycoefficient
gammaeliminationhalflive
timetoprogression
peakserumlithiumlevel
terminalphasevolumeofdistribution
areaundertheplasmaconcentrationcurveaucfrom0to96hour
areundertheconcentrationtimecurveat06h
maximumaccumulation
auc15360min
totalbrainuptake
firstorderoralclearance
maximumtoleratedauc
clcreat
summatedrecoveryrate
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinity
tmaxins
basalsecretion
area
formationclearance
qbbb
areaunderthecurveauctomicratio
firsteliminationhalflife
areaundertheplasmaconcentrationcurveaucfromtimezeroto72h
kab
areaundertheprothrombintimevstimecurve
dosenormalizedaucratio
peakplasmagtnlevel
wholebloodplasmaratio
areaundertheconcentrationtimestimecurveauc024
pot
ultrafiltrationdrugclearance
plasmatobloodratiooftotalradioactivityconcentration
maximalotcconcentration
aucthreshold
fractionnot
mode
steadystatecnstotalplasmaconcentrationratio
maximumanc
cotac
clpv
faecalwaterconcentration
areaundertheplasmaconcentrationtimecurveoverthedosingintervaltauauctau
aucfromtimezerohtothetimeofthelastmeasurableabirateroneacetateconcentrationsauct
zeroorderinvitrorelease
plasmaconcentrationofunboundropivacaine
cpss
maximaleelevel
transporterindependent
minimumsao2
maximumbloodconcentration
intrahepaticconcentrationofunchanged
freefractiondeterminationf1
timetoseizuretermination
steadystatepeakconcentrationcmax
peakchlormezanoneplasmalevel
rd
clrcg
va
steadystatetxaplasmaconcentration
ec50thehalfmaximaleffectiveconcentration
reactiontime
auc012
halftimeoftherapidremovalphaset112
efficacytau
ft4
finalconcentration
durationoffirstremission
maximalapparentserumconcentration
maximumconcentrationinbonecmax
plasmahalflifetime
faucserummic
peripheralvolumev2
transferconstant
relativeoral
absorptionauc0
apparentvolumeofdistributioncentralcompartment
relaxationrateconstant
tirstumorinhibitionrate
fub
salivatowholebloodratiosb
peripheraltocentralk21
cmaxtmaxratio
input
rateofspontaneousdetoxification
areaunderconcentrationcurve
aucp
secretionrate
vdpaa
peakplasma
truene
r2
osmoticpressure
bloodflowratio
icustay
ce10m
serumpeak
vascularperoxynitrite
logpcoct
biologichalftime
synovialfluidplasmaratio
areaundertheconcentrationtimecurveaucfromdosingtoinfinity
bloodelimination
amnioticfluidtomaternalplasmaratio
mo
troughverapamilconcentrationscmin
centralvolumeofdistributionvcentr
heightoftheplateauvalue
pulmonarycapillarywedgepressure
eliminationconstantratek
clinicalresponserate
timetotherelapseofinfection
totalareaundertheconcentrationversustimecurve
maximummeasuredplasmampaconcentration
coefficientofelimination
clf03
timestomaximumplasmaconcentrationtmax
selectivityratioeffectiveconcentrationec50
timeontreatment
albuminsolution
peakhydroxyzinelevel
effectiveplasmaconcentrationsfor50paralysisecp50
surfaceunderthecurveaucolead
toccrratio
halflivesareaunderthecurve
totalbodyclearancecl
boundratio
peakeffectsatsteadystate
steadystatedopamineconcentration
maximalacetaminophenconcentration
maximalmeasuredplasmatramadolconcentration
percentpenetration
timetoreachmaximumbloodconcentrationcmaxtmax
cmaxdn
absoluteba
k2
max
dispositionrateapparentabsorption
plasmaauc0
maximalcmin
totalropivacaine
lke
maximumconcentrationsofmoxifloxacininplasmacmax
clin
constantkm
efflux
areasunderthetemozolomideconcentrationtimecurve
membranepermeability
eliminationclearance
serumconcentrationcurve
tl2
clfapparentclearance
effectdelayhalflife
stationarygrowthphaseminimalbactericidalconcentration
maximalhumanplasmaconcentration
areasunderthecurveaucs
bloodbrainbarrierclearance
volumeofdistributionareavarea
freefattyacidconcentration
cleared
totalareasunderthecurveauc
totalradioactivityrecovered
alconcentration
tue
clearanceofthefreedrugintrinsicclearance
areaundercurveaucratio
serumeliminationhalflife
halflive
plasmaauc06
auc0360min
aucoftheringopenedformaucopen
mrt01
c60
eliminationhalflifet05el
peakenrofloxacinplasmaconcentration
recirculationratiofc
tclor
particlesizedistribution
effluxrateper
apparentdistributionclearance
invivobinding
areaundertheplasmaimatinibconcentrationversustimecurveauc
timetomaximumeffecttmax
halflifeforclearance
maximalplasmahippurate
totalclearanceofdrug
arterialumbilicalcordtomaternalconcentrationratio
timetofailure
areaundertheconcentrationtimecurvefromtimezerotoinfinityauc0
concentrationsperdose
timeforreachingthehalfmaximumeffect
areaunderconcentrationtimecurveaucbrainaucplasmaratio
recoveryoft4t1
eliminationrateconstantb
ed90
unboundplasmaconcentration
lagtimesbeforeonsetofabsorption
bloodtoplasmapartitionratiobp
rate
apparentatsteadystate
firstexponentialphasehalflife
areaunderthecurveaucinfinity
areaunderthecurveextrapolatedtoinfinityauc0infinity
minimumdetectabledose
maximumbrain
totallocallybioavailable
objectiveresponserateorr
sustainedpeakplasmaconcentration
ratioofintrinsictransportclearancedividedbydiffusionclearance
cssratio
ratioofsodiumchlorideexcretion
boundfraction
minimumdetectablequantitie
aucatsteadystateauctau
levl
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityaucinf
freetissuefreeserumconcentrationratio
plasmatogenitaltissueratio
overallconcentration
inductionhalflife
timestocessation
totallineareliminationclearancefromcsf
aucbileaucvp
maximumtolerateddosesmtd
peakbloodethanolconcentrationsbec
percentageexcreted
ratesoffuraformation
relativeaeinfinityratio
tlag
totalplasmabupivacainelevel
nonrenal
areaundertheconcentrationtimecurveaucfromtime0htoinfinityaucinf
areaundercurvefrom0to12hoursauc012
hillfactor
c3
total24heffectareaauetc
areasunderthecurveauc
apparentintestinalextraction
lineardynamic
percentof
excretedunchangedin
maximumdrugeffectec50
totalareasundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc
maximumauc
tumornecrosisratio
cl1eliminationclearance
timetomethotrexateclearance
concentrationintheeffectcompartmentat50block
gastricresidencetimegrt
auc096h
peakserumatropineconcentration
rateconstantfortheelimination
volumeofdistributioninthecentral
tmaxtimetoreachmaximumplasmaconcentration
infectedcelllossrate
timetoreach10of
maximaloccupancie
coefficientb
maximumtolerateddosemtd
auc0540min
kmacro
peakplasmacortisolconcentration
ktran
concentrationathalfmaximumeffectsec50
maximumserumconcentrationscmax
clottingtimect
timecorrespondingtocmaxtmax
maximumentrapmentefficiency
apparentvolumeofdistributionvzf
onsetoflossofrightingreflexlrr
auc0last
glucosepeak
intrinsicmetabolicclearance
peakserumcortisollevel
fractionunboundinserum
x3
timetoreachthemaximaldrugconcentration
total
maximummean
totalplasmaclearanceclp
steadystateplasmaconcentrationcp
aucinfratio
peakhalfclearance
maximummeanauc0
totalextractionrecovery
constantflowrate
areaundertheinsulinconcentrationcurve
areaunderthekillingandregrowthcurvefrom0to48haubc048
ultrafiltration
residenttime
troughaqueoushumorlevel
timefromfirstoccurrenceofaresponsetofirstoccurrenceofanonresponse
completecytogeneticresponserate
slopefactorg
peakcyaconcentration
peakflowrate
directtransportpercentage
bileliverunboundconcentrationratio
extractiverecovery
hepaticextraction
m6gm
peakserummethylprednisoneconcentration
resolutionfactorr
unboundclearance
mesorconcentration
50growthinhibitoryconcentrationic50
maximalbloodconcentration
totalanalyticaltime
qtmin
halflifeoftherapideliminationphase
systemicbioavailability
overallcompleteabortionrate
areaunderdrugconcentrationtimecurve
accumulationpermeationpercentage
timetopeak
maximumchange
csfserumratio
initialhalftime
maximumnimesulideplasmaconcentration
returnauc
distributionhalflifet12distribution
apparenteffectsiteconcentration
correctedrenalclearance
concentrationcav
urinaryextraction
bp
fractionalrate
transplacentaltransfer
timeabovetheminimumtherapeuticconcentration
apparentvolumeof
mcrb
halftimeofdistributiont12alpha
couplingratio
totalmolarquantity
bispectralindexbis
apparentfirstorderabsorptionka
clearanceofcentralcompartment
systemicclearanceperabsorption
ctci
steadystatemaximalconcentrationcmaxss
boundtofreeratio
labelingefficiency
relativebiologicavailability
studyduration
peakchloroquinebloodlevel
timetomaximumconcentration
troughserumdrugconcentration
clearanceviacapdcl
maximumggaplasmaconcentrationcmax
effluxclearanceclout
cfen
minimalalveolarconcentration
coefficientsofelimination
serumproteinbindingpercent
areaundertheconcentrationversustimecurveofetoposideoverthetreatmentperiodtotalauc
annualizedrateofinfection
plasmamidazolamconcentration
timefort110
cpred50
clearanceoverbioavailabilityclf
tumourbloodratio
totaltroughconcentration
apparenthalftime
initialeliminationhalflife
areaunderthetimeconcentrationcurveauc012
tl2z
lem
timetoabsorb95
ontime
systemicpeakconcentration
rclr
halflifeatalphaphaset12alpha
apparentvolumesofdistributionduringtheeliminatorybetaphasevdbeta
tratscore
areaunderthecurveaucss0t
unboundpeakconcentration
areaundertheplasmalevelvstimecurveauc
c0breathalcoholconcentration
circulatingconcentration
totalmphexcreted
totalvolumesofdistribution
minimum12hourplasmaconcentration
basalmcr
onsetofgastricemptying
halflifeofabsorptiont12ab
salivaplasmaproguanil
stablediseaserate
accumulationtime
totalareaundertheplasmaconcentrationtimecurvefromtimezeroto8hrauc08hr
typical
apparentvolumeofdistributionduringtheterminalphasevzf
halfmaximalinhibitoryconcentrationic50
totalmetabolicclearance
timeaveragedrenalclearanceclr
leaching
auctdn
apparentinfluxclearance
nasalbioavailability
dl
totalaverageexcretion
areaunderthecurveforconcentrationvstimeuntil600minfromdrugadministrationauc0600
peakplasmaldconcentrationcmax
index
steadystateemtx
ratioatsteadystate
halflifeoftheearlyphase
clearancedividedbybioavailabilityclf
firstordereliminationrateconstantk30
tstoratio
areaundertheconcentrationtimecurveinhibitoryratio
timesto999kill
peakclearanceindex
relativeauc
volumeofdistributionofcentralcompartmentvcf
eliminationhalftimet12b
halflifeofinterconversion
totalradioactivity
initialmaintenancedose
tumortissuedrugconcentration
clearancefromthecentralcompartment
plasmaauc024
maximumfreeplasmalevofloxacinconcentrationfcmaxss
plasmaauc
volumeofdistributionvcf
50inhibitoryconcentrationforinhibitionof
aucfrom0toinfinity
k50
halflivesofeachphase
survivalspan
dosenormalizedbioavailability
systemictemperature
halflifeforreachingequilibrium
terminalplasmahalflivest12
plasmaglucoseconcentration
oralvolumeofdistribution
urinaryrecoveriesur
salivavsplasmaspratio
srratiosofauc
auccsf
steadystateinfusionrate
aucpg05h
netoutput
kiz
peritonealfluid
noobservableadverseeffectlevelnoael
concentrationsathalfmaximalinhibition
ratioofconcentration
accumulationindexe
urinaryrecoveryin24h
firstpassextractionratio
steadystatecocaineconcentration
areaunderthecurve0to6hour
tissuetoserumratio
apparentintercompartmentalclearanceqf
rateofclearance
fractionofdoseexcreted
volumeofdistributionvdareaf
ktc
apparentclearanceclapp
areaunderthefreemtxconcentrationvstimecurve
auc0tn
maximumplasmamianserinconcentrationcmax
aucfromtimezeroto12hpostdosingauc012
timetospontaneousrecovery
intercompartmentalclearanceqf
aucnt0infinity
maximalplasmaketoprofenconcentration
tissueconcentrationofdoxorubicintisscdox
wholebloodhalflife
areaundertheplasmamidazolamconcentrationtimecurve
steadystate5fuconcentration
secondphasehalfdisappearancetime
dosecorrectedauc24h
aucinrratio
doselevelsdls
areaundertheplasmaconcentrationtimecurveaucfromtimezerotothetimeofthelastquantifiableconcentrationauclast
cb50
nonglomerularclearance
peakrecovery
apparentrateconstant
plasmaavailabilitie
p8h
specificactivitie
excretedhalflive
areaundercurvefrom0hourtoinfinityauc0hr
aucextrapolatedtoinfinity
limitedabsorptiontime
totalamountabsorbed
areaundertheplasmafpconcentrationtimecurveuptothelastquantifiableconcentrationauclast
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityaucinf
maximumpredictedeffectemax
central
biletoplasmaaucratio
relativeauc60min
apparenteliminationrateconstantk2
da
dial
relativebioavailabilityindex
hairconcentration
areaundertheplasmaconcentrationcurveauc
maximumtoleratedinfusionrate
hepaticperfusaterate
halflifeofthedistributionphase
peakgoal
initialhalflivest12alpha
halflifematching
terminaldispositionrateconstant
floatingduration
apparentdepositionfraction
eclmet
steadystatedeliveryrate
fr
auc048
maximumnetplasmaconcentrationcmax
serumunboundfraction
plasmaantixaactivitie
bioavailabilityof
venousvolume
timetoreachthemaximumconcentrationstmax
areaundertheconcentrationtimecurvetime0tolastquantifiableconcentration
peakplasmaactivereninarconcentration
clearancefromtheperfusatecl
parkplasmaconcentrationcmax
areaundertheplasmaconcentrationtimecurvesfrom0to24hoursauc
clearanceofnapacld
meanrecoverytime
inhibitorybindingaffinity
areaunderthecurveauctot
auicoinfinity
apparenteliminationhalflivest12
meanresidencetimebasedontimezeroextrapolatedtoinfinitymrtinfobs
amnioticfluidconcentration
auc480h
timetotheprocedure
plasmareninactivitypra
fudr
thalfkeo
peakserumasaconcentrationscmax
brainexposure
areaunderthecurve010h
troughspecificlevel
areaundertheplasmaconcentrationtimecurvefrom0to9h
serumca
vc
tabs12
ivclearance
vdofthecentralcompartmentvda
gammaphasehalflive
unboundclearancebioavailability
apparentcentralvolumevf
p450content
peakumax
halfsaturatingconcentrationkm
mtdrd
ratioofauc048h
ppl
antixamax
timeofthatpeak
accumulative
effluxtransportclearancepscsfeff
aucat168h
auc024hssmic
totalmetaboliceffectaucgir010h
effectiveplasmaconcentration
cmaxratiodoxepi
integratedconcentrationtimecurveauc0112d
concentrationdosecdratio
peakfreedruglevel
ueg
crossmembranepermeabilitypm
concentrationratioat
peakplasmacilazaprilatconcentration
vz
intra
timetomaximalserumconcentrationofinsulintmax
peakparacetamolplasmaconcentration
tm
aucsthe
steadystateplasmaclearanceclss
areaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc
cavg
polydispersity
fixcplasmalevel
100
apparenttopotecanclearance
volumeofdistributionduringtheterminalexponentialphaseofdrugelimination
eliminationhalflifefromthemembranefraction
cumulativebiliarygoldexcretion
hazardindex
areaundertheplasmanifedipineconcentrationtimecurveauc0alpha
timeofmaximumserumconcentrationtmax
timeofthepeakconcentrationtmax
spillover
apparentoralvolumeofdistributionatsteadystate
ec50a
liverextractionratio
mortalityrate
proteolyticdegradationclearance
totaloralclearance
pulse
areaundertheconcentrationtimecurveat60min
equilibriumdissociationconstantkdiss
thirdorderassociationrateconstant
maximalmeanconcentration
cmaxvalue
uter05
peakplasmaamiodaroneconcentration
cbucpu
vmaxi
timetoapproachsteadystatetissuelevel
doseconcentrationratiodcratio
auc0inf
aucglucoselevel
lnratio
instrument
peakwholebloodcsalevel
clearancesofthecentralcl1
firsthalflife
protaminetoheparin
aucfororalabsorption
totalplatinumconcentration
mse
steadystatetumourplasmaratio
50inhibitoryic50concentration
firstpassextraction
ratiosofareaundertheplasmaconcentrationtimecurveover24htominimuminhibitoryconcentrationauc024mic
apparentvolumeofdistributionofatgv
bloodconcentration
plasmaconcentrationovershoot
peakmefloquineconcentration
onsethalftime
timefortofratioto
urinet12
aucpd06h
maximummtxconcentration
auctheareaunderthecurve
fmratio
unboundsteadystatevolumeofdistribution
aciddegradation
washoutt12
q040
eliminationhalflifetime
volumeofdistributiondividedbybioavailabilityvf
insc
areaundertheconcentrationtimecurvefrom0to12hour
coext
2
s50
timeofcpeak
timeofmaximumserumconcentration
accretion
oraldoseabsorbed
aucmilktoaucplasmaratio
halftimeofaneffectcompartment
braintoserumconcentrationratio
bioeffect
halflifeofthedistributionphaset12alpha
tu
basalplasmaplpconcentration
volumeofdistributionofcsaatsteadystatevdss
peakmoxifloxacinlevel
bgmax
maximalle
eliminationhalflifetl2beta
areasundertheserumconcentrationcurvesoftramadolhydrochlorideauc
blood
maximumdrugplasmaconcentrationscmax
t12fast
peakimmunoreactivebuserelinlevel
ratesoftargetattainmentforcmaxmic
aque
inputrate
bloodtobraintransferconstant
k30
oobr
t4t8ratio
accumulationpotentialeacc
maximumserumactivitycmax
biliaryexcretionrate
pseudosteadystatetargetconcentration
glucoseinfusionrate
fm
area1
absolutebioavailabilityab
fromtheperipheraltocentralcompartmentk21
totalbodyclearanceofunbounddrug
plasmaconcentrationscavgt
elutionprofile
permeabilityclearancepsbbb
steadystatetransdermaltznconcentration
troughc8h
clearancescl1
overallbreastmilkplasmaratio
antifxaactivity
ex2
totalplasmaclearancecl
uctotalplatinumratio
peakindomethacinplasmaconcentration
areaunderthecurveauc036h
secondorderrateconstantofreceptorassociationkon
peakvaluesofserumconcentration
kamt350
apparentvolumeofdistributionatsteadystate
betaphasehalflive
encapsulationefficiency
initialclearancerateconstantki
lowerdetectionlimit
areaunder
epoxidetoparentratio
aer
absorptiont12partialdifferential
colonarrivaltime
loadingefficiencie
terminalplasma
centraldistributionvolume
eliminationrateconstantk2
steadystateserumlithiumconcentration
peakplasmarifampinconcentration
timesto50recoveryoftwitch
tsolgel
volumeofdistributionvlambda
12hour
aucadriamycinolaucadriamycinratio
steadystatevolumesofdistributionvss
troughwholeblood
citrateclearance
terminalphasehalflifet12beta
timetopeakactivatedpartialthromboplastintime
secondphaset12beta
peakmethotrexateconcentration
susceptibilitydistribution
day1
cl14096h
tissuetowholebloodratio
ciiso
areaunderthecurvefordrugconcentrationinplasmaxtimeat024hour
aeaz0
oralvolumeofdistributionofthecentral
areaundertheconcentrationtimecurvefrom0to6hauc06
cl2f
lymphatic
hearinglo
areaunderthecurveofthedrugconcentrationsintime
absoluteiodide
halflifeofplasmaeliminationduringbetaphase
aerasunderthecurveauc
peakconcentrationc
maximalantifxaeffect
doublingtimefortumoraccumulation
oralauc
association
second
plasmaradioactivityconcentration
auctratio
steadystatefluxe
apparentvolumeofdistributionforthecentralcompartmentv1
recoveryofdruginurine
peakconcentrationcpeak
halflifeofdrugintheeffectcompartment
prostatictissueserumratio
auc06h
bioavailabilityaucpoauciv
chromatographicruntime
fractionofunbound
maximumplasmalidocaineconcentrationsatsteadystate
drugloadingcapacitie
oxidation
maximumserumtestosteroneconcentration
areaundertheplasmalzdconcentrationtimecurveauc24minimuminhibitoryconcentrationmic
areaundercurvefrom0to24hauc024
percentagesof
tc50
kic
timetopeakconcentrationcmaxor
apparentplasmahalflive
maximumquantity
auc02
skin
24hour
relativeclearance
semenplasmaratio
peakplasmaaaconcentration
overalltissuetoplasmapartitioncoefficient
halflivesofthedistribution
elftoplasmaratio
cmax012h
areaundertheplasmaunboundphenytoinconcentrationtimecurveauc0infinity
maximumattainableconcentrationcmax
apparentq
apparentfirstorderabsorptionrateconstant
matrixfactor
fractionofunbounddrug
auc0264h
areaunderthecurvefromadministrationtolastmeasuredconcentrationauc0last
specificreleaserateconstant
washoutratio
biologicalhalflifeofthealphaphasetalpha12
mrt0
cerebrospinalfluidplasmaratio
inhibition
areaundertheplasmaconcentrationtimecurveratio
100serumequivalentcurve
areabelowthecurveconcentrationtimeauc
samplethroughput
lipidwaterpartitioncoefficient
areaundertheconcentrationtimecurveauctau
braincsfpartitioncoefficient
areasundertheplasmatimeconcentrationcurveauc
serumunboundconcentration
inhibitoryconstantki
ratetmax
distributionconstant
fractionalabsorbance
timeofthemaximumconcentrationtmax
vfc
totalradiolabelrecovered
maximumprothrombintime
totalbodyclearanceoftheabsorbedfraction
bloodconcentrationratiors
ratesofcd4changeacd4
halflifeintheblood
snratio
predose
f2
levelatsteadystate
liverplasmaunboundconcentrationratiokpu
minimuminhibitoryconcentrationmic
tumortonormaltissueratio
cumulativeexcretedfraction
areasundertheplasmaconcentrationtimecurveupto2h
detectionthreshold
redcellplasmapartitionratio
vfvolumeofdistribution
timeofhalfmaximalincreaseinclt50
timetopeaklisinoprilserumconcentration
gammahl
peakfviiilevel
ostime
distributionhalflifet12alpha
apparentmeantotalclearanceclt
gastricretentionperiod
t2gamma
relativesystemicavailabilitie
peaksteadystateazimilideconcentration
ktrans
peakserumconcentrationcmaxofsystemicabsorption
t3clearance
med
biliaryexcretionk
eliminationhalflifeattheterminaleliminationphaset12beta
minimumconcentration
cls
gammaphasehalflife
appearancehalflife
auc048areaunderthecurve
volumeofdistributionatsteadystatevdbeta
cavgt
peakplasmaddnmconcentration
steadystateplasmaconcentrationscss
potencyfactor
volumeofdistributioninthebetaphase
parasiteclearancehalflife
wholeanalysistime
tsh
clc
brac
apparentvolumesofdistribution
timetofirstanalgesicrequest
eliminationhalflifet12lambdaz
halfmaximalclearance
unboundmetabolicclearance
excretionhalftime
accumulationfactor
un
plasmaareaunderthecurveauc0105h
sensitivity
auc024hss
severityofillne
areaundertheconcentrationvstimecurvefrom0to24hr
highestmeasuredplasmaconcentration
cltotf
maximalpostinsulinbolusconcentration
colonictissueserumconcentrationratio
residualplasmaconcentration
maximalduration
plasmadrughalflife
t12lambda2
apparenttotalbodyclearancecl
ratioaucperitoneum
plasma
areaunderthecurve048h
reabsorptionratera
timecourseofabsorption
valpha
cmaxplasmalevel
distributiontime
potencyratio
ratioofk12k21
totalfluorescence
meanresidualtime
aucepo
halflifeforaccumulationt12acc
halflifeofunchanged
timeforfloatation
areaundertheplasmaconcentrationtimecurveaucminimuminhibitoryconcentrationmicratio
steadystated
thcl
cardiac
maximalkill
volumeofdistributioninthecentralcompartmentv1
ettot
t12eliminationhalflife
timeofattainmenttmax
gt
intermediatedistributionphaset12alpha
ratioofaucaauc
kelim
in
vzf
areaunderthecurveauc010h
latencyto
k45
maximumplasmadrugconcentrationcmax
halflifeoftheterminalelimination
interstitial
areaundertheplasmaversusconcentrationtimecurve
plasmat05alpha
areaundertheplasmaticdigoxinconcentrationcurveauc12h
bodyweightnormalizedapparentoralclearance
availabilitytothesystemiccirculationf
bloodhalflifeduringthebetaphase
cmaxins
initialvolumeofdistributionincsf
steadystatevolumeofdistributionvdss
totalcaduration
relativetotalclearance
kmmet2
q1
maximumconcentrationat12hour
residualm
eliminationhalflivesbeta
bloodtolymphclearancerateofcyacllb
centralcompartmentvolumev1
i50
peakplasmainsulinconcentration
drughalflife
plasmaproteinbindingquota
totalradioactivityrecovery
peakserumfluvastatinconcentrationcmax
halflike
t1z2
timetoreachpeaklidocaineconcentration
peakfmorconcentration
dissolutionratio
sn
intrinsicclearanceoftotaldrugclint
salivatoplasmamethadone
areunderthecurve
atsteadystate
peakplasmabuprenorphineconcentration
areaundertheplasmaconcentrationtimecurveaucratio
fauc24hmic
halflifeofeliminationphase
peakmeanplasmadrugconcentration
timeaveragedplasmaketoprofenconcentration
steadystatepeakconcentration
halflifeforthedistributionphaset12a
areasunderthetimeversusconcentrationcurve
plasmaclearancedpc
c0
intertissueclearance
cp3h
daystoinitiationoftesting
relativebioavailabilityfrb
totalserumclearance
ff
auc07h
plasmatroughlevel
clintliver0
areasundertheserumconcentrationversustimecurvesaucs
maximumapparentsteadystatealmitrinelevel
iki
bloodplasmaratio
paco2
cellulardistributionvolume
areaunderthebactericidalcurveaubc
percentageabsorbed
eliminationhalflifet12m
rateofeliminationkelim
effluxrateconstantsratio
areaundertheconcentrationtimecurveaucc
terminalfirstorderrateconstantbeta
bloodtoplasmaradioactivityaucinfratio
vdvt
flux
halftimet05beta
drugclearanceclf
troughcminconcentration
urinerecovery
maximummidazolamconcentration
plasmaalfaxalone
measurable
maximumflowrate
steadystateserumphenytoinconcentration
apparenthalflifeoftacrolimust12z
doseplasmaconcentrationratiodc
annualizedinfectionsrate
fractionofunboundpethidine
c0threshold
meanresidencetimemrt0
areaundertheconcentrationtimecurveauc09days
delaytime
areaundertheconcentrationtimecurvefrom0htoinfinityauc0infinity
rf
timetofirstoccurrence
cmaxblood
gelstrength
bioconversiont12
halflifeofgametocytaemia
percentin
dosenormalized
auccsfaucserum0120minconcentrationratio
auc08ratio
durationoftime
maximumtolerabledose
aucincreaseratio
wholebloodclearancebioavailability
areaauc0infinityundertheplasmaconcentrationtimecurve
peakplasma5fuconcentration
aucfromtimezerotothetimeofthelastmeasurableconcentrationauclast
maximumvelocityofeliminationvmax
disin
am
peaklevelofdrugconcentrationin
peakplasmaconcentrationsmic
areaunderthecurvefromtime0totheendpoint
sir
highestmeasuredconcentration
confirmedcompleteresponserate
initialhalflifet12lambda1
timeofmaximalconcentrationtmax
biologichalflifeintheeliminationphase
steadystatemaximumconcentration
vgamman
bloodtroughc
halflifeinserum
terminalvolumesofdistribution
peakpbzplasmaconcentration
quasisteadystateconstant
percenturinaryexcretion
intraperitonealbioavailability
timetorecovery
apparentplasmadisappearancehalflivest12
interfaceflowrate
clearanceratio
tissuet12
natriuresi
effectsiteamount
cmax012
concentrationratioslymph
conversionyield
areaunderthetimeconcentrationcurvefrom012hauc012
maximuminhibition
plasmahalflifetbeta
unboundprednisoloneclearance
clfim
urineconcentrationratio
maximumprednisoloneplasmalevel
recoveryefficiencie
clearancemrt
areaundertheconcentrationtimecurveover24hoursieonedosingintervalauctau
productionrate
areaundertheconcentrationtimecurvefromtimezerotothetimeoflastnonzeroconcentrationauc0t
timeoftransferringfromcentraltoeffectcompartment
recoverypercent
timetothepeakplasmadrugconcentration
peakcontent
braindistributionspace
totalfaecalrecovery
minimumobservedconcentrationcmin
freeareaunderthecurvefrom0to8hfauc08
michaelismentenconstant
steadystateantifactorxaactivitie
maximumplasmalevelsreached
glucuronidation
halftimet12beta
clearancerateconstantkmono
volumesofdistributionvcf
terminalhalflifet12alpha
halflifet12eff
maximumirinotecanplasmaconcentration
maximumplasmafolateresponse
halflivesofserumlevel
steadystatefluxjss
skinpermeation
halflifeofbetaelimination
volumeofdistributionvssratio
apparentvolumeofdistributionforthecentralcompartmentvdf
areaunderplasmaconcentrationtimecurveextrapolatedtoinfinityauc0
incorporationcapacity
aucfromtimezerotothelastmeasurableplasmaamilorideconcentration
steadystateauct
dnf
normalizedrecovery
t9
masstransition
hepaticfirstpassextraction
basalplasmaplconcentration
vdc
apparenthalflife
kf
volumeofdistributionof
plasmaresidencetimesmrt
reten
renalplasmaflow
auc08hdose
stre
lagtimebeforeabsorptioncommenced
permeationrateconstant
viscosity
auc072
operativeapparentvolumeofdistributionvdf
distributiont12a
plasmaconcentrationtime
apparentpermeabilitypapp
peaklisinoprilserumconcentration
maximumurineconcentration
maximalplasmaunboundpropiverineequivalentscmax
areaunderthe8c2plasmaconcentrationtimecurveforthelengthofthestudyauc014d
maximalplasmaurodilatinlevel
areaunderthecurveexposurefromt0tot8hoursauc08
ureaclearance
overallclinicalresponserate
peakplasmatheophyllineconcentration
bioavilaibility
determinationlimit
twentyfourhour
minimalplasmaconcentrationctroug
systemicplasmalevel
distalabsolutereabsorptionofsodium
peaklevelsofradioactivity
totaleliminationhalflife
clbile
areaunderthecurvefromtime0tothelastquantifiablesampleauc0tlast
diameterszaverage
plasmaresidencetime
totalareaunderthetotalplasmaconcentrationtimecurveauc012
betaphaseeliminationhalftime
fastingcpeptide
maximumnimesulideconcentration
cls1
troughmmflevel
plasmabloodconcentrationratio
peaktheophylline
maximumplasmalidocaineconcentration
extractionefficacy
tumourgrowthdelaytime
areaunderthebiliaryexcretionratetimecurveauc
oralfluidconcentration
tissuepenetrationfactor
eliminationofalcoholfrombreath
auctargetattainment
timetohalfrecovery
bec
aucpl
areaundertheplasmaconcentrationvstimecurve
normalizedfreeplasmaconcentration
pefr
concentrationinbrain
mi
nocturnalsleeptime
areasundertheplasmavstimeconcentrationcurvein24hauc024
apparentke0
uvdetectionwavelength
totaldistributionvolumeduringtheterminalslope
mf
apparentcornealpermeabilitycoefficient
recoveredpercentage
sustained
auc0tlqc
cp21stday
tr
apparentequilibriumdissociationconstantkd
em50
terminalhalflivest12gamma
metabolicclearance
areaundertheconcentrationtimecurveauc012hours
mic80
oralintercompartmentalclearance
conversionratio
terminalhalflifet12lz
ec90
ke0model
maximumconcentrationratio
limit
transitfromcentraltoperipheralcompartmentskcp
tsc
kalphapac
intrinsicrate
oralsystemicclearanceclf
secondcomponenthalflife
penetrationofunbounddrug
plasmacurve
maximumobserveddrugconcentrationcmax
peaksteadystateserumconcentration
absorptionhalflifek01hl
perfusion
timetopeakplasmaconcentrationcmax
decelerationrate
drugcontent
systemicmeanresidencetime
adsorption
transdermalcmax
terminalphaseeliminationhalflifet12z
initialapparenthalflive
mweff
sfv
apparenttheophyllineclearance
average
highestdetectedconcentration
auc0approximatelyinfinityratio
areaunderthecurvefromtime0tothelastquantifiableconcentration
areaundertheconcentrationtimecurvefrom0to48h
rapidphaset12
plasmaturnover
skeletalretention
areaunderthecurveauc048
bloodlambda3
nagg
halflifeofhepaticuptake
turnoverhalflife
concentrationat1hc1h
timetoattainmaximumconcentration
vmax2
areaundertheconcentrationtimecurvefromzeroto8hrauc08hr
apc
dnaadductformation
plasmaconcentrationofo
globalt12
vssvolumeofdistributionatsteadystate
ic50ki
clinicalcurerate
timetoattaincmaxtmax
bioavailibility
areaundertheplasmaconcentrationtimecurvefrombaselineto8hoursratio
pf
areaunderthecurveofthefirst4hauc04
terminalhalflifeofdrug
peakhydralazineconcentrationcp
peako6bgcsfconcentration
masstochargemzratio
fractionsmetabolizedfm
peakcfen
residualthrombu
peakmphconcentration
renalfraction
percentdrugreleased
durationofthezeroorderabsorptiontk0
volumeofdistributionratiovdcvdt
totalserumdrugconcentration
ratioofauc08hsteadystateauc08h
fractionalsurvival
distributionvolumeofthecentralroom
halfmaximaleffectpec50
maximuminitialdose
peaktotroughfluctuationratio
tissuearterialbloodratio
auc0336
steadystateserumlevel
maxima
extractrecoverie
halflifeoftotalradioactivityelimination
activityresponseatpeaklevel
bindingki
cbcfratio
clodv
totalptconcentration
25recoveryoftwitchheight
peakserumdigoxinconcentration
totalplasmaprednisolonelevel
clearanceofhemodiafiltration
timetoreachpeakheartrate
thke
areaundercurveauc04h
apparentperipheraldistributionvolumev3f
vdsslkg
clinicaleffectivenessratio
maximumdoxcellularconcentration
intrinsicclearanceclintvmaxkm
cumulative
biologicalhalflifet12el
relativeironbioavailabilitie
timetoreachearlyburstsuppression
steadystateplasmaareaundertheconcentrationtimecurveauc
potencyed50
timetotof
apparentsteadystatevolumeofdistributionvss
steadystateconcentrationofdrug
clearancetime
n
vmaxinduced
unbounddrugcl
renalexcretoryclearancetogfrratio
525recoverytime
halllife
volumeofthecentralcompartmentv1
mtd
bindingratio
freeauc06
sap
postinjectiontimetmax
areaunderthecurveau
cardiacindex
molarratio
dissociationconstant
competitiveki
areaundertheconcentrationtimecurvefromdosingto12hourspostdoseauc012h
emaxmaximumeffectoninputrate
90effectiveconcentration
bloodbrainbarrierpenetratingpotential
fastedstateabsolutebioavailabilityf
serumeliminationhalflivest12
aucfromtime0toinfinity
plasmawholebloodconcentrationratio
auc24mpc
steadystateserummorphineconcentration
effectiverenalplasmaflowerpf
mic90minimuminhibitoryconcentrationrequiredtoinhibit
eliminationhalflifeofalfentanilt12beta
areaundertheeffecttimecurveover8h
space
vp
totalpharmacokineticflow
partitioningratio
areaunderthecurvebetween0and24hauc024
peakplasmafamotidineconcentration
volumeofdistributionf
timestothepeaklevel
t12kel
aucupto12h
auc0infinity
targetplasmaconcentrationtpc
peaknitroglycerinconcentration
dynamicrange
50inhibitoryconcentrationsic50s
gradientelutionflow
livervolume
plasmaexposuresauc
maximumobservedplasmaconcentration
size
depressionofskeletalmuscletwitchheighted95t
areaunderthepercentinhibitiontimecurveover72hour
auv0infinity
bloodconcentrationat50ofmaximumeffect
maximalbindingcapacity
overallsurvivalperiod
peakflavopiridolconcentration
clearanceratek1
biliaryexcretionindexbei
energiesofactivation
bloodconcentrationcp
aucskinwindowaucserumratio
trueabsorption
kpl
potencyic50
neointimalarea
areaunderthecurvefromtimezerotoinfinityauc0
clpxf
minimumeffectiveserumconcentration
q055
halflifeinthesecondphase
dti
oralrelativebioavailability
apparenttotalclearanceafteroraladministrationcltotf
plasmaaucmicratio
halftimet12ke0
h
apparentvolume
peakplasmalevelcmax
mrth
feno
initialclearanceoffdopatostriatumk1d
urinaryclearance
apparentvolumesofdistributionv1
areaundertheplasmaconcentrationtimecurveaucfromtime024hauc24
timeofnadir
areaunderthebloodconcentrationtimecurvefromtime0totimeinfinity
dissociationconstantkd1
steadystatebraintoplasmaunboundconcentrationratio
maximumconcentrationintheplasmacmax
volumeofthebodycompartmentvareaf
bbbeff
timetosteadystatetss
brainblooduptakeratio
fluorescenceintensity
peakplasmaconcentrationcmax090min
inhibitoryeffect
maximalbileplasmaconcentrationratio
arterialoxygentensionpao2
maximaldrugabsorption
sdc
iic50
ventricularrateatpeakplasmaverapamilconcentration
effectivetimeuntilreturnto50deltapdet50
maximumtotalplasmatopotecanconcentration
concentrationplasmaconcentrationratio
omaxec50
areaundertheconcentrationversustimecurveauc04hour
apparentcompartmentalvolumesofdistribution
boneconcentrationmic
dissociationconstantk
areaunderthetimeconcentrationcurvefrom0to12h
plasmane
ratioofauc0
annualizedbleedingrateabr
areaundertheconcentrationtimecurveaucfromtimezerohourstoinfinityaucinf
auc024hresponse
cpeak
inratio
auclastmic
confirmedresponserate
annualjointbleed
washouthalflive
invivorecoverie
rateofsecretion
kpuuliver
activityfactor
unboundareaundertheplasmaconcentrationtimecurveminimuminhibitoryconcentrationmictarget
urxf
percentdoserecovered
cd4cellcount
apparentoralclearancecl
placentalclearanceindex
distributionphaset12
absolutebioavailabilityfab
timetomaximumvenousconcentration
maximumpercentcumulativedrugrelease
percentreductionratio
steadystatemaximumplasmaconcentrationcssmax
areaunderthecurvewindow
permeationinfluxrate
areaundertheconcentrationtimecurvefrom0toinfinity
timetosinussterilization
eliminationhalflifefromplasma
maximumalendronateplasmaconcentrationcmax
secretoryrate
areaundertheconcentrationvstimecurveauc0infinity
orallethaldose50ld50
vd
overallvolumeofdistribution
ldr
mtx
halfsaturationconcentration
volumeofdistributionofperipheralcompartmentvpf
penetrationinto
transportrate
mr
areaunderthecurvefrom0to12hauc012h
timelagtlag
peakwidth
t0
ft207
ic50the
timetorecoveryof25neuromusculartransmissiont25
selectivityratio
csfplasmasteadystateconcentrationratio
testosteroneconcentrationcave024
45minuteto5minuteratio
clearanceclpred
ftr
fractionofdoseabsorbedfa
susceptibilitybreakpoint
unboundbloodfraction
areaundertheplasmaactivereninversustimecurve0to24hours
tissueplasmaareaundertheconcentrationtimecurveratio
bleedingtime
cd
kamt150
areaunderthefentanylplasmaconcentrationtimecurvefrom0to18h
invasionconstant
apparentvolumeoftheperipheralcompartmentv2
auc09h
pra
cmaxmic
areasundertheconcentrationtimecurvesaucs
troughplasmaphenytoinconcentration
timetopeakgirtmaxgir
areaundertheplasmaconcentrationtimecurve0168hours
redcellconcentration
uosm
biologicalhalflifet2
waitingtimefor
aucs4h
peakplasmasch39304concentration
vdatsteadystate
rateconstantfortransportto
distributionhalflive
processefficiencie
areaundertheconcentrationtimecurveover12h
maximumheartrateincreaseemax
penetrationhalftimeintocsf
invivorecovery
normalizedareasunderthecurve
timetonormalization
plasmaclearence
kint
maximumserumconcentrationc0p
timetoreachtheconcentrationpeak
accumulationindexaucday19aucday1at
distributionalclearance
oralclearancerate
terminaleliminationhalflife
halfmaximalinhibition
maximummeasuredplasmataconcentration
ic95
volumeofdistributionvarea
intrinsicclbiliary
timerequiredtoreachthecmax
partitioningtoerythrocyte
timetoreachmaximuminsulinactiontgirmax
method
serumpeakvalue
detectionlimitsn
fetalmaternal
peakplasmaalendronateconcentration
maximumvelocityofelimination
timeuptothemaximumserumconcentration
terminalexcretionhalflife
bioavailabilityenhancement
volumeofthebodyfluidspaceexpanded
dosecorrectedcmax
maximumplasmatrovafloxacinconcentration
arterial
maximumplasmadrugconcentration
peakfviiic
maximumnasalmucusdrugconcentration
recoverytimestot1
clearanceratescl
drugtolipidratio
timetocastratesuppression
rateofeliminationfrombodyb
endometrial
terminaleliminationhalflifevaluest12
cmaxmaximalldopaconcentrationreached
maximumlidocainelevel
areaunderthecurveofbloodcsaversustimeauciv
hemofiltrateclearance
bioconcentrationfactorbcf
partialpressureofoxygenathalfsaturation
aucnt
peakflow
mobilityratio
precursorproducttransition
polydispersitypdi
lastdetectableplasmaconcentrationtmax
auc48hours
hepaticclearanceclhpre
crrate
peakcsfmtxconcentration
auc0
adipose
maximumserumglucoseconcentrationcmax
totalglucoseinfused
timetofirstasthmaexacerbation
internalvolume
intracellularpersistingfraction
timetocompletedisintegration
overalldrugtargetingefficiencyte
fractionalturnoverrate
absolutef
areaundertheconcentrationtimecurveat24hauc24
clearanceperfractionofdoseabsorbed
doserecoverypercent
areaunderthecurveauc12hours
firstdosetroughlevelcmin1
du
apparentdissociationhalflive
constant
maximuminhibitionimax
biophasedistributionrateconstant
timetosteadystateserumttconcentration
eliminationhalflifet12
plasmaaxaactivity
saturableeliminationkm
inputkin
centralv1
arterialclearance
plasmaconcentrationscmax
o
percenttime
t1
terminaleliminationhalflifet12lambdaz
csstot
renalsynthesi
pr
maximumserumtheophyllineconcentration
areaunderplasmaconcentrationtimecurveauct
lagphase
freeaucpo
highestunboundropivacaineconcentrationcumax
totalanalysisruntime
timetopeakbloodconcentration
areasundertheconcentrationcurvesaucs
volumeofdistributionofthecentralcompartmentv1
timestomaximalserumconcentrationtmax
areaundertheconcentrationtimecurvefromzerotoinfinityauc0inf
steadystatemolarratio
criticalmicelleconcentration
resistancebreakpoint
drainageflowrate
areaundertheplasmaconcentrationtimecurvesfromtime0toinfinityauc0inf
peakplasmaatralevel
minimalmeanconcentrationsat
bloodtobiledistributionratioskaucbileaucblood
relativebraindistributioncoefficient
brainplasmapartitioning
fatbloodconcentrationratio
apparentvolumesofdistributioninthecentralv1
ratiobetweenplasmaclearanceand
maximumppbg
atsteadystateplasmaconcentration
exposuretovilaprisanauc
volumeinthesteadystate
freefractionsrfxratio
tumorweightinhibitionrate
vssn
areaundertheserumconcentrationvstimecurveauc
molarratioofdailyproductionrate
minimumquantifiablelevel
clz
timetonormalizationofrespiratoryfunction
partialclearance
peakglp2level
complete
betaphaseeliminationhalflive
passivetransdermalflux
peak3hlevel
areaundertheconcentrationtimecurveaucfromtimezerotothelastquantifiableconcentrationauc0tlqc
auc0were
tmaxh
maximumurineconcentrationcumax
maximumrateofmetabolismvmax
distributionvolumeplasma
apparentc
ratioofintercompartmentalrateconstantsk12k21
clexcretion
peakheight
maximalconcentrationofdruginplasmacmax
halflifeofthefirstphase
peakaqueoushumorconcentration
efficacie
areaundertheconcentrationtimecurvefrom0hto12h
peakplasmaphelnaaratio
totalareasundertheimipenemserumconcentrationcurvesaucstoinfinity
plasmaeliminationhalftime
areaunderthecurveauc0720min
biologichalflive
eliminationconstantratemax
auc0yen
maximalnasalabsorption
areaunderplasmaconcentrationstimecurve
areaunderthetimeactivitycurve
areaundertheconcentrationtimecurveuntil24hour
volumesofdistributionofthecentralcompartment
kg1
eliminationt12ehalflive
apparentvolumeofdistributionvd
areaunderthecurvefromtimezerotoinfinity
bioaccessibilitie
maximumgemcitabineplasmaconcentrationcmax
areaundertheconcentrationversustimecurvefromthelastdosetoinfinity
rateconstantoflambdaiv1
areaundertheserumconcentrationversustimecurve
corneal
serumbioavailability
apparentvolumeofdistributionforthecentralcompartment
volumeofdrugdistribution
acidsecretion
oilgaspartitioncoefficient
totalalload
cthalflife
semihydrolysistime
recovery
areaunderplasmaconcentrationtimecurve
absorptionfromdosingto30minutesauc30
altalto
troughatsteadystate
timetopeakcmax
cmax1mic
cellularaccumulationratio
peaksalivarycaffeineconcentration
areaundertheplasmaconcentrationtimecurveaucfromtimezerotoinfinityaucinfinity
steadystatemaximumplasmaconcentrationscmaxss
sslope
percentageof
apparentelimination
renalclearancevr
serumhalflife
interstitialfluidspace
serumhalflivest12s
morningplasmaconcentration
morningtrough
plateautime
percententrapmentefficienciesee
cmaxcminratioatsteadystateconcentration
areaundertheconcentrationtimecurvefromtime0toinfinityauc0
troughiggconcentration
auc01
tubularsecretionclearance
residual
serumhalflive
areaundertheplasmaconcentrationcurve
absorptionrateka
glucoseproduction
overallratio
areaundertheplasmadrugconcentrationtimecurve012hoursauc012
dosenormalizedplasmaconcentration
50effectivedosesed50
urineproduction
peaktotroughasenapineplasmaconcentrationratio
terminalrateconstant
auchyd
terminaleliminationhalflifeatsteadystate
apparentmeaneliminationhalflife
volumecorrectedbyrealbodyweightvsskg1
concentrationratiouvmv
maximumaveragecmax
totaldrugtroughconcentration
terminalelimination
areaundertheconcentrationtimecurvefromzerotothelastmeasurabletimepoint
aucskin012h
peakplasmamorphineconcentration
renalplasmaclearance
percenttumornecrosi
medianplasmaconcentration
lagtimebeforeappearance
relativerecovery
serumbinding
areaundertheinsulinaspartvstimecurve
totalsmz
maximumalmitrineplasmaconcentrationcmax
durationofcr
timefor75tobereleasedt75
volumeofdistributionbytheareamethod
durationofbleeding
oralmidazolam
maintenanceconcentration
areaunderthetimeversusconcentrationcurveauc
minimumthreshold
physicalhalflife
totalbloodclearanceci
intermediatet12
areaundertheplasmaconcentrationtimecurveauc0tau
firstdosetimeatwhichmaximalconcentrationisreachedtmax
gasflowrate
freefractionfp
auecinfinity
aqueouspeak
aucmilkaucplasmaratio
redbloodcellplasmadistributioncoefficient
totaleliminationconstantk10
ec99
maximumforcedexpiratoryvolume
totalclearance
troughc0
totalnumberoftransitcompartment
plasmafinalhalflife
volumesofdistributionbioavailabilityv1f
serumclearancecls
apparentexcretion
eliminationhalflifet12gamma
terminalmelphalan
apparenteliminationhalflife
eliminationhalflivest12lz
od
apparentmichaelismentenconstantkmapp
latebiologicalhalflifeplasma
freeauc024mic
auc024h
totalplatinumptconcentrationpttotal
arterialbloodconcentration
renaleliminationrateconstant
steadystatemedian
steadystatetroughserumconcentration
peakplasmavpaconcentrationcmax
dosenormalizedpeakplasmaconcentrationcmax
clfatsteadystate
maximumobservedlevel
areaundertheplasmaconcentrationcurveaucbetween0to8hour
spinlatticerelaxationtime
apparentoralmidazolamclearance
t12oftheterminaldeclineinplasmaconcentration
maximumplasmamilrinoneconcentration
areasunderthebloodconcentrationtimecurvesauc0infinity
hepatobiliaryexcretionratio
intercompartmentaltransportclearance
inhibitionemax
areaunderthecurvefrom0to24hoursauc
peakprinterval
timetopeakmexi
detectiontimeadvice
maximumplasmadoxycyclineconcentration
maximumfreeplasmaconcentration
totalareasundertheconcentrationtimecurve
ramsaysedationscorerss
formationrateconstant
apparenttotalbiliaryclearance
criticalmicelleconcentrationcmc
totalturnover
clactive
timetoplateau
plateauserummtxconcentration
txb2
biovailability
maximumvitrealconcentration
steadystatevolumeofdistribution
steadystatedistributionvolumesvdss
halflifeextensionratio
axaactivity
absorptionhalflifetime
photoncount
troughsmethadoneplasmalevel
csf
dispositioneliminationhalflife
relativeoralfastedbioavailability
meanabsorptiontime
cpmaxivcpmaxihep
perfusatetoplasmadrugleakage
sraucratio
tissuebloodratiosofradioactivityconcentration
oralcecaltransittime
cmaxofradioactivity
timestoreachpeaklevel
areasundertheplasmastconcentrationversustimecurvesauc
timestoprogression
timeofingestion
apparentvdvdapp
peakganciclovirconcentration
volumeofsteadystate
maximumpeakofexcretion
volumeofthesecondcompartment
apparentvolumeofdistributionvssf
volumeofdistributionbytheareamethodvarea
penetrationindex
aucoinf
areaunderthefirstmomentcurve
watercontent
minimummeasurablelevel
totalg
apparenteliminationrate
surfacecharge
timeofmaximumplasmaconcentrationtmax
lp
areaundertheconcentrationtimecurvewithinadosingintervalauctau
aucnorm
deltae
maximumnonlinearclearancevmaxkm
fractionof
michaelistypeconstant
metabolicratiorm
maximumseruminsulinconcentrationcmaxins
intrahepaticconcentration
auc50cauc50
peakserum5asaconcentration
spplasmaratio
braintissueletrozole
vmaxinfinity
ratioofformationabsorptionrateconstant
plasmaurate
areaundertheplasmaconcentrationtimecurvecxt
wholebloodclearance
c1h2h
ctr
firstordereliminationbioavailability
auc07
plasmaunboundfractionfu
effectsiteconcentrationcausing50ofemax
maximumserumcarbamazepineconcentration
fractionofthedoseeliminated
areaundertheserumconcentrationcurvefrom0toinfinity
releasepercentage
areaunderthecurvefromtime0toinfinityauc0inf
totalclearancecltf
releasepercent
meanresidencetimemrt072h
maximumminimumratioofplasmaconcentration
apparentrenalclearanceclrf
clbi
numberofbleedingday
secondintercompartmentalclearance
auczerolastratio
survival
ventricularrate
invivobindingrate
transdermalpermeationrate
timetoreachpeakserumconcentrationtmax
distributionvolumeofthecentralcompartmentv1
peaktroughdifference
individualplasmaconcentration
peakplasmaconcentration
maximumgranisetronplasmaconcentration
dosenormalizedareaunderthecurveaucdnauc24h
ec50concentration
timetakentopeakconcentration
maximummeasuredplasmaconcentrationcmax
durationofthemotorblock
populationoralclearance
plasmaconcentrationatsteadystatecss
interpuffinterval
runcycletime
entrapmentpercent
peripheralvolume
apparentclearancedosescauc
absoluteavailabilitie
eliminationhalflifet12yz
concentrationmax
timetoreachmaximumplasmacodeineconcentrations
pre
unboundcentralvolumeofdistribution
cpeptide
intercompartmentalcl
timetopeakserumconcentrationtmax
totalcave50
highestendometrialconcentration
c05h
totalmeanrecovery
ggt
auc24h
maximumantibioticconcentration
serumconcentrationcmax
mucoadhesiveforce
restingplasmaanflevel
areaunderthesildenafilplasmaconcentrationtimecurvefromtimezerotoinfinityauc0infinity
maximumserumlevel
areaundertheconcentrationtimecurveto12hour
timeoflastdetection
freefractioninserum
aucmilkaucplasma
concentrationratiosincsfserum
volumesofdistributionvf
halflivest12beta
apparentoralplasmaclearance
apparentvolumeofdistributionvbeta
areaundertheplasmaconcentrationtimecurveauc0tn
elasticmodulu
apparentoralclearancerate
maximumvelocitie
basalpower
cpss90
daucgluc
time
rectalabsorptioncondition
auc005
areasunderplasmacurve
timetoobtainthepeakplasmaconcentrationtmax
timetopeakinsulinconcentration
clearanceratiocsagfr
halflivesoftheinitialphaset12alpha
unboundvolumesofdistribution
peakplasmaclzconcentrationcmax
areaunderthecurveaucfrom0to24hoursauc024
sedimentationrate
radiolabeling
durationofinfusion
tmaxthetimetoreachmaximumconcentration
kform
specificsurface
kmtheapparentinvivomichaelisconstant
prostateconcentration
extractione
totalareaundertheplasmaz
eliminationbeta
aucextrapolatedtoinfinityaucinfinity
permanentclosurerate
peakic
oraldoseequaling50occupancy
percentagecumulativeexcretion
weightnormalizedcentralcompartmentvolume
rateofurinaryelimination
slopeks
tbr
areasundertheconcentrationtimecurvesauc0
drugdeposition
maximumciprofloxacinconcentration
tlagtime
areaunderthecurveuntildrugremoval
troughlevelc0
timetoreach200nmoll
csfplasmaunboundratio
areaundertheplasmaconcentrationtimecurvefrom0to3hoursauc03hr
partitioncoefficientslogp
c01havg
vmax
intracellularconcentrationtoextracellularconcentrationratio
apparentvolumeofdistributionvdsf
timetoreachmaximumdrugconcentrationtmax
areaundertheserumconcentrationtimecurvefromtime0tothelastbloodsamplingtimeattimett
residualactivity
basalconcentrationc0
timetothepeakconcentration
halflifeofelimination
bonetoserumratio
ttag
areaundertheserumconcentrationversustimecurveauc
t12re
areaunderthebloodethanoltimecurveauc
peakcisaprideconcentrationc0
areaundertheplasmaconcentrationversustimecurvefromtime0to72hauc072h
polydispersityin
effectivehalflifet12acc
auc8
numberofrespiratoryeventsper
peakmtxpdxconcentration
hydroxyl
lateproximaltfpli
clearancewith
meanresidencetimeinperipheraltissuesmrtp
pd50
k10halflife
maximalconcentration
timetoundetectablerituximab
minimumconcentrationscmin
unboundclearancecluf
maximumobservedserumfentanylconcentration
ratioofperipheraltocentrallungdeposition
terminaleliminationrate
terminaleliminationrateconstantlz
halfthemaximaleffectec50
timefrom
detectionwindow
volumeofdistributionduringtheeliminationphase
areaunderthesalivaflowtimecurve
apparentrenalclearanceoftheactiveantipsychoticfraction
volumeofdistributionbasedontotalarea
shedantigen
keliminationrateconstant
volumeofdistributionattheterminalphasesvdlambdaz
drugtoantibodyratiodar
apparentterminalhalflifet12beta
areaunderthecurveoveradosingintervalauc
maximaldrug
tntratio
apparentec50
duration
eliminatedquantitie
activatedpartialthromboplastintimeaptt
halfmaximaleffect
maximumadditionalexcretionrateofsodium
percentageinhibitioniss
areaundertheeffectcurveauec
saturableelimination
t12t
acute
steadystatecsfplasmaratio
peakdiazepamconcentrationcmax
maximummilkotcconcentration
aucinfinitymeanratio
formationclearanceclf
pseudosteadystatelevel
auc2436h
clinicalresponseratecrpr
pressure
accessibleplasmalevel
steadystateaucattimetaucsst
normalizedclearancerate
maximumtoleratedplasmaconcentration
grupo1
total14cdoserecoverie
auc024mictarget
maximumconcentrationobservedcmax
heartplasmaaucratio
areaunderthecurvegirauc
limitsofquantification
maximalchangeineffectmeasurefrombaselineemax
areaundertheconcentrationtimecurveauctruncatedat2daysauc2
residualclearance
maximumarteriallevobupivacaineconcentration
cssmaxd
mic70
portionofthefreefraction
renalclearanceclt
maximummeanincrease
volumeofdistributionduringtheterminaleliminationphasevdbeta
normalizedareaunderthecurveaucd
dispositiondistributionhalflife
talpha
incre
eliminationt12betahalflife
troughdrugconcentration
auc0mic
initialhalflifet12
maximumnalbuphineconcentrationscmax
totaldrug
totalbioavailability
effectiveexposure
tumorgrowthrate
columnlife
firstorderabsorptionrateka
vas2h
maximummetabolizingcapacity
tmaxobservedtimetomaximumconcentration
plasmafreefraction
areasundertheserumconcentrationtimecurvesauc028
maximaltoleratedauc
areaunderthebloodconcentrationcurveauc0
peakplasmaflurbiprofenconcentration
peakpcthreshold
oralbioavailibility
steadyrateserummorphineconcentration
betaeliminationhalflife
tdflux
csubmaxsub
specific
aucplasma012h
liquidpassagefrom
plasmaaucratio
timetoreachthemaximumplasmaconcentrationtmax
t12alpha
fractionofthedrugunboundinplasma
lagtimeofabsorption
srl
timetoatrainoffourratio
renalurateclearance
maximumconcentrationofdrugcmax
areaunderplasmaconcentrationtimecurvefromtimezerototimeinfinityauc
peakrd
halfofemax
beta12
halflifeoftherapid
entrydistributionvolumevc
analyticalrecovery
peaknimodipineplasmaconcentration
highestachievedconcentration
hepaticbioavailability
overalleliminationconstantke1
bodysurfaceareaatsteadystate
apparentuptakerateconstant
eliminationrateconstantk34
clearanceclforal
ratiosofexcretion
absorptionauc0tlast
c0d
clearancenormalizedforbioavailabilityf
areasunderthetimeconcentrationcurvesauc
pef
bioavailabilityrate
areaundertheserumfentanylconcentrationtimecurve072h
hepaticextractionratiofh
saturatedeliminationratevxvmax
penetrationrateconstant
excretedamount
activationenergyofthermaldegradation
steadystateareasundertheconcentrationtimecurve
adsorptioncapacitie
rapiddecayconstant
limitsofdetectionslod
lagtimeinabsorption
extension
maximalplasmadrugconcentrationcmax
maximumcmax
peakconcentrationtmax
troughwholebloodlevel
cmaxmaximumplasmaconcentration
initialvolumeofdistributionv1
skinretentionpermeationratio
gastricemptyingt90
fpxloading
apparentk11
transportconstant
renalelimination
auc240ria
maximumcbzconcentrationscmax
kmiu
ctrough8a
fluideliminationhalflive
areaundertheplasmamycophenolicacidconcentrationversustimecurvesauc012
plasmaconcentrationsratio
cmaxmaximumconcentration
milkcmax
areaundertheplasmaconcentrationversustimecurvefromtime0hto12hauc012
timeabovethesu
l
accuracy
glucuronide
areasundertheplasmaconcentrationtimecurveoveroneadministrationintervalof12hoursauctau
terminaleliminationhalflifet12beta
lineardynamicrange
overallresponseratesorrs
ratesofethanolelimination
systemicbioavailabilityratio
nonspecificclearance
c6h
c05hour
timetorecoveryfromanesthesia
ed95t
areaunderconcentrationtimecurveaucfrom0to12hour
timetoalleviation
timetoreachmaximalserumconcentrationtmax
responserate
bodyclearancecl
areasundertheconcentrationversustimecurve012hauc012
areaunderthetimeconcentrationcurveaucfromzerotoinfinity
morphineaucblood
lungclearancerate
serumclearance
neteffluxbaab
accumulationratiosaucsteadystate024haucsingledose0infinity
radiochemicalpurity
peripheralcompartmentvolumeofdistribution
maximumplasmaconcentrationofmesalazinecmax
sodiumclearance
ic50cox1ic50cox2ratio
terminalplasmahalftime
ctrough1
flowtime
brainextractionratio
apparenttotalplasmaclearance
effluxrateconstantk2
forcedexpiratoryvolumein1secfev1
acd4
2hc2
timetoreachpeakplasmaconcentrationtmax
peakendof
areaundertheplasmaconcentrationtimecurvefromtime0to12hauc024h
longterminalhalflife
apparentvolumesofdistributionvdf
peakgefitinibplasmaconcentration
concentrationscmax
biliaryexcretionration
morcod
pulmonaryhalflife
aucgas24
mpt
admissionplasmaconcentration
terminalhalflifetime
microbiologicallyactiveconcentration
ratiosoffauc024hmic90
weightnormalizedauc08
aucmtx
maximumtumorsuv
maximumofplasmaconcentrationcmax
halflifeofserumelimination
accumulationratiorac
areaundertheserumconcentrationcurvetoinfinityauc
totalapparentvolumeofdistributionvdss
absorptionenhancementratio
volumeoftheperipheralcompartmentvt
percentage12hrenalelimination
areaundertheconcentrationcurveratio
breakthroughresponse
peakplasmamidazolamconcentration
bloodpoolhalflife
peakplasmalorazepamconcentration
red
slowerphaset12
instillationabsorptionrate
relativeoralbioavailabilityfr
aucss
halflifehl
maximalencapsulation
s05
steadystatelevel
dosenormalizedareaundertheconcentrationtimecurvefromtime0to120hour
areaunderthecurvefrom0to36h
inputratekin
eliminationphasedispositionhalflifet12beta
maximumsafeplasmaconcentration
salivatotalplasmaconcentrationsspratio
peakoccupancie
extractionrate
percentbound
intercompartmentalclearanceconstantsfromcentraltoperipheral
bindingpotential
maximalincreaseinfvc
terminalphasehalflifet12
particlesizesz
plasmaareaundertheconcentrationtimecurveauc
percentageofdrugabsorbed
transportefficiency
progressionfreesurvivalpsf
sweatclearance
timetoachievethismaximumconcentrationtmax
areaundertheplasmaconcentrationtimecurvefromtimezerotolastsamplingtimeauc0t
areaundertheconcentrationtimecurvefrom0
storage
areasundertheconcentrationtimecurvesaucsfrom0to9h
absolutebioavailabilityf
percentageofrecovery
peakmaconcentration
drugloadedamount
t12betaatsteadystate
areaundertheconcentrationtimecurveratio
intervalofmaximum
fractionalavailability
elutiontime
signalnoise
areaundertheplasmarosiglitazoneconcentrationtimecurvefromtime0toinfinityauc0infinity
survivalperiod
percentabsolutebioavailability
maximumtroughplasmaconcentration
michaelisconstant
oralextractionratio
vtau
permeabilitysurfaceareaproduct
areaunderthecurvefor6hour
auc012hr
loading
steadystateminimumconcentrationcmeas
maximumcmaxconcentration
detectionlimitssnof3
auc022h
polydispersityindexpi
plasmaareaundertheplasmaconcentrationtimecurveauc
overallsystemicexposure
concentrationgiving50
dosenormalizedmaximumplasmaconcentration
fv
peripheral
deconjugationclearance
mzratio
areaunderthebloodcyclosporinconcentrationtimecurveafteroraladministrationaucpo
plasmatargetconcentration
peakbupivacainelevel
maximumtotal
inhibitionpercentage
renalclearanceduetofiltration
timetomaximumconcentrationofdruginserum
proteinbindingdegree
spratio
areaunderthecurvetoinfinityauc0infinity
areasunderthecurvesauc010h
apparentfetalplasmahalflife
er50
maximumbioaccumulationfactor
abbc
earlyplasmahalflife
fractionalchloridedelivery
michaelismentenconstantforrenalreabsorptionkmr
volumeofdistributionfvdf
entrappingefficiency
auc0720
clearanceratesfromblood
volumeofdistributionduringtheeliminationbetaphase
areasundertheplasmaconcentrationtimecurvesaucsover12h
maximalethyleneglycolglycolateconcentration
areaundertheresponsecurve
flowratesqd
auctlast
differencefactorf1
timetolisproplasmapeaktmax
paraaminohippurateclearancecpah
timetomaximumobservedserumconcentration
majormolecularresponserate
areaundertheserumconcentrationtimecurveauc096h
vcl
troughcsalevelc0
rateconstantfortheeliminationphase
peaksba
concentrationbackextrapolatedtotimezero
maximaltelithromycinconcentrationatsteadystatecmaxss
apparenttruebiliaryclearanceratio
intraportalintrinsicclearance
expansionratio
totalwartarea
the
steadystatehalflife
plasmahalflife
intermediaryhalflife
equilibriumdistributionvolume
areaundertheconcentrationtimecurvein0auc0
maximumconcentrationscmax
vmax1
timeofpeakabsorption
minimalinhibitoryenrofloxacinconcentration
areaundertheconcentrationtimeprofile
brainserumratio
maximumtearpenciclovirconcentration
excretionintourine
concentrationsatapparentsteadystate
watersolubility
areaundertheplasmadrugconcentrationvstimecurvefrom0to4h
cumulativetransportedamount
fix
steadystatephenytoinconcentration
totalcentral
halflifeoftransfer
reabsorbedfractionofbioavailabledose
initialrate
minimumtargetconcentration
peak2r4r
concentrationtodosecdratio
aucbrainaucblood
clearanceclfree
ratesofabsorption
areaundertheglucoseconcentrationtimecurvefor0240min
areasunderplasmaconcentrationtimecurve
urinaryoxalateexcretion
therapeutictroughconcentration
t85
kglucose
totalquantityofdrugremoved
infusionrateko
areaunderthebloodconcentrationtimecurveto12hauc012h
tmaxtimetomaximumplasmaconcentration
finaldecayconstantlambda2
clearancebasedonunbounddrugconcentration
krbc
auc0x
cerebrospinalfluidplasmaconcentrationratio
factor
plasmaclearancerate
relativelungbioavailability
deathrate
timefromsugammadextorecoverytot4t1ratio09
centralcompartmentvolumeofdistribution
fgluc
rl
affinityconstant
concentrationdose
influxrateconstant
clearanceratecls
clsfn
biodisponibility
areaundertheplasmatimeconcentrationcurvefrom0to24hoursauc024
painintensityscore
bioavailabilityindicescmax
uroprotectiveconcentration
creq
inductionfactor
peakacyclovirlevel
braindirectdrugtransportpercentage
areaundertheconcentrationtimecurvefrom0to24hour
unboundmelpha
initialclearance
absorptionemissionwavelengthlabsem
affinitykb
minimumdoserequiredformaximumcalciumloweringdminmax
biletoblooddistributionratiosaucbileaucblood
maximallysi
peakserumprogesteroneconcentration
timetopeakmidazolamconcentration
t4t1ratio
meansurvivaltimemst
plasmatotalbodyclearance
concentrationdoseratio
intracellularauc
totalareaundertheplasmabuspironeconcentrationtimecurve
finalclearancerate
minimumeffective
halflifeatlphaset12l
concentrationathalfmaximumeffect
aqueousconcentration
unboundcmax
molarpotencyratio
areaunderthecurvefrom06hoursauc06
auc08
apparentmetabolicclearance
renalmetforminclearance
influxclearance
clpf
timetomaximumconcentrationcmaxtmax
initialdistributionvolumev1
ratioofareaundertheplasmaconcentrationtimecurvesaucr
areaunderthecurveauc0x
troughconcentrationctrough
catabolichalflife
totaldrugexposure
dialyticclearance
peakantixaactivitie
totalresponserate
systemicclearanceclsys
dialysance
timeconstant
cip
cmaxfit
filtrationefficiency
maximumdiameter
overallvdss
kelt12
plasmacmaxatsteadystate
apparentmeanserumhalflife
bloodcirculationtime
cumulativepriordose
minuteventilation
bloodconcentrationat
peakdrugconcentration
steadystateserumprllevel
areaundertheinhibitorycurveover24hauic24
clearanceofpermeation
volumeatsteadystatev
burstrelease
auc60
myocardialplasmaamiodaroneratio
clearanceclmtx
timetoreachserumfentanylconcentration
glucoseauc06h
totalmeanresidencetime
pki
totalfloatingtime
plasmaterminalhalflifeofelimination
halfthemaximumeffect
criticalthresholdconcentration
cmaxmic90ratio
peakplasmalevelsattained
mutantselectionwindowmsw
distributionvolumevdbw
distributionvolumeduringtheeliminationphase
areaundertheconcentrationcurveaucratio
apparentpulmonarytissuevolume
compartmenttoplasmaratio
tmin
peripheralvolume1
peakreachingtimetmax
nauseabehaviourscore
painthreshold
areaundertheconcentrationtimecurvefromtimezeroextrapolatedtoinfinityauc0infinity
cliv
steadystatebleomycinconcentration
apparentplasmahalflife
eliminationhalflifeofunboundconcentration
eliminationrateke
hillcoefficienth
maximum
peakserumrifampinconcentration
inhibitoryconcentration50ic50
peaksirolimuslevel
aeazo
releaseefficiency
urinaryurate
steadystateserumtheophyllineconcentration
absolutebioavailabilty
timetopeakimipramineconcentration
troughplasmaatenololconcentration
partitioncoefficientpb
minimaleffectiveconcentrationcmin
peakserumibuprofenconcentration
areaundertheplasmaconcentrationtimecurveauc012
fourhourconcentration
initialantibioticconcentration
totalsystemicclearanceclts
apparentvolumeofdistributionvz
sodiumexcretion
t2beta
peakaverageserumconcentration
fractionabsorbed
dosenormalizedareaunderthecurvenlauc0infinity
axa
timetocessationof
timetonormalizationof
50effectiveconcentrationec50
maximummeanconcentrationcpmax
recoverie
steadystatemean
terminalserumhalflife
concentrationsrequiredfor50inhibitionec50
fena
earlyhalfmaximal
terminaleliminationratelambda
arauaracratio
troughserumigglevel
mucosaserumratio
auc0a
auctmaxrefratio
systemicclearancecltot
totalapparentclearancesclf
hydrodynamicparticlesize
redbloodcelleplasmapartitionratio
areaundertheplasmaconcentrationtimecurveduringdosingintervalauctau
peakserumrcd4iggconcentration
eliminationhalflifetbeta12
equilibriumer
peaktissueplasmaconcentrationratio
schoolmissed
overallobjectiveresponse
steadystatekd
timetomaximumglucoseinfusionrate
absolutebioavailabilityfraction
timeofonsetof
peakradioactivityconcentrationscmax
totalvolume
timerequiredtoreachpeakplasmalevelstmax
urinaryexcretionfraction
dosenormalizedareaundertheplasmaconcentrationversu
dosenormalizedareaunderthecurve012h
salivaplasmadd
fetaltomaternalplasmaconcentrationratio
steadystatecmax
deltadeltaqtc
vbetavolumeofdistributionofeliminationphase
intraabdominalfatvolume
totalbodyclearanc
maximalplasmatramadolconcentrationcmax
plasmaeliminationhalflifetimet12b
totalareaundertheplasmaconcentrationcurve
clfree
activationentropyds
secondphasehalflifet12beta
targetratio
plasmaradioactivity
maximumplasmaconcentrationstmax
troughnomacconcentrationcav
modedose
dosecorrectedauc012
csftoplasmaaucratio
minimaleffectivedose
maximumplasmaphelnaaratio
clfmtx
maximumacetylcholinesteraseinhibitionimax
totalareaundertheconcentrationversustimecurve0hourstoinfinity
apparentvolumeofdistributionofcentralcompartmentv1
tumorsuppressionratetsr
maximalratiosoftotaltononspecificuptake
fractionrecovered
plasmaproteinbinding
totalassaytime
availablefraction
apparentplasmat12
timetolastpositivesample
eliminationor
molaraucratio
t123
timeatwhichthi
neutrophilnadir
hepaticextractionofdrug
formationrateconstantka
rapideliminationhalflife
mrtab
maximummetaboliceffect
feli
toreach50maximumactiont50girmax
maximumserumvalproateconcentration
areaundertheplasmaconcentrationtimecurvefromzeroto48hoursauc048
dosenormalizedpeakconcentration
fattissuelevel
minimumauc
proteinbindingpercent
urina
reverse
timetofirstmorphinedose
terminalphaset12
areaundertheplasmatimecoursecurve
peakplasmaplatinumpt
timetoreachmaximalbloodlevel
integralradioactivityratio
ocularhalflifet12
steadystatetconcentration
apparentterminaldispositionrateconstantk
renalthresholdforglucosertg
arterialwallconcentration
kdehydronorketamine
draineddialysatevolume
auccsfaucplasmaratio
ratioofthe
ratio
areaunderthetimeresponsecurveaur
areaunderthecurveaucfrom0to6hour
drugexposure
peak10bconcentration
auc072h
plasmabinding
apparenttotalcolchicineclearance
orrate
overallresponsecompleteresponsecrpartialresponseprrate
distributionvolumeof
bloodhalflive
oralbioavailabityf
t50
minimumgastricph
totallarvalvolume
infectionresolutionrate
concentrationsatsteadystate
freefractionsfu
permeationamount
arterialbloodph
ds
arterialplasmame
totalclearanceclf
volumeofcentralcompartmentv1
steadystateremifentanilconcentration
areaunderthereceiveroperatingcharacteristiccurveauc08
areaundertheghcurve
liverbloodflow
durationoftheblockade
proteinbindingrate
areasunderthecurvewithin72hour
distributionatsteadystatevdss
ratioofauc
troughcyserumlevel
areasundertheserumconcentrationcurve
cave
amnioticfluidtoplasmaratio
maximalantifxaactivity
percentresistance
bioaccessibility
troughconcentrationsc0
maximumobservedplasmaconcentrationcmax
overalltreatmentsuccessrate
distributionvolumeoftheterminalphasevz
initialreleaserate
oesoduodenaltransittime
peakbronchialsecretionlevel
recoveryinurinaryexcretion
meantransittimesthroughthepulmonarycirculationtp
proteinbindingtoserumalbumin
clrugfrratio
plasmaconcentrationofropivacaineattheendofepiduralinfusionc48h
oralfluidtoplasmaratio
eliminationconstant
areaunderthecurveauc072
kmono
auc9
terminalphasebetaphaseplasmahalflife
areaunderthedrugconcentrationinaqueoushumorvstimecurve
timeafteroraladministration
eliminationoft12z
halflivesoftheterminalphase
steadystatementconcentration
fetaltomaternalratio
clearancehalflife
totalhepaticmetaboliteconcentration
areaunderthebloodplasmaconcentrationtimecurveauc
oraltotalbodyclearancecl
csfplasmasteadystateaztconcentrationratio
loadingcapacitie
livertoplasmaratio
troughplasmaconcentrationcs
relativeauc012ratio
maximumplasmaconcentrationtimetmax
aucpo
drugreleaserate
positiveatretentiontime
nausea
tumorresponseratecompletepartialresponse
c0mpalevel
peaksaccadicvelocity
wholebloodtoplasmabpconcentrationratio
urinaryexcretion
plasmaproteinunboundfractionspfratio
appearanceclearance
timestosustainedresponse
eliminationcoefficientkbeta
fct
clbsalh1m2
halflifeoftestosteroneeliminationt12
metabolicratiosauc
normalizedmcr
volumeofdistributionarea
equilibriumdissociationconstantkd
mb
t12b
serumclearancecl
systemicportalaucratio
peakpc
areaunderthecurvet0168hours
tumorbrainratio
percentageremoval
timeofmaximumconcentration
auctissueplasmaratio
recoveryrateth2575
prehepaticextractionratio
areasunderthedrugconcentrationtimecurveauc0d
halflifetimeofthealphaphase
areaundertheconcentrationversustimecurvefrom0to24h
timetopeakeffecttpeak
cumulativeefflux
adverseeventrate
auc4872h
micatwhich80ofisolatesareinhibitedmic80
plasmaauc0360
effectcompartmentrateconstantke0
peakintracellularconcentration
initialeliminationhalflive
totaldrugclearance
timeneededtoattainthepeakconcentration
auc5
aucaumc
t1221
peakimipenemconcentration
peaktumorlevel
auc014
metabolictransittime
steadystatedistributionvolume
mobilephaseflowrate
freetestosteroneindexfti
percentdissolution
troughplasmaconcentrationcmin
steadystatecmaxcmaxss
kiapp
fwr
areasunderthecurvesauc
halflifeforretention
glucosehalflife
peakalfentanilconcentration
totaldose
timefor80drugreleaset80
limitsofreliabledetection
cumulativeamountabsorbeduptotime6h
compartmentvolume
initialvolumeofdistribution
plasmacarnitine
areaunderthecurverepresentingtheconcentrationofdiazepamovera24hourperiodauc024
aptt
halftimesforelimination
occupancyrate
timetoreachthatmaximum
circulatingt12
cpavecpave
initialplasmaconcentrationc0
refractiveindex
bestoverallresponserate
extrahepaticclearance
timeatwhich
systemicexposureauc06
t12k
areaunderthefourhourplasmaphenylalanineconcentrationtimecurve
nondecaycorrectedcumulativeurinaryexcretion
areaunderthecurvefrom0to24hrauc024minimuminhibitoryconcentrationmicratio
metabolitemilkplasmaauc012ratio
timeto90cumulativeinput
cre
detectionlimitpeakarea
peaklhresponse
timeec90
limitsofdetectionlod
disappearanceclearanceclint
peaktimololconcentration
reachedsteadystatelevel
areaunderthepropranololconcentrationtimecurvefrom0to24hours
hight
timetotofratio
incorporation
timetomaximumbloodconcentration
tat
peritonealpeakconcentration
peakteverilixplasmaconcentration
steadystatecp
timeauc
gamma
lineardisappearancerate
ultrafiltrateflowrateufr
areaundertheplasmaconcentrationstimecurveauc0infinity
areaundercurveauc0a
totalch
initialconcentrationc0
maximalcsfconcentration
halflivesofelimination
plasmabindingunboundfraction
fractionexcretedinurine
qtcmax
urinaryrecoveryratewithin
totaltimethattheplasmaconcentration
seroquel
timetopeakplasmaheparinconcentration
mpratio
timeabovethethresholdconcentration
intestinalabsorption
cmax410
fluidexce
steadystateplasmaacetyl5aminosalicylicacidconcentration
secondpeakcortisol
eliminationphasebeta
halftimesofelimination
timetoreachmaximalserumconcentration
rateofappearance
apparentdistributionvolumeforphasebeta
peaktroughterbutalineplasmaconcentrationsratio
distributionserumhalflifet12alpha
waitingtime
friability
aucsaaucpl
flowgradient
auc16
totalbodyclearancesclf
levelc0
milkmaternalplasmaconcentrationratio
gastricresidence
plasmadisappearancehalftime
radioactivity
aucduringthedosingintervaltatsteadystateauctss
relativebioavailabilityf
extractionratiosthroughthesystemiccirculationes
maximaltoleratedoraldose
concentrationcavg
lossindex
functionaleliminationhalflife
plasmaunboundconcentrationofc10c10f
tmax
cmaxtmaximumconcentration
totalbodyeliminationrateconstant
maximalmoricizineconcentration
csubmax
masstransitionionpairsmz
maximuminspiredconcentration
minimumbactericidalconcentration
plasmahalflifet12b
auc0micratio
poreradiusdvr
timetocontrol
freedomfromprogression
peaksystolicbloodpressure
areaundertheplasmaconcentrationtimecurve0infinity
heartbloodconcentration
overallplasmaclearance
mhmz
album
cumulativedrugrelease
serumareaundertheconcentrationtimecurve024h
ud50
firstpasseffectf
peakcortisolcmax
peakexcretiontime
t12frompeak
ratiooftheaucmic
tumornecrosi
intestinalpermeabilitycoefficient
mst
areaunderthecurveauc028
steadystatesspeaks
2575recoveryindex
areaunderthecurveauc0180min
effectivejejunalpermeability
absoluteinfantdose
peaktriamcinoloneconcentration
tdelinabsorption
tumormuscleconcentrationratio
areaunderthecurveover24hauc24
steadylevel
ratesofdrugclearance
auc011
specificvolumevd
logk
areaunderthecurveover48hauc048
tmaxmedian
apparenteliminationhalflifet2e
tumorinhibitionratio
steadyplasmaconcentration
absolutebioavailabilityfabs
kin
kel
t3
percentagesofrelease
durationofremission
totalclearancecltotal
responseratecrpr
timeaboveminimalinhibitoryconcentration
biodegradabilityrate
areaunderthecurveaucauc0264
halflifeoftheterminalphaseofthecurve
limitsofdetectionlods
peaktotalconcentration
peaktotroughconcentrationratio
endogenou
zeroordersynthesisrate
concentrationrequiredfor50emaxec50
faucmic
peaktestosteroneconcentration
maximumplasmaconcentrationcmax
serumminimum
ebfmbfratio
criticalflickerfusionthreshold
pct50
peakplasmathcconcentration
t120
halflifeofdistributiont12alpha
sua
maximalglucoseinfusionrate
steadystaterenalextractionratio
lambdaex
minimalconcentration
minimuminhibitoryconcentrationsmic
peakchemiluminescenceresponse
cumulatedrecovery
tab
lowerlimitofdetectionllod
abz
totalbodyclearancetbc
areaunderthecurve032h
eliminationtime
areasunderthedrugconcentrationtimecurve
plasmavolume
clsfp
fetaltransferrate
volumeofdistributionper
timetoreachdischargecriteria
timetoattain100twitchdepressiononsettime
distributioncoefficientvdarea
unboundclearanceclu
maximumplasmabepridilconcentration
ratiocsskc50
plasmatotalclearance
rptd
sleepingtime
areaundertheactivitycurveauac024h
unboundaucblood
ec50u
aumc
firstbloodtroughlevel
finalphasehalflife
overallannualizedbleedingrateabr
clearancevolume
timeatwhichcmaxwasreachedtmax
cmro2
auc05h
timetopeakanc
totaloralbioavailability
ehalflife
deacylationhalflife
freewaterclearance
50effectivedose
relativebioavailabilityrf
areaundertheconcentrationtimecurveover24hoursauc24
apparentvolumeofdistributioninthepostdistributivephasevdbetaf
areaundertheconcentrationtimecurvefromzerotoinfinite
fbio
aphase
timestopeakplasma
absolutebioavailabilityba
venousumbilicalcordtomaternalconcentrationratio
ic50saturation
volumeofdistributionvd
bloodctroughlevel
demanddose
vh
timesrequiredtoreachthemaximumconcentrationtmax
metabolicrate
peakarearatio
areaundertheconcentrationtimecurvefrom0to360day
maximumconcentrationincmax
peakbloodacetaldehydeconcentration
clearanceratetbc
beta60min
drugentrapment
frel
tissue
cloralf
012hauc
plasmaconcentrationtimecurve
concentrationofthemetabolite5fuatsteadystatecssaver
troughlevelctrough
maximumpercentageinhibition
durationofsensoryblock
areaundertheplasmaconcentrationcurveovertimeauc
timetoreachmaximumplasmaconcentrationfollowingdrugadministrationtmax
auc024micall
lagtimealag
timeofmaximumconcentrationsofdrugsinplasmatmax
tailflicklatencie
firstorderrateconstant
pulmonarytransittime
rateoftotalbodyclearance
totalthroughnaproxenconcentration
absolutescbioavailability
024mic
peakantifactorxalevel
tph
post
biologicalhalflifetbeta12
plasmahalflive
peritonealclearance
maximumtwitchdepression
maximalinsulinconcentration
firstpassextractionratioeg
rbcplasmaconcentrationratio
influx
durationuntil
t12ke0halftime
arterialdrugconcentration
lung
timeofoverallsurvivalos
plasmaareaunderthecurve
effluxrateconstantkout
meanresidencetimesmrt
highestobservedplasmaconcentrationcmax
eliminationrateconstantkmu
residualvariability
bindingcapacitynp
steadystateoctreotideserumdruglevel
responseratesdeltahamilton
synovialfluidserumaucratio
rscitratio
salivarylevel
drugloadingefficacydl
areaundertheplasmaconcentrationversustimecurvefrom0to32hauc032h
mtmd
steadystateareaundertheplasmaconcentrationtimecurve
maximumobservedeverolimusbloodconcentrationscmax
overallexcretion
fecalciprofloxacin
tmaxss
um
imax
percentrelativebioavailability
depthofmicroprojectionpenetration
auc0168h0336h
onsetto90paralysi
areaundertheplasmaconcentrationtimecurvefor24hour
areaundertheplasmaconcentrationversustimecurveauclast
apparentvolumeofdistributiondividedbybioavailabilityvdf
apparentclearancefromthecentralcompartmentclf
bolushalflife
halftimeofdisappearancefromtheserum
absorptionka
steadystatedistribution
plasmac
peak
ic50desaturation
gastricretention
progressionfreesurvivalduration
peakplasmamoricizineconcentration
areasunderthecurveauc08h
radioactivityratio
volumesofdistributionarea
maximumthermalthresholdtt
dominanthalflifeofelimination
au
peaksignaltonoiseratio
maximalplasmaapomorphineconcentration
tissueconcentrationplasmaconcentrationratio
vmaternalf
halflifeofdrugeliminationduringtheterminalphaset12
absoluteenteralbioavailability
centralcompartmentvolumesofdistribution
apparentt12el
centralcompartmentapparentvolumeofdistribution
celltomediumconcentrationratio
plasmat12alpha
apparentwr1065clearance
rateofdrugadministrationtothesystemic
clpo
timeabovefix
thydht
minimumeffectiveconcentrationmec
meltingpoint
concentrationsteadystatecss
areaundertheplasmaconcentrationcurveauc060
auc024ratio
pool
maximalratesofdruginducedkilling
dd
oralplasmaclearanceclf
percentagesofunbound
areaunderthecurvemic90ratio
clearancebetweencentralandperipheralcompartmentcl2
timeatwhichmaximumconcentration
areaunderthecurvefrom024hour
dissociationconstantki
maximumresiduallevel
areaundertheplasmaconcentrationtimecurvefromtimezerotothelastquantifiableplasmaconcentrationauc012
effectivepermeabilitycoefficient
ratioofintrinsicformationclearance
steadystateaucaucss
inputratekinput
blood14cconcentration
peakepinephrineconcentration
parasiteeliminationhalflife
concentrationathalfvmaxkm
rmse
centralvolumev1
maximumlysi
apparentfirstorderrateconstantskobs
biliaryexcretionratiofb
biologicaleliminationt12
timetomaximalinsulinconcentration
tumortomuscle
apparentinactivationconstant
totalbodymetabolicclearance
timetopassthreshold
peakfreet3
troughvwfrco
areaundertheplasmaconcentrationversustimecurvefrom0to6hoursauc06
halflifeduringtheterminaleliminationphaset12lambda
biovailabilityf
vdf
halflifeofabsorption
q12h
ae
areaundertheplasmaconcentrationtimecurvefromtime0toinfinity
apparentv1i
areaundercurveratio
systemicbloodclearance
areaundertheplasmaconcentrationvstimecurveauc0t
decompositionhalflive
bloodtobraincoefficientofdistribution
bloodalcohollevel
freefractionf
rbctoplasmaratio
maximumobservedplasmahydrocodoneconcentrationcmax
areaundertheconcentrationversustimecurvefrom0to6hauc06
24hserumconcentration
meanretentiontimemrt
timestomaximumtheophyllineconcentration
steadystateplasmaconcentrationscav
inhibitoryactivitiesic50
bloodclearanceclb
totalamountofteriflunomideremoved
ed25
volumesofthecentralcompartmentvc
activityincrease
k42
areaunderthecurvefromtime0toinfinityauc0infinity
netabsorption
clt
auec0t
maximumarterialplasmathiopentalconcentration
micsmic50
tumorconcurrentplasmaratio
dispersibility
firstorderterminalhalflife
capacityfactorsmax
kilow
firstordereliminationrate
slowdistributioncompartmentv3
maximumm2concentrationscmax
clinicalbenefitrate
serumlevetiracetamconcentration
clearancecorrectedbybioavailability
proteinunboundexposure
quantificationloq
uave
effectiverenalplasmaflow
samplingtimeafteradose
deliveryrateadjustedserumfentanylconcentration
halflifeofdistribution
volumeofseminalplasma
maximalareasundertheconcentrationtimecurve
cssmm
areaundertheconcentrationtimecurveaucdosex1000
peakcmax
ke0halflife
steadystatecsaconcentration
peakheighttmc50
initialalphahalflife
timetotheonsetofsleep
timerequiredtoachievesteadystateconcentration
cumulationhalflifet12beta
clearanceclhd
durationofinfieldresponse
apparentvolumeofdistributionatsteadystatebioavailability
steadystatevolumeofdistributionvd
steadystatetroughserumlevel
areaundertheplasmaconcentrationtimecurve
volumesofdistributionofthecentralcompartmentvc
totalbloodvolume
saturationsolubility
eliminationhalflivesk10hl
lipophilicitylogkw
maximummetabolicvelocity
areaunderthetimeconcentrationcurveaucoverthefirst4hofthe12hdosageintervalauc04
troughconcentrationscmin
apparentturnoverrateconstantoftheenzymekout
peakslc
firstorderrateconstantofabsorption
overallrenalexcretion
targetmediatedeliminationrateconstant
en
fractionofunboundetofu
terminaldispositionhalflifet12
apparentoralbioavailability
12
maximumserumfshctpconcentration
timetoreachmaximumpropranololconcentration
frenal
t05
apparentvss
overalldispositionhalflife
haliclife
v3f
peakplasmadopaconcentration
equilibriumassociationconstant
percentageexhalation
0to6hoursauc06
intrinsicdissolutionratesidrs
areaundertheconcentrationcurvesauc
percentproteinbinding
areaunderconcentrationtimecurveauc0300
timeoftheplasmaconcentrationpeak
peakgentamicinconcentration
therapeuticsteadystateconcentration
aucsub0inf
cp50asleep
plasmaticconcentration
c0mpa
massratio
bioavailabilityfactorf
timetothefirstdemandforanalgesia
activatedcharcoaldrugratio
skinconcentration
effectivemconcentration
mrtinfinity
aucfromtimezerotoinfinityauc0
csfplasma
areasundertheconcentrationtimecurvefrom0to24hauc024
troughvancomycinconcentration
percentageofdoserecovered
troughbloodconcentrationcmin
peakmilkotcconcentration
minimumsputumconcentrationcmin
halflifeinblood
cmaxauci
timetoreach50ofarterialsteadystateconcentration
plasmaclearanceclel
peaktotroughratioscmaxc24h
eliminationhalflivest12beta
areaunderthedrugconcentrationtimecurveoveradosingintervalauc
50inhibitionic50
timetoprogressionordeath
effectsiterateconstant
eliminationphaseconstantbeta
areaunderplasmalevelcurveofmidazolamaucmidazolamdose
aucdose
eliminationphasedistributionvolume
bioavailabilityindice
timetopeakgrowthhormonelevel
steadystateapparentvolumeofdistributionvss
totalplasmaplatinum
timetomaximalconcentration
microsomalmetabolism
aucovera24hourdosingintervalauctau
secondorderrateconstant
ratioofbr
clp
plasmaec50
t12keleliminationhalflife
ratesofinsulinrise
halfabsorptiontime
totalbiliaryelimination
peakplasmaconcentrationatsteadystate
contextsensitivehalftime
metabolitetodrugratio
gutbloodbarrierpermeability
tumourbackgroundratiostbrs
slowtransferrateconstant
perfusionbloodflowrate
eliminationhalflifet12el
timetoachievethemaximumplasmaconcentrationcmax
elution
renalo
troughminimumconcentration
diffusionalcoefficient
areaunderthecurvesauc024
c1serumconcentration
apparentantimode
concentrationscausing50inhibitioni50
timetoachievepeakplasmaquinidineconcentration
maximalplasmaquinineconcentration
partialresponse
steadystateblood
peaklevamisoleplasmalevel
ratiooft3to
50ofthemaximumeffect
percentbioavailability
minimumtherapeutictroughplasmaconcentration
halflifeinbile
halflifeatalphaphase
lowerlimitsofdetectionllod
p24antigen
fractionalintestinalabsorption
fracti
reconstitutiontime
intervalfromoraladministrationuntilmaximumconcentration
areasundertheconcentrationtimecurvefromtime0tothelastmeasurabletimepointauc0t
kdep
effectcompartmentclearance
epa
volumeofdistributionoftheplasmacompartment
limitofdetectionsn31
absorptionhalflifet12alpha
troughconcentrationsatsteadystate
maximumplasmatrazodoneconcentration
acutecellularrejectionrate
absolutesystemicavailability
areaundertheserumconcentrationtimecurvewithinthefirst6h
peakconcentrationmicratio
ratiosatsteadystate
maximumratio
oralclearancecl
timetoanabsoluteneutrophilcountof
rateofsystemicclearance
varead
clhda
timetoreachpeakplasmaleveltmax
t12phase
areaundertheplasmametoclopramideleveltimecurveauc
troughbloodconcentrationtbc
terminalt12
apparentt12beta
dosefractionexcretedunchanged
caucendoscopy
volumeofthecentralcompartmentv
fataldose
feverindex
partialthromboplastintimeprolongation
peaksynovialmorphineconcentration
areaundertheconcentrationtimecurvefrom0to24hauc0tau
maximumltgconcentration
peakplasmamefloquineconcentration
timetoatofratio
maximumplasmabupivacaineconcentration
totalciprofloxacinclearance
timetoobservedmaximumplasmaconcentration
weightnormalizedclearance
peakextracellularlevel
bloodke
maximumaverageplasmaconcentration
auc0infinityserum
eliminationofhalflive
distributionalhalflife
firstorderdecayconstant
clearancecoefficient
overallic50
peakmorphineconcentration
observedhalflife
freefractionofdrugf
systemichalflive
maximumterbinafinelevel
terminaleliminationhalflive
maximaltyrosinaemia
aucper6h
areaundertheconcentrationtimecurveauc012h
auc0tldc
lactate
highestserumconcentration
halflivesforserumelimination
effectcompartmentexposure
t12dist
areaunderthecurveat024hoursauc024
timetotheresolutionoffever
drugdistributioncoefficient
absorbeddose
timereachmaximumconcentrationtmax
gcrba
areaunderthechloroquinewholebloodconcentrationtimecurvenormalizedtobodyweightauc024hbw
efficiency
blood24hourtroughconcentration
apparenttotalsystemicclearanceclf
hepaticfirstpasseliminationhfpe
peakserumrifampinlevelcmax
pulmonaryclearance
observedpeakserumlithiumconcentration
initialpihalflife
t
absoluteclearance
troughlevelsc0
totalamountsofradio
steadystatedoripenemcsfconcentration
clcf
survivaltimemst
releasekinetic
peakexpiratoryflow
maximalviralloadvl
injectionflow
distributioncoefficientalpha
pqratio
durationofexamination
recoveryofradioactivity
rateofexcretionofsodium
t12appin
limitofdetectionlod
auc010h
auci
timetoonsetofdyskinesia
absolutesystemicbioavailability
timerequiredafterdrugadministrationtoreachpeakconcentration
entrapmentratio
timedelayforthepeakresponse
timetakentoreachthepeaktmax
fractionoftheintratra
nonrenalelimination
eliminationhalflifeoftheterminalpartoftheeliminationphaset12b
absoluteplasmalevel
upsilone
plasmahalflifest12s
highaffinity
maximaltissuelevelscmax
noxidemetaboliteratio
timetoprogressttp
timetorosc
areaunderbloodconcentrationtimecurveauc
penetrationintolung
timeforconcentrationstodecrease50frommaximal
aucmetaboliteparentratio
totalexposure
aucsub0lastsub
apparentvolumeofdistributionbased
maximummeanconcentrationinplasmacmax
maximumplasmacurcuminconcentration
geldryingtime
cl0120app
relativeaffinity
totalfractionofthedoserecovered
aucareaundertheplasmaconcentrationtimecurve
sedationscore
peaknorfloxacinconcentration
t12eliv
freefractioninblood
totalamountofradioactivityexcreted
clpb
steadystatedistributionvolumevssf
eliminationhalflivest05a
2h
rateconstantofspecificclearancedecay
serumtroughrifampinconcentration
mpa
pulmonaryperfusionclearance
areaunderthecurvefromzerotoinfinityauc072
cmaxst
absorptionhalflifet12
bioefficacy
salivaplasmaspratio
areasunderthecurvefrom0tolastmeasurabletimepointauc0t
kideltakimu
perfusionpressure
maximumciprofloxacinplasmaconcentration
clearance3
clrenr
ld5030
aucfurd
auc6
depletionhalflife
capsuleactivationtime
terminalhalflifet12lambda
peakplasma17aagconcentration
ic50k1
apparentoralclearancesclor
fractionofelimination
abclevel
neointimaarea
t15
firstordertransitabsorptionrateconstant
maximumallowedtime
flowofinfusion
timetomaximumplasmatrazodoneconcentration
areaunderthecurve024
unboundbrainunboundplasmalevel
ratiooftheareaunderthecurve
production
insulincontent
biliaryclearanceratio
tumoraucratio
maximumtumoralconcentration
halfmaximalinactivationki
apparenteliminationrateconstantlz
residenttimemrt
volumeofdistributionvfree
maximumenzymeinhibitionic50
tissueplasmaconcentration
mature
rateofdegradation
fractionoforalmethotrexate
volumeofdistributionofcompartment4
freeauc
a2
peakserumaspartateaminotransferaselevel
halflifeforliverretention
totalsystemicnormalizedclearance
auc0obs
sampleanalysistime
populationclearancecl
halflifefortheeliminationphase
synovialconcentration
aucbuspironeauc1ppratio
cavgss
clinicaleffectivedurationofaction
dl50
nettubularsecretion
maximalantixaactivity
fty720
bioavailabilityf0infinity
troughcsa
peaksofserumconcentrationcmax
peakheartratechange
c
maximumplasmaepinephrineconcentration
auc012500
solubilityratio
peakofthedistribution
aucof
localabsorptiontimeta
troughfixactivity
areaundertheconcentrationtimecurveauc0last
areaundertheplasmaconcentrationtimecurvefrom0to2hoursauc02h
prepeaknadirconcentration
inhibitoryconcentration50
oral
systemicabsorption
distributiont12alpha
uptakeclearancecluptake
voralf
halfmaximalresponse
intestinalelimination
totalhepaticbloodflow
overallsurvivalos
timetothemaximumconcentrationtmax
troughmpalevel
maximumserumacetaminophenconcentration
apparentmeanoralclearance
absorptionhalflivest12a
retentiontimestr
eliminationconstantke1
min
serumt
populationdistribution
maximumratevm
peaktimeacrophase
effective
clearanceclstd
volumeofdistributionintheperipheralcompartment
aucmic90
specificamidolyticactivity
timetopeakdoxepinplasmaconcentration
ic50vmax
peakplasmaconcentrationlevelscmax
totalrunningtime
totalmorphineconsumption
feversubsidencetime
auc24micratio
systemicavailabilitie
timetoachievethecmaxtmax
areaunderthemesentericbloodtimecurve
vdpa
biliaryrecoveryrate
areaundercurvesauc
auc0brainauc0plasmaratio
plasmaalfentanilconcentration
lzhl
apparentpa2
maximaldailydosetobeclearedvmax
peakfviiiconcentration
invivohalflife
timestomaximumplasmaropivacaineconcentrationtmax
rvr
conversionrate
pulmonaryvascularresistanceindexpvri
peakgametocytaemia
volumeofdistributionduringtheterminalexponentialphaseofdrugeliminationvdbeta
timetocompleteremissioncr
maximumsemaximibplasmaconcentration
chronict12
peakplasmafentanylconcentrationsfmax
peakpczplasmalevel
oralclearanceofthesolutiondose
maximaltolerabledose
ceff
solub
cumulativereleasepercentage
pasi
troughmarimastatlevel
timetofirstresponse
haemofiltrationclearance
steadystateareaunderthecurve
braineliminationhalflife
earlytroughlevel
maximalmeanserumconcentration
areaundertheconcentrationcurvefrom0to6hoursauc06
peakplasmaepinephrinelevel
totalsystemicclearance
rateconstantsalpha
zetapotentialzp
c2dose
apparentvolumeofdistributionvmfm
permeated
apparenthalflive
ghb
lengthof
spilloverrateintoplasma
get
areaundertheserummtxconcentrationtimecurveauc
requirement
durationdeltaplateau
cna
areaundertheconcentrationtimecurvefromtimezerotoinfinityaucinfinity
auctaumd
areaundertheplasmaconcentrationtimecurvefromzeroto48hauc048
continuousflux
peakplasmadnmlevel
areasunderthetimeserumsalicylateconcentrationcurveover6hour
areaunderthecurvefromtimezerotothelastsamplingtimeauc0t
hepaticmetabolicclearance
th
saturationlevel
volumeofdistributionbasedonterminalphasevdz
midminimumdose
cmaxtooccur
apparentinvivodissociationconstant
areaundertheplasmaconcentrationtimecurvefromtime0to6hoursauc06
targetconcentrationtc
areaundertheconcentrationtimecurvefrom0mintoinfinity
percentageofunbounddruginplasma
aucfromtimezeroextrapolatedtoinfinityaucinfinity
rateofcompletebonemarrowresponse
clearancecorrectedforbioavailability
csflevel
faecalbloodlo
areaundertheconcentrationtimecurveauc0tlast
areasundertheplasmaconcentrationtimecurvesaucs
steadystatepaclitaxelconcentrationscss
areaundertheconcentrationtimecurveat2324hr
breastmilkversusserumconcentrationratio
invivorecoveryivr
cm
particlesized50
areaunderconcentrationtimecurvefromzerototimeoflast
areaundertheconcentrationtimecurveaucss
ratiosr
concentrationsof
freelungtissueconcentration
ft4level
auc02524h
apparentpermeabilitysurfaceareaproduct
terminalplasmat12
timetoreachthemaximumconcentration
effectsiteconcentrationcet
maximumplasmaconcentrationofdo
peakplasmapaclitaxelconcentration
arterialph
areaunderthecurveaucinf
plasmadigoxinconcentration
halfmaximumabsorptionratekma
apparentbodyclearance
relativedrugavailability
steadystateplasmaconcentrationscmax
timetoreachthepeaklevel
timetoresponse
peakvenousplasmaconcentrationscmax
maximumunboundchlorcycloguanilconcentration
redistributionhalflife
distributionvolumesvarea
hcl
ciadult
areasundertheplasmacurveauc024
areaunderthecurveaucratioauc
plasmaauc0t
steadystatecerebrospinalfluidconcentration
maximalplasmaamitriptylineconcentrationcmax
peaktimetmax
pcr
totalbodyeffectivedose
timetomaximumconcentrationtmaxd
totalbodyclearanceclbf
retentiontimemrt
durationofanalgesia
kasol
serumenrichment
areaundertheconcentrationcurveauc
90minimalinhibitoryconcentration
aucdeaqauc
bei
steadystateparacetamolconcentrationcssmean
cmaxdn10mg
volumeofdistributionbioavailability
steadystatecerebrospinalfluidplasmaratio
timetomaximumplasmaconcentrationtmax
curve
payloadcapacity
plasmaconcentrationcavg
levelofdetection
meanresidencetimeofabsorption
maximumconcentrationofdruginserumcmax
areaundertheconcentrationtimecurveextrapolatedtosteadystateaucss
bloodclearancerateofcortisolbcr
effectivebloodvolume
maximumtotalplasmaropivacaineconcentration
areaundertheconcentrationtimecurvefromzeroto24hafteradministrationauc024h
tissuepenetrationratiotissueserumfaucratio
clearanceofglucosefrombloodtobraink1
tbil
arterialbloodflow
observedhalflive
fcl
d3
centralcompartmentclearanceclcf
transportfractiontf
interburstinterval
maximumclf
halflifeforgastricemptying
peakconcentrationsofnicotineinplasmacmax
morningtroughconcentration
aurc
halflifeofdarbepoetint12
betahalftime
0
tmaxpredicted
accumulativedrugrelease
areaundertheplasmaconcentrationtimecurveoveronedosingintervaltau012hafterdrugadministrationauctau
intravascularfraction
nonhepaticglucoseuptake
stratio
maximumplasmafpconcentration
braindrugconcentration
apparentrenalextractionratioexcretionrateformationrate
troughplasmaitraconazoleconcentration
plasmaclearancec1
bloodeliminationhalflife
epratio
micx8
steadystateauc024
cumulativebiliaryexcretion
timeofadministration
eliminationrateconstantofproteinunbounddrugke
terminalbiologicalhalftime
timetakenformaximumplasmalevelstobereached
serumconcentrationcp
dyspneaindex
fractionfd
masstochargeratiomz
immunoactivity
totalareaundertheplasmaconcentrationtimecurveaucinfinity
maximalchbtomaximalcbratio
therapeuticwindow
percentageoftime
boronconcentration
plasmaabsolutebioavailability
waterreabsorption
timeabovetheminimumeffectiveconcentrationtmec
terminaleliminationphaset12beta
tumorpenetration
unboundauc0
gradientelutionatflowrate
maximumobservedplasmaconcentrationratio
yield
eliminationhalflifebt12
areaunderthecurvesauc
highesturineconcentration
absorptionconstant
dtp
intrinsichepaticclearanceclintlv
achieved
volumeofperipheralcompartment
meansize
ab50
timeofmaximaltoxicity
halflifeforabsorption
overalloralbioavailability
bioavailabilitiesfabs
lagtimebeforedrugabsorption
cumulativesystemiceffectparameter
initialantigenlevel
bloodlevel
areasundertheplasmaconcentrationtimecurvesauc0leadsto12
ed
equilibriumconstantofdissociationkd
maximumcapacity
apparenteliminationclearance
troughpeakratio
timetoeradication
clb
overallexposure
pulmonarytissuecompartment
maximumbloodplasmalevel
forcedexpiratoryvolumein1secondfev1
maximalfelodipineplasmaconcentration
lengthoftreatment
areaundertheplasmaconcentrationversustimecurvesauc
pfserumratio
ultimatehalflife
timetoreachmaximumobservedplasmaconcentration
aucbileaucvhratio
rateofigeproduction
epc
volumeofdistributionatsteadystate
50inhibitionconcentrationic50
hepaticbloodclearance
apparenturinarycsaclearance
apparentinhibitionconstant
rateofuptake
metabolicclearancerateundersteadystatecondition
areaundertheplasmadrugconcentrationcurve
eqm
cumulativepercentagedrugrelease
peakarterialconcentration
alphaphaserateconstant
drugtargetingpotential
maximumhairconcentrationscmax
gelationtime
totalmaravir
lockouttime
maximumdnrconcentration
lcst
nox
coronaryperfusionpressure
peakpaco2
timeofmaximumobservedconcentrationtmax
k23
detectedplasmaconcentration
peakfreeropivacaineconcentration
timetoreachtargetauc
steadystatemidazolamconcentration
aumc0t
skinfluxe
plasmaapparenteliminationhalflife
trough6hr
absorptionhalflifetabs
halfmaximumprueffect
cumulativepercentagerelease
areaundertheplasmaconcentrationcurveauc012h
steadystateconcentrationcssmean
micci
timeuntilpeakplasmaconcentration
totalmeanpercentrecovery
inhibitorybindingaffinitie
progressionfreesurvivalrate
betahalflifebiologicalhalflifeforterminalslope
timeatwhich632
serumconcentrationsc0
areaundertheplasmaalphaifnconcentrationtimecurve
areavdarea
abac
volumesofdistributionvss
steadystatet
apparentvmax
terminaleliminationphasehalflife
plasmabnconcentration
024hour
onsettimeuntilmaximumblock
affinityconstantka
qtintervalqtc
brainconcentration
carriercellrecovery
aucgir0120min
auc0600
survivalfraction
qb
cue
areaundertheplasmaconcentrationtimecurveaucfromtime0toinfinity
volumeoffastinitialdistribution
timetoreachmaximumplasmaconcentrationstmax
surfaceareasa
peripheralvolumevp
fixactivity
maximaltherapeuticdosage
timetoreachittmax
apparentclearanceofdistributionqf
steadystatetroughlevel
cmaxcmin
minimumplasmaconcentrationscmin
areaundertheglucoseinfusionrategircurveinthefirst30minaucgir030min
totalauc24hmicratio
earlyplasmapeak
areaunderthetimeversusconcentrationcurve
auc04h
desorptionkd
maximumpercentinhibitionsimax
aucu012
peakplasmalanthanumconcentration
plasmaradioactivityhalflife
areaunderthebloodconcentrationtimecurvefrom0to24hr
onsetofneuromuscularblockingeffect
peakchange
peakfreeplasmaconcentration
circulatoryhalflife
passivediffusionclearance
molarauc048
troughconcentrationcmin
dispersion
faecalrecovery
aucroflumilastnoxideaucroflumilastratio
maximumbupivacaineplasmalevel
releasetime
sodiumshift
tissuetoplasmaconcentrationratio
k1e
nka
activationhalflife
areaundertheplasmaconcentrationtimecurveauc0infinity
unboundcmin
mpe
nettubularreabsorption
aucssday10
recurrencefree
msob
terminalt12betahalflive
peffcms
dosenormalizedareaundertheserumconcentrationtimecurve
lymphlevel
bloodlevelafterdosingc2peaklevel
maximalplasmaconcentrationofsacmax
concentrationmicratio
overallsystemicavailability
steadystateconcentrationcss
plasmadistributionhalflifetimet12a
areaundertheglucoseconcentrationtimecurve
ratiofortheauc
efficiencie
maximalsbpresponsesemax
tissuetoserumaucratio
terminalcatabolichalflife
gastricemptying
folding
poolsize
totalbileproduction
maximumplasmavareniclineconcentrationcmax
logdseddsreleasemedium
maximumlumbarcsfconcentration
timerequiredtoreachthemaximalconcentration
dosingfrequency
peakserumrapamycinconcentration
areasundertheconcentrationvstimecurvesauc010days
areaundertheserumconcentrationtimecurvefromtimezeroextrapolatedtoinfinity
extraction
vda
recirculationratio
overalldrugrecovery
observedsteadystatepredosetocilizumabconcentration
sat
volumedistribution
bioavailabilityt
maximumplasmaconcentrationofotccmax
timetoachievemaximumplasmaconcentration
maximalrateofinactivationkinact
auc1224h
percentagesofremainingperitonealfluidvolume
vssf
areaundertheplasmaconcentrationtimecurvefromtime0to12hauc012
relativeurinaryexcretion
distributionvolumeatsteadystatev
peakratio
auc28
ratiocsfplasmaconcentration
apparentclearancefromblood
timesto
logpoct
durationoffever
timetoclinicalremission
peakarahconcentration
oralvolumeofdistributionvd
correctedlungplasmaratio
targetattainmentratesofaucmic125
apparentmeanresidencetime
50effectiveanticonvulsantdose
peakfourthventriclecsfmethotrexatelevel
selfemulsificationtime
capillarybloodconcentration
additionalremoval
absolutesodiumexcretion
initialdissolutionrate
u
volumeofdistributionofthecentral
areaunderthecurveauc360min
durationofthe
steadystatecy
24
durationofdrugabsorption
plasmaaccumulationratio
timetoachievepeakconcentration
ratioofaucphtoaucdrugconcentration012hour
tumourtoheartauc024ratio
apparentpermeabilitycoefficientpapp
targetattainmentpotential
halflifetsub12
oralbioavailabilityforal
90inhibitoryconcentration
eliminationphasehalflive
timetoreachthemaximalconcentrationtimetomaximumconcentration
peakplasmalngconcentration
transplacentalclearance
terminalurinaryeliminationt12
auc07hour
maximumunbounddapsoneconcentration
timetoreachaclinical
releasingrate
auctauatsteadystate
steadystatetroughplasmaconcentrationcminobs
eliminationhalflifet12y
areaundertheplasmasertralineconcentrationtimecurveaucfrom0toinfinity
initialterminalhalflifet12
lateraldiffusion
dx
percentageexcretion
observedauc
ratiosofclearance
ic50insulin
equilibriumplasmabloodcellsconcentrationratio
dosauc
aucfromtimezeroextrapolatedtoinfinityauc
latencyperiod
rsplasmaconcentrationratio
peakplasmaconcentrationmicratio
peaktotalplasmaconcentrationscmax
apparentclearancecl
oralfluidplasmameth
cp0
50cytotoxicdose
affinitie
apparentcentraldistributionvolume
minimumbioavailability
infusiontime
conversiontooc
kf1
peakplasmadoxylamineconcentrationcmax
ratioofmilktoplasmaauc
fractionalurinaryexcretion
totalelutiontime
troughserumofxconcentration
vmaxc
clearancedividedbyformationfractionfm
alphaphasehalflive
80
percentcoefficient
cl1
plasmaconcentrationat2minute
targetplasmaconcentration
bispectralindexic50
maximumcolonictissueconcentration
auc0tratio
auc09
oraldisintegrationtime
attainedmaximumlevelscmax
halftimeof
steadystateaucmtx
apparenttotalbodyclearanceclf
serumdisappearancerate
firstorderrateconstantsfor
rectalretentionforce
peakserumdoxofyllineconcentration
transferrateconstantsfromthecentraltoperipheralcompartmentk12
bioavailabilityfrel
proteinbinding
auc044
relapsefreesurvival
clearancefclf
steadystateplasmabuprenorphineconcentration
distributionhalflifet12a
percentageofthe
auc0htz
maximumrecovery
penetrationratiofauctissuefaucplasma
plasmaconcentrationofdrug
volumeofdistributionduringsteadystatevdbeta
timenormalizedauc
eliminationt12beta
areaundercurveauc0
t12beta
timeonstudy
sensitivityfactor
ph4holdingtimeratio
minimumcmin
totalsampleprocessingtime
tmec
volumeofdistributioninthecentralcompartmentvc
ce95
flowrate
clastt
apparentplateauphasesteadystate
peritonealdialysance
logoctanolwaterpartitioncoefficient
peakadinazolamplasmaconcentrationscmax
sloweliminationphaset12beta
initialpeakplasmaconcentration
inhaledflowrate
sputumplasmaconcentrationratio
skinbloodratio
amplitude
percentageoftotaladministereddoserecovered
absorptiont12ka
fu
durationofprogressionfreesurvival
apparenthalflifet12
halflifefordermalabsorption
maximummiosi
concentrationatsteadystate
timesofdisintegration
aucfromtimezerohourstothetimeofthelastmeasurabletiotropiumconcentrationauct
polar
fractionofdoseexcretedunchangedin
potency
arterialtovenousplasmapirenzepineratio
areaundertheconcentrationtimecurvefromtime0extrapolatedtoinfinityauc0infinity
drugdiffusioncoefficient
vmfm
kind
concentrationofdrugproducing50inhibitionic50
apparentsystemicclearance
fractionofmorphineabsorbed
firstpassmetabolism
areaundertheplasmadrugconcentrationtimecurvetoday7auc07
fractionofdoserecoveredinmilk
cmax750
calciumretention
c0dose
plasmai
x1
apparentvolumeofdistributionofthecentralcompartmentvce
timeforsecondpeakconcentrationtmax2
timestopeakincrease
fractionalcatabolicrate
peakmeanlevel
areaunderthecurveforthegivendoseintervalauctau
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinity
plateautimest75cmax
tw
repeatabilitycoefficient
alag
timestofirstmeasurableplasmaconcentration
frl
extendedtoimmediatereleasebioavailability
mlc
absorbedamount
momenthalflifetimetm12
interdialytichalflife
plasmaflowrate
tv
ratioofcmax
finalreversibility
maximumencapsulationefficiency
zeta
clearanceofinfluxintolungtissue
mrt
micfor90
areaundertheconcentrationtimecurvefrom0toinfinitivetime
apparentdissociationconstantkd
areaundertheinhibitorycurveauic
receptorbinding
tumourtomuscleratio
steadybloodalcoholconcentrationsbac
firstpeakplasmacmax
deltaglucoseconcentration
peakwholebrainuptake
timeabovetherapeuticlevel
cumulativeamountofdrugpermeated
raiu
formationratio
areaundertheconcentrationversustimecurveaucfromtimezerotoinfinityauc0infinity
peakplasmalphenylalanineconcentration
escharconcentration
metabolicclearanceratesmcr
timetoreachmaximumconcentrationofdrug
alphat12a
24hourrecovery
totalinsulinresponse
plasmaconcentrationec50
aucss0t
peakconcentrationsisinflammatoryfluid
bioavailabilityfractionalabsorption
auctot
t12ofthefirstdistributionphase
peakdruglevel
inhalationtime
kiiv
ratiok12k21
kelcorrectedrelativebioavailabilitie
braintobloodcoefficientofdistribution
activehepaticuptake
ratesofmucociliaryclearance
peakaqueou
aucnapa
volumeofperipheralcompartmentvp
stableplasmaconcentration
accumulativebileexcretion
f0
25recoveryt1t0
oralsystemicbioavailability
lungtobloodtransferrateconstant
lungtissuebloodaucratio
halflivesoftheterminalbetaphase
plasmaslowhalflifet12
areasunderthebloodconcentrationtimecurve
maximumtolerated
timetomaximumplasmaconcentrationstmax
pulmonaryintrinsicclearance
tissueplasmaareaundertheconcentrationcurveaucratio
aucgg
c21min
vunb
polydispersibilityindex
tubularsecretoryclearance
auc05hour
peripheralvolumeofdistributionf
hepaticclearanceclparallel
aucb
areaundertheplasmaconcentrationtimecurvefromtime0to12hauc012h
areaunderthecurvefrom0to360minute
halflifeofdisappearancefromserum
permeabilityflowratio
timeafteringestiontopeakconcentration
cmaxs
nominalretentiontime
cer20min
m1
ver
timetoattainthispeak
areasunderthecurvefromtimezerotoinfinity
overallpfs6
constantct
apparentdistributionvolumeofcentralcompartmentvsubcsubf
apparentsteadystatevolumeofdistribution
oralcltotf
incorporationefficiencyie
timetomaximalneuromuscularblock
upc
plasmaunboundinhibitionconstant
rectalsystemicavailability
maximumlevel
limitofqualificationloq
areaundertheprednisoloneconcentrationtimecurve
areaunderthebloodconcentrationtimecurves012hours
minimumdetectablelevel
aucgir
aucelf
clrpo
transdermaleliminationhalflife
conversionhalflifet12
areaundertheconcentrationtimecurvefrom0to24hours
percentofdailydoseexcreted
serumt12b
apparentredbloodcellplasmapartitioncoefficient
plasmaconcentrationsofnilcnil
timestonadir
m
peakblood
mothertocordrateconstant
totalvolumeofdistributionvdtot
t12iv
totalplasmadrugclearance
biosynthesi
positiveresponserate
peakintraocularconcentration
volumesofthecentral
t12absorption
serumareaunderthecurvefor24hour
eventfreesurvivalrate
minimumobservedtotalplasmaconcentration
dissolutionefficiencie
distributionvolumeatthesteadystate
tumor
extra
intracellular
fractionabsorbedorally
distributionalclq
areasunderthemetronidazoleplasmaconcentrationtimecurveauc024
milkproduction
relativebioavailabilityrb
passivepermeation
auc024mic90
areaundertheconcentrationtimecurvefrom0to24hmicratio
relativef
halflifeoftheterminalportion
ccr
maximumdailyqtcinterval
relativesurvivalratescmaxs
eliminationhalflifet12e
areaunderthecelecoxibplasmaconcentrationtimecurve
desirability
plasmaconcentrationsatsteadystate
iii
lungtoplasmaratio
maximumresiduelevel
associationrateconstantkon
50crossreactivity
s1recoverie
meanresidencetimebasedontimezerotolastsampletimemrtlast
terminaleliminationhalflifetimest12beta
injectiontoinjectionrunningtime
steadystatebrainconcentration
distantrecurrencerate
plasmaareaundertheplasmaconcentrationtimecurve
overallhalflifet12
areaundertheconcentrationtimecurveaucfromtimezeroto6hauc6
steepnessparameter
totalencapsulationefficiency
concentrationc24
timetoreachaminimumtherapeuticthreshold
cv
timeshiftacrophase
mpc
totalabsorption
plasmaclearancescl
cssmin
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityauc90infinity
eliminationhalflifet12k
tissueplasmaratio
bronchialconcentration
serumhalflifet12beta
leveldoseldratio
halflifet12a
unboundvolumeofdistributioninbrainvubrain
c2hr
clearanceinthedistributionphaseofdrugdispositioncld
accumulationindexai
cmaxcminratio
totalbraintissueconcentration
biologicalhalflivesforelimination
a2a1ratio
timeabovelc50
clpc
clearanceofintercompartment
tmaxt12
apparentda
steadystateplasmaexposure
urineexcretion
d30
inhibitorylevel
kidneyclearance
unboundpaclitaxelclearance
v2l
timetoachievemaximalsystemicconcentrationstmax
trainoffourrecoveryratio
vmaxbaseline
maximumplasmadiflunisalconcentration
extentofconjugation
analysistimeperinjection
number
clearancefraction
troughtotalplasmaantibioticconcentration
peakbreastmilkconcentration
cordbloodmaternalplasmaconcentrationratio
sc50
fractionabsorbedthrough
apparentplateauinplasmaconcentration
terminalphaseeliminationrateconstantkel
peakpaclitaxelconcentration
excreted
areasundertheconcentrationtimecurvesduringthe12hdosingintervalauc0taus
finaleliminationphasehalflife
aucconcentration
cle
troughactivity
ddqtcib
salivatoplasmaconcentrationratiocscp
peaksulfamethoxazole
ultrafiltrationrate
totalclearanceofdmicldmi
lowdetectionlimit
radiocarbonrecovery
overallexposureauc0
auc0144
maximalresponseemax
redbloodcellplasmawaterpartitioncoefficient
areaundertheconcentrationtimecurvefromtime0to24hmeasurableconcentrationauc024h
totalexposureauc012h
totalnumberofrotation
effectivebloodconcentration
molarpercentageofdose
cc50
initialwholebloodconcentration
na
plasmaelimination
apparentoralmdzclearance
areasunderthepropranololconcentrationtimecurve
totalifx
activationenergie
bloodexpiredairratio
baseline
absolutebioavailabledose
t12
cmaxhaparatio
maximummeasurableconcentration
qtcinterval
molardosefraction
apparentpopulationclearance
cess50
totalplasmaclearanceclsf
concentrationsinducinghalfmaximaleffect
unboundnonrenalclearance
t12k10
totalrelease
plasmaind
halflifeofbuserelinrelease
kon
unboundquinidineconcentration
totalbindingcapacitie
auc0tlast
effluxtransportclearancepsbbbeff
auc24mpcratio
troughfev1
areaundertheplasmaconcentrationtimecurveoverdosingintervalt
concentrationthatinhibited50lymphocytesec50
absorptionoforaldose
sct
aparameter
peakplasmadigoxin
percentagestime
pretreatmentrecoveryrate
totalkidneyclearancecit
apparentintercompartmentalclearanceofatorvastatinlactoneqmf
ddtci
peakrate
troughcsaconcentration
basalrate
tissuetoplasmatpratio
timetomaintaingastricph4
art
terminaleliminationplasmahalflive
tosr
timeofmaximalplasmaconcentrationtmax
auco
lateeliminationhalflife
areaundertheconcentrationtimecurveover48hour
therapeuticserumconcentration
steadystatelidocaineconcentration
freebuprenorphine
ctroughauc
clearanceofhaemodiafiltration
timeabovethe
vesseldensity
distributionvolumev
maximumsecretorycapacitytmpah
pulmonaryconcentration
maximalserumconcentration
areaunderthefreeconcentrationtimecurvefauc
firstorderclearance
intestinalextraction
runningtime
timetomaximumtmax
apparentserumclearance
maximuminhibitionoflossofresponseimax
fractionofdrugexcretedinurine
1kappa
plasmasufentanilconcentration
endtidalconcentrationfa
intracellularconcentration
eliminationhalflifet12beta
eliminationhalflifet05e
ratiooftheauc010h
ratioofareaundertheconcentrationtimecurveminimuminhibitoryconcentrationaucmic
maximumofconcentrationcmax
diffusiveclearance
halflifetimeoftheterminalphase
encapsulationefficiencie
cfucmu
saccadiclatency
milkconcentration
maximumparacetamolconcentration
aucss012
rateofmeandrugclearance
phasesystemicplasmaclearance
absoluteneutrophilcountnadir
kaabsorptionrateconstant
viablebacterialcount
steadystatemxconcentration
apparentvolumeofdistributionofethanolvz
overallextractionrecovery
timestopeakbloodconcentration
csfmtx
areaundertheserumconcentrationtimecurvefromtimezerotoinfinityauc0infinity
areaundertheplasmaconcentrationtimecurveaucss08
effectiveconcentrationtoattaina50maximalresponseec50
timewhenthemaximumconcentrationreachedtmax
areaunderthetimeversusdeltaqtccurve
maximalplasmaconcentrationcpmax
or
coldpainthreshold
halflivesofurinaryexcretion
ahalflife
troughforcedexpiratoryvolumein1second
zaverageparticlesize
overallbioavailability
peaktroughcarbamazepineserumlevelratio
augtau
areaunderthecurvefromtimezerotothelastsamplingtime
steadystatecitalopramlevel
erectbp
ktransfer
clearancesatsteadystate
timestoonset
areaundertheplasmaconcentrationversustimecurvefromtimezerotoinfinite
distributionhalftimet12lambda1
totaldurationsofsensoryblockade
apparentvolumeofdistributionofthecentralcompartmentvf
brainbloodconcentrationratio
withdrawalperiod
halfmaximalactivity
peakaraclevel
peakritodrineconcentration
kdna
k12hl
terminaleliminationhalflifeofradioactivity
tounboundplasmaaucratio
areaundertheplasmamexiletineconcentrationtimecurve
lossofbioavailability
plasmafreedrugconcentration
disappearancehalftime
overallurinaryrecovery
peakplasmavitamincconcentration
recoveredradioactive
peakex
halflifefortheterminalphase
eliminationrateconstantfromthecentralcompartment
intercompartmentclearancescl2
michaelismentenconstantconstant
quin
enrichmentfactoref
aucxo
maximumconcentrationsofvilaprisancmax
auc0infinityh
rateconstantsofdegradation
kidneyplasmaratio
aucfrom0to12hour
timetoachieve50ofsteadystatelevel
cumulativeamountexcretedunchanged
timetothemeanobservedpeakserumlithiumconcentration
areaundertheconcentrationtimecurvesfrom024hour
skinabsorption
dosecorrectedpeakplasmaconcentrationcmax
vmaxkm
totalplasmatopotecan
terminalhalflifet12c
totalmetabolicbloodclearance
wbc
aucoe
inhaledflow
areaundertheplasmaconcentrationversustimecurvesauc0infinity
areaundertheconcentrationtimecurvefrom0to21day
totalbodyclearancecltf
areaunderplasmaconcentrationtimecurve0to12hour
total12h
terminaleliminationhalflifet12b
liverextractionratioaucliveraucplasma
fauc024
troughc
maximumaverage
percentsrecovery
initialdruglevel
volumeofdistributionbodyweight
equilibriumdissociationconstantskd
maximume
centralvolumeofdistributionv2f
steadystatetrough
heparintoprotamine
timeforabsorptionof50
bbbpermeabilitysurfaceareaproduct
maturationhalflife
peakcyclosporineconcentration
associationconstant
limitof
bloodgaspartitioncoefficient
fviiac
areaundertheplasmaconcentrationtimecurveaucfromtimezeroto72hoursauc72
reductionratio
cumulativeamountofdrugrelease
zeroorderreleaserate
auctnormal
auc0metabolicratiomr
peripheralclearance
plasmaliconcentrationattimezero
weightadjustedclf
effectiveplasmalevel
plasmameanresidencetimemrt
steadystateconcentrationcmss
serumofloxacinconcentrationpeak
areaunderthecurvefor0to24hour
peaktriazolamconcentration
extracorporealclearance
apparentvolumeofdistributionvcf
timeofonset
clinicalbenefitresponserate
apparentterminalphasevolumeofdistribution
unboundhydroquininefraction
steadystateplasmaconcentrationc
ratioofplasmaauc0infinity
tilde
serumcmax
aucfreefattyacids024h
tumorplasmaratio
extractionrecovery
maximalvenousblooddrugconcentration
minimumlungintracellulartnconcentration
peakserumpaconcentration
renalranitidineclearance
peakplasmadampaconcentration
survivaltime
peakbupropionbreastmilkconcentration
apparentvolumesofthecentralcompartment
areaundertheplasmaconcentrationtimecurveatsteadystateauctau
maximummeanurineosmolalitie
extractionefficiencie
maximumeliminationratevm
steadystatedtcplasmaconcentration
peakbileconcentration
nonplacentalclearance
biliary
plasmasteadystatempconcentration
maximalserumconcentrationcmax
peakplasmadesethylamiodaroneconcentration
maximumdrugload
minimumdetectionlimit
convectiveclearance
totalplasmatheophyllineclearance
peakscmax
freeconcentration
residualintracerebrospinalfluidconcentration
ratiosoffolinicacidtomtx
oralnooveralladverseeffectlevelnoael
volumeofdistributionvzf
plateaulevel
logka
apparentcilazaprilatclearance
recoveredamount
intestinalpermeability
relativeconversionfraction
kineticdissociationrateconstantkoff
terminalhalflifeofdisposition
areasundertheconcentrationcurveaucs
peakplasma125d3concentrationscpmax
removalhalflifefirstcompartment
sizeratio
eliminationrateconstantk10
bioavailabilityauc
uptakeratio
auc0lloq
peakplasmaprogesteroneconcentration
totalsum
timestopeakplasmalevel
workofadhesion
initialslopededc
total6hour
ld50
aucd728
maximumtaconcentration
linkrateconstant
halflifeofradio
volumeofdistributionintheterminalphase
plasmaeffectsitetransferrateconstantke0
clearanceapcl
nn
apparentabsorptionrateconstantintothesystemiccirculation
apparentsteadystateclearance
fractionalperoralbioavailability
serumethanolclearancerate
endoftreatmentresponserate
intoxicationrate
cmax024
percentbioinversion
areaundertheplasmafentanylconcentrationvstimecurve
parasiteclearancetime
diseasefree
csfpenetration
plasmaaucinfinity
coefficienta
maximalplasmaconcentrationofketoprofencmax
wholebodyclearancecltot
concentrationquotient
percentmetaboliteconversionratio
renalextractionratio
rateconstantoffdop
initial
areaauc016h
tonsillartissueplasmaconcentrationratio
tumorturnovertimeconstant
apparentfirstordereliminationrateconstant
detectablelevelsduration
maximumbloodradioactivityconcentration
ejaculateplasmaratio
settlingvelocity
halflifeofthedistributionphasealpha
areaundertheplasmaconcentrationtimecurveauc0inf
volumeofdistributionvforal
residualvar
peripheraldistributionvolume
auc0t
washouthalflifet12
steadystateauctau
areaunderthetimeconcentrationcurve
bacterialkillingandregrowthcurve
amountofmtxexcretedinurinexu
t25
cmincmaxratio
wholebody
t11beta
percentageproteinbinding
completionrate
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc0
circulatingtotalmmiconcentration
nonrenalclearence
apparentvolumeofdistributionofthecentalcompartmentv1
peakdoxycyclineconcentration
rhofactor
pdratio
insulinclearancerate
maximalnordiazepamconcentration
timeuntilcmaxtmax
halflifeofmyocardialuptaket12d
j
braintosystemicexposureratio
halflifeofaccumulation
plasmacl
p450level
cmax1
steadystatebenzeneconcentration
maximumrecordedplasmalevel
halfofthemaximumabsorptionratewasachieved
maximumextentofinhibition
maximalincreaseininsulinsecretion
ctrpmin
vmf
physicalhalflifet12
exposureover24hauc024
cordbloodmaternalplasmaratio
plasmadistributionratio
ad
initialabsorption
weightnormalizeddistributionalclearance
peaktransplantedlungconcentration
auc028
terminaleliminationphaset12
compliance
minimumsteadystateconcentrationcmin
auc049d
elasticity
proteinbindingpercentage
maximalconcentrationintheserumcmax
eliminationrateconstantskurine
peakserumpiroxicamconcentration
timetoseizureoccurrence
terminaleliminationhalflifeofmeperidinet12beta
percentofdoseexcretedinurine
systemicwholebloodclearance
prostateplasmaratio
timerequiredto
maximumbloodlevelcmax
systemicallyavailable
eliminationrateconstantskes
areasundertheconcentrationtimecurvefromtimezeroto24hatsteadystate
invivodissolutiontimetdissvivo
areaundercurveabovefastingdeltaaucglucose
minimumeffectivedosemed
terminalhalflivest12z
maximummeanplasmafenconcentrationcmax
thermallatencie
clearanceperbioavailability
timetocultureconversion
peakserumlidocaineconcentration
ted90
cu50r
completecurerate
terminalhalflifevaluest12beta
intraoculareliminationhalflife
qainterval
apparentvolumeofdistributioninthecentralcompartment
peakciprofloxacinconcentration
emax
milkserum
timetoreachthetargetconcentration
halftimeteq
betaphaserateconstant
v88duofunbounddrug
fractionofarmbloodflow
invitrorecovery
extractionfractionse
troughserummoxifloxacinconcentration
meanresidencetimet
relativedegreeofbioavailability
steadystatebraintoserumconcentrationratiokpbrain
plasmahalflifeeliminationtime
peripheralv2compartment
relativeextentofavailability
troughserumconcentration
peakserummtx
csfeff
drugplasmamaximalconcentrationcpmax
maximumtime
enhancementratiosers
extentof
auc024hmicratio
dailyrelease
totalduration
timetotrough
minimumtherapeuticconcentration
mucociliarytransporttime
maximumaptt
mcr
aucss08
firstpassretentionfraction
frequenciesofspontaneousresistance
transdermalflux
minimaleffectiveconcentrationmec
nearsteadystateserumconcentration
durationofsleep
braintargetingefficiency
rateof
troughbloodconcentrationstbc
unboundpercent
nasalbioavailabilitie
timetoreach50completematuremidaz
timetoonsetofinduction
apparentplasmaclearancecl
maximumcnainhibitionimax
fractionabsorbedf
transferconstantfromcompartment1tocompartment2k12
sojourntime
accumulationhalftime
arterialconcentration
halflifeoftheterminalpartofthecurve
apparentsolubility
areaundertheplasmaconcentrationtimecurvefromtime0tolastmeasurabletime
totalareaundertheplasmaconcentrationcurveauc0infinity
maximumrateofsubstrateconversion
areaundertheserumconcentrationtimecurvefromtime0toinfinityauc0infinity
maximumfulvestrantconcentration
peakmicratio
painreliefrate
lowestplasmaconcentrationsatsteadystate
gm
norflx
peaktotroughconcentrationratiocmaxcmin
passivediffusionrateconstant
redispersibilityindex
timetoancrecovery
plasmaclearanceclf
plasmabioavailabilityf
saturabletransportwashalfmaximal
onsettime
vdtd
apparentclearanceofthemetaboliteclmf
durationoftherapy
secretorytransport
percentagebioavailability
areaundertheconcentrationtimecurveto24h
maximumdurationofitseffect
detectableantifxaconcentration
plasmafen
totalinhaledbioavailability
apparentbetaphasehalflife
totalmethodcycletime
rateofcsfbulkflow
inblinratio
encapsulation
maximumintravenousinfusionrate
apparentdistributionvolumeofperipheralcompartmentvsubpsubf
peakmousebloodlevel
constantreleaserate
bloodratio
standardcurve
venouscapillaryplasmaconcentrationratio
kacka
eliminationfromtheeffectcompartment
areaunderthecsfconcentrationtimecurve
concentrationefficiency
keo
drugtargetingindex
therapeuticrate
lengthoftime
terminaleliminationhalflifet12yz
tbc
serumpeakconcentration
aucof04hoursauc04
peakplasma6mplevel
aucat72hour
durationofabsorption
exhalationrate
cytotoxicityratioshcr
auc015
timestosufficientplateletinhibition
absorptionbioavailability
coefficientsa
systemictotalclearance
tumorcortexratio
auctmaxref
mreffectratio
alveolarcellconcentration
tmbp
fractionremovedbydial
timeforreturntoo
totalrecoveredamount
pp
peakserumconcentrationscmax
timetakentocleartheparasitespct
rafio
systemclearancecls
areaundercurvefor08hrauc08hr
volumeofdistributioncorrectedbythefractionofdoseabsorbedvdf
areaundertheplasmaconcentrationagainsttimecurve
survivalday
tubularsecretoryintrinsicclearancevmaxkm
ic50avb6
t12koff
maximalrateofclearance
peakpercentage
mztransition
effectcompartmentconcentrationat50ofmaximalobservedeffectec50
peakplasmassalevel
minimalsteadystate
tototalserumconcentrationratio
therapeuticindexld50ed50
distributionrateconstantscentraltoperipheralcompartmentk12
volumeofdistributionintheterminalphasevbeta
areaunderthecurve12
peakphtplasmaconcentration
influxclin
meanconcentration
analyticalruntime
kdforbinding
50ofeffectiveconcentration
administereddose
steadystatemorphineconcentration
clearancecltb
eliminationhalflifet12b
troughdaclizumablevel
tissuelevelbloodlevelratio
peakmeanserumconcentration
firstorderrateconstantofreceptordissociationkoff
halflivesoftheinitialdistributionphasealpha
aubc
cockcroftcalculatedclearance
maximumeliminationratevmax
tsb
ccimgfr
tmaxtimetofirstoccurrenceofcmax
extentofabsorptionareaundertheconcentrationtimecurve
c2hour
maximumhydroxychloroquinebloodconcentrationcmax
relativebioavailabilityf024
totalfraction
cmaxpeakconcentration
peakc
maximaldegreeof
skinliverratio
c2
peaktiter
maximalaggregation
peakcaptoprilconcentration
ratiooflethalityld50ld1
t12eliminationt12el
areasunderthecurveauc010
betaeliminationrateconstant
objectiveresponseraterr
peakserumpenbutololconcentration
mid
volumesofdistributionatsteadystate
latehalflifet12beta
timetoachievemaximumconcentration
volumeofperipheralcompartmentv2
radioactivityrecovery
maximumdrugdiffusion
oralcmax
co
apparentfirstorderabsorptionhalflife
plateletnadir
peakblooddrugconcentration
rectalbioavailability
timeofmaximumbloodglucoseresponse
concentrationproducingthehalfmaximumeffect
peakconcentrationachieved
areaunderthetheophyllineconcentrationtimecurve
netperitonealdialysisclearance
peakcortisonecmax
timetothemaximumobservedamifloxacinconcentration
areaundertheserumconcentrationtimecurveaccumulationratio
elf
pltc
auctau0
coefficientofdistributionk
timetotmax
areaundertheconcentrationtimecurvefromtimezero
maximumplasmasodiumdichloroacetateconcentration
cumulative14cradioactivityexcreted
kt0
bindingrate
timestorecoveryoft4t1to
masstochargemz
aucfrom0to12h
areundertheconcentrationtimecurvetoinfinityauc0infinity
totalfractionofinsulindoseabsorbedfa
exposureratio
eliminationfromthecentralcompartment
logd74
timetomaximumsalivaconcentrationstmax
radioactivityconcentrationratio
contribution
apparentbreastmilkclearance
systemicoralclearancerate
effectcompartmentconcentrationscorresponding
areaundertheconcentrationtimecurvesauc
growthinhibitionrateir
cluint
areaundertheconcentrationtimecurvefromzerohourtoinfinity
plateletcount
apparentavailabilitie
ratioofmilktoplasmaradioactivity
kmf
fg
plasmaconcentrationratio2nglucltg
pulsesimilarly
halflifeofplasmaelimination
2575recoverytime
peakoxygenconsumptionvo2peak
halflifet12beta
steadystateauc
totalfactorconsumption
areaunderthetimeserumconcentrationcurveauc
areaundertheserumconcentrationtimecurvefromzerotoinfinityauc0infinity
excretionof
apparentchronicreleaserateacrr
totalbody
volumeofdistributionofthedrugatsteadystate
steadystatesalivary
eliminationrateperminute
maximumplasmanicotinamideconcentration
maximalbh4concentration
halfmaximalkinactki
eliminationhalftimet12z
nebulizer
apparentoralbloodclearance
halflifefordistributionplasmatocsf
halflifeofdisappearance
auecrtauc
renalfecalexcretionratio
dosenormalizedplasmaauc012h
areaundertheplasmaconcentrationtimecurveoverthedosingintervalt
steadystateapparentvolumeofdistribution
basalbileflowrate
areaundertheplasmaconcentrationtimecurvefromtime0untilthelastquantifiableplasmaconcentrationauc024h
fflu
tumourbackgroundratio
maximumogtaconcentration
cpre
dispositionresidencetime
areaundertheconcentrationversustimecurveauc01
apparentdrugentrapmentefficiency
fpf
tumourtoplasmaratio
ca8
hardne
timesfromadministrationoflastincrementaldoseuntil25offirstresponseoftrainoffourtofrecovery
vfthreshold
peakofserumconcentration
pulmonaryarterial
maximumincreaseinreactiontime
duinfinity
maximalatropineconcentrationcmax
aubt
areaundertheserumconcentrationvstimecurve
steadystatedtcconcentration
cooperativityconstanta
wallpermeability
distributionvolumeofethanolv
clearanceofunbound
yintercept
maximummegxconcentration
diuresi
metabolicratioaucdmiaucindomethacin
timetoattainundetectablehivvl
totalquantity
tissuedrugconcentration
apparentoverallvolumeofdistribution
aucfromtimezerotoinfinityauc
terminalslopehalflive
residualdrugactivity
pec50
maximumabsorptionrateconstantka3max
troughamikacinconcentration
livertumoruptakeratio
totalareaundertheplasmaconcentrationtimecurve
relativerectalbioavailability
distributionrateconstantsalpha
mic90m
amountofcumulativedrugreleased
auc240min
cloralclf
analyticalrecoverie
absorptionratetransitrateconstant
rateofventilation
durationofmotorblockade
v2volumeofcentralcompartment
maximalrate
withholdingperiod
braintoserumratio
volumeofdistributionatsteadystatevdssf
overallextractionefficiency
auc048hour
effectivene
t12oftheterminaldecayphase
drugtargetingefficiency
volumeofdistributionatsteadystatevdss
areaunderthepercentchangeinprvstimecurve
areaunderthecurveoftheplasmaconcentrationtimecurveauc
plasmat12beta
a50
durationofsecretion
areaundertheplasmaconcentrationtimecurvefromtimezeroto120hauc0120
nonrenalclearance
metabolismrateconstantskmblood
circulatinghalflife
areaundertheplasmaconcentrationtimecurvefromtime0tothelasttimepoint
maximumconcentrationproduced
volumeofditributionatbetaphase
areaundertheconcentrationtimecurveaucratiocyatacofauc
logoctanolwaterpartitioncoefficientslogpvalues
hazardratio
areaunderconcentrationtimecurveauc024
mrtim
attenuation
permeabilitypeff
plasmaeliminationhalflifetime
fractionunboundinplasma
steadystatevinblastineconcentration
timetopositiveparasitemia
pathologicalcompleteresponse
fafi
bt
plasmalidoc
velocity
oralavailability
intrinsict12
clfkg
50maximumclearance
depthofnecrosi
removalrate
e
bodyweightnormalizedareaundertheconcentrationtimecurve
areaundertheplasmatimecurve
totalmaternalbodyclearance
transitcompartmentrate
trainoffourratiotoreturnspontaneously
absorptionratiofa
initialpainintensity
cw
steadystateplasma
dosenormalizedconcentration
terminaleliminationrateconstantlambdaz
initialdistributionhalflifeinitialt12
timetoleukocyterecovery
availability
overallappearancerate
plasmaconcentrationsat10
peakplasmaatropineconcentration
aucratio
xu024h
rateofexcretion
maximumnicotinelevel
plasmaareaunderthecurveauc
timetoreachpeakconcentration
timetothemaximumconcentrationcmaxofroflumilasttmax
viability
cbcecf
bohavailability
delaysinceg
semenbloodconcentrationratio
terminaleliminationhalflifet05betaor
t12betaserum
steadystatedistributionvolumevss
auc024vale
csftoplasmaratio
minimalparasiticidalconcentration
timeinvariantpartitioncoefficient
absoluterectalbioavailability
timereceivingdrug
volumeofdistributionv
maximumtransportnmaxvecf
bloodclearancerate
sodium
apparentcentralvolumeofdistribution
unboundvegflevel
apparenttotalclearanceafteroraladministrationclf
c45
areaundertheplasmaconcentrationversustimecurveauc024
hospitaldischargetime
auc024mdauc024
maximumnifedipineplasmaconcentration
lagtimesfor
adequateplasmaconcentration
vbac
aucpancreasaucblood
cumulativebiliaryexcretionamount
maximumpeak
concentrationpeakinblood
areasundertheplasmaconcentrationtimecurveauc0infinity
areasundertheconcentrationtimecurveaucs
peaksofmeanconcentration
areaunderthecurveaucratio
totaloraldiltiazemclearance
oralbioavailabilityfpo
apparentvolumeoftheperipheralcompartmentvpf
bioavailablefraction
cumulativerecovery
totalareaundertheplasmaconcentrationtimecurvefromzerotoinfinityauc
overallapparentvolumeofdistribution
ppb
aucbonemic
visibledetection
peakw554serumlevel
distributionalclearanceqf
areaunderthecurvefromzerotoinfinityauc0
fclearance
maximummeasuredplasmaconcentration
apparentsystemicmetforminclearanceclf
overallduration
rateofdecay
apparenteliminationt12
areaundertheplasmaconcentrationtimecurvefromzerotoinfinity
slp
areasundertheplasmaconcentrationtimecurve
concentrationathalfmaximumeffectec50
percentagepenetrationintotheinflammatorycompartment
t12formation
ed501
braineliminationhalflivest12
minimumplasmaciprofloxacinconcentration
timetoparacetamolcmax
urinaryhalflife
osmolalgap
normalizedaucssnorm
m2
maximumserumconcentrationcmaxss
peakaztplasmaconcentration
areaundertheconcentrationversustimecurvefromzerotoinfinityauc0
er
ce50
flowinjection
overallhalflive
minimumobservedunboundconcentration
maximumsulfadoxine
apparentpartialclearance
aucuptothelastmeasurableconcentrationauc0t
later
concentrationat50effect
intrinsicequilibriumbp
drugloadingrate
serumhalflivesinthebetaeliminationphase
freetotaltiagabine
braintumortoplasmasteadystatetmzconcentrationssctcpratio
peakgh
maximumpercentageinhibitionimax
peakmeanplasmaconcentration
bonehalflife
durationoftherapeuticconcentrationdtc
corpuscularvolume
clareaf
deformabilityindex
areaundertheserumcaffeineconcentrationtimecurveauc0infinity
50effectiveconvulsantdose
retardquotientdeltar
instmax
initialmidazolam
steadystateplasmauridinelevel
timetoeuthanasia
distributionhalflifetalpha12
absolutepercentbioavailabilitie
milkeliminationhalflife
timeofpeakplasmadrugconcentration
gutextractionratio
areasundertheplasmaconcentrationtimecurvesfromtime0tothelasttimepointauc0t
maximumconcentrationminimuminhibitoryconcentrationcmaxmic
sievingcoefficientsc
timeatwhichitoccurredtmax
minimalplasmadiazepamconcentration
peakglycaemia
volumedistributionofsteadystate
peakobservedconcentrationsintheblood
aucazt
peakvalueofmaximumplasma8mopconcentrationstmaxcmax
plasmasteadystatevolumeofdistribution
s50app
totalcdratio
areaundertheconcentrationversusthetimecurvefrom0tothelastsamplingpointauc0t
amountofdrugtransported
halflifeperiodofthebetaphase
intrinsicmeanresidencetime
maximumproteinbindingbmax
globulediameter
peakmediantriamcinoloneconcentration
apparentmeanvolumesofdistributionatsteadystate
bodyresidencetime
peakmeasuredconcentration
absolutemetabolicclearance
skinmrt
areaunderthecurveuptothelastconcentrationauc0t
fractionfb
ko
ethanoloralclearanceclf
q
peakbrainconcentration
absorptionrate
plasmadialysisclearance
postplasmaconcentration
formationclearancecl2m
bloodserumconcentration
cminconcentration
glucosetolipidsratio
timetomaximalplasmaconcentrationtmax
totalserumdruglevel
vgamma
overallprocessefficiency
cellulart12time
eliminationphasekineticparameter
minimumalveolarconcentration
earlybactericidalactivity
troughconcentrationsc24h
ubt
steadystatefetalmaternalunboundvpaplasmaconcentrationratio
apparentvolumeoftheperipheralcompartmentofad
timetobloodneutrophil
c12
apparentvolumeofdrugdistribution
remission
recoveryphasehalflife
halfmaximalproductionp50
clqh
particlesizezavg
kant0
insulinogenicindex
renalclearancecl
90effectivedose
areaunderthecurveratiosaucrs
peakmeloxicam
aucr
maximumplasmaproguanilconcentration
halflivesofdistribution
transdermalbioavailability
timetoreachthepeakconcentration
areasundertheconcentrationcurvesaucs024h
bioactivity
chromatographicanalysistime
areaundertheplasmaconcentrationvstimecurvefrom012hauc012
v3fuprostate
plasmahalflifebeta
lungmeanabsorptiontime
eliminationclearancecl
loq
neteffluxratio
lct50
drugconcentrationratio
cp
areaundertheconcentrationtimecurvebetweenzeroandthelastsamplingpointauc0t
areaundertheconcentrationtimecurvefromtime0toinfinityauc0infinity
lunglevel
totaltime
balconcentration
lagtimebetweendosingandfirstappearance
chlorideexcretion
aec012
totalbodyclearanceci
appearancerate
auctaubssratio
apparentvolumeofdistributionoftheplasmacompartmentvc
maximumdetectedconcentration
totalcefazolinbodyclearance
secondaryphasehalflife
totalfictivevolumeofdistribution
inhibitionconstantkiratio
totalamountlost
areaunderthebloodlevelcurveauc
relativebraindistributioncoefficientaucbrainecfaucplasma
uar
signaltonoiseratiosn
peakstimulatedlhconcentration
peakmtxlevel
plasmadistributionhalftimet12alpha
cmaxarithm
lc5050lethalconcentration
areaundertheisoxicamplasmaconcentrationtimecurveaucinfinity
timetomaintainfviiilevel
halflifeoftransport
kiinhibitionconstant
clcl10
humanoralbioavailability
auec
plasmaareaunderthecurveauc024
polydispersionindexpi
areaundertheconcentrationtimecurvefromzerotoinfinityaucinfinity
betarateconstantofelimination
averageconcentrationcavg
k11
vven
respiration
enteralabsorption
csfpenetrationratio
percentageurinaryrecovery
volumeofthecentralcompartmentofthetwo
timetofirstoccurrenceofcmaxtmax
maximumconcentrationofdalarelininthebloodcmax
maximumconcentrationinplasmacmax
apparentunboundclearancecluf
dte
overallpregnancyrate
acuterejectionrate
totalcumulativerecovery
overalleradicationrate
averageplasmaconcentration
halfvalueduration
peakd2receptoroccupancy
biologicalt12
auc02areaundertheconcentrationtimecurvefrom0to2hours
areaundertheplasmaconcentrationtimecurveauc08h
steadystateplasmatopotecanlactoneconcentration
totalareasunderthecurveauc0
ba
ld10
apparentvolumeofdistributionforthecentralcompartmentv2f
partialapparentmetabolicclearance
halflifeofeliminationkelt12
maximumareaundertheconcentrationtimecurvefrom012h
areaundertheconcentrationtimecurvefrom024hour
pseudoequilibriumplasmaconcentration
portalclearance
volumeofthemetabolitecompartment
tumorcumulatedactivity
timestoreachpeakconcentrationtmax
tumoroversubcutisratio
amountexcretedunchangedinurine
firsteliminationhalflifet12alpha
percentageofrenalclearanceclrcltotal
oralbioavailabilitie
intercept
occupancyatsteadystate
minimuminhibitoryconcentrationsmics
peakenoxacinconcentration
areaunderthecurveauc028day
throughlevel
timetoproteinadjusted90inhibitoryconcentration
immunoreactivesecretinconcentration
cmaxpeakplasmaconcentration
maxconcentration
peaktheophyllineplasmaconcentrationcmax
peakplasmadrugconcentrationcmax
maximuminflammatoryfluidlevel
volumeofdistributionofperipheralcompartmentq3f
plasmaproteinbindinglevel
maximumbrainplasmaratio
minimumdetectableamount
ninetyminuteplasmaretention
t12elin
recoveryrate
maximummeasuredplasmaconcentrationtmax
f0infinity
systemicmtxclearance
volumesofthecentralcompartmentv
cerebrospinalfluidcsflevel
pseudosteadystateconcentration
rateofabsorptionka
inhibitionconstantski
distributionphase
volumeofskinblister
renalexcretion
freeintrinsicserumclearance
specificactivity
nonrenalclearanceratiocrnr
timethattheserumcimetidine
hepaticbloodextractionratio
steadystatetotalconcentration
maximumsketoprofenconcentration
totalareaundertheplasmaconcentrationtimecurvefromtimezerotothelastmeasuredtime48h
lumbarcsflevel
areaundertheconcentrationcurveauc0
percentagerecovery
volumesofdistributionatsteadystatevss
areaunderthedrugconcentrationtimecurvefrom0to4haftertreatmentauc04
eliminationrateconstantlambdaz
cavitaryserumlevofloxacinratio
inulinclearance
auic24
plasmat12
fractionmetabolizedtodoxolfm
fgfrate
rateoflo
auc091
entrapmentefficiencie
biologicavailability
peakdabigatranconcentration
t12ofelimination
areaundertheconcentrationtimecurvefrom0to27hoursauc027
relativeciclearance
maximalbloodlevel
apparentdelayedterminalphaset12
halftimeofelimination
samplecollectiontime
t100
doseweighttoreachthetargettroughconcentrationc0
overalleliminationrateconstant
plasmaproteinbindingpercent
renalclearancesper
venou
ec98
steadystatemaximumobservedplasmaconcentrationcssmax
auclinfinity
areasundertheplasmaconcentrationtimecurveaucvalues
snaareaundertheconcentrationtimecurve
washouthalflife
areaundertheplasmaconcentrationtimecurveauc012h
bmax
timetosteadystate
timeofattainmentofpeakconcentration
trougheculizumabconcentration
cumulatedrenalexcretion
weightcorrected
concentrationathalfthemaximumvelocityofmetabolismvmax
terminalhalflive
apparentrenal
minimuminhibitoryconcentrationmic90
tumorconcentration
peakrmpconcentrationcmax
timetothemaximalneuromuscularblockingeffect
peakserumciprofloxacinconcentration
centralcompartmentdistributionvolumev1
maximumheartrateduringexercise
totalsteadystateplasmaconcentration
overallbloodeliminationhalflife
aucaccumulationratio
halfliferatio
peakconcentrationatsteadystate
effectivedose
aucoralauc
hyperforinconcentration
volumeofdistributionofnaloxonevd
captureefficiency
minimaltherapeuticlevel
pulmonarydeposition
biliarytransportmaximum
sumplasmatroughconcentrationctrough
cmaxmaximumplasmaconcentrations
percentageentrapmentefficiencie
peaktroughratio
apparenteliminationhalflifet12
internationalnormalizedratio
peakleukemiccelldaunomycinoldnmolconcentration
timetoattainmentoftargetconcentration
durationofstabledisease
absorptionrateconstantkacr
das28
timeofmaximumdrugconcentrationtmax
boneuptake
lowest
steadystatetissueconcentration
areaunderconcentrationtimecurveauc
maximalropivacaineconcentration
clapp
timeofprogression
timetotherapeutictacrolimusconcentration
salivaconcentration
incorporationrateconstant
cumulativeoccurrencerateofadverseevent
fractionofdoseexcretedthrough
basalplasmaconcentration
extubationtime
troughcminday28
timetotherapeuticta
accumulationratiooftheauc
auc0tdose
lagtimesofabsorption
i
mad
arterialtovenousavconcentrationratio
peaknapaconcentration
freecmax
sna
rateofabsorptiontmax
aucinfinityfaaucinfinityma
aucmic
auc0inifinity
lungbloodconcentrationratio
volumesofdistributionvdlambdaz
maximumcumulativeamountpermeatedin24hoursq24
overalleliminationhalflifemtxt12
methodrecovery
maximumplasmaconcentrationofradioactivity
50inhibitoryconcentrationsic50
subcutaneousbioavailability
halflivesofuptakeinto
uptakerate
uh2uratio
entryrate
areaunderthebloodethanolcurveauc
maximumserumconcentrationofmorphinecmax
terminalhalflifet12gamma
fractionofunboundprednisolone
firstorder
absolutebioavailabilityfauc
timetorepeatbolu
killrateconstant
fractionoftheoraldoseabsorbed
livertoserumtotalwarfarin
urinaryexcretionae0
halflifeofdecline
cmaxtotal
auc012hxvmicratio
ct
pulmonaryarteryconcentration
fractionallithiumclearanceclicin
peritonealhalflive
tissuetoplasmadistributioncoefficientkp
maximummetabolicreactionvelocityvmax
ae08h
intracellularhalflifet12
peakplasmaconcentrationwascmax
apparentvolumeofdistributionofthecentralv1f
auc0720min
eliminationhalfliket12
maximumadministereddose
plasmarenalclearance
areaundertherifapentineplasmaconcentrationtimecurveauc0infinity
totaldrugdose
troughpef
sensitivitylimit
recurrencerate
intramuscularbioavailability
h0
fetalplasmacmax
terad
absorptionrateconstantka
intracellularserumratio
totalporosity
absorptiontimedelay
firstordereliminationke
inhibitoryrateoftumorirt
terminaldispositionhalflife
mn
volumeduringeliminationphase
timeabove01micro
cpeptideconcentration
timetomaximalbloodconcentration
totalbrainconcentrationratio
alveolarhalflife
peakurineconcentration
troughplasmavrczconcentration
steadystatemaximumplasmaconcentration
absorptionfirstorderrate
initialbloodclearancet12earlyphase
hepaticintestinalspilloverrate
terminalhalflifet12
druginhibitoryconstantki
maximalheartrateincrease
t12pla
halflifeoftheterminaldistributionphase
halflivesoftheexcretion
cma2
maintenanceinfusionrate
peakplasmaconcentrationcmaxabs
fb
maximumserummmiconcentrationscmax
bioavailabilitie
tdoc12
stabilityconstant
halflifefordistribution
metabolicratiosmr
areaundertheparasiteclearancecurve
totalproteincontent
areaunderthe48hrplasmaconcentrationcurve
apparentvolumeofdistributionduringtheterminalphaseafteroraladministrationvzf
areaundertheplasmaconcentrationversustimecurvefrom0toinfiniteauc0infinity
firstorderreactionconstant
durationtoatofratio
tsub12
turnovertime
encapsulationefficienciesees
acirculationhalflife
timetomaximumconcentrationofdrug
vmaxb
peakconcentrationofdruginserumcmax
maximumta
plasmaclearanceplcl
apparentcentralcompartmentvolumeofdistributionvff
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityauc
timetoreachpeakplasmamidazolamlevel
volumeofdistributiontvv
ofmaximumconcentrationcmax
auc04800
mini
activityclearance
plasmaconcentrationcmax
relativefreeconcentration
ptr
areaunderthecnaversustimecurve
percentofdosesystemicallyabsorbed
timetoreacheffectiveconcentration
peakclozapine
hepaticextractioncoefficient
compartmentclearanceq
totalbiliaryexcretion
detectionpotential
hepaticplasmaflow
oraladsorptionf
absolutivebioavailability
aucor
peakplasmabupropionlevel
hi
drugtargetindexdti
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinity
effectivedoseof50thrombolysised50
limitsofq
plasmaepinephrineconcentration
halflifeofoccupancydisappearance
areaundertheplasmaconcentrationtimecurvefrom0toinfinityauc0infinity
extravascularpenetration
areaunderconcentrationtimecurveauc0t
effectcompartmentconcentrationcorrespondingto50
doseperweight
auctarget
recoveryfrom
droplet
maximaldruglevel
gastric
micsmic
clearanceper
maximumabsorptionratevma
f8h
flipangle
timetomaximumlevel
concentrationapparentinhibitionconstantkiratio
cl21
normalizedareaunderthephosphatevstimecurve
completeclearancerate
maximumdecline
lungt12
rateofentry
totalperipheralresistance
stc
maximumplasmaconcentrationscmax
vdpla
peakplasma5ismnconcentration
volumesofdistributionin
maximalbeta1blockingeffectemax
hepaticenzymesaturation
areaundertheeffectcurvetothelastobservationauec0last
ic50u
boneplasmapenetrationratio
steadystatevalue
k24
cissrf
totalurinaryexcretion024h
cardiacoutput
amountofabsorbed
plasmaclearanceoverbioavailabilityratioclf
maximumend
steadystateinfusionconcentration
durationofabsorptiond1
normalizedurinaryrecovery
minimumsalivaflow
conversionindex
k12k21
volumeofdistributioninthehipjointcapsulecompartmentvjc
cumulativesurvivalrate
imaxd
maximalplasmaantixaactivitie
relativeinvivorecoverie
mrtpregnant
halflivesofplasmalevel
umaxmaximalexcretionrate
maximalqtprolongation
areaundertheplasmaconcentrationtimecurvesfrom0to12hauc012
halflifeoftheterminaleliminationphase
k1k2
vu
peaktrovafloxacinconcentration
halflifet12alpha
steadystateauc012
hepaticextractionratioher
maximumbloodplasmaratio
ratesof
intercompartmentalclearance
steadystatecl
apparentcl
plasmadrughalflife0693vmkm
hepaticintrinsicclearance
lz
peakconcentrationscmax
apparentdurationofeffect
similarityfactorf2
eliminationphasehalflifet12beta
minimumparticlesizeps
dissolutionefficiency
dqtcf
volumeofcentralcompartmentisvc
areaundertheconcentrationtimecurvefrom0to12hauc12
timetoonset
recoverytimesoft4t1ratio
mw
centralbloodvolume
areaunderthecurveofmetforminauc0540min
availabilityafterthefirstpasshepaticextraction
releasehalflife
de30
meaninputtimemit
areaunderthecurvebreakpoint
bioadhesivestrength
minimumobservedplasmatroughconcentrationctrough
biologicalavailability
eliminationhalfline
overallhalflivesofeliminationfromthecentralcompartmentt12
vdz
clearanceofpinacidilclp
areaundertheconcentrationtimecurvefromtimezeroto48hauc48
initialdilutionspace
areaundertheconcentrationtimecurveminimuminhibitoryconcentrationmic
plasmaunboundconcentration
media
vitaminb12
safetymarginratio
steady
kagi
areaundertheconcentrationversustimecurveupto24hafterthedose
relativebindingaffinitie
auctausd
plasmaticpeak
residence
apparentplasmahalftime
fractionalendtidalalveolarconcentrationfa
apparentt12
aucelfexposure
systemicdisposition
liverlevel
peaktolvaptanconcentration
plasmaareaundertheconcentrationversustimecurve
fluidtobloodratio
progressionfreesurvivaltime
v2fl
peaksynovialfluidconcentration
fbioavailability
alphaphasehalflife
peakinsulinconcentration
signaltonoise
tumorbloodratio
meantransittimetau
km2
areaundertheconcentrationtimecurveauc0
extractionfraction
maximumplasmaconcentrationtmax
percent
preliminaryresponserate
apparentv
f1
maximumserumconcentrationattained
peakserumtotalmexiletineconcentration
volumeofdistributioninthebetaphasevdbeta
eliminationofhalflife
vlambdazf
timetoattainpeakserumconcentration
iuc
accumulationhalflife
timetorecoverytoanabsoluteneutrophilcount
cavitybloodratio
areaunderthecurve
halftimes
areaunderthecurvefor08h
sievingcoefficients
maximalbloodconcentrationscmax
t05el
valleyconcentration
troughsirolimusconcentration
extractedfraction
steadystatepeakplasmaconcentration
maximumtotaldrugconcentrationcmax
slowdisappearancehalflive
aucsublastsub
plasmasteadystatetroughvoriconazolelevel
oralbloavailability
detection
apparentplasmaterminalhalflive
maintenancesteadystatetrough
milktoplasmaratio
maximumwholebrainconcentration
relativecellsurvivalrate
initialmeanconcentration
apparentdailyclearance
villousheight
apparentextrarenalclearance
centralvolumesofdistribution
areasundertheplasmaconcentrationtimecurve072h
renaltissuetoplasmaconcentrationratio
unboundauc
cytotoxicityratio
pc
zaverage
volumeofdistributionperfractionabsorbed
adherence
ic5
maximumserumconcentration
mzmh
maximaldrugcontent
totalalphalevel
maximumblock
metabolicclearancerateofamcra
areaderivedvolumeofdistributionvdarea
tumortonontumorratio
recoveryperiod
salivary
areaundertheserumconcentrationtimecurveauc0infinity
muscle
uptakeatpeak
totalgadoliniumclearance
drugloadingcontentdl
c50s
annual
mac
aucration
intrinsicplasmaclearancecli
volumeofdistributionofthecentralcompartmentv2
areaundertheconcentrationtimecurvefor12hoursafterthedoseauc012
troughplasmatheophyllinelevel
minimumrecommendedconcentration
brainuptakeclearanceclup
totalcmax
neutralisingcapacity
spontaneousabr
clbsa
peakibuprofenconcentration
maximalcontent
eliminationhalflivesatbetaphase
areaunderthe24hourconcentrationtimecurve
maximalresponsecave50
timefor70dissolutiont70
peakserumranitidineconcentration
timetosteadystateplasmalevel
cumulativeurinaryrecovery
intercompartmentalrateconstant
apparentclearanceatsteadystate
maximumloading
lengthofstay
oralabsolutebioavailabilityf
drugfluxe
tissueterminalhalflife
maximalrateofelimination
timetakentoreachthepeakconcentration
areaundertheexogenousseruminsulincurvefrom0to6h
exudateplasmaconcentrationratio
steadystateconcentrationscss
signaltonoiseratio
peakdrugconcentrationcmax
kabs
integratedconcentration
mediansurvivaltime
peakbrompheniramineconcentration
concentrationproducing50inhibitionic50
maximumcaffeineconcentration
ra
volumeofdistributionvdgamma
0tot
apparenteliminationrateconstantkel
areaundertheconcentrationtimecurveduringoraladministrationaucpo
initialdistributionvolume
cmaxauc
volumeofdistributionofthebetaphase
peaklcflevel
ratioscmaxmic
t12eff
terminalbiologicalhalflife
eliminationperiod
plasmatmax
maximumlymphcialevel
durationoftreatment
dissociationrateconstant
effectivedoseed50
serumauc024
auc24mic
50efficientdoseed50
peakconcentrationsofunboundplasmaconcentration
auc024hrmicratio
rsratio
volumeoffluidremainingin
salivaplasmamhdratio
cumulativepenetrationamount
unboundauc012
timetoreachcmaxtmax
vbeta
ofpratio
durationofcompleteresponse
productratio
totalglucoseinfusion
detectable
brainplasmaaucratio
molarextinctioncoefficient
apparentterminaleliminationhalflife
cmaxtominimuminhibitoryconcentrationratio
troughfe
kbobeta
interstitiumtoserumconcentrationratio
overallcompletepluspartialresponserate
heartratenadir
totalamountofabsorbedlindane
teralb
cumulativepercentreleasesigmar24ratio
recoveryratio
apparenthalflivesoffirstorderabsorption
urineflowrate
troughsteadystatemetforminplasmaconcentration
cli
timeadvantage
completeresponse
peaksirolimusconcentration
transportratio
absoluteneutrophilcount
minimalantiarrhythmicplasmaconcentration
maximaltt4concentration
cumulativeareaunderthecurvecauc
peakconcentrationsinplasmacmax
auc012hd
cumulativeradioactivityexcretedvia
limitofsensitivity
tissueplasmaaucratio
totaldelivery
kineticsoftumorcelldeathk1
areasundertheconcentrationversustimecurveauc
oralbioavailablity
serummeanresidencetime
peakfetalbetamethasoneconcentration
areasauc
percentagesofpenetration
peakplasmalevelsofvtbcmax
areaundercurveauc0t
appx
timetom3gpeakconcentration
auc026h
aucsub0sub
hepatic
areaundertheplasmaconcentrationtimecurvefromtime0to24h
ivhalflife
aucauc50
areaundercurvefromzerotoinfinityauc
maximaldose
centralcompartmentconcentration
absolutebioavailabilityfa
halflifeofunbound
hepaticclearanceofeviniferinvmaxkm
maximumpeaklevel
salivaplasmaconcentrationratio
absolutebioavailabilityforal
halftimeofdistributionphase
aucalpha
areaundertheplasmaconcentrationtimecurvedextrapolatedtoinfinity
peakserumimipenemconcentration
aucinfinity0
timeofthepeakconcentration
apparentclearanceclitraconazole
tran
chb
timetomaximumglucoseinfusionratetrmax
durationofcompleteresponsecr
apparentterminalplasmahalflife
fi
fecalexcretion
transepithelialpermeabilityratio
halftimeofeliminationt12
tmaxmodel
rateconstantk3ki
maximumvelocity
timetomaximumpt
rateofdrugadministration
volumeofthecentralcompartmentvcf
fbal
maximumlevelofradioactivity
extentofdrugboundtoplasmaprotein
maximumabsorbeddose
endometrialconcentration
areaundertheplasmaconcentrationversustimecurvefromthetimeofadministrationofthelastdoseto24hoursafterthattime
tsh2tsh1ratio
chesttubeoutput
totalareaundertheplasmatriazolamconcentrationtimecurve
incrementalrecoveryir
percentageofdoseexcreted
areasunderthecurveauc0infinity
areaunderthedrugconcentrationtimecurveratio
girmax
plasmatictarget
c1a
enhancementratiosser
penetrationhalftime
maximumantagonizingeffect
areaundertheplasmaconcentrationtimecurvefrom0to12hoursatsteadystate
maximumtolerateddosage
dar
timerequired
criticalsolutiontemperature
cumulativerelease
tof
matrix
auc2448
maximalsilodosinconcentrationinplasmacmax
plasmaproteinbindingrate
plasmadrugconcentrationproducing50ofmaximaleffectec50
timerequiredforcompletedegradation
ethanolconcentrationinmilkat
peakapapconcentration
volumeofdistributionvdbetaf
aucofblooddrugconcentrationtimecurve
db
observedmaximumplasmaconcentration
auc036h
distributionhalftimet12alpha
fetaltransferrateftr
imprecision
totaloralplasmaclearance
areaunderthepropranololconcentrationtimecurve
deltap
timeneeded
arrivaltime
cumulativeexcretionrate
oralf
ratiosofareaundertheconcentrationtimecurveauctomic
areaunderthedocetaxelplasmaconcentrationtimecurveextrapolatedtoinfinityauc
areaunderthecurveauc07h
screa
rateconstantsofreceptorassociationkon
fractionabsorbedfabs
relativeba
steadystateconc
centralcompartmentofdistribution
fractionofdoseabsorbed
maximumcalculatedeffectsitemorphineconcentration
areaundertheplasmaconcentrationtimecurvefromtime0toinfinityauc0
timestoparasiteclearance
painreliefscore
maximumconcentrationofdruginserum
plasmamorphineclearance
intrinsicmetabolicactivityvmaxkm
vfemale
timeperiodabove
apparentpercentage
halflifeofformation
aucauc04h
sclevel
salivaversusserumconcentrationratio
1h
apparentvolumeofthecentralcompartment
maximalcellularuptake
massaerodynamicdiameter
totalareasundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityauc
timetoreachthecmaxtmax
antifactorxaantithrombinratio
percentagetime
concentrationratio
basalconcentration
serumaccumulationratio
peakexcretionlevel
percentdissolved
c2h
pleuralplasmaratio
centralvolumeofdistributionvc
plasmaeliminationt12
peakdifference
x2
timetopeakconcentrationtp
t1relaxivity
timetoreachmaximumfentanylplasmaconcentration
aucid
distributionalclearancecldist
terminaldispositionhalftime
mz275
clpop
auc12h
lengthofhospitalstay
troughserumiggconcentration
overallmetaboliceffect
volumefraction
totalrenalelimination
x
xu024
oralbioavailabilityauc0t
cor
peakmiosi
renalsalbutamolclearance
encapsulatingefficiency
totalropivacaineplasmaconcentration
peakserummtxconcentration
totalbodyplasmaclearancecltot
unabsorbedfraction
maximumtenoxicamplasmaconcentrationcmax
timetoreachpeakbloodleveltmax
minimumparasiticidalconcentration
timetoplacement
steadystateminimumplasmaconcentration
fecalrecoverie
kc
areaundertheconcentrationversustimecurveauc06h
csa
fractionofdose
influxrateconstantkin
areaundertheplasmaconcentrationcurveforsteadystate24hintervalauc024
eliminationhalflivest12k10
loqsn
timetodoubleinvolume
maximumantibioticgastricjuiceconcentration
peakgemfibrozilconcentration
vvm
areaunderthecurve012
cltsratio
peakserum
maximalva
ctroughratio
plasmaeliminationhalflifet12z
permeabilityareaproductpa
steadystatedruglevel
fetalmaternalratio
venouslactateconcentration
auc50
ratesofmetabolism
unboundfractionfu
aucto24hour
totalsodiumnaexcretion
intracellularinitialhalflife
peakibuprofenplasmaconcentration
thrombosisrate
areaundertheplasmaconcentrationvstimecurvefromtimezerotothelastmeasurableconcentration
volumesofthecentralcompartment
ceilingconcentration
areaunderplasmaconcentrationtimecurveextrapolatedtoinfinityauc0infinity
apparentoralsystemicclearance
sleeptime
apparentassociationconstant
volumeofcompartmenttwov2
auc090min
areaunderthetimecurvefromzerotoinfinity
areaundertheplasmaconcentrationtimecurve012h
maximalprolactinresponse
plasmaresidencetimemrt
timetmaxtocmax
areaunderthebloodconcentrationnutimecurve
clzdosenormalizedc0dratio
timeofoccurrenceofthemaximumconcentration
molecular
volumeofdistributionofthecentralv1
clearancefromthebodycl
areasunderthecurveatinfinity
peakplasmasuraminconcentration
timetocr
areaundertheconcentrationtimecurvefrom0htoinfinityaucinfinity
areaundertheplasmaconcentrationversustimecurvefromtime0to24hauc024
lsstime
lymphplasmamtxratio
uptakekm
interassayrecovery
absorptionrateconstantkab
observedpeakafter
areaundertheplasmaconcentrationtimecurvefrom0to24hauc024
auc010hratio
peak1hourplasmalevel
absorptionratekr
tumorvolume
minimumwholebloodmefloquineconcentration
qualifiedresponserate
auctau
formationclearanceratio
maximumtotaltopotecanconcentration
minimumanestheticconcentration
trough
unbound3h
timetoreachamaximumconcentration
active
maximumconcentrationofroxithromycincmax
fractionoftheoraldosesystemicallyavailable
apparentvolumeofdistributioninsteadystate
areaundertheadmconcentrationstimecurveauc
volumesofdistributionatsteadystatevd
fetalmaternalplasmaconcentrationratio
maximumobservedserumgolimumabconcentrationcmax
clmfkm
t2alpha
ratiooftheareaunderfreedrugplasmaconcentrationtimecurveover24hfauctomic90faucmic
totalchromatographytime
areaundertheserumconcentrationtimecurveauc0120h
plateaulevelmaxima
peaktotaldoxorubicinconcentration
wetting
peakblisterfluidconcentration
auc48h
areaovertheegpcurve
areaundertheconcentrationtimecurvefrom0to360minauc0t
eliminationhalflifeoff
maximumplasmanicotineconcentrationcmax
paincontroltime
maximumazmconcentration
unboundbrainconcentration
id50
areaundertheconcentrationtimecurve012hour
areaundertheplasmaconcentrationversustimecurveatsteadystateaucss
serumconcentrationsc
peakplasmaldopalevel
areasunderthewholebloodconcentrationtimeprofile
rateofdeclineofresponse
troughantixa
betahalflife
noncompartmentalclearance
timetothemaximumconcentration
areaundertheconcentrationtimecurvesfrom0hto24hauc024h
rateofdrugabsorption
areaundertheserumconcentrationtimecurvefor72hauc072
areaundercurvebetweenzeroandinfinity
aucmetaboliteatvratio
ww
totalareasundertheplasmaconcentrationcurve
aucareaunderthecurve
constantpartitionratio
safetythreshold
cu
degreeofpenetrationintoblisterfluid
totalbodyclearancedosecss
tmax04
maximumserumconcentrationofterbutalinecmax
oxygenconsumption
ratioofauc08h
humanclearance
emaxdpressure
timetomaximalplasmaradioactivity
arterialportalaucratio
timetoreachthismaximumtmax
dc50
timetopeakoflisproabsorptiontmax
peakconcentrationtominimuminhibitoryconcentrationratio
absorptionratek12
t90
timetoclearresponsetoverbalcommand
troughgefitinibplasmaconcentrationcmin
initialplasmahalflife
plasmaclearancerelativetobioavailabilityclpf
ratioofrenalclearancetoplasmaclearance
tumortohealthybrainregionratio
tmaxtimeofoccurrenceofcmax
salbutamol
tp2
totalchromatographicrunningtime
hydrolysi
formationrateconstantkf
heartconcentration
timeofpeakplasmaconcentrationtmax
timeforextubation
totalcumulativedose
serumareaundercurveauc
totalintracellularconcentration
cumulativefecalexcretion
clrfu
halflifeofeliminationfromthebody
endogenoussecretionrate
fractionsofdrugremoved
last
numberofbindingsitesn
ratesofclearance
steadystatecsfconcentration
timestotwosegmentregression
steadystateareasunderthecurve
timetoachieve90steadystatepre
steadystatearteriallevel
steadystate
maximumavratio
washouttime
transformationrate
timetoreach75ofthereleaseplateaulevel
peakbloodethanolconcentration
gastrointestinaluptake
metabolitesdrugratio
renalexcretionrateconstant
finaldistributionvolume
initialdrugclearance
timetopeakglyburideconcentrationstmax
auctmax
transferclearance
vpf
maximumnacetyltransferaseactivity
peakmalotilateplasmaconcentration
vasscore
percentagebioinversion
areaunderthecurveconcentrationtime
ratesofexcretion
halfclearancetime
criv
timerequiredtoreachmaximumbrainconcentration
terminalhalflifet12tbeta
meanresidencetimemrt0t
tolerability
biliaryindex
influxrateconstantk1
maximumtrimethoprimconcentration
areaundertheconcentrationtimecurvefrom2to5hauc25
peakfreeoxaprozinserumlevel
volumeofdistributionatsteadystatevss
thirdcompartmentph
mlz
plasmaotc
areaunderthewholebloodconcentrationversustimecurvefrom012hauc012
clm6b
t12ter
minimaldetectionlimit
unboundtotalclearance
systemicprednisoloneclearance
drugrelease
slowphasehalflife
halflifegamma
peakunboundropivacaineconcentration
ic50avb3
timestoreachthemaximumconcentration
areaunderthecurveofplasmainsulinconcentration
therapeuticplasmaconcentration
activatedpartialthromboplastintime
troughsteadystatelevel
minimalfreewaterclearance
areaundertheconcentrationtimecurvefromtimezerotothelastquantifiableconcentrationauc0t
tissuebloodpartitioncoefficient
halflifein
totalcefazolinclearance
relativeaucratio
oraltransittimemtt
c24trough
halflifet12z
steadytargetbloodconcentration
varea
clo
interpulsevalleyconcentration
apparentmr
linearity
fiftypercentinhibitoryconcentrationsic50
ai
bindingsitesn
cxtconcentrationxtimeratio
fractionalbioavailability
initialhalftimeofabsorption
troughserumlngconcentration
apparentplasmadisappearancet12
urinaryrate
frequencie
cirttp
separationfactoralpha
residue
oculardistributionhalflive
oralhalflife
areaundertheplasmaconcentrationtimecurveto48hauc048h
whealarea
normalized
halflifeofbiophasedistribution
halflifeofinhibitionofacidsecretorycapacity
areaunderthecurvet0inf
v1vd
mec
timetomaximalactivity
aucfromtime0to1hour
oxidationclearance
timeover
apparentvolumeofdistributionofthecentralcompartmentv1f
permeabilityclearancepscsf
lofl
peritonealtoplasmaareaunderthecurveratio
areaunderthecurveplasmaconcentrationversustimeauc
distance
localabsorptionratiofa
pth
rateofperfusion
clbeta
mrt024
plasmadrugeliminationhalflife
concentrationmaximumscmax
logclearance
timetopeakapaptmax
sur
terminalserumhalflive
glucose
fecalrecovery
transferconstantktran
extractioncoefficient
apparentabsorptiont12
apparentvolumeofdistributionatsteadystatevdss
mrm
steadystatelorazepamlevel
maximumprueffect
disappearancerate
peakplasmacodeineconcentration
clnonorgan
areaunderthebloodconcentrationtimecurveauc0infinity
c2target
maximumobservedserumtrovafloxacinconcentration
aerosolrateofoutput
plasmagaconcentration
fractionalfreewaterclearance
timetostopseizure
k3
necroticpancreatictissueserumconcentrationratio
plasmaantixaactivity
kco2
totalclearanceratescltol
steadystatedfdclevel
unboundc
halfduration
concentrationatasteadystate
zetapotentialz
timetopainrelief
pdi
halflifeofthealphaphase
constantratevalue
volumeinthecentralcompartment
maximumconcentrationsofdrugcmax
plateautimet75cmax
areasundertheconcentrationtimecurvefrom0htoinfinity
freeintrinsicclearance
plasmaconcentrationinterval
areaunderthebloodconcentrationtimecurve0
apparenttotalsystemicclearancecl
durationofclinicalrelaxationdur25
detectionlimitslod
peaklaudanosineconcentration
tissuedistributiontime
completeresponsecrunconfirmedcrrate
apparentnonrenalclearanceclnrf
areaundertheconcentrationtimecurveauc08
transferconstantfromthecentralcompartmenttotheoutsidek10
vdfkg
areasunderthecurvefromtime0tothelast
weightadjustedplasmaclearance
totaldurationof
1ke
vo2max
maximumrateofeliminationofethanoleliminationcapacityor
percentminimumbloodglucoselevel
totalbodyclearancect
steadystatepeaklevelsofdigoxincmaxss
systemicbioavailabilitie
meanresidencetimemrt0a
k2max
plasmaclearanceofunboundcisplatinclfree
insulinaction
rateconstantke0
permeabilitysurfaceareaps
bloodtoplasmapartitionratio
biliaryindexe
drugdoserequiredfor90inhibitionofcfu
halfpeakclearance
peakheroinconcentration
terminalamifloxacinhalflife
seriousadverseeventfrequencie
tc01
cmaxauc036
proteinunboundfraction
vdl
060min
areaundertheconcentrationversustimecurvesfromtimezerotoinfinityauc0infinity
halflifeofhydrolysi
totalurineexcretion
freetotaldipyridamoleratio
maximumnontoxicdose
solubilitie
auc07day
steadystateplasmacimetidineconcentration
clearance1h
eliminationhalflifet1
totalnitrazepamclearance
cmaxec90ratio
ratiocmaxmic
insulinsensitivity
percentdoseexcreted
timetomaximumresponse
pdif
compartmentalvolumeofdistributionatsteadystatevss
volumeofdistributionofflunarizineperfractionofthedoseabsorbedvdf
peakpleuralfluidconcentrationcmaxpf
halflifeofpulmonaryretention
apparentvolumeofdistributionvditraconazole
percentfree
peaktotroughplasmaconcentrationratio
peakalcoholconcentration
apparentvolumeofdistributionvc
urinaryexcretionrateconstant
troughafxa
areaundertheserumcurveauc
brainplasmapartitioncoefficient
bacteriologicaleradicationrate
peaktotalplasmaconcentration
hydrolysishalflife
timeto50fractionalabsorption
apparentvolumeofthecentralcompartmentv1
steadystateconcentrationcfss
auc0areaundertheconcentrationtimecurvefromtimezerotoinfinity
areaundercurveauc024
t12zterminalphasehalflife
maximalglucoseinfusionrategirmax
kpuucsf0
inhibitorytiter
auc012hoursatsteadystate
50growthinhibitoryconcentration
plasmaproteinbindingfreefraction
cmintroughlevel
areaundertheplasmalevelcurve
cordtomaternalplasmaconcentrationratio
vdfapparentvolume
trans3hydroxycotininetocotinine
tbcf
leveldoseratiold
msratio
peakleukemiccelldnmconcentration
maximumplasmaheparinactivitie
areaundertheplasmaconcentrationtimecurveauct0tinf
areaunderthehrversustimecurveauec
peakvaluescmax
timeofdiseasecontrol
timetopsaprogression
micx4
steadystatefelbamateconcentration
vmfkm
peakplasmalevelsppl
bindingconstantkd
percentageabsorptionfrom
rateofhe
specificvolumeofdistribution
clmn
crossreactivitie
ratioofdrugconcentration
timetotumourprogression
steadystateminimalplasmaconcentration
fractionofabsorbed
targetedbloodflow
bioavailabilityclf
hepaticrecurrencefreetime
apparentvolumeofdistributionofperipheralcompartmentv2
hydrodynamicradiu
apparentv2i
troughtargetconcentration
serumproteinboundfraction
eliminationrateconstantlz
timetotherapeuticrange
bioavailabilitylevel
percentagecmax
amountofdrug
t12f
peakcocaineplasmalevel
steadystateserumadalimumabtroughconcentration
vpl
isoflurane
toxicity
renalclearanceoftheunbounddrug
mean
tolerateddose
enterohepaticcirculation
gastrointestinalabsorption
areasunder6hourconcentrationversustimecurve
hwrl
halflifeofthedistributionalphaphase
volumeofdistributionvbetaf
seauc
permeationhalflife
foral
cumulativedelivery
wholebodyclearancecl
volatilecontent
peakplasmalumefantrineconcentration
conversionhalflive
troughoclevel
areasunder
areaundertheconcentrationversustimecurveupto6hour
areaunderthecurveauc030
aucplasma
peakpleuralfluidlevelcmax
totalsystemicavailability
hillcoefficient
firstorderabsorptionrateconstantska
dosenormalizedauc0tmax
areasundertheconcentrationcurve
spectraldissociationconstantks
eliminationhalftimet12
icg
peakventricularconcentration
aucmicatmic
peakplasmamitoxantroneconcentration
absoluteextractionrecovery
rateofaccumulation
timeofrecoveryto50
fractionaldegradation
isocraticflow
auc0negativeinfinity
term
tpt
aucratioaucmaucp
maximumclearance
initialvolumeofdistributionv0
aqueouslosscoefficient
zero
initialdisappearancetimet12
peakplasmaantifactorxaactivitie
t12glucose
unboundcfzfraction
overallprogressionfreesurvival
transferhalflifet12t
suppressiont12
maximumserumdrugconcentration
fractionalsodiumexcretion
mzq1q3
areaundertimeversusconcentrationcurvefrom0to10hoursauc010
volumedoublingtimevdt
unboundfractionsfu
targetconcentrationct
volumesofdistributionforthecentralcompartment
timetomaximumplasmahi6concentrationtmax
apparentkm
gamma2
systemicbioavailabilityf
aumc0
srratio
timetohalfmaximumconcentrationt50max
maximumvelocityofmetabolism
subjectiveresponse
halfemptyingtime
drugpermeationrate
totalapparentcaffeineclearancecl
firstdosesteadystateconcentration
constantredcellbufferpartitionratio
ea
c0cmin
halflifeatbetaphase
maximumhydromorphoneplasmaconcentrationcmax
apparentdistributionvolumevdf
areasundertheplasmaconcentrationtimecurveauc
oralabsorptionconstant
unboundplasmadrugic50ic50u
eliminationmicroconstantske
areaunderthecurvefrom36to48hour
cumulativeexcretionpercentage
concentrationsintheeffectcompartmentgeneratinghalfmaximalanalgesiaec50
clearancebytotalefflux
ced
areaunderthecurveaucfrom0to12h
steadystatemaximumconcentrationcmax
celllossratedelta
auciauc
steadystatereservoir
percentagereleased
steadystateaverageplasmaconcentration
urate
peakwholebloodconcentration
oralclearancecif
serumfreefraction
totaldruglevel
aucic50
halflifeofplasmadisappearance
plasmadrugconcentration
centralvolumeofdistributionvcf
aucinsulinlevel
aucs024s
troughplasmaticagrelor
inhibitorydosesid50
steadystatepeakplasmaalmitrinelevel
halflifetimeofelimination
plasmatg
totalflowrate
maximumbloodthiopentoneconcentration
intercompartmentalclearanceclq
concentrationscausing50inhibition
sketorolacconcentration
biologicalhalflivesateliminationphaset12
pulmonaryspillover
intercompartmentclearanceqf
initialplasmaconcentrationco
maximumkill
timetomaximumtemperaturedecrease
day15day0ratio
areaunderconcentrationtimecurveauc012
overallserumeliminationhalflife
leveldoseratioldr
redcelltoplasmaratio
inductionabortioninterval
clogp
maximuminsulinconcentrationinblood
urinaryexcretionof
volumeofdistributuion
urinarydigoxinrecovery
cumulativeurinaryelimination
peakbloodconcentrationscmaxs
areaundertheantifxaactivitycurvefrom012h
observedmaximumplasmaconcentrationcmax
areasundertheserumdphconcentrationtimecurvesauc
3rdperipheralcompartmentvolume
cfcm
t3distributionspace
braintoplasmaauc0240ratio
content
timeoftissueextraction
timestoawakening
absorptionhalflifest12s
betat12b
maximalrateoflysi
areaunderthecurveauctau
rateofdisappearance
effectdelay
timeforthetofratio
timetomaximumconcentrationstmax
timetowalkingwithoutataxia
absoluteconcentration
peakplasmalevel
apparentfirstordereliminationt12
steadystatedrugflux
tcl50
kmmet1
liveruptake
timetoreachpeakserumconcentration
vt0
initialserumconcentration
bindingaffinitie
terminalphase
steadystatemaximalplasmaconcentrationscmax
dissociationrateconstantki
bindingaffinityconstant
saturationduration
vdn
organclearance
forward
apparentvolumebeingdistribution
auct0tinf
chigh
drugdeliveryefficiency
serumeliminationhalflive
effectcompartmentconcentration
distributiona
t02
apparentbetahalflife
stoolexcretion
tb12cin
peakrtpaconcentration
disappearancerateconstant
elimination
maximumamount
rst
maximumdrugloading
uptakehalftime
cmc
relativedoseintensity
auc050
areaundertheplasmaconcentrationtimecurvefrom0to12hauc012h
tissuetoplasmapartitioncoefficient
volumeofdistributionduringthedistributionphase
timetopeakconcentration
peakplasmaetoposideconcentration
progressionfreerate
transferrateconstant
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityaucinfinity
areaundertheconcentrationxtimecurve
clr
fabs
pappba
halflifeofslowspace
initialbioavailability
maximumunboundplasmadrugconcentrationcmaxuic50
apparentvolumeofdistributionatthesteadystatevdss
minimalbasallevel
unboundfraction
braint12
initialvolume
timetoreachmaximumconcentrationcmax
tissuedistributionv
iv
predosepeakrange
timeelapsedtopeakconcentrationtmax
peakacvlevel
maximalt
clearancebioavailability
timetoabsoluteneutrophilcount
intercompartmentdistributionclearance
percentagepenetrationintoblisterfluid
bloodcl
concentrationgiving
betahalflifetime
systemicclearanceclt
populationabsorptionhalflife
forcedexpiratoryvolumeinoneminutefev1
peakserumghlevel
areaundertheplasmaconcentrationversustimecurveauc024h
totalradiationdose
areaundertheconcentrationtimecurvefrom0htoinfinityauc0
bioavailabilityratio
linearconcentration
maximalserumprogesteronelevel
auc190
maximumrhil3serumconcentration
gastrictransittime
cmaxmicratio
terminalplasmaeliminationhalflifebetaphase
halflifeofrecovery
ana
auctotal
initialplasmalevel
timetothefirstmeasurableconcentration
apparentrenalclearanceclr
volumeofdistributionperabsorption
linearclearance
my
24hourpostdoseconcentrationc24
feedrate
areaundertheconcentrationtimecurvesaucs
cmaxmicmaximumplasmaconcentrationminimuminhibitoryconcentrationratio
diffusioncoefficient
overallfractionalattainment
totalplasmaclearanceofflunarizineperfractionofthedoseabsorbedclpf
cmax48
metabolicclearancerateof
peakthpplasmaconcentration
cellulartoextracellularconcentrationratio
timetoreachthemaximummabserumconcentrationtmax
areaundertheconcentrationtimecurve012h
t2
peakbleomycinplasmalevel
renalvascularresistance
distributionclearancecld
plasmatroughconcentration
processextractionefficiency
sulphationclearance
halflivesofaccumulation
areaunderthemethadoneconcentrationcurve024hauc024h
totalamountof
oralabsorption
maximumbound
cld
peakplasmamethotrexateconcentration
maximalserumplasmaconcentration
t12hd
areaunderplasmaconcentrationcurve
renal
terminalplasmahalflive
24hourrecoverie
ddimer
globule
serummethanol
drugconcentrationpeaked
steadystateserumtroughminimumconcentrationcminss
specificclearance
totalplasmaoralclearance
urinaryexcretionhalflife
areasunderdrugconcentrationtimecurveaucratio
numberofbindingsite
maximumdrugeffectemax
volumeofcentralcompartment
apparentvolumesofdistributionsaliva
absolutepeakconcentration
plasmaconcentrationcp
clu
peakserumbromazepamconcentration
aucfrom08hour
steadystateadductconcentration
totalclearancecl
peakplasmanicotineconcentration
clorgan
areasundertheserumt4concentrationversustimecurvefrom0to8hauc
gammadistributionrateconstantktrpo
plasmacarnitineclearance
concentrationsincsf
ureasynthesisrate
cmax04
infarctsize
vapp
peakcaf
apparentvolumeofdistributionatsteadystatevss
cumulativeurinaryexcretionrate
sirauc
clearanceratecl
cumulativedose
halflivesofthedistributionphase
initialdeliveryrate
ae012
timetoreach50maximumconcentration
timecorrespondingto80dissolutiont80
acutephaseeliminationhalflife
maximumconcentrationsofdruginserum
relativerecoverie
liver
terminaleliminationhalflifet12gamma
timeintervalsfromdosingtocmaxtmax
biologicalhalflifetime
detectablelimit
volume
ic
bronchialmucosalconcentration
eliminationratebeta
maximumadministered
aucfaece
troughfsi
netfluorideexcretion
partitioninghalflife
halflifeofterminalphase
terminalhalflivesofelimination
areaunderconcentrationtimecurve
totalrecoveryofdruginmilk
maximumdmphplasmaconcentrationcmax
auccsf08
auc0360
serumprogesteroneconcentration
terminaldispositionhalflifet12gamma
mt
eliminationt12alpha
residualtimemrt
totalexcretedfraction
timepeak
entrapmentefficiencypercentage
maximumresponseemax
apparentoralbodyclearance
ratiotosystemicunboundconcentration
troughinclearance
ct50
tumoraccumulationrate
timetoreachtroughantihbslevel
systemiccirculationauc024
absorptionpeaktimetmax
effectiverefractoryperiod
clumday7
weightnormalizedvolumeofdistributionofvdarea
diseaseduration
halflifeoftherapidphase
tmaxtimerequiredtoattainmaximumblooddruglevel
kd2
plasmastability
oralmidazolamclearance
solgeltransitiontemperature
fdr
serumthiopentalconcentration
areaundertheplasmaconcentrationversustimecurvefromtimezerototimeinfinity
inter
ratioatc0
apparentbioavailability
fractionofunboundquin
timeneededtoreachthepeakconcentration
receptordensity
octanolpartitioncoefficient
absolutetransnasalbioavailability
mrt024h
areaundertheplasmaconcentrationtimecurvefromtimezeroto1hauc1
totalplasma
hepaticfirstpassextractionratio
erpf
peakcocainelevel
areavolumeofdistribution
volumeofdistributionplasma
timetocpmax
oralmaximumplasmaconcentrationcmax
areaundertheplasmaconcentrationtimecurvesfrom0toinfinityaucinfinity
maintenancedoserate
auc0180
csfclearance
tolerance
fractionalexcretion
constantbloodflowrate
apparentvolumeoftheperipheralcompartment
effectsiteconcentrationforhalfmaximumeffect
k15
serumt12
apparentoralcyclosporineclearance
areaundercurveduringdosingintervalatsteadystate
peakdruglevelinblood
timetoreachthecmax
retentionindex
maximalketamineconcentrationcmax
c1
timetopeakterbutalineconcentration
peakplasmamen10755level
peakventricular5fuconcentration
apparentplateau
plasmaconcentrationatsteadystate
mauc0inf
inc
eliminationhalflifet12z
decayrate
totalbodydrugclearancetcl
totaldailyofftime
totalapparentbodyclearanceclf
auectracking
effectsiteconcentrationatlossofconsciousne
halflifeofdrugremoval
distributionalhalflifet12alpha
clearanceclsf
minimalplasmaconcentrationscmin
timeofthelastquantifiableconcentration
peakplasmapbzconcentration
areaunderthecurvesaucs
peakconcentrationofunboundplatinum
plasmaconcentrationofmpaatsteadystate
areaundertheconcentrationauc0infinity
t12bterminalhalflife
doseadjustedconcentration
timetoviralclearance
peaklevodopalevel
wholebloodsteadystateconcentration
maximumcanrenoneplasmalevel
highestropivacaine
totalt4absorption
totalamountofunchanged
proteinunboundfreefraction
apparentspecificvolumeofdistributionvdarea
timeofmaximumresponse
peaktrfconcentration
areaunderthecyclosporineconcentrationtimecurve
clearanceofmidazolamcyp3a
clse
cumulativeareaundertheplasmaconcentrationtimecurve
level
kiratio
auc0tsc
conversionhalflife
pae
timeforpeakabsorption
lbratio
troughserumactivitie
repetitiontimetr
tserum
normalizedareaundertheplasmaconcentrationtimecurvefrom0to45minute
maximumcytolysi
ratiooftheauc0180
areaunderthetimeplasmaquinidineconcentrationcurve
contactangle
absorptivetransport
eliminationofethanolfromthebodyvxko
aucfrom0to25hour
maximumsimulated
cvauc
eliminationrateconstantke
maximallidocaineplasmaconcentration
hepaticclearanceduringfirstorderelimination
p90
absorbedfraction
eliminationhalflifeatsteadystate
peakventricularcsfgemcitabineconcentration
totalbodyclearancecorrectedforbioavailability
completerenalresponserate
aucfrom0toinfinityauc0infinity
peakglucoseconcentration
kbeta
maximumqtcintervalprolongation
terminalserumeliminationhalflife
maximumarterialbloodconcentration
auc045min
plasmasteadystatelevel
plasmaunboundcefazolin
ptxtc
cmaxecmic90
clplasma
timeartem
maximumflecainideplasmalevel
clinicalefficacyrate
dissolutionrate
timetmaxtoreachcmax
apparentvolumeofdistributionderivedfromauc
clf415
drugaccumulationsite
totalurinaryrecovery
totalclearanceclt
peakplasmafolateconcentration
mrmtransition
permeabilityarea
bileclearance
resolutionrate
titer
apparentmetaboliteclearanceclmcfm
humanhalflife
renalvenousarterialreninratio
auchalftimeofelimination
timetoreachit
p
cmax04h
plasmabetahalflive
netexposure
observedmaximalconcentration
halflifeoftheterminalphaset12beta
absorptionhalflive
maximumdanazolexposure
inhibitoryconcentrationic50
peakunboundphenytoinconcentrationscmax
weightnormalizedclf
vmaxmet2
meanresidencetimebetween0and24h
aucsfor024h
totalclearanceofthedrugfromserum
brainplasmauptakeratio
centralcompartment
timetomaximuminsulinconcentration
apparentmetaboliteclearance
steadystatemilktoplasma
deltaunav
durationofsurvival
maximalincrease
ke
tumorbloodflowktrans
durationofanalgesiceffect
meansurvivaltime
betaslope
lossterm
iontransitionsmz
areaunderthecurvevaluesover12hauc012h
ma
activesurfacearea
timetmaxtoreachmaximumplasmaconcentrationcmax
halflifeofcortisoldisappearance
extractionfractionratioe
peakacetaminophenconcentration
urinaryeliminationhalflife
receptorequilibriumdissociationconstant
aucs015min
sweatchlorideconcentration
totalmeanscore
maximumreceptoroccupancy
intervalfromadministrationuntilmaximumconcentrationtmax
tritiatedwaterspace
clutb
vascularcardiaceffectratio
timetopartialresponse
aucfromtimezerotothedosingintervalauc0tau
kinc50
clintugt
deltah
concentrationcd7
percentagesofmoisturecontent
totalareaundertheplasmaconcentrationtimecurvefromtimezerototimeinfinityaucinf
motor
peakaragconcentration
plasmaaucinf
renalclearancecre
parasitemiahalflifehalflife
percentdrugcontent
k32
fractionbioavailability
peroralclearance
auc8tau9tau
areaundertheconcentrationtimecurvetotheendofthedosingperiodauctau
areaunderthecurveconcentration
cminitra
analyticaltime
timetoreachimaxtmax
greatestconcentration
maximumsteadystatedoxorubicinconcentration
areaunderthedrugconcentrationversustimecurveauc08
quantification
maximalmedianconcentrationsofplasma
percentageoftumorgrowthsuppressionratetc
volumeofthecentralcompartment
steadystatevolumeofdistributionv
bloodproductionrate
dkd
fractionreachingthesystemiccirculation
volumeaerodynamicdiameter
tumortobloodratio
plasmaclearanceofunbounddrugclu
attenuationosmoticratio
maximummeanplasmaconcentration
auc24ratio
measurabletrough
timetomtd
acuteoraltoxicitiesld50
kng
areaundercurveminimuminhibitoryconcentrationaucmic
maximalplasmaconcentrationofldopacmax
peakrifampicinconcentration
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc0infinity
drugclearancehalftime
nanoenc
halfvaluedurationhvd
baselinecorrectedcmax
maximumpapp
serumclearanceoffurosemidecls
ece95
peakalprazolamlevel
percutaneousabsorption
areaundertheconcentrationtimecurvefromt0tothelasttime
auc12areaundertheconcentrationtimecurveovera12h
tmpigfr
sr
diameter
maximalresiduelimitmrl
clsec
totalsc
peakplasmadiazepamlevel
injectionpain
uge06h
inactivationefficiencieskinactkiu
plasmametabolicclearancerate
peakplasmalnconcentration
apparentdistributionvolumevd
circulation
timetolysi
timetoreachmeasuredmaximumplasmaconcentrationaftermultipleadministrationstmaxss
maximumplasmachlorproguanilconcentration
couplingmolarratio
gcr
correctedqtinterval
smallintestinetransittime
serumconcentrationat8hour
plasmaclearanceofunbound
timeformaximalconcentrationstmax
clearanceclq
serumhalflifetime
glucoseconsumption
excretionofradio
cellplasmaconcentrationratio
iron
slowdecayconstant
dosenormalizedareaunderthebloodconcentrationvstimecurveauc
maximumuptake
fractionexcreted
peripheralvolumeofdistributionv3foral
pulsedreleasetime
clearancet12
volumeofdistributionvc
radiationdosebed10
timefromfirsttosecondtransplantation
alphahalflive
fetalnonplacentalclearance
aucipsapironeauc1ppratio
loadingdose
maximumdecrease
apparentepoauc024
k01hl
peakfleroxacin
areaunderthechangeindiastolicbloodpressurecurve
areaundertheconcentrationtimecurvefrom0to8hour
areaundertheconcentrationtimecurvefrom0to12hoursauc012
peripheralcompartmentvolumev2
auc0loq
fractionalconcentrationofinspiredoxygenf1o2
distributionhalflifet12
95
relativesystemicavailability
maximumlidocaineconcentration
radioactivitydose
renalexcretoryclearance
areasundertheconcentrationtimecurveauc
timetoreachmaximalinhibitiontmax
auc024c
maximumarterialconcentrationscmax
serumunboundfractionfs
totalruntimeofanalysi
apparentpermeabilitycoefficient
renalclearanceclr
selfmicroemulsifyingtime
prb
peakmuscleconcentrationscmax
plasmamangiferinconcentration
maximumvaluescmax
volumeofdistributionvssd
brainecfplasma
interassayrecoverie
distributionvolumeratiodvr
plasmaextractionrecovery
salivaserumconcentrationratio
plasmaconcentrationpeakedcmax
micratio
buccaldwelltime
areaunderthecurveauc0infinity
renalclearanceclrclclh
braintoplasmaratio
timesuntilpeakinsulinconcentration
emaxc50
timetosensoryblock
areaundertheconcentrationtimecurvefromtimezerotoinfinityafterfirstdoseaucinf
minimaltherapeuticplasmalevel
totallevobupivacaineconcentration
aucareaunderthecurveaboveminimumeffectiveconcentration
halftimeoftheapparentfirstorderdeclineofplasmaconcentration
halflifeofdegradation
95inhibitoryconcentration
volumeoftheinitialdistributionspacev1
systemicclearancescl
finaleliminationhalflive
enhancingratioer
steadystatetumorplasma
durationofactiontdur
aucratiosofbraintoblood
timetakentoreachpeak
totalbloodclearanceclb
clearancevaluesclf
cl2distributionclearance
plasmaconcentrationassociatedwithhalfthemaximumeffectec50
rh
initialtrougheverolimu
cellpermeability
halflifeofitsbetaphaseofelimination
maximalcoronarydilation
cdc
lymphconcentration
degradationhalflifet12
metaboliteratio
t48
areaunderthecurveuntilthelastmeasurableconcentrationauclast
amountsexcretedunchanged
maximaldrugconcentrationcmax
abosrption
firstpeakcortisol
timesto50
plasmahalftime
totsil
timetoachievepeakplasmaconcentration
aucpt0120
permeationcoefficientpapp
peakmeantroughcarbamazepineserumconcentrationratio
bpcrrate
pulmonaryarterialsystemicarterialextractionratio
areaunderthecurveaucinfinity0
restingheartrate
turnaroundtime
timeelapsinguntilappearanceoffirstorderdrugabsorption
terminalhalflifet12beta
totaldistributionvolumevd
rateofencap
plasmaproteinboundfraction
maximalplasmasalicylateconcentrationcpmax
totalprocessingtime
endofinfusionconcentration
apparentvolumeofdistributionofscgvdbeta
unboundmichaelismentenconstantkmu
rootmeansquareroughnessrq
retentiontime
t125tot175recoveryindex
qbcb
serumfreetotalserumlevetiracetam
systemicbioavailablity
minimumtherapeuticimconcentration
excretionmetabolisationt12
cmaxtomicratio
proportionseliminated
redispersibilityindice
steadystatebac
llq
aucratiosaucperitonealfluidaucblood
cumulativefaecalexcretion
aucratioofunbounddrug
loadingcapacitylc
steadystateantigenconcentration
aucfromtime0toinfinityauc0inf
peakplasmatissueratio
earliest
steadystatevolumevssofdistribution
betaparticleenergie
k0
maximumplasmaetoposidelevel
aucalb
peakserumdyphyllineconcentration
areaunderthemomentcurveaumc
residuelevel
apparentclearanceofthebioavailablefractionclf
maximalresponse
phaseclearance
timeatwhichthemaximumpeak
asciticfluidvolume
mbobs
treatmentresponserate
de
concentrationtimeareaunderthecurveaucfrom0toinfinity
steadystateplasmaconcentrationelicitinghalfofthemaximumresponse
absoluteclearancecl
rid
polydispersibility
plasmamaximalpeakconcentrationcpmax
troughimmunoglobulingconcentration
m1gm1total
steadystatetroughserumcefazolin
fel
peakplasmadigoxinconcentration
receptoroccupancy
totalmetoprololclearance
vdssvolumeofdistributionatsteadystate
fatplasmaratio
biologict12
auc06mic
cpratio
halftimeforclearancefrompeakuptake
apparentterminaleliminationhalflifet12beta
lambda1
timetopeaklevel
maximumpreoperativeplasmaconcentration
troughlevelstls
assaytime
timetmaxtoreachpeakconcentration
steadystateplasmaalpra
maximumconcentrationinpfcmaxpf
overallcmin
aucs0infinity
carryover
dialysateflowrate
halflivesofdistributiont12alpha
micsinhibiting50
metabolicto
placentalclearanceclpl
areaunderthecurveofconcentrationversustimefromzerotothelasttimepoint
cliot
administrationtime
maximumnimodipineplasmaconcentrationscmax
mitochondrialhalflive
areaundertheplasmaconcentrationversustimecurvefromtime0to72hauc72h
apparentmeanhalflife
uer
totaloralbodyclearance
concentrationneededtoattain50ofmaximumeffectec50
areaundercurvein120minauc0120
vslope
totalbupivacaine
annualizedspontaneousbleedingrate
peakpenicillinconcentration
rapidruntime
maximumsafedosage
auc0tau
activatedpartialth
maximumserumconcentrationcmax
micofcimicci
eliminationhalflivest12ke
unboundfractionofcefazolininplasmafp
timetoradiologicalprogression
cerebrospinalfluidpenetrationrate
timeof
90maximumclearance
volumeofdistributioninthesteadystate
drugloadingamount
bindingto
intercompartmentaldistributionrateconstant
timetoreachmaximumserumconcentrationtmax
areaundertheplasmaconcentrationtimecurvefromtimezerototimeoflastmeasurableconcentrationauclast
vcvalpha
associationequilibriumconstantka
minimummeanconcentration
auc0n
maximaleffectemax
accumulationratio
timetomaximumblock
fractionofabsorbeddosef
maximumpyrimethamineconcentration
peakplasmatmpconcentration
50probabilityofmovement
peakserumtt4concentration
biliaryclbclearance
ecftoplasmadistributionratio
terminalhalflifetimeofplasmaconcentration
inhibitionratio
primaryphasehalflife
vascularleakage
relative
timetopeakcerebrospinalfluidmorphineconcentration
pa
selfdiffusioncoefficientd
percentageextractionrecoverie
timestosternal
peritonealtoplasmaaucratio
minimumurinaryconcentration
timetomaximumplasmanicotineconcentrationtmax
neo
apparentclearancesclf
maximumcortisolreleaserate
steadystatemsratio
timeto50emptying
vdfcentral
mrtmi
peakmaximumplasmaconcentrationcmax
volumeofdistributionvdf
concentration
absolutebioavailability
biliaryexcretion
ri
timetoachievethatmaximum
tumorabsorbeddose
degreeofpenetration
areaunderthecurveover2h
areasunderthecurvempaauc012h
associationconstantska
meanabsorptionrate
eliminationconstantsbeta
slop
wettingtime
areaunderthecurvetothelastmeasuredconcentration
urinaryexcretiont12
areaunderthecurveextrapolatedtoinfinity
bloodradioactivity
plasmaterminalhalflive
pulmonaryretention
initiallagtime
clrens
constantflow
totalurinearsenicoutput
clpl
peaktimetomaximumconcentration
metabolicclearancecld
plasmacsfratio
endtidalisofluraneconcentration
biletoblooddistributionratioaucbileaucblood
auctauratio
peakmeanx
serumlevel
distributionvolumerate
areaundertheconcentrationversustimecurveauc08h
sustainedv
csftototalserumconcentrationratio
vlf
halflivesalpha
areaunderthebloodconcentrationtimecurveauc
ultrafilterable
areaundertheserumconcentrationtimecurvefrom0to6hoursauc6
prenin
timetomaximumplasmaconcentrationcmaxtmax
coefficientof
length
rat
redistributionrateconstant
micthreshold
areaundertheplasmaconcentrationtimecurvefromtimeofadministrationto24hoursafterdosingauc024
peakserumketoconazoleconcentration
apparentvolumeofdistributionvdss
cumulativeamountsexcreted
trohalflife
ratioofic50
fluorescenceintensitie
peakserumtriazolamlevel
onsetoffsethalflife
aucinfinityratio
signaltonoisesn
peakplasmapczlevel
qretention
totalpaclearance
renalextraction
maximumapparentinhibition
maximalconcentrationsinplasmacmin
areaunderthecurveofplasmadrugconcentrationauc
systemicexposureauc
maximumctrough
terminaleliminationbetahalflife
hepaticextractionratioe
peakdeliveredamount
fractionalelimination
timestopeakplasmaconcentrationtmax
maximumtotaldosage
aud024aptt
cafter
eliminationrateconstantofplasma5fuk40
areaunderthecurve0toinfinity
maximalrateofformationofmetabolitevmax
zeroorderelimination
timetotumorprogressionttp
maximumbloodconcentrationcmax
peakplasmavenousconcentration
totalunboundclearance
overallclinicalimprovementrate
maximalpossiblebioavailability
totalvolumeofdistribution
mpauc
aucmic90ratio
peakserumlevelscmax
totaldrugrecovery
timetoreach
tearfluidconcentration
maximumgabapentinplasmaconcentration
nailplasmaratio
fractionofdruginthecentralcompartment
rootmean
halfdistribution
d23
halflifeforsedationt12ke0
betat12beta
plasmaconcentrationcpt
freesmz
vcmean
maximumarterial
maximumsteadystateconcentrationscmax
tumorinhibitoryrate
cue48
emin
voidvolumevo
peaklidocaineplasmaconcentration
glucoseuptake
dailyurineoutput
timetolastpositive
residualconcentration
areaundertheplasmaconcentrationtimecurveauc048
totaltimefor
overallplasmaeliminationt12
tmx
completeresponsecrrate
mrtmeanretentiontime
steadystateplasmaconcentration
steadystateapparentvolumesofdistributionv1vdss
ratioofmeropenem
timetoreachmaximalconcentrationtmax
eliminationhalflifet12ss
relativerecoveryrate
fractionalclearance
ae0168h
totalkill
auc24ssratio
peakeelevel
distributionhalflivest12alpha
tgel
ratioofareaunderthecurve
macbarsevo
vss
apparentfirstorderregression
bloodclearancet12a
volumeofdistributionafteroraladministrationvdf
apparentdistributionvolumevzf
limitofquantitation
areasunderthecurve0to12h
adsorptionporewidth
injectionsitepainscore
reabsorptionratior
halflivesinthebetaphase
eliminationhalflifeofindomethacint12beta
minimumobservedunboundisfconcentration
areaunderthetumourleveltimecurve
totalamountexcretedinurine
distributionvolumeatthesteadystatevdss
maximumsteadystatecsfconcentration
biliaryrecoverie
fractionofsteadystateachieved
tissuetoplasmaratio
cumulativeurinaryrecoveryrate
maximumheartrateec50
aucwithinadosingintervalatsteadystate
areaunderthecurvefromtimezerotoinfinityauc
totalfirstpasseffectegitliver
unboundphenytoinfraction
cauc12
dissociationconstantforbinding
apparentvolumeofdistributionfortheophyllinevf
areasunderthedrugconcentrationcurve
timesto90
amountofdrugnotabsorbed
totalareaundertheconcentrationversustimecurvesauc
timeabovethresholdconcentration
ecp
ed50
apparentvolumeofthecentralcompartmentvc
areaunderthetimeeffectcurveauec
clinicalrecoverytimepostsedationresponsiveness
zeroorderabsorptionduration
apparentplasmacl
latelo
timetopeakglycaemia
aucduringthetimeintervaltbetweentwoconsecutivedosesatsteadystateauct
areasundertheconcentrationtimecurvefrom0to24h
mage
effectiveconcentration50
maximumethanoleliminationrate
auc024s
terminalplasmahalflifet12beta
peakapixabanconcentration
rateofrenalclearance
peakcsfconcentration
plasmacthroughlevel
fractionaleffluxrateconstantfromthecentralcompartment
c0concentration
absoluteabsorption
clearanceforelimination
volumeofdistributionofthecentralcompartmentvdc
separationtime
milkproteinconcentration
shelflifet09
minimalplasmaconcentration
peakretentiontime
pulmonaryextraction
saturation
serumvalue
ta12
liverretention
aucst
initialclearancehalftime
peakinsulinconcentrationscmax
brainvolumeofdistribution
auc0approximatelyinfinity
x4
bioavailabilityba
p1h
lc50
eliminationplasmahalflife
lagtimetl
bodyswayeyesclosed
hillrelatedexponentgamma
halflifeofrenalexcretion
areaundertheconcentrationtimecurve08
areasundertheplasmaconcentrationcurve
troughevrlevel
doserequiredtoproducehalfmaximaleffected50
distributional
steadystatepeakserumlevel
areaundertheconcentrationtimecurvefrom0to12h
maximumvaluecmax
peakplasmaptauconcentrationscmax
areaundertheplasmaconcentrationtimecurveaucho
doseexcreted
cin
auc0tauss
dosenormalizedcmax
peakcsftemozolomideconcentration
timetoonsetofbronchodilation
timeofmaximumbloodconcentration
durationofpainrelief
rapid
apparentpostpseudodistributionvolumeofdistributionvdbeta
ae024h
minimumanalgesicbloodconcentration
totaldistributionvolume
timetomaximumserumacetaminophenconcentration
percentdistribution
halflifeofgastricfoodremoval
peaklevofloxacinconcentration
tic50
timetoemax
wr1065
releasetimespread
maximumwaitingtimeforblooddraw
apparenttherapeuticrange
eng
auct032
response
cellularuptaket12
overallclearance
areaundertheplasmaconcentrationtimeprofilecalculatedbetween0and168hauc0168
zeroorderrateconstant
timetoprogressionsurvival
areaundercurvefromtime0totheendpointauclast
cmax500
cumulativebiliaryexcretionrate
tmaxtimetoachievemaximumplasmaconcentrations
auc010
macbar
areasundertheconcentrationvtimecurveauc
areasundertheconcentrationtimecurvesaucsfrom0toinfinity
overalltreatmentresponserate
withdrawalrate
peakserumcetirizineconcentration
peakoccupancytimepot
css90
plasmaconcentrationtimeareaunderthecurveauc024
distributionphasehalftimet12alpha
troughplasmaimipenemconcentration
bioavaiability
peakplasmaradioactivityconcentrationcmax
apparentph
percentagebiliary
remissiontime
auc1824h
volumeoftheperipheralcompartmentbioavailabilityvpf
maximumflutamideplasmaconcentration
koff
timetopeakeffect
fiftypercenteffectivedosesed50s
intercompartmentclearanceqforal
timetoachievemaximumaspirinconcentration
absoluteoralbioavailabilityf
aue
gi50
apparentvolumeofdistributionvdareaf
apparentvolumeofdistributionatsteadystatevssf
maximalenzymeactivity
halftimeoftheinitialphase
michaelismentenconstantkm
dominanthalflife
areaundertheconcentrationversustimecurvefromzerotoinfinity
halflifeofeliminationt05beta
tmax1
accumulatedamountatsteadystate
faucmicratio
halflifet12b
auc06hours
apparentsteadystatelevel
maximumabsorption
peakserumcalcitriolconcentrationcmax
cpmax
maximumcsfconcentration
80inhibitoryconcentrationic80
volumeofdistributionbasedonarea
steadystateplasmacsalevel
durationofanalgesiamesor
faa
clfm
mucositisscore
sul
observedrecovery
c24h
conversion
areaundertheplasmaconcentrationtimecurvefromtime0to24hour
pwrmax
clinicalcure
percentagedrugreleased
areaundertheconcentrationtimecurvefromdrugadministrationtolastobservedconcentrationafter12hoursauc012
tofratio
totalapparentvolumeofdistributionv
lowconcentration
rateofspillover
maximalgestodenelevel
firstordereliminationrateconstantk10
c25
idg
totalbodyclearanceofacthclb
firstordereliminationhalflife
dosenormalizedmaximumplasmagsconcentration
vl
totalvenouslevobupivacaineplasmaconcentration
steadystateconcentration
aucfrom0to30minutesauc30min
timetoreachthem
transferratefromplasmatocsfkplasmacsf
processefficiency
solubilisation
areaunderthecurvefromtime0to120min
accumulationfactorrac
areaundercurveauc06h
plasmaosmolality
cycletime
minimumserumconcentrationscmax
meanresidencetimemrt0infinity
maximumisdnconcentration
secondphasebiologicalhalflivest12beta
maximaltimeconcentration
vlvolumeofdistributionofcentralcompartment
areaundertheplasmaconcentrationtimeprofileareaunderthecurve
mrtinf
cmin
extentofabsorption
occupancy
timetoonsetofaction
relapserate
coefficientofrbc
maximumeffectec50
rateofpartialseizuresper
livertoserumratio
absorptionlagtimealag
peakplasmamilrinoneconcentration
apparentabsorptionrate
tumourtobloodratio
areaunderthetotaligficoncentrationcurve
cumulationt12
halfmaximumeffect
concentrationmaximum
masstransitionion
steadystateplasmaa771726concentration
releaserateenhancement
plasmadopamineconcentration
rateofurinaryexcretion
areaundertheconcentrationtimecurvefrom0to72hoursauc072
secretion
vv
rateofzeroorderethanolelimination
maximaldrugconcentration
intrinsichepaticclearance
areaundertheconcentrationtimecurvefromtimezerotothetimeofthelastquantifiableconcentrationauclast
serumhalflifet05beta
bloodcirculationhalflife
totalliclearance
milkplasmaconcentrationratio
maximumcircuitconcentrationscmax
glucoseeliminationratek
accumulationratiosr
cumulativepercentdrugrelease
apparenterythrocyteplasmapartitioncoefficient
auc24humic
initialmucosalpeak
maximumconcentrationatsteadystate
terminalbetaphasehalflife
peakbronchodilatoreffect
emit
oralvolumeofdistributionvf
extractionefficiency
maximumplasmamethohexitalconcentration
urinaryterminaleliminationhalflive
cellularelimination
peakplasmaoxaprozinconcentration
apparentserumeliminationhalflife
concentrationratiosfm
meac
rateconstantsofelimination
steadystateplasmaotconcentrationcss
totallcanalysistimeperinjection
difference
overallclb
maximumdrugencapsulationefficiency
tissuestore
eh
cior
urinaryexcretionofsodium
percentagesrecovered
biologicalhalflifet12
metabolicaucratioauclast
auc01440
fma
micbreakpoint
peakbrac
peakplasmalnglevel
objectivetumorresponserate
tfi
areaunderthebloodconcentrationtimecurveto24hauc024h
steadystateapparentoralclearance
influxclearanceintothebrain
timestodetectableconcentration
timestoreachsteadystate
percentageofplasmaextraction
lungtrovafloxacinlevel
areaunderthecurvevaluesauc
timetoreachmaximum
bindingpotentialbp
kiinhibitorconstant
to
timetoattainapeakserumconcentration
lag
absorptionlagtime
maximumplasmainsulinaspartconcentration
peakdacconcentration
areaunderthecurvefrom012hauc012h
keff
absorptionhalflifet12abs
peakgrowthhormonelevel
plasmabrainratio
biological
totalrecoveryofradioactivity
areasundertheserumconcentrationtimecurveauc0infinity
areaunderconcentrationtimecurveauc048h
auc030min
terminaleliminationhalflifeinblood
centralvolumeofdistributionv1f
absoluterecoveryrate
terminalhalftime
timetofirstresult
t12betaphaseelimination
steadystateserumconcentration
durationsofresponse
abomasalbioavailability
totalexposureaucinfinity
maximalintrinsicclearance
aucfigure
areaundertheconcentrationtimecurveauc024
kg2
suvmean
areaundertheplasmaconcentrationtimecurveduringadosageintervalauct
apparentintercompartmentclearanceqf
peaksofthemeanconcentrationcurve
productionratecalcidiolratio
gexmax
overallsurvivall
fastphasehalflife
overallclinicaldrugefficacie
d2occupancie
terminalhalflifetimet50
rebound
rateconstantka
hillcoefficientss
auc0360plasmaauc0360ratio
wholebloodoralclearance
totalexposureauc0inf
peaklidocaineconcentration
linear
mrtstoplast
enzymaticactivity
oralapparentvolumeofdistributionatsteadystatevssf
timetomaximumconcentrationtmax
peakcefazolin
renalclearanceofthedrug
peakplasmaglutamineconcentration
accumulationindexrac
oralformationclearance
areaundertheserumconcentrationcurveauc
efficacyimax
timetothemaximumnicotineconcentration
tissuehalflife
initialhalflifet12alpha
maximalmeanplasmaconcentration
areaunderthetimeconcentrationcurve0to12hours
volumeof
cldistribution
halflifefortheelimination
specificmaximalbindingcapacitybmax
atsteadystatecss
perfusionrate
halflifeofdruginblood
ki
synovialfluidexitrateconstant
areabetweenthecontrolgrowthcurveandthekillingandregrowthcurvefrom0to48h
fastcomponenthalflife
aucsub0tlastsub
doseadjustedauc012
distributionphaset12alpha
interdialysisclearance
percentageofunbound
ratiooftoxictotherapeuticplasmaconcentration
renaldrugclearance
vi
recoveryhalflife
poststeadystateapparentt12
apparentdistributionclearanceqf
overallresponserate
steadystateareaundertheconcentrationtimecurve
orr
auccsftoaucplasmaratio
permeation
arterialplasmaconcentration
unboundsecretoryintrinsicclearanceclusint
onset
halflifeduringthetissueuptakephase
steadystatetestosteroneconcentration
vssvc
te
cumulativereleaserate
clnr
unboundsteadystatevpaconcentration
partialresponseduration
maximaleffectec50
peakbloodethanol
timetoextubation
sqc
methodologicrecovery
intrinsicaqueoussolubility
bioavaila
areaundertheconcentrationtimecurveaucmicratio
weightnormalizedvolumeofdistributionatsteadystate
absorptionconstantka
bioavailabilitycoefficientsfauc
aumc5
timerequiredtoreachthepeakplasmalevel
auc24ssd
halflivesforclearance
fractionexcretedunchangedinurine
peakacyclovirconcentration
fractionofdrugeliminatedduringtheterminalphase
hemofiltrationclearance
daysopen
areaundertheplasmaconcentrationtimecurveofo
maximalrelaxation
totalinstrumentalruntime
totalrecoveryof
lengthofinfusion
targetingtime
maximumsensitivity
brainuptake
areaunderthebloodconcentrationtimecurveauc0t
snr
halfmaximal50inhibitoryconcentrationic50
totalaucra
terminalhalflifeofradioactivityelimination
overallfungaleradicationrate
tgirmax
peakefatutazonebloodlevel
tp
plasmamidazolam
eliminationconstantke
timeofmaximumexcretionrate
aucfdurd
areasunderthepruritusintensitytimecurve
cumulativelevelsofrenalexcretion
minimumconcentrationofdrug
tumortobrainratio
gastrichalfemptyingtime
intrinsicclearanceclintratio
detectionlimit3sigma
pearlindex
peakcortisollevel
intercompartmentalclearancesq2
durationofeffect
recoveryindex
totalbodybloodclearance
absorptionconstantk1
halftimet12
undertheplasmaconcentrationtimecurvefromtime0to12hourspostdoseauc012
timetothehighestconcentrationtmax
meanplasmaconcentrationsat30minute
kobs
maximumcomtinhibitionemax
meanabsorptiontimesmats
timetomaximumserumconcentration
unboundplasmaconcentrationsatcmax
ftmic
freepeakplasmalevel
timetoachieve
areaundertheconcentrationtimecurveaucratio
timetoachievemaximumplasmacodeineconcentration
terminaleliminationhalflifet12lz
areaunderthecurveperdoseaucd
maximalrateofeliminationvm
kf2
t12ofthesecondphase
wholebodyclearance
percentageoftotaldoserecovered
apparentserumhalflife
rateofremoval
milkplasmaquotient
areaunderthecurvefromtoto4h
dkrd
steadystatemaximumcmax
totalremoval
dosenormalizedcmin
peakserumdoxycyclineconcentration
cyclinginterruptedclearance
maximumexposure
tumorskinconcentrationratio
survivalrate
eliminationhalflifeoftiv12
ahconcentration
qp
aucmilkplasmaratio
internalizationrateconstantkint
fractionalproximalreabsorptionfpr
areaunderthecurvefrom0to6hour
peaktotrough
enhancementratio
rateconstantsbeta
atsteadystatevdss
aucinsulin0360
chiralinversion
peakplasmaradioactivity
fluidflowrate
urinarycalciumexcretionuca
fractionboundtoplasmaprotein
steadystateplasmalevel
timetopeakplasmainsulinaspartconcentration
signaltonoisebaselineratiosn
phint
oralareaundertheserumconcentrationtimecurveauc
areaunderthecurveofplasmaconcentrationt
unbound
areaundertheconcentrationtimecurveaucfromtimezeroto24hpostdosingauc024
clintr
totalplasmaclearanceclptotal
terminalhalflivest12beta
progressionfreeratepfr
auctm
timetoequilibrium
pseudosteadystatebreathalcoholconcentrationbrac
peritonealfluidhalflife
returnofrightingreflex
serumhalflifevaluest12
effectivepermeabilitycoefficientpeff
areaundertheplasmaeeversustimecurve
timetopeakplasmadiltiazemconcentration
meanretentiontime
overallpenetrationintoinflammatoryfluid
areasundertheplasmaconcentrationtimecurvesauc
totalregionallybioavailablehe
firstorderabsorptionrateconstant
plasmalevel
auccsfauc
rateofincreaseintwitchtension
initialeliminationof14c
kdeg
totalbodyclearance100nonrenal
maximumstriatumtocerebellumratio
auc0h24h
apparentoverallvolume
tissueconcentration
tmaxtimetocmax
exposure
saliva
maximumapapconcentrationapapmax
localconcentration
responderrate
volumeofthecentral
passiveinfluxintokin
peakplasmabupivacaineconcentration
totalplasmaclearancecltp
auciv
dheartrate
maximumplasmaconcentrationatsteadystatecmax
cbratio
recoveryofthetofratio
timetomaximalplasmaconcentration
peakbloodalcoholconcentrationsbac
circulatingplasmaconcentrationcmax
maximumplasmamycophenolicacidconcentrationcmax
areasundertheplasmaconcentrationversustimecurve
apparentoraleliminationclearance
plasmaitc
apparentlivervolume
penetrationfactor
eliminationhalflivest12s
populationeliminationhalflive
aucfrom0to12hauc012
canaliculareffluxclearanceclintbile
absorptionlag
nong
maximalplasmaconcentrationcmax
halfsaturatingplasmaconcentration
auc0mictarget
minimumlanreotideconcentrationscminatsteadystate
timeatwhichcmaxoccurredtmax
populationclearance
krel
areaundertheconcentrationtimecurveauc033h
residualplasmalevel
initialphaset12alpha
bloodhalflife
steadystateritonavirconcentration
bloodvolume
bindingaffinity
concentrationsat
oralcl
ikiratio
recoveryoftracerinurine
volumesofdistributionvdarea
auc0loqh
dosenormalizedauclast
areaundertheinterstitialfluidconcentrationtimecurve
halflifetime
transformationefficiency
maximalinfusionrate
timeformaximumconcentrationtmax
plateautimeofconcentrationsaboveminimumeffectiveconcentrationsmec
tcmicratio
cumulativeexcretoryrate
dissolutionnumberdn
timewhen
vesiclesize
maximalratio
emaxobservedauce
striatumtofrontalcortexcountratio1stfc1
retentionhalflive
minutevolume
integratedeffectauec0288h
maximumselfotellevel
capillaryplasmaconcentration
extent
surfacetension
dmpef
apparentsteadystatedistributionvolume
plasmaactivity
aucss024
faecalexcretion
olt12
timetoonsetofabsorption
peakmesnaconcentration
peakplasmaquinineconcentration
timetoabsoluteneutrophilcountrecovery
intrinsicclearancecli
v3volumeofperipheralcompartment
drugcarrierratio
cde
volumeofdistributionintheperipheralcompartmentvp
lagtimetlag
influxrate
cl2m
apparentrateofformation
steadystateaverageserumconcentration
doseadjusted
numberoftheoreticalplate
timespent
plasmaterminalphasehalflifet12
fractionalinhibitoryconcentration
minimumurineph
totalurinerecovery
aucprostate
d8d2ratio
carboxyterminalhydrolase
ke0
minimumtime
centralcompartmentexcretionhalflife
urineaccumulatedexcretoryrate
criticalconcentration
meantransittimemtt0last
clvpa
renalclearanceof
vdzf
totalamountsofurinaryexcretion
maximumplasmaconcentrationcpmax
qa
maximumrateofelimination
plasmaeliminationclearance
dailydoserequirement
plasmaunbounddrugconcentration
clmean
dynamicresidencetimekoff
areaundertheconcentrationversustimecurvesratio
timetotrsscoremaximumeffect
freeauc0infinity
areaundertheconcentrationtimecurvetothelastmeasurabletimepoint
stabledose
nitcontent
cmaxper
totaltransit
areaunderthecurve024h
relativebioavailability
mrtlactating
excretedunchangeddu
drugloadingefficiency
auc4
ft3
halflifeinbrain
specificsurfacearea
plasmameanresidencetimesmrt
absorptioncoefficient
steadystatetroughserumcbzconcentration
fractionescapinggutwalleliminationfg
kah1
maximumexcretionrate
hepaticefficiency
areasundertheconcentrationtimecurvefromtimezerotoinfinityauc0infinitys
relativepeakenhancement
bioavailabilityextenteba
areaundertheplasmamorphineconcentrationversustimecurve
twelvehour
maximumconcentrationreached
c0todoseratio
timetothisnadir
totalreleaseof
timecmaxwasachievedtmax
shedding
apparentbiologicalhalflife
lastdetectableplasmaconcentrationtlast
timeto10ofgirmaxgirmaxt10
cumulativeurinaryexcretion
numberoftransitcompartment
logpbutanolwater
tissueplasmaconcentrationratiok12k21beta
plasmaperitonealfluidconcentrationratio
tissueplasmapartitioncoefficientkpuu
molarfabtodmiratio
riv
rmax
plasmanla
clearanceplasmaconcentration
plasmaterminalhalflifet12
t60
halftimeln2ke0
ratiosclvcrclvsli
areaundertheconcentrationtimecurveaucmic
integraloftheareaundertheconcentrationtimecurveauc0t
k0d
recoverypercentage
totalauc
steadystateplasmaepinephrineconcentration
peakacyclovirplasmaconcentration
pulsedreleasetimet0102
hydroxylationindex
quantificationlimit
distributionvolumeatsteadystatevss
diseasecontrolrate
serumconcentrationareaunderthecurveat5hour
maximumconcentrationpeak
plasmahepaticclearance
eliminationphase
troughitraconazolelevel
clearanceofcentralcompartmentcl1
peakplasmainsulinlevel
pe
timeaveragedclearance
fluxrate
hct
vdtp
peakserumlevel
ion
serumconcentrationpeak
betaphasehalflifeofelimination
csfflux
excretoryfluidplasmaareaundertheconcentrationtimecurveratio
localabsorptionratiosfma
maximumrateofpermeationcoefficient
tidalvolumevt
apparentrecoveryrate
equilibriumdistributionvolumevem
excretoryefficiency
intermediatephasehalflife
areaoverthecurve
skinplasmaratio
timetakentoreachmaximumconcentration
auc0360ratio
partialintrinsicclearance
halftimeofabsorptiont12ka
areaundertheconcentrationtimecurvefrom06hour
withdrawaltime
totalcount
percentagerecoverie
cmean
tumoraccumulationratio
daystotaskmastery
slowdistributionclearancecl3
minimumserummorphineconcentration
desaggregationtime
standardizeduptakevaluessuvs
tumortoipsilateralbrainratio
netcmax
totalbodyhalflive
steadystateotcplasmalevel
k10
oralt12
diseasefreeinterval
concentrationcss
ucin012h
areasundertheplasmaconcentrationversustimecurves0toinfinity
peakinsulincmax
timetoreachthepeakplasmaconcentration
areaunderthecurvefromthetimeofdosingto24hrminimalinhibitoryconcentrationmic
totalplasmaclt
postdistributionphasevolume
antithrombinactivity
lethaldoseld50
tissuehalftime
drcsstrough
distributioncoefficient
halflifeeliminationfrombodyt12b
meanresidencetimeofdrug
areaundertheconcentrationtimecurveauc0n
transdermalclearance
emaxcontrol
timeofmaximumabsorptiontmax
areaunderthetimecurvemicratio
slope
fio2
retentionrate
maximalbeta1receptoroccupancy
ratesofserum
relativebioavailabilitie
dosecorrectedamlevel
totalpermeation
50recoveryt1t0
mtt
tdhtratio
distributionrateconstantalpha
t12lambda1oral
maximumsteadystateconcentration
50inhibition
clearanceto
t12app
cumulativeurineexcretion
apparentvc
areaundertherlpccurve
fractionalrateconversion
troughfixlevel
terminal
observedmethadoneconcentration
aucvaucmratioaucr
maximumconcentrationf
totalglucosedisposal
areaunderthecurveauc0last
intradialysisclearance
timetomaximumdrugconcentrationtmax
bo
halflifeinthedistributionphase
recycledfraction
volumeofdistributionbeta
urinarycumulativeexcretion
troughitraconazoleconcentration
tf
auc000
mortality
filterclearance
renalmetabolicclearance
initialpeakatra
totalamountofunchangeddrugexcreted
fractionalinversionfinv
steadystatevolumeofdistributionvss
p50
timeofonsetin
mrt0t
aur
cravingscore
auc0400min
halflifeofwashout
clearancecltyp
disintegrationtime
areaundertheconcentrationtimecurvefrom0to24hauc024micratio
minimalsteadystateplasmaconcentration
auc010aucareaunderthecurve
lex
halflifeperiod
cmaxmaximummtxconcentration
detectionlimitsn3
drugtoantibodyratio
ecrcl
operatingtime
troughlevelsc24h
timeatwhichpeakprocainamideplasmaconcentrationsoccurred
cmaxx
percentageofabsoluterecovery
dynamic
apparentplasmaclearancedoauc
maximumbrainconcentration
tumortonormalliverdoxratio
minimumquantifiablelimit
areaunderthemiosistimecurve
c1trough
maximumincreaseintt
26alexcretion
pbrain
timetoreachmaximumplasmaconcentrationscmax
areaundertheplasmaconcentrationtimecurveauc06
maximumrateofsecretorytransporttm
permeability
centralcompartmentv1
troughcna
renalclearanceratio
hr
terminalplasmaeliminationhalflifet12
areaunderthereceiveroperatingcharacteristiccurveauc
log10parasitereductionratio
plasmalevelmaxima
auc014h
pericardialtoserumratio
areaundertheplasmaconcentrationtimecurveaucfrom0htoinfinitypostdoseauc
distributionvdlambdazf
pic50
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityauc0
areaunderthecurveauc0inf
systemicexposureof
maximumpupildiameterchange
apparentmaximumcapacityforrenaluptakevmax
vdintheperipheralcompartmentv2
ratiourineosmolalityplasmaosmolality
ed100
apparentperipheralvolumeofdistributionvpf
troughplasmampalevel
ratetoreachsteadystate
terminaleliminationhalflifet12g
absorptionhalflivest12ab
maximalglibenclamideplasmaconcentration
v1
totalplasmalevel
totalflow
extraenergyexpenditure
steadystateplasmaglucose
tgmin
inhibitoryconstantski
sustainedeffectiveplasmaconcentration
availabilitie
deltacbfdeltapaco2
biletoplasmaratio
totaldurationoflrr
minimumeffectiveserumdoxycyclineconcentration
totalbodyclearancecib
50effectiveconcentrationsec50s
auc120
pfs6
kmu
peakoleuropeinconcentration
bioavailabilityki
peakleftventriculartissueconcentration
clwomen
areaundertheconcentrationtimecurvefrom0to24hoursauc024
pa2
ventricularcsfplasmaratio
alclearance
steadystatelidocaineplasmaconcentration
totalruntime
maximumintravascularconcentration
t6
aucglucoseinfusionrategir0120min
75recovery
fractionalcatabolicratefcr
halflifeofcort
t12d
conversionfactor
maximumpropofolconcentration
primaryhalflifet12
plasmatimetopeak
peakheighttph
apparentsteadystate
rateofeffectivene
turnovert12
distributionofthemic
areaunderthecurvefor24hauc024
percentdrugentrapment
troughcsabloodlevel
maximumresiduelimit
tissuemediumratioatequilibrium
le
vb
cmaxsst
maximumbinding
cordtomaternalratio
peakbloodcyclosporineconcentration
minimumdeterminableconcentration
aucotlast
volumeofcompartmentonev1
absorptiondurationta
maximumworkload
steadystatevolumedistribution
rejectionrate
basalplasma
bloodflowrate
areaundertheconcentrationtimecurvefrom0to12hauc012
peakserumconcentrationcmax
lloqlod
timeofachievementofmaximumbloodserumnadololconcentration
oraldoseplasmaclearance
lategainlo
infusion
extractedrecoveryefficiency
treatmentfailure
timetoreachthepeaktmax
fractionofadoseofethanolconvertedtoacetatefaca
timesofpeakconcentration
uca
halflifeforaccumulation
inductiondeliverytime
maximumrise
areaundertheplasmaconcentrationversustimecurve
adsorptioncapacity
maximumeegeffect
timelag
steadystateflx
t12lz
inhibitoryconcentrationof50
minimalplasmaticconcentration
synovia
masstransitionpair
unboundfractioninplasma
areaunderthebloodconcentrationtimecurveauc08
apparentdrugdistributionvolumevdlambdazf
areaundertheconcentrationtimecurvesauc024h
hepatobiliarytransportmaximum
apparentoralcentralvolumeofdistribution
ld50concentration
puff
oralbioavailabilitycoefficient
effectsiteconcentrationce
apparentki
mrtti
kininputrate
plasmacmaxmicratio
bloodconcentrationat2hpostdosec2
fractionsabsorbed
transdermalabsorption
distributionclearanceq
peakconcentration
gastricionconcentration
timetotargetlevel
hydrolyzedplasmaconcentration
cltpt
percentunboundpiroxicam
areaundertheplasmaconcentrationtimecurveto1h
forceofdetachment
strokevolume
plasmahalflifeofthebetaphase
lowflowrate
leakage
bbbtransportclearance
timetoattainmentofseizurecontrol
steadystatemeancmax
maximalalcoholconcentrationinblood
khkd
totalturnaroundtime
vmale
maximumconcentrationinserum
intestinalextractionratioerg
maximumtolerateddosesmtds
plasmatolymphclearancerateof
dissociaterateconstant
serumtroughlevel
halflivesof
areasunderthecurveauc0t
tauc
timeofpeakplasmamorphineconcentrationtmax
interdialyticeliminationhalflife
lymphplasmaaucratio
opticnervetoplasmaratio
maximumfolliculardiameter
vaspainscore
dissociationconstantkd
ratiosofauc0infinity
areaundertheconcentrationtimecurveaucupto8h
concentrationmaximac
halflifebetaphase
steadystateconcentrationattheendofthedosingintervalctau
firstmaximumtime
maximumplateaulevel
maximumrabeprazoleconcentration
peakmidazolamserumconcentration
clearanceclhda
maximummucoadhesiveforce
cerebralbloodflowvelocity
eliminationconstantofthesecondphase
lengthtodetector
auc096
unboundareaundertheconcentrationtimecurveaucuratio
peakserumliconcentration
totaldrugloading
areaundertheplasmaconcentrationtimecurveauc0120
plasmaclearanceclp
freedrugclearance
t12forthisproce
tissuehalflifet12
fus
fractionofdrugremoved
volumeofdistributioninthesteadystatevdssf
vs1
overallsurvivalpfsos
deltag
areaundertheplasmaconcentrationtimecurvefromtime0to12hour
firstdetectableplasmafentanylconcentrationtime
timeto1i
fp
areasunderplasmaconcentrationtimecoursecurvesauc
t1212
peakmetoclopramideconcentration
clearanceoflithiumclli
steadystateplasmaconcentrationsc
degreeofplasmaproteinbinding
peritonealdialysateconcentration
maximumaqueoushumorconcentrationcmax
surfaceroughnessra
maximumofloxacinconcentration
tbeta12
plasmaantifactorxalevel
freeunboundfraction
apparentprednisoloneclearance
seriousbacterialinfectionrate
offset
peakethanolconcentration
clearancedrug
totalamountsexcreted
coefficient
dosenormalizedsteadystateplasmalevel
bloodtoplasmaconcentrationratioof
skinplasmaconcentrationratio
effectiveconcentrationc50
onsettimeformaximumblock
associationconstantka
peakconcentrationcpmax
integratedgastricacidity
ad50
plasmaconcentrationcausinghalfmaximaleffect
areasundertheconcentrationtimecurvesfrom0toinfinityaucinfinity
peakplasmaaraclevelsat3hcp3h
terminaleliminationhalflifebetat12
unboundcsffraction
serumbetahalflife
absolutesystemicavailabilityf
portalvenousflow
extrarenalclearance
relativemolarbindingactivitie
maximumbloodethanolconcentrationcmax
serumlevelpeak
factorconsumption
areaundertheplasmadrugconcentrationversustimecurveauc
thcratio
survivetime
tnratio
14
apparentvolumesofdistributionvdssf
roundwindowpermeability
maximumserumibutilideconcentration
completiontimeof
concentrationatsteadystateathalfvmaxkm
peakdigoxinlevel
auc06areaundertheplasmaconcentrationsvstimecurve
maximumantinociceptiveeffectcmax
maximalserumconcentrationofinsulincmax
areaundertheconcentrationtimecurvetothelastsamplingtimeauc012
areaundertheconcentrationtimecurveauc0loq
systemicareaunderthecurveauc
ib
ce50na
polydispersityindexpdi
doserequired
ce05
volumeofdistributionofnflxgaatsteadystatevdss
q3hrelease
steadystatetroughconcentrationcminss
aucss08ratio
clearanceclratio
halflifeofdrugrelease
freeclearance
ratiosoftheaucsfrom0to24h
span
centralvolumeofdistributionvcentral
meanabsorption
massofmelatoninreleased
intrinsicclearanceclint
cssmaxmic
fractionexcretedinbile
timetopeakplasmaconcentrationstmax
peakvalue
areasundertheplasmaconcentrationtimecurveauc024
t9t10
percentagerecoveryof
measured
timeatwhichtheplasmaconcentrationwasmaximaltmax
totalplasmatmtxclearance
plasmaclearanceclt
areaundertheplasmaconcentrationtimecurveaucfrom0tothelastmeasurableplasmaconcentrationauc0last
plasmaconcentrationtc
minima
areasunderthecurveauc028days
eauc
pfstime
timetopeakcande
hepatictissueuptake
slopeoftheterminalphase
steadystateadalimumabserumconcentration
extrathoracicdeposition
areaundertheplasmaconcentrationversusthetimecurveauc
place
oralterminalexponentialvolumeofdistribution
ratiobetweentheauc
rateoftransferofdrugfromthecentraltotheperipheralcompartmentk12
zetaelectricalpotential
timetomaximalconcentrationofradio
t12h
functionalhalflife
valleyserumconcentration
troughplasmaconcentrationctroughratio
areaundertheplasmaconcentrationvstimecurveauc0infinity
timetopeakconcentrationstmax
firstcompartmentvolumeofdistributionv1
areaunderthecurveaucpred
apparentplasmaeliminationhalflifet12
exchangetime
peakconcentrationtimetmax
timeforattainingthepeakconcentration
peakplasmaadmconcentration
freewaterreabsorption
totalexposureauc024
t05ofelimination
halflifet2
areaunderthecurvefrom0toinfinityauc0infinity
peakserumcbzconcentration
plasmaticcmax
dpdt
ep
halflivest12lambdaz
areaundertheplasmaconcentrationtimecurvefromzerotoinfinityaucinfinty
percenturinaryrecovery
livertissuetoplasmaconcentrationratiokpliver
maximumobserved
fetaltomaternalconcentrationratio
intestinalclearance
abscessfluidplasmaconcentrationratio
aucsoauc
survivaltimesmsts
peripheralvolumeofdistributionvp
overalldoseadjustedconcentrationc2dose
totalbodyclearanceclf
totalamountofntgtransdermallyabsorbedaucxcl
unboundsteadystatedistributionvolume
fastphaseofthedisappearancecurve
apparentlamotrigineoralclearance
kef
steadystatetosingledoseaccumulationratio
apparentvolumeofdistributionatequilibrium
areaundertheconcentrationtimecurvefromzerotothetimepointwiththelastmeasurableconcentrationauclast
steadystatepredosebloodconcentration
areaundertheconcentrationtimecurvefrom021hoursauc021
biologicalbioavailability
rateofk12
overallsurvivaltime
areaundertheplasmaconcentrationtimecurvefromtime0to12h
minimummaximum
maximummeasureddetomidineconcentration
timefor90absorption
extravascularlevel
gastricemptyingtime
timetomaximumobservedplasmaconcentrationtmax
bhalflife
vepsilon
effectsitetarget
zerodrugdeliverytime
maximumaverageboneconcentration
peakconcentrationcmax
plasmafiltratevolume
plasmahalflivest12
cumulativesurvival
aucfrom0to8h
steadystatevolumeofpentobarbitaldistribution
areaunderplasmaconcentrationcurveauc08h
absorptionlatencytime
intravascularhalflife
associationrateconstant
relapse
effectivenesstroughlevelsctrough
peakhemolymphconcentrationcmax
firstorderrateconstantofdegradation
maximumdrugconcentrationcmax
proberecovery
ventricularlactoneconcentration
timestoloc
intracellularhalflive
swellingratio
redispersedtime
auc24hmicratio
areasundertheserumconcentrationtimecurvesfrom024hoursauc024
hv
kalphaaac
constanttrough
reflexthreshold
meanarrivaltime
recoverytimestotwitchheight
extracellularpeakconcentrationcmax
brainbloodratio
milktoplasmaflecainide
lagtimeofrelease
kinact
timeofmaximalplasmaconcentration
vmaxkmratio
fractionofunboundpethi
renalclearance
timetopeakaction
apparenthalflivesofelimination
hydrodynamicdiameter
areaundertheplasmaconcentrationtimecurvefromtime0tothelastmeasurementauc0t
maximalrateofeliminationvmax
logpe
plasmapeakplatinumconcentrationscmax
ratepulse
relativeretention
tounboundplasmadrugconcentrationratio
durationofneutropenia
renalbloodclearance
responseareaunderthecurve
dissociationkoff
salivavs
oralbiologicalavailability
kd1
boundfractionof
oralvolumeofdistributionvdf
terminalphasehalflifeofeliminationfromserum
quantitation
equilibriumdissociationconstant
volumeofdistributionvda
timeuntilacommandwasfollowed
plasmareleasehalflive
clhf
areaundertheserumconcentrationtimecurveextrapolatedtoinfinity
theoreticalmaximumserumconcentration
durationofmotorresponse
inhibitionhalflife
apparentplasmaterbutalineclearance
equivalentsteadystateplasmaconcentration
apparentvolumeofdistribution
areaundertheethanolconcentrationtimecurve
timestothepeakplasmaconcentration
aucsstau
fmao
totalsingleruntime
areaunderthedrugconcentrationtimecurvefromtime0toinfinityaucinfinity
auc24hrmic
auc7276
recoveryof
residencetime
partialpressurepaofoxygen
tb12pip
vesselarea
aucfromtimezerotoinfinity
transferhalflife
apparentpermeability
maximumplasmaclenbuterolconcentration
auc05
volumeofdistributionperbioavailability
minimumdosage
timetothepeakplasmaconcentration
eliminationt12zhalflive
sodiumoutput
tissuepenetrationratiostissuefaucplasmafauc
timeofoccurrenceofthepeakplasmalevel
tk0
tumorresponserate
serumpeakghconcentration
maximalplasmalevel
eax
specificquantumyield
peakzidovudinelevel
halftimefor50release
drugloadingcapability
areaundertheserumcipconcentrationtimecurveaucfromtimezerotoinfinity
ratioofaucmilk
terminalplasmahalflifet12
steadystateareasundertheconcentrationtimecurvesduringthedoseintervalauctss
areaunderthebloodconcentrationversustimecurve
areaunderthecurveauclast
systemicclearanceci
aucssareaundertheconcentrationtimecurveoveradosageintervalatsteadystate
peakbloodconcentrationcmaxblood
peakplasmacialevel
peakvenousserumconcentrationscmax
mtcontent
inhalationholdingtimeratio
radioactivitie
firstdosepeak
areasundertheserumconcentrationtimecurvesauc0infinity
bileserumratio
peakabsolutemonocytecount
mictr
inhibitoryquotientiqcmaxmic
apparentlinearclearance
maximuminhibitoryeffect
inhibitionconstant
halflivesoft12alpha
c2concentration
peakcodeineplasmaconcentration
bloodtoplasmaconcentrationratio
areaunderthemidazolamconcentrationtimecurve
e1
overallsuccessrate
totaldurationofsecretoryactivity
bloodtobiledistributionratiok
percentage
timestorecovery
d7lum
effluxratiobaab
peaknitricoxidemetabolitesconcentration
rateconstantbeta
areasunderconcentrationcurve
apparentdistributionvolumevf
areaundercurveauc012
totalbindingconstant
bindingpercentage
areaunderthecurveauctratio
steadystateplasmaconcentrationelicitinghalfofmaximume
plasmahalflifeofelimination
bioavailabilityfraction
peakarterialbloodconcentration
peakplasmaglibenclamideconcentration
eliminationclearanceoftheperipheralcompartmentcl2
dynamiclungcompliancecdyn
matpo
areaundertheinhibitoryconcentrationcurveauic
concentrationsscac
terminaleliminationhalftime
areaunderplasmaconcentrationtimecurvefrom0to24hauc024
fractionbound
areaundercurvefromtimezeroto24hoursauc024
areaundertheplasmaconcentrationtimecurvefor24hatsteadystateauctss
timetomaximalmetaboliceffecttmaxgir
hclgda
peakarterialplasmalidocaineconcentration
synovialfluidconcentration
maximumwholebloodconcentrationcmax
apparenthalftimeofelimination
twentyfourhoururinevolume
unboundvegfconcentration
peakprprolongation
volumeofdistributionintheeliminationphase
cumulativepercentrelease
qrsduration
areaunderthecurvefrom012hauc012
cim
interresponsetime
absorptionduration
aerodynamic
tumortobloodtbratio
halflifel
areaunderthecurvefrom0to60hauc060
ratiosforauc
steadystatevd
troughifxlevel
areasundertheplasmaconcentrationtimecurveextrapolatedtoinfinityauc
tumourenhancementratio
csstarget
auc240
areaunderthefreeplasmaconcentrationversustimecurveauc
auc120hr
tmp
maximumfeasibledose
aucvstime
clren
intracellulardistributionrateconstant
totalbodycl
steadystatebioavailability
generalexcretion
serum
relativeoralintramuscularbioavailability
maximumenfconcentrationcmax
logbeta1
correctedtransfer
polarizationrate
material
aucmaucp
biologicpotency
ratioofthetotaldrugconcentration
rapidlyeffectiveplasmaconcentration
dialysateplasmaconcentrationratio
auctissueaucserumratio
paintolerance
totalurinaryexcretion
peakdigoxinconcentration
apparentvdbeta
glucuronideconcentration
areaundertheconcentrationtimecurvefromtimezeroto24h
residualtime
areaunderthetimeresponsecurvesauc
timerequiredtoreachmaximalconcentration
50effectivedoseed50
percentageaucratio
peakremifentanilconcentration
24hourauc
incl
troughplasmalevel
halflifeofdrug
maximumplasmadetomidineconcentration
kome
transfer
hepaticuptakeratio
cmaxmaximumobservedplasmaconcentration
absorptionrateconstantofdigoxinka
apparentltgoralclearance
areaundertheserumconcentrationtimecurve
flowrateofmobilephase
areaunderthetimecoursecurveauc024h
peaktheophyllineconcentration
overallbacterialeradicationrate
ar
apparentpampap
aqueoushumorconcentrationpeak
areaundertheplasmaconcentrationtimecurvefromzero0hourstoinfinityauc0
timeofanalysi
steadystatevss
areasunderthecurveauc024h
meanresidencetimefororalabsorptionmrtabs
vssivt
rerr
recoveryfromsedation
tfirst
timestoreachpeakserumconcentration
rateofmetabolism
transportfraction
eliminationrateske
maximumspecificactivity
d2
initialbrainconcentration
totalanalysistime
recoveryof14c
reab
inhibitorconstantki
areaunderthecurveauc0720
entrapmentefficacy
para
c0level
areaundertheconcentrationtimecurvefor24hauc24
areaundertheplasmaconcentrationtimecurvefromtimezero
serumtobileratio
visco
toxicthresholdconcentration
absorptionhalftime
maximalobservedplasmaconcentrationofbuprenorphinecmax
aucrsratio
voutput
timetolastmeasurableradioactivity
urinelevel
relativetissueefficiencie
td1
fd
apparentintestinal
plasmaconcentrationat30minc30min
dzratio
glucoseconcentration
120h
areaunderthecaffeineconcentrationtimecurve
skinequivalentdosedistribution
degradationhalflife
bothrenalclearance
peakrpqconcentration
scoreatpainflare
bioavailablef
maximalphenytoinplasmaconcentration
timeabovethreshold
timeto005i
alphadistributionrateconstant
spreadof
areaundertheplasmaconcentrationtimecurveofpravastatinfrom0to10hoursauc010
intercompartmentclearance
arterialvenousextraction
maximummeanplasmaconcentrationscmax
oralapparentclearance
oralabsolutebioavailability
daystona
areaunderconcentrationtimecurve0720min
timetoachieveapparentmaximumibuprofenconcentrationtmax
maximalvelocityofabsorption
bioavailablity
concentrationc0
durationsofaction
timeto80block
mucosalextractionratio
peakbloodcsaconcentration
halflifeofg
cumulativerenalexcretion
halftimeofdisappearance
terminalphaseeliminationhalflife
t2max
vk1
arac
vesselmuscleratio
cmax24h
areaundertheplasmaconcentrationcurvefromtimezerotoinfinityauc0
relativemaximumeffect
peakdetachmentforce
forcedexpiratoryvolumein1second
urineclearance
peakplasmasalevel
subjectivethreshold
peakmeloxicamconcentration
50lethaldose
observedtimetomaximumplasmaconcentrationtmax
bu
ionmassspectrum
terminaldrugaccumulationphase
druguptake
fngt
lowestdetectableconcentration
so
dissociationrateconstantkoff
rateconstantkeo
absorptionratio
maximummeanserumconcentration
mz1
totalplasmaepinephrine
systemicclearanceclf
absolutebioavailabilitybioav
logauc
terminalhalflivet12
iauct90
ke12
csftoplasmaconcentrationratio
absoluteeliminationhalflifet12ab
peakcbzplasmalevel
molarratiooftheareaundertheconcentrationcurveauc
halflifeofequilibrium
timestoreachpeakplasmaconcentrationstmax
maximumplasmamoxifloxacinconcentration
totalamountofdrugrecovered
areaunderthefaecalconcentrationtimecurve
areaundertheconcentrationtimecurveaucfromtime0tothelastquantifiabletimepointauc0t
areaunderthetimeconcentrationcurveauc
relativebioavalability
peakplasmaflumazenilconcentration
peaktocainideconcentration
steadystateconcentrationcss48168h
totalphenytoinclearance
t12ka
t024h
terminalbetaserumhalflife
timetoprogressionttp
achlevel
troughconcentration
24hoururinevolume
steadystatevolume
ratiosoftheareaunderthecurveaucovera24hdosingintervalauc24tothemic
kidneytoplasmaconcentrationratio
effluentrate
c1max
depletionrateconstantkdep
lineareliminationhalflife
bindingconstantkb
peakliverenhancement
clearanceofunboundteniposide
organretention
noncompartmentalhalflive
t05b
edi
intrinsicdissolutionrate
plasmahalflifet12alpha
distributionvolume
hepaticclearanceofverapamilcllver
auclevel
eliminationcapacity
dialysateclearance
apparenteliminationrateconstantlambdaz
mz310
peakconcentrationofpaclitaxelcmax
biologichalflife
fractionrecoveredinurine
absorptionration
auc0300
terminalhalflivest12lz
molarnitrateconcentration
maximummedianplasmaconcentration
md
apparentaffinitykm
v1v1m
extractionrecoveryr
peaktheophyllineconcentrationcmax
lactoneclearance
tumorresponse
unboundapparentoralclearance
morning
apparenttissuebinding
steadystatemoxifloxacinratio
volumeofdistributionbyarea
totalapparentvolumeofdistributionvbeta
auc0tmic
peakarterialwallpaclitaxellevel
cssmusclec
logbeta2
apparentoralclearancecloratio
areaundertheconcentrationtimecurvefrom0to10h
f
maximumreversal
areaunderthedrugconcentrationtimecurveauctarget
areaunderthedrugplasmaconcentrationvstimecurveauc
retardationfactor
dosecorrectedaucaucdosex1000
serumtroughsteadystateconcentrationcminss
steadystateareaundertheplasmaconcentrationtimecurveaucss
areaundertheoxipurinolplasmaconcentrationtimecurveauc
tabslate
maximumbisoprololconcentration
areaundertheplasmaconcentrationtimecurveextrapolatedtoinfinityaucinfinity
maximalserumetomidateconcentration
plasmaconcentrationratior
maximalreduction
apparenthalflivesoftheabsorption
areaunderthecurveforplasmafentanylconcentration0144h
timerequiredtoreachpeaklevel
areasunderthecurveauc06
peritonealplasmaaucratio
jetne
equilibriumdistributionvolumeved
timetopeakethanolplasmaconcentration
timeofthemaximalplasmaconcentration
population
renalclearancecl012h
spreadability
totalvolumeofdistributionvd
lmax
firstphaseeliminationhalflivest12alpha
lambtoewe
areasundertheplasmaconcentrationcurvesauc
arterialpco2
distributionvolumevdbeta
areaundertheconcentrationversustimecurvefrom0to12hour
timetoachievethispeak
chromatographicrunningtime
timetoreachmaximumpeakplasmaconcentrationtmax
plasmatotalclearancecltot
apparentvolumeofdistributionincentralcompartment
maximumbupivacaineplasmaconcentration
auc96hmic
overalleliminationhalflife
timestopeak
biliaryclearanceclb
saturatedattachmentratio
maintenancetroughlevel
maximumrateforsaturabledistribution
percentageofproteinbinding
halflifeofeliminationt12
auc030minute
peakexcretionrate
vmaxapp
tissuetobloodpartitioncoefficient
annualizedrelapserate
halftime
percentagerelativebioavailability
timeforpeakplasmadruglevel
brainpenetrationhalftime
mycologicalcurerate
totaleliminationtime
transferconstantbetweencentralandperipheralcompartmentskcp
totalapparentvolumeofdistributionvz
maximumsaconcentrationcmax
bloodtoplasma
gammahalflife
areaundertheplasmaconcentrationtimecurvebetweentime0and24h
clearanceofunboundoxa
normal
injectionvolume
zeroorderinput
eliminationhalflifefromblisterfluid
maximumplasmaantixaactivityamax
miccipmic
apparentmaximumcapacityoftransportvmax
volumeofdistributioninthecentralcompartmentvcf
cbefore
fractionsbound
areaundertheconcentrationtimecurveforthefreeunboundfractionofthedrug
apparentplasmaclearance
eliminationhalflifetimest12
maximumtheophyllinaemiacmax
observedmaximumctcconcentrationscmax
oralbioavailabilityf
areaundertheconcentrationtimecurveaucinf
renalclearance02h
totalactivefolateconcentration
peakfev1change
apparentvolumeofdistributionofthemetabolitecompartmentv3f
plasmaeliminationhalflifet12beta
steadystateplasmaavtlevel
maximumalemtuzumabconcentration
areaundertheplasmaconcentrationtimecurvefromtimezeroextrapolatedtoinfinityaucinfinity
percentagetumorcelldeath
troughdrugconcentrationatsteadystatecssmin
lymphabsorptionrate
medicationpossessionratio
relativedistributionvolume
timetoreachthemaximumserumconcentration
aucsublast
maximaldesethylamiodaroneconcentration
dosenormalizedmp
drugrequirement
absorptionratconstant
clearancecl
oralauc08h
nf
feversubsidencetimefst
halflifeceiling
peakofmeanplasmaconcentration
ec40
peakperitonealconcentration
fluidtobloodaucratio
maximalrateofabsorption
pseudosteadystateplasmaconcentration
id50concentration
maximalipa
depurationtime
hepaticbloodflowrate
totalfecalba
aucinfareaundertheconcentrationvstimecurvefromzerotoinfinity
csfplasmaconcentrationratio
totaldurationofneuromuscularblockade
maximalbloodglucose
targetattainmentratesofaucmic
areaundertheeffecttimecurveauce0120
percentageabsorption
cluf
tbaf
aucover
salivaryhalflive
doseper
acrophasepeaktime
maximalpeak
peaksc
plasmaconcentrationcap
maximumbloodethanolconcentration
absoluteoralbioavailabilitie
areaundertheeffectauecabove212
lagtimeafteroraladministration
clearanceintothebrain
hepaticclearanceofblood
serumfentanylconcentration
percentcumulativedrugrelease
steadystateaverageplasmanicotineconcentration
timeforittoreachpeaktmax
arterialpropofolconcentration
oe
skinreleaserateconstantkr
distributionalclearanceattheterminalphase
hourlyeliminationratebeta60
tissuetoplasmadrugconcentrationgradient
plasmamaximumconcentration
steadystatediltiazemconcentration
t12kappa
halftimeofabsorption
lit12
boneuptaket12
volumeofdistributionofthecentralcompartmentvc
limitofdetermination
nh3auc024hr
ten
t12ab
halflifeoftheadditionalinitialdistributionphaset12lambda1
observedpeakplasmaconcentration
maximalresiduelevelvaluemrl
eliminationrateconstantk
auc0tareaundertheconcentrationtimecurve
apparenttel
overallrecovery
timetothemaximumconcentrationofdrug
minimumlevelofdetection
timestopeakplasmaconcentration
onsettimeofsensoryblock
timeafterdosingwhencmaxoccurred
maximummorphineplasmaconcentrationcmax
halflifeinurine
cycle
timestoachieve50reduction
peakacetoneconcentration
a9concentration
concentrationmultipliedbytimeareaundercurve
timetoabsoluteneutrophilcountancrecovery
peakafxalevel
peakserumconcentration
retainedma
maximalcm
doseweightadjustedauc0infinity
maximalipversusplasmaconcentrationratio
ultrafiltrationclearance
breathclearance
tid20
bloodplasmaconcentrationratio
totalbinding
aspectratio
s
exchangevolume
totalrecoveryofradioactivedose
noobservedeffectconcentration
relativepercentageof
biologicalhalflivesoftheabsorption
peakplasmalevelscssmax
annualbleedingrate
timeofviability
areaunderthecurveauc0tlast
slopeoftheeffectconcentrationrelationship
peaklungconcentration
firstordereliminationrateconstantke
apparenttransbuccalmucosalpermeabilitycoefficient
feverclearancetimefct
timetoonsetofresponse
concentrationofdruginserumat12hc12h
apparentvolumeoftherapidperipheralcompartment
areaundertheplasmaconcentrationversustimecurvefrom0to24hoursauc024h
fatmilkconcentration
t12distribution
maximumrelaxation
massmedian
aucfromtime0totmax
dhalflife
plasmaproteinbindingdegree
areasundertheplasmaconcentrationtimecurvetothelastquantifiabletimepoint
unboundauc024
ratioofld50toeffectivedose
peripheralvolumesofdistribution
completeremissioncrrate
talpha12
dosenormalisedaucratio
areaunderthecurveratioaucr
fmax
peakplasmaconcentrationcmax
pulmonaryfirstpasselimination
aucabovethemic
minimumlevel
totalurinaryd
dosenormalizedareaundertheconcentrationtimecurveauc
fauc024micratio
peakzincconcentration
distributionclearance
sonicationtimest
areaunderthecurvefrom0hto10hauc010
areasundertheplasmaconcentrationtimecurvesduringthedosingintervalauct
cllung
eo
serumconcentrationversustimecurve
areasunderthecurvesauc0infinity
maximummpaconcentration
fimvss
timestoreachcmax
areaundertheplasmaconcentrationversustimecurveaucratio
viscositie
venousserumpropofolconcentration
peakpenbutololconcentration
clearancec1
cxt
clfd
t12keo
bk1
plasmaterminaleliminationhalflive
plateauheightcplateau2112d
timeinwhich
fcmax
aucfrom0to12hoursauc12
intervalfrominjectionuntilmaximumconcentration
oralclearanceclpo
distributionalclearancecld
eliminationhalflive
numberoftreatmentscycle
steadystateserumultrafiltrate
prehepaticextraction
areaunderthecurveauc0220min
areaundercurveofplasmaconcentrationuntilthelastconcentrationobserved
onsetofeffect
totalmorphinerescuedose
bioavailabilityofthe
steadystateconcentrationratio
basalzeroorderproductionrateofglucosekgprod
terminaleliminationrateconstant
maximumobservedconcentrationcmax
terminalserumhalftimet12
recoverytot1t0
serumhalflifeduringtheeliminationphase
heartrate
fractionunboundfu
tumortoplasmaratio
halflifet12d
quantitativelimit
metabolicclearancebasedonunbounddrug
invivoresponse
stabilitie
maximumserumdrugconcentrationcmax
entrapmentefficiency
t12abs
clearanceantigen
volumeofanti
tumorto
responseraterr
unboundfractionsofdrug
auc120360
selectivityfactoralpha
need
peritonealconcentration
percentunbound
maximalnifedipineplasmaconcentrationscmax
progressionfreesurvivialpfs
aucoraldose
unboundpeakcsfconcentration
coagulantactivityfviic
weight
auctissueaucplasmaratio
apparentpaclitaxelclearance
ap
areaundercurvefor0to24h
ratecmax
kpaucbrainaucplasma
24hareaunderthecurveauc
infusionduration
pka2
maximumeliminationrate
pkb
preparationtime
totalplasmamaximumconcentrationcmax
plasmahalflifebetat2
plasmalevelatsteadystate
peakphenobarbitalserumconcentration
timetomaximumpleuralfluidconcentrationtmaxpf
steadystatetotalplasmareducedfolateconcentration
zatapotential
dh
flung
totalamountofunchangedtorasemideexcretedin
aucdistribution
viablebacteriumcount
auc024mic90ratio
minimumserumlevetiracetamconcentration
oralbodyclearanceclf
fractionalexchangeratebetweencompartment
vzfss
areaunderserumconcentrationtimecurve
totalrecovery
areaunderthecurvetothelastmeasurableconcentrationauc036
ec90concentration
troughseruminfliximabconcentration
auc8h
bloodtroughlevel
totalapparentplasmaclearance
peakcortisolconcentration
areaundertheconcentrationversustimecurveauc024
maximumexcretionratesddudtmax
areasundertheplasmaconcentrationversustimecurveaucinfinity
paldo
areaundertheplasmaconcentrationtimecurvefromtime0to12hoursauc12
permeationflux
ethanoltoetgratio
apparentmaximalconcentrationkm
areaunderthefamotidineplasmaconcentrationcurve
systemicextraction
steadystateunboundplasmadrugconcentration
rateofdecrease
tmaxin
nonsaturableuptakerateconstantk4
topeakconcentration
concentrationat24hcmin
plasmaconcentrationpeak
averaged
concentrationathalfmaximuminhibitionic50
baselinee0
t12l
sf
peakplasmaleuprorelinconcentrationscmax
ammonia
resistance
tumortobonemarrowratio
steadystateminimumconcentrationcmin
localbioavailability
secondhalflife
precursor
smxa
areaundertheindomethacinplasmaconcentrationcurveauc0alpha
minimallyeffectiveplasmaconcentration
deepcerebraldistributionvolume
csslevel
peaklevelscmax
plasmaconcentrationsduringsteadystatecondition
apparentvolumeofdistributionvbetaf
combinedresponserate
aucfromtime0to30hour
unbounddrug
totalplasmaclearancecltot
urinaryeliminationhalflive
halflifet12el
peakdeltadeltaqtc
apparentterminaleliminationt12
areaundertheplasmaconcentrationtimecurvefromtimezerotoinfinityauc
timetoreachzerobac
absoluteneutrophilnadir
halfmaximaleffectiveconcentration
pulmonaryvascularresistance
cpbtime
612
absorptionratehalflife
basplasmaconcentrationratio
latencytime
amplitudesof
rinaryrecoverie
terminalhalflifephaseofelimination
totalrtdose
centralvolumev2
amountexcretedinurine
areaunderthebloodconcentrationtimecurvefrom0infauc0inf
clearancethroughglucuronidation
rbcrecovery
timetopeakplasmalevel
t12serum
peakplaceboeffect
peakserumv
selfem
maximummeanplasmaconcentrationcmax
saturationconcentration
maximalurinaryosmolality
maximumplasmacholinesteraseinhibition
50growthinhibitoryconcentrationsic50
dosenormalizedareaundertheplasmaconcentrationtimecurve
peakendogenousmelatoninconcentration
free
spaceofdistribution
ocularbioavailability
totalamountofcimetidineeliminated
overalldrugtargetingefficiency
peakch1418plasmaconcentration
timetoreachmaximumplasmadrugconcentration
apparentclearance
areaundertheplasmamidazolamconcentrationtimecurveauc0infinity
k203
tciduration
tcav
sedationtargetconcentration
aucmicbreakpoint
loadingcapacity
tounboundplasmaconcentrationratio
absoluteoral
areaundertheacetam
liverplasmapartitioncoefficient
apparentauc024
maximalkillmaximumeffectemax
halflifet12betaphase
accumulationcoefficient
areaundertheplasmarosiglitazoneconcentrationversustimecurve
deacylationrateconstant
braintoperfusate
waterexcretion
areaunderthecurvefrom0to120min
minimumgluconcentration
select
timetoreachmaximalplasmaconcentrationtmax
maximumpeakplasmadrugconcentrationcmax
remaintimemrt
serumareaundertheconcentrationtimecurveauc
renalalexcretion
apparentoralclearanceclssf
clearancefor
relativeinfantdose
t12betaeliminationphase
volumeofthecentralcompartmentvc
apparentterminaleliminationhalflifet12
parasitereductionratio
icr
longcirculatinghalflife
timeaboveic50
timetoreachaplasmaconcentration
matureclearance
apparentvolumeofdistributionvdarea
volumesofdistributionatsteadystatevdss
oralsystemicavailability
q3
areaundertheconcentrationtimecurvefromtimezeroto24hoursafterthedoseauc024
cp24h
volumeofdistributionofcompartment1
pulmonarypercentagepenetration
combinationindex
biliaryexcretionindex
kcatkm
areaunderthecurveextrapolatedtoinfinityauci
eliminationhalflivest12lambdaz
relativeavailability
totalbodyclearanceclpl
biliaryclearance
effectiveplasmahalflife
impedance
relativepercentagebioavailabilitie
ratiosofauc024
areaunderthemomentcurve
durationofreceptorsaturation
maximumconcentrationcmaxfit
lagtime
sedationsuccessrate
peakcocaineplasmaconcentration
areaunderthecurve0168h
durationsof
totalplasmaclearancebioavailabilityclf
timetopeakfall
relativebioavailabilityba
steadystateauc0
terminalexponentialvolumeofdistribution
bindingability
antifactorxaactivitie
oralbioavailabilityba
timetopeakplasmafab2
concentrationsconcentration
ka2
drugdeliveryrate
0to24h
areaundertheplasmaconcentrationvstimecurvesfromtime0to24hauc024
electricalconductivity
totalurinaryrecoverie
totalmeanradioactivityrecovery
areasundertheplasmaconcentrationversustimecurvefrom0to24h
timetothepeakserumconcentrationtmax
v4f
latencyofonsettoclinicaleffect
massmedianaerodynamicdiametersmmads
rateconstantkd
apparentabsolutebioavailability
auc0480
maximumplasmalomefloxacinconcentration
terminaleliminationhalflivest12
buccalbioavailability
peakincrease
serumdrugconcentrationatsteadystate
peaksplasmaconcentrationcmax
deltaauc
brainblood
eliminationphasebetahalflife
timetomycologicalcure
sustainedvirologicresponserate
plasmaclss
slopesoftheterminalphasek10
areaundertheplasmaconcentrationtimecurvemauc0inf
cumulativepercentageofdrugreleased
minimumdetectionrange
fixc
cumulativeurinaryexcretionpercentage
constantcurrent
imaxi50
kaalpha
ratiooftheaucoinfinity
nonresponse
prostatetoseminalvesiclesconcentrationratio
remissionduration
washintimetop50
halflivesoftheabsorption
absolutegran
buccalflux
uptake
peakplasmaverapamilconcentration
michaelisconstantfor
maximumplasmaprobenecidconcentration
bodyweightnormalizedoralclearance
overalldoseadjustedpredoseconcentrationc0dose
postantibioticeffectspaes
lungdeposition
nocturnal
maximaletoposideplasmaconcentration
terminalhalflivest12
decreasehalflife
gmax
troughplasmacilastatinconcentration
timetomaximalserumlevel
fever
minimalbactericidalconcentration
neutrophilcount
mbec
peaknitrazepamplasmaconcentration
maximuminsulinconcentration
areaundertheket
growthinhibitionic50
timerequiredtoreachthepeak
effectsiteconcentrationce50
drugloadedspace
kitt
precision
halflifebeta
urinarydetectiontime
zeroorderkineticfr
octt
cltotal
eliminationhalflifeofterminalexcretionphaset12lambdaz
disposition
ultimatehalflifet12
areaundertheplasmaconcentrationtimecurvesoffurosemidefromtimezeroto4hauc04h
timeresponsetoprogression
eliminationkinetic
nasalresidencetime
mcfb
plasmaeliminationhalflivest12
prothrombintimept
peakplasmasalicylatelevel
maximumconsumption
fractionalturnoverratekt3
timetoreach1
maximallytolerateddose
peakplasmatriamcinoloneacetonideconcentrationscmax
midazola
totalaresunderthebloodconcentrationtimecurve
finaleliminationhalflife
steadystatedepletion
timetoperformancestatusworsening
aucrumenauc
laterestenosisrate
clpof
biologicalhalflifeintheterminalphaset12beta
maximumlungtissueconcentration
pco2gradient
peakplasmaconcentrationatthesteadystate
concentrationxtime
auc1112
k21
areaundertheplasmaconcentrationtimecurveaucinf
eliminationcoefficientke
areaunderthecurveauc0tau
tmaxtmaxss
serumtrough
clearancethroughsidechainoxidation
peakinspiratoryflowrate
distributionrateconstanta
logapparentoctanolwaterpartitioncoefficient
timefor50absorption
maximumtransportcapacitytmax
areaundertheplasmaconcentrationtimecurvefrom0to4hour
kpapp
peakfetalplasmaconcentration
timetorecover50ofthemaximumdrugeffectrt50
metabolicclearanceofdrug
50ofmaximumeffect
auc2436
timeofcmax
relativedrugexposurere
vvratio
areaundertheplasmaindometacinconcentrationtimecurve
peaklevel
venousconcentration
timerequiredtoreachmaximumplasmaconcentrationtmax
maximumtransportcapacityvmax
areaunderthetimeconcentrationcurveauc090min
eliminationplasmahalflifet12
areaundertheconcentrationtimecurvefrom0to144hour
concentrationsatsteadystatecss
halftimefortransfer
rateconstantk1m
alveolarmacrophage
vdssbw
efficacy
cmaxomegaalpha
timeofobservedcmax
maximalclonidineconcentration
tp1
auc08hr
mbf
mmad
volumeofdistributionatasteadystate
troughcortisollevelcmin
maximalplasmaamiodaronedesethylamiodaroneconcentrationratio
areaundertheconcentrationtimecurveauc024tomicratio
ratesofformation
auc024hratio
pao2fio2
urinaryclearancetime
peritonealfluidserumconcentrationratio
timetakentoreachmaximumconcentrationtmax
limitofdetectionsn
kal
plasmatoerythrocyteconcentrationratio
troughmpaconcentration
concentrationmaximumcmax
apparentvolumeofdistributionofatgvd
maximumplasmaolopatadineconcentration
ld50r1
gastrichalflifet12g
halflifeofdistributionthroughthecirculation
peakrifampinconcentration
interferonlevel
betaphase
fractionalexcretionfe
totalplasmameloxicamconcentrationsauc
ramsaysedationscore
durationofgrade4neutropenia
tb
apparentaffinityka
totalverapamil
percentageofabsorptionfor
apparentmaximumplasmaconcentrationscmax
effectivehalflifetsub12accsub
maximumwhealsuppression
distributionvolumevss
timetomaximumnaloxoneconcentrationtmax
subcutaneousbioavailabilitie
auecratio
timeneededtoachievethi
oralmedianlethaldoseld50
eba
maximalplasmacobalaminconcentrationcmax
areaundertheconcentrationtimecurveover24hinthesteadystatedividedbythemic
percentageofadministereddoseexcretedunchanged
peaksalicylateconcentration
areaoftheplasmaleveltimecurveauc
meanplasmalevel
sc
gastricretentiontime
unboundhydro
netsecretionclearance
annualizedbleedingrate
intrinsicaffinitie
braintoplasmahalfliferatio
kb
peakofnicotineconcentration
auco24
inactivationrateconstant
serumconcentrationsc88
timeaveragedextractionratio
overallfilterefficiency
slowdispositionphaserateconstant
timestoreachmaximumeffect
drugloadinginto
tpeak
plasmaclomipramineclearance
areasunderthecurveauc12h
totaldrugcontent
initiallagperiod
areasundertheconcentrationversustimecurve
auc09level
inflammatoryfluidlevel
truerelativebioavailability
overalldruglikingmaximumeffect
maximaltime
aucminimuminhibitoryconcentrationmicratio
apparentreleaseflux
sbet
dosenormalizedrelativebioavailability
metabolicdebtrepayment
auc0to12hour
intercompartmentrateconstantsk12
maximumafatinibplasmaconcentration
sexratio
serumtconcentration
total24hexcretion
maximalprilocaineserumlevel
aucsfrom0toinfinityauc0
zeroordereliminationratek0
ratiosofaverageconcentrationover48hcav048hmic
c25h
halfmaximalclearanceamichaelismentenconstant
refractivepoint
timetoseveredyspnoea
pan
apparentterminalplasmahalflive
observedpeakplasmaconcentrationcmax
areaundertheplasmaconcentrationvstimecurveauc
areaundertheplasmaethanolconcentrationtimecurveauc0t
halflifedrug
areaunderthenicotineconcentrationtimecurveauc
totalclearancefromtheblood
minimumparticlesize
gammat12ghalflive
metabolicformationrateconstant
recoveryto25ofbaselinetwitchheight
percentageofdose
minimumconcentrationinserumcmin
mz321
auc010d
peakiggconcentration
vft
bw
mrt0infinity
peakbiliaryexcretion
folatelevel
degradationrate
yieldof
apparentvolumeofdistributioninthesecondcompartmentv2
systemicclearance
areaundertheconcentrationtimecurvefrom0to24hauc024mic
mbc50
drugdelivery
distributionvolumevbeta
peritonealmasstransfer
ratioofarea
timeto50copie
urinaryrecoveryurxf
maximumbloodlevel
percentsurvival
fractionofthedoseexcreteda
basalspacing
t12elimination
mon
fractionofmetabolism
limitsofdetection
livertoblooddistributionratiosaucliveraucblood
solubilization
maximumabzsxconcentrationcmax
apparentvolumeofdistributionofsteadystate
aucpop
halflifeofabsorptiont05ab
emergencetime
recoverytime
plasmadistributionhalflifet12alpha
areaundertheconcentrationversustimecurve
totali
oralclearanceofmidazolam
areaundertheplasmaconcentrationcurveaucfromtimezerotothetimeoflastquantifiableconcentrationauclast
ks
tissuepeakconcentration
steadystateplasmaconcentrationcssratio
timetoreachpeakplasmamidazolamconcentration
faecaltourinaryexcretionratio
minimumquantifiableconcentration
overallinversionefficiency
maximumtargetoccupancie
maximumaqueoushumorlevel
fdumpdumpratio
sustainedvirologicalresponseratessvr
partial
timetoachievearecoveryoftrainoffourratio
overallsynthesistime
timetomaximumpeakplasmaconcentrationcmax
areasunderthecurveauc0
oraldrugbioavailability
auc050h
percentdrugrelease
reocclusiontime
alphapeakfractionalabsorptionh
serumconcentrationatsteadystate
apparentclearanceclfm
salivaserumratio
c10min
weightadjustedclearance
maximumtauro
steadystateplasmacmax
tmaxf
relativetumoruptakeratio
minimalinhibitoryconcentrationfor90mic90
cdmirlevel
particlesize
maximalresiduelimit
aerodynamicdiameter
peakketconcentration
lengthofthelutealphase
amountoflabelrecovered
unboundsecretoryclearance
24h
steadystateareaunderthecurveauctau
renalclearancerc
epec
clearance1
clearancefromplasmadividedbybioavailabilityclf
percentfractionunboundfu
meanabsorptionlagtimetlag
rpo
resolutioncoefficient
antixaactivity
areaundertheplasmaconcentrationovertimecurvetominimuminhibitoryconcentrationratio
90
ktm208
auc051
areaundertheconcentrationtimecurvefromtimezeroto24hoursauc024
hillexponent
target
halflifeofapparentterminaldisposition
maximumlorazepamconcentrationachievedduringsteadystate
terminalt12washout
era
cshtsatsteadystate
aerodynamicdiametermmda
formulaseetext
ld25
bileexcretionratio
serumpeakconcentrationscmax
timeofmaximumincrease
half
apparentsteadystateoralavailabilitie
peritonealtoplasmaratioofunbound
distributionhalflife
weightadjustedapparentvolumeofdistributionvdf
kpf
concentrationpeakcmax
concentrationsc50
initialzeroorderreleaserate
terminalhalflifewast12beta
steadystatebloodvolumeofdistribution
maximumflaresuppression
plasmatroughatevirdineconcentration
timetoc
aucareaunderplasmaconcentrationtimecurve
centralvolumeofdistributionv
troughconcentrationc0d
maximumconcentrationtimetmax
percentextractionefficiency
antifactorxa
finalhalflife
turnoverhalflive
timesatmaximumconcentration
wholeplasmaclearance
singletonoiseratio
clrfgfr
t12alpha2
tissueplasmatmax
apparentni
timeofwithdrawal
aucslcmsm
dissolution
correctedrenaldrugclearance
inhibitorydoses50id50
areaunderthetimeconcentrationcurveat0to90minutesauc090
redbloodcellstoserumfreedrugconcentrationratio
fractionofmoxifloxacinclearanceto
interresponsetimesirts
tmor
volumeofdistributionvdbeta
steadystatefluxj
totalvolumeatsteadystate
terminalphaseplasmarateconstant
racc
maximumantixaactivity
tgt
kakd
eliminationphaset12beta
aucsst
absoluteintranasalbioavailability
areaundertheconcentrationtimecurvefromtimezerotothelastquantifiabletimeauc0t
areaundertheplasmadrugconcentrationtimecurvefromtimezerotoinfinity
areaundertheconcentrationtimecurvefrom0to6h
urineoutputdose
maximumsalbutamolplasmaconcentration
halflifefor
urineph
apparentvolumeofthecentralcompartmentvcf
releasehalflivest50
maximumglucoseinfusionrategirmax
serumdistributionhalflife
invasionhalflife
areaunderthecurveaucfromtime0totimeoflastmeasurableplasmaconcentrationauc0t
lambdamax
urine
volumeofdistributionoftheperipheralcompartment
peakserumdabigatranlevel
ebf
extractionratiothroughthepulmonarycirculationep
timestosteadystatemaximumplasmaconcentration
drugencapsulationefficiencie
systemicclearancerateclsf
intrinsicactivityalpha
oralclearance
wholebloodtoplasmaratio
totalbodyclearanceoverfractionofdoseabsorbed
c1csratio
totalradioactivitydose
metaboliccapacityvmaxc
analysistimeof
areaundertheconcentrationsversustimeauc0infinity
oralplasmaclearance
urinarymetabolicratio
maximumdose
oralabsorptionrateconstantka
centralvolumeofdistributionv2
sustainedvirologicalresponserate
cta
calciumexcretion
percentageoftimeabovemic
troughserummetforminconcentration
eliminationhalflifet12elim
totalclearancesclt
delayedreleasetimet01
incrementalrecovery
c2level
effectiveconcentrationceff
volumevd
antiiiaactivity
lowerlimitofdetection
receptor
overalleliminationrateconstantk
globalextractionratio
persistentplasmalevel
tn
totalclearancecltotf
areaundertheserumdigoxincurve
absoluteavailability
areaunderthecurveauc012h
maximumstandardizeduptake
minimumtoxicconcentration
painlevel
timeofoccurrenceformaximumdrugconcentration
areaundertheconcentrationcurvein
auc042
rateofabsorption
systemic
plasmawholebloodratio
apparentvolumeofdistributioninsteadystatevdiss
rateofbioavailability
clearancesofproduction
maximumconcentrationlevelscmax
timetomaximumserumdrugconcentration
totalradioactivityexhaled
concentrationofthefirstpeakcpeak1
lod
apparentvolumesofdistributionofthecentralcompartment
maximumplasmastconcentration
secondcompartmentvolume
drg
areaundertheconcentrationvstimecurveaucfromtime0to24hoursaucun
lethalconcentration
aucfrom0to24hour
c0h
bloodflowrateqb
halflifeofreceptoroccupancy
rateofredcellcountertransport
brainserumconcentrationratio
minimumtherapeuticplasmaconcentration
serumconcentrationauc0120h
freesulfateconcentration
apparentketoprofeneliminationhalflive
peakflowratepfr
steadystatetroughplasmadigoxinconcentration
arearatio
activityratio
absolutevolumeofdistributionvd
rateofbiophaseequilibrationke0
areaundertheeffecttimecurveauec01
postdoseconcentrationclast
linearrejectionrate
totalapparentvolumeofdistributionatequilibrium
timetotumorprogression
lungpenetrationfactor
ltratio
terminalhalflifet12el
jss
apparentplasmaeliminationhalflife
plasmat12b
renalexcretionratio
peakampicillinplasmaconcentration
aucgluc
increasedbioavailability
maximumincrease
apneaindex
areaunderthecurveauc0tldc
mrtiv
steadystatefviiiactivitytroughlevel
totalplasmaclearanceclt
earlyt50
redbloodcellplasmawaterconcentrationratio
lambdaz
apparentvolumeofdistributionofthecentralcompartmentvc
eliminationhalflivest12k
timetoneutrophilengraftment
gradient
final
salivatoplasmaconcentrationratiospratio
bioactivation
cumulativedistribution
maximumpdfconcentration
urineoutputper
absorptionpercentage
rhhepaticrecoveryratio
brmmpratio
maximumplasmadiazepamconcentration
wholebodyvolumeofdistribution
relativeextent
apparenttotalclearance
auc024hour
intraextracellularratio
peaktheophyllineplasmaconcentration
totalplasmaacetaminophenclearance
transferinfantdose
timeofoccurrenceofobservedmaximumdrugplasmaconcentration
maximaldrugplasmaconcentration
electrophoreticmobility
timetofirstuse
insulinauc240480
halflifeassociatedwithbetaphaset12beta
effectivedetectionlimit
peakconcentrationinplasmacmax
terminaleliminationhalftimet12beta
betadecay
maximumplasmalevelscpmax
salivatoplasmadrugconcentrationratiosspratio
maximumplasmaaripiprazoleconcentration
intercompartmentaltransferrateskcpkpc
maximumplasmaconcentrationofmycophenolicacid
timestoattaina
maximumarterialplasmanicotineconcentrationscmax
oxygensaturation
ida
boweltobladderconcentration
totalclearanceclbf
maximumliexcretion
peakcsfconcentrationtimetmaxf
recoveryoftotalradioactivity
excretedfraction
serumtobloodvratio
auc7day
areaunderserumconcentrationtimecurveauc0micratio
bacteriaclearancerate
